U.S. patent application number 10/412690 was filed with the patent office on 2004-04-01 for pyrrole substituted 2-indolinone protein kinase inhibitors.
This patent application is currently assigned to SUGEN, Inc. & Pharmacia & Upjohn Co.. Invention is credited to Hawley, Michael, Li, Xiaoyuan, Liang, Congxin, Miller, Todd A., Nematalla, Asaad S., Shirazian, Shahrzad, Sun, Li, Tang, Peng Cho, Vojkovsky, Thomas, Wei, Chung Chen.
Application Number | 20040063773 10/412690 |
Document ID | / |
Family ID | 27391578 |
Filed Date | 2004-04-01 |
United States Patent
Application |
20040063773 |
Kind Code |
A1 |
Tang, Peng Cho ; et
al. |
April 1, 2004 |
Pyrrole substituted 2-indolinone protein kinase inhibitors
Abstract
The present invention relates to pyrrole substituted
2-indolinone compounds and their pharmaceutically acceptable salts
which modulate the activity of protein kinases and therefore are
expected to be useful in the prevention and treatment of protein
kinase related cellular disorders such as cancer.
Inventors: |
Tang, Peng Cho; (Moraga,
CA) ; Miller, Todd A.; (Bend, OR) ; Li,
Xiaoyuan; (San Jose, CA) ; Sun, Li; (Foster
City, CA) ; Wei, Chung Chen; (Foster City, CA)
; Shirazian, Shahrzad; (Corte Madera, CA) ; Liang,
Congxin; (Sunnyvale, CA) ; Vojkovsky, Thomas;
(San Mateo, CA) ; Nematalla, Asaad S.; (Concord,
CA) ; Hawley, Michael; (Kalamazoo, CA) |
Correspondence
Address: |
FOLEY AND LARDNER
SUITE 500
3000 K STREET NW
WASHINGTON
DC
20007
US
|
Assignee: |
SUGEN, Inc. & Pharmacia &
Upjohn Co.
|
Family ID: |
27391578 |
Appl. No.: |
10/412690 |
Filed: |
April 14, 2003 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
10412690 |
Apr 14, 2003 |
|
|
|
09783264 |
Feb 15, 2001 |
|
|
|
6573293 |
|
|
|
|
60182710 |
Feb 15, 2000 |
|
|
|
60216422 |
Jul 6, 2000 |
|
|
|
60243532 |
Oct 27, 2000 |
|
|
|
Current U.S.
Class: |
514/414 ;
548/465 |
Current CPC
Class: |
C07D 233/56 20130101;
A61P 37/00 20180101; A61P 37/06 20180101; C07D 231/12 20130101;
A61P 3/10 20180101; A61P 35/00 20180101; C07D 401/12 20130101; A61P
9/00 20180101; A61P 43/00 20180101; C07D 207/33 20130101; A61P
19/02 20180101; C07D 403/14 20130101; C07D 403/12 20130101; C07D
209/44 20130101; C07D 249/08 20130101; C07D 403/06 20130101; A61P
29/00 20180101; C07D 401/14 20130101; A61P 17/06 20180101 |
Class at
Publication: |
514/414 ;
548/465 |
International
Class: |
A61K 031/404; C07D
43/02 |
Claims
What is claimed:
1. A compound of Formula (I): 205wherein: R.sup.1 is selected from
the group consisting of hydrogen, halo, alkyl, cyclkoalkyl, aryl,
heteroaryl, heteroalicyclic, hydroxy, alkoxy, --(CO)R.sup.15,
--NR.sup.13R.sup.14, --(CH.sub.2).sub.rR.sup.16 and
--C(O)NR.sup.8R.sup.9; R.sup.2 is selected from the group
consisting of hydrogen, halo, alkyl, trihalomethyl, hydroxy,
alkoxy, cyano, --NR.sup.13R.sup.14, --NR.sup.13C(O)R.sup.14,
--C(O)R.sup.15, aryl, heteroaryl, and
--S(O).sub.2NR.sup.13R.sup.14; R.sup.3 is selected from the group
consisting of hydrogen, halogen, alkyl, trihalomethyl, hydroxy,
alkoxy, --(CO)R.sup.15, --NR.sup.13R.sup.14, aryl, heteroaryl,
--NR.sup.13S(O).sub.2NR.sup.14, --S(O).sub.2NR.sup.13R.sup.14,
--NR.sup.13C(O)R.sup.14, --NR.sup.13C(O)OR.sup.14 and
--SO.sub.2R.sup.20 (wherein R.sup.20 is alkyl, aryl, aralkyl,
heteroaryl and heteroaralkyl); R.sup.4 is selected from the group
consisting of hydrogen, halogen, alkyl, hydroxy, alkoxy and
--NR.sup.13R.sup.14; R.sup.5 is selected from the group consisting
of hydrogen, alkyl and --C(O)R.sup.10; R.sup.6 is selected from the
group consisting of hydrogen, alkyl and --C(O)R.sup.10; R.sup.7 is
selected from the group consisting of hydrogen, alkyl, aryl,
heteroaryl, --C(O)R.sup.17 and --C(O)R.sup.10; or R.sup.6 and
R.sup.7 may combine to form a group selected from the group
consisting of --(CH.sub.2).sub.4--, --(CH.sub.2).sub.5-- and
--(CH.sub.2).sub.6--; with the proviso that at least one of
R.sup.5, R.sup.6 or R.sup.7 must be --C(O)R.sup.1; R.sup.8 and
R.sup.9 are independently selected from the group consisting of
hydrogen, alkyl and aryl; R.sup.10 is selected from the group
consisting of hydroxy, alkoxy, aryloxy,
--N(R.sup.11)(CH.sub.2).sub.nR.sup.12, and --NR.sup.13R.sup.14;
R.sup.11 is selected from the group consisting of hydrogen and
alkyl; R.sup.12 is selected from the group consisting of
--NR.sup.13R.sup.14, hydroxy, --C(O)R.sup.15, aryl, heteroaryl,
--N.sup.+(O.sup.-)R.sup.13R.sup.14, --N(OH)R.sup.13, and
--NHC(O)R.sup.a (wherein R.sup.a is unsubstituted alkyl, haloalkyl,
or aralkyl); R.sup.13 and R.sup.14 are independently selected from
the group consisting of hydrogen, alkyl, lower alkyl substituted
with hydroxyalkylamino, cyanoalkyl, cycloalkyl, aryl and
heteroaryl; or R.sup.13 and R.sup.14 may combine to form a
heterocyclo group; R.sup.15 is selected from the group consisting
of hydrogen, hydroxy, alkoxy and aryloxy; R.sup.16 is selected from
the group consisting of hydroxy, --C(O)R.sup.15,
--NR.sup.13R.sup.14 and --C(O)NR.sup.13R.sup.14; R.sup.17 is
selected from the group consisting of alkyl, cycloalkyl, aryl and
heteroaryl; R.sup.20 is alkyl, aryl, aralkyl or, heteroaryl; and n
and r are independently 1, 2, 3, or 4; or a pharmaceutically
acceptable salt thereof.
2. The compound or salt of claim 1 wherein: R.sup.1 is selected
from the group consisting of hydrogen, halo, alkyl, cyclkoalkyl,
aryl, heteroaryl, heteroalicyclic, hydroxy, alkoxy, --C(O)R.sup.15,
--NR.sup.13R.sup.14, --(CH.sub.2).sub.rR.sup.16 and
--C(O)NR.sup.8R.sup.9; R.sup.2 is selected from the group
consisting of hydrogen, halo, alkyl, trihalomethyl, hydroxy,
alkoxy, --NR.sup.13R.sup.14, --NR.sup.13C(O))R.sup.14,
--C(O)R.sup.15, aryl, heteroaryl, and
--S(O).sub.2NR.sup.13R.sup.14; R.sup.3 is selected from the group
consisting of hydrogen, halogen, alkyl, trihalomethyl, hydroxy,
alkoxy, --(CO)R.sup.15, --NR.sup.13R.sup.14, aryl, heteroaryl,
--NR.sup.13S(O).sub.2R.sup.14, --S(O).sub.2NR.sup.13R.sup.14,
--NR.sup.13C(O)R.sup.14 and --NR.sup.13C(O)OR.sup.14; R.sup.4 is
selected from the group consisting of hydrogen, halogen, alkyl,
hydroxy, alkoxy and --NR.sup.13R.sup.14; R.sup.5 is selected from
the group consisting of hydrogen, alkyl and C(O)R.sup.10; R.sup.6
is selected from the group consisting of hydrogen, alkyl and
--C(O)R.sup.10; R.sup.7 is selected from the group consisting of
hydrogen, alkyl, aryl, heteroaryl, --C(O)R.sup.17 and
--C(O)R.sup.10; R.sup.6 and R.sup.7 may combine to form a group
selected from the group consisting of --(CH.sub.2).sub.4--,
--(CH.sub.2).sub.5-- and (CH.sub.2).sub.6--; with the proviso that
at least one of R.sup.5, R.sup.6 or R.sup.7 must be --C(O)R.sup.10;
R.sup.8 and R.sup.9 are independently selected from the group
consisting of hydrogen, alkyl and aryl; R.sup.10 is selected from
the group consisting of hydroxy, alkoxy, aryloxy,
--N(R.sup.11)(CH.sub.2).sub.nR.sup.12 and --NR.sup.13R.sup.14;
R.sup.11 is selected from the group consisting of hydrogen and
alkyl; R.sup.12 is selected from the group consisting of
--NR.sup.13R.sup.14, hydroxy, --C(O)R.sup.15, aryl and heteroaryl;
R.sup.13 and R.sup.14 are independently selected from the group
consisting of hydrogen, alkyl, cycloalkyl, aryl and heteroaryl;
R.sup.13 and R.sup.14 may combine to form a group selected from the
group consisting of --(CH.sub.2).sub.4--, --(CH.sub.2).sub.5--,
--(CH.sub.2).sub.2O(CH.sub.2).sub.2--, and
--(CH.sub.2).sub.2N(CH.sub.3)(CH.sub.2).sub.2--; R.sup.15 is
selected from the group consisting of hydrogen, hydroxy, alkoxy and
aryloxy; R.sup.16 is selected from the group consisting of hydroxy,
--C(O)R.sup.15, --NR.sup.13R.sup.14 and --C(O)NR.sup.13R.sup.14;
R.sup.17 is selected from the group consisting of alkyl,
cycloalkyl, aryl and heteroaryl; and; n and r are independently 1,
2, 3, or 4; or a pharmaceutically acceptable salt thereof.
3. The compound or salt of claim 1 wherein R.sup.5 is --COR.sup.10
wherein R.sup.10 is --NR.sup.11(CH.sub.2).sub.nR.sup.12 wherein:
R.sup.11 is hydrogen or lower unsubstituted alkyl; n is 2 or 3; and
R.sup.12 is --NR.sup.13R.sup.14 wherein R.sup.13 and R.sup.14 are
independently unsubstituted lower alkyl.
4. The compound or salt of claim 1 wherein R.sup.5 is --COR.sup.10
wherein R.sup.10 is --NR.sup.11(CH.sub.2).sub.nR.sup.12 wherein:
R.sup.11 is hydrogen or lower unsubstituted alkyl; n is 2 or 3; and
R.sup.12 is --NR.sup.13R.sup.14 wherein R.sup.13 and R.sup.14
combine to form a group selected from --(CH.sub.2).sub.4--,
--(CH.sub.2).sub.5--, --(CH.sub.2).sub.2--O--(CH.sub.2).sub.2-- or
--(CH.sub.2).sub.2N(CH.sub.3- )(CH.sub.2).sub.2--.
5. The compound of claim 1 wherein R.sup.5 is
N-(2-dimethylaminoethyl)amin- ocarbonyl,
N-(2-diethylaminoethyl)-N-methylaminocarbonyl,
N-(3-dimethylaminopropyl)aminocarbonyl,
N-(2-diethylaminoethyl)aminocarbo- nyl,
N-(3-ethylaminopropyl)-aminocarbonyl,
N-(2-ethylaminoethyl)aminocarbo- nyl, or
N-(3-diethylaminopropyl)aminocarbonyl.
6. The compound of claim 1 wherein R.sup.5 is
N-(2-diethylaminoethyl)amino- carbonyl or
N-(2-ethylaminoethyl)aminocarbonyl.
7. The compound of claim 1 wherein R.sup.5 is
3-pyrrolidin-1-ylpropylamino- carbonyl,
3-morpholin-4-ylpropylaminocarbonyl, 2-pyrrolidin-1-ylethylamino-
carbonyl, 2-morpholin-4-yl-ethylaminocarbonyl,
2-(4-methylpiperazin-1-yl)e- thyl-aminocarbonyl,
2-(3,5-dimethylpiperazin-1-yl)ethyl-aminocarbonyl,
3-(4-methylpiperazin-1-yl)propylamino-carbonyl or
3-(3,5-dimethylpiperazi- n-1-yl)propylamino-carbonyl.
8. The compound or salt of claim 1 wherein R.sup.6 is --COR.sup.10
wherein R.sup.10 is --NR.sup.11(CH.sub.2).sub.nR.sup.12 wherein:
R.sup.11 is hydrogen or lower unsubstituted alkyl; n is 2 or 3; and
R.sup.12 is --NR.sup.13R.sup.14 wherein R.sup.13 and R.sup.14 are
independently unsubstituted lower alkyl.
9. The compound or salt of claim 1 wherein R.sup.6 is --COR.sup.10
wherein R.sup.10 is --NR.sup.11(CH.sub.2).sub.nR.sup.12 wherein:
R.sup.11 is hydrogen or lower unsubstituted alkyl; n is 2 or 3; and
R.sup.12 is --NR.sup.13R.sup.14 wherein R.sup.13 and R.sup.14
combine to form a group selected from --(CH.sub.2).sub.4--,
--(CH.sub.2).sub.5--, --(CH.sub.2).sub.2--O--(CH.sub.2).sub.2-- or
--(CH.sub.2).sub.2N(CH.sub.3- )(CH.sub.2).sub.2--.
10. The compound or salt of claim 1 wherein R.sup.6 is
N-(2-dimethylamino-ethyl)aminocarbonyl,
N-(2-diethylaminoethyl)-N-methyla- minocarbonyl,
N-(3-dimethylaminopropyl)-aminocarbonyl,
N-(2-diethylaminoethyl)-aminocarbonyl,
N-(2-ethylaminoethyl)-aminocarbony- l,
N-(3-ethylaminopropyl)-aminocarbonyl, or
N-(3-diethylaminopropyl)aminoc- arbohyl.
11. The compound or salt of claim 1 wherein R.sup.6 is
N-(2-diethylaminoethyl)aminocarbonyl or
N-(2-ethylaminoethyl)aminocarbony- l.
12. The compound or salt of claim 1 wherein R.sup.6 is
3-pyrrolidin-1-ylpropylaminocarbonyl,
3-morpholin-4-ylpropylamino-carbony- l,
2-pyrrolidin-1-ylethylaminocarbonyl,
2-morpholin-4-ylethylaminocarbonyl- ,
2-(4-methylpiperazin-1-yl)ethyl-aminocarbonyl,
2-(3,5-dimethylpiperazin-- 1-yl)ethyl-aminocarbonyl,
3-(4-methylpiperazin-1-yl)propylamino-carbonyl or
3-(3,5-dimethylpiperazin-1-yl)propylamino-carbonyl.
13. The compound or salt of claim 1 wherein R.sup.5 is --COR.sup.10
wherein R.sup.10 is --NR.sup.13R.sup.14 wherein R.sup.13 is
hydrogen and R.sup.14 is lower alkyl substituted with hydroxy,
aryl, heteroalicyclic, heteroaryl, or carboxy.
14. The compound or salt of claim 1 wherein R.sup.5 is
3-triazin-1-ylpropylaminocarbonyl,
2-triazin-1-ylethylaminocarbonyl,
3-imidazol-1-ylpropylaminocarbony, pyridin-4-ylmethylaminocarbonyl,
2-pyridin-2-ylethylaminocarbonyl or 2-imidazol-1-yl
ethylaminocarbonyl.
15. The compound or salt of claim 1 wherein R.sup.6 is --COR.sup.10
wherein R.sup.10 is --NR.sup.13R.sup.14 wherein R.sup.13 is
hydrogen and R.sup.14 is lower alkyl substituted with hydroxy,
aryl, heteroalicyclic, heteroaryl, or carboxy.
16. The compound or salt of claim 1 wherein R.sup.6 is
2-triazin-1-ylpropylaminocarbonyl,
2-triazin-1-ylethylaminocarbonyl,
3-imidazol-1-ylpropylaminocarbony, pyridin-4-ylmethylaminocarbonyl,
2-pyridin-2-ylethylaminocarbonyl or 2-imidazol-1-yl
ethylaminocarbonyl.
17. The compound or salt of claim 1 wherein R.sup.5 is --COR.sup.10
wherein R.sup.10 is --NR.sup.11(CH.sub.2).sub.nR.sup.12 wherein:
R.sup.11 is hydrogen or lower unsubstituted alkyl; n is 2 or 3; and
R.sup.12 is --NR.sup.13R.sup.14 wherein R.sup.13 and R.sup.14
together combine to form a heterocycle.
18. The compound or salt of claim 1 wherein R.sup.5 is --COR.sup.10
wherein R.sup.10 is --NR.sup.11(CH.sub.2).sub.nR.sup.12 wherein:
--R.sup.11 is hydrogen or lower unsubstituted alkyl; n is 2 or 3;
and R.sup.12 is --NR.sup.13R.sup.14 wherein R.sup.13 and R.sup.1"
together combine to form a 5, 6 or 7 atom heterocycle containing a
carbonyl group and one or two nitrogen atoms within the ring.
19. The compound or salt of claim 1 wherein R.sup.5 is
2-(3-oxopiperazin-1-yl)ethylaminocarbonyl,
2-(imidazolidin-1-yl-2-one)eth- ylaminocarbonyl,
2-(tetrahydropyrimidin-1-yl-2-one)ethylaminocarbonyl,
2-(2-oxopyrrolidin-1-yl)-ethylaminocarbonyl,
3-(3-oxopiperazin-1-yl)propy- laminocarbonyl,
3-(imidazolidin-1-yl-2-one)propylaminocarbonyl,
3-(tetrahydropyrimidin-1-yl-2-one)propylaminocarbonyl, or
3-(2-oxopyrrolidin-1-yl)propylaminocarbonyl.
20. The compound or salt of claim 1 wherein R.sup.6 is --COR.sup.10
wherein R.sup.10 is --NR.sup.11(CH.sub.2).sub.nR.sup.12 wherein:
R.sup.11 is hydrogen or lower unsubstituted alkyl; n is 2 or 3; and
R.sup.12 is --NR.sup.13R.sup.14 wherein R.sup.13 and R.sup.14
together combine to form a heterocycle.
21. The compound or salt of claim 1 wherein R.sup.6 is --COR.sup.10
wherein R.sup.10 is --NR.sup.11(CH.sub.2).sub.nR.sup.12 wherein:
R.sup.11 is hydrogen or lower unsubstituted alkyl; n is 2 or 3; and
R.sup.12 is --NR.sup.13R.sup.14 wherein R.sup.13 and R.sup.14
together combine to form a 5, 6 or 7 atom heterocycle containing a
carbonyl group and one or two nitrogen atoms within the ring.
22. The compound or salt of claim 1 wherein R.sup.6 is
2-(3-oxopiperazin-1-yl)ethylaminocarbonyl,
2-(imidazolidin-1-yl-2-one)eth- ylaminocarbonyl,
2-(tetrahydropyrimidin-1-yl-2-one)ethylaminocarbonyl,
2-(2-oxopyrrolidin-1-yl)ethylaminocarbonyl,
3-(3-oxopiperazin-1-yl)propyl- aminocarbonyl,
3-(imidazolidin-1-yl-2-one)propylaminocarbonyl,
3-(tetrahydropyrimidin-1-yl-2-one)propylaminocarbonyl, or
3-(2-oxopyrrolidin-1-yl)propylaminocarbonyl.
23. The compound or salt of anyone of claims 3-7, 13-14 or 17-19
wherein: R.sup.6 is selected from the group consisting of hydrogen
and lower unsubstituted alkyl; and R.sup.7 is selected from the
group consisting of hydrogen, alkyl, aryl, heteroaryl, and
--C(O)R.sup.17 wherein R.sup.17 is hydroxy, unsubstituted lower
alkyl or aryl.
24. The compound or salt of claim 23 wherein: R.sup.6 is selected
from the group consisting of hydrogen, and methyl; and R.sup.7 is
selected from the group consisting of methyl, hydrogen and
phenyl.
25. The compound or salt of any of the claims 8-12, 15, 16, or
20-22 wherein: R.sup.5 is selected from the group consisting of
hydrogen and unsubstituted lower alkyl; and R.sup.7 is selected
from the group consisting of hydrogen, alkyl, aryl, heteroaryl, and
--C(O)R.sup.17, wherein R.sup.17 is hydroxy, unsubstituted lower
alkyl or aryl.
26. The compound or salt of claim 25 wherein: R.sup.6 is selected
from the group consisting of hydrogen, or methyl; and R.sup.7 is
selected from the group consisting of methyl, hydrogen or
phenyl.
27. The compound or salt of claim 23 wherein: R.sup.1 is hydrogen,
unsubstituted lower alkyl, --C(O)NR.sup.8R.sup.9, unsubstituted
cycloalkyl or aryl; R.sup.2 is hydrogen, halo, lower alkoxy, cyano,
aryl, or --S(O).sub.2NR.sup.13R.sup.14 wherein R.sup.13 is hydrogen
and R.sup.14 is hydrogen, aryl or alkyl; R.sup.3 is selected from
the group consisting of hydrogen, lower alkoxy, --C(O)R.sup.15,
--NR.sup.13C(O)R.sup.14, aryl optionally substituted with one or
two substitutents selected from the group consisting of lower
alkyl, halo, or lower alkoxy, and heteroaryl; and R.sup.4 is
hydrogen.
28. The compound or salt of claim 23 wherein: R.sup.1 is hydrogen
or phenyl; R.sup.2 is hydrogen, chloro, bromo, fluoro, methoxy,
ethoxy, phenyl, cyano, dimethylaminosulfonyl,
3-chlorophenyl-aminosulfonyl, carboxy, methoxy, aminosulfonyl,
methylaminosulfonyl, methylsulfonyl ethylsulfonyl, benzylsulfonyl,
phenylaminosulfonyl, pyridin-3-yl-aminosulfonyl,
dimethylaminosulfonyl, or isopropylamino-sulfonyl; R.sup.3 is
hydrogen, methoxy, carboxy, phenyl; pyridin-3-yl,
3,4-dichlorophenyl, 2-methoxy-5-isopropylphenyl, 4-n-butylphenyl,
or 3-isopropylphenyl; and R.sup.4 is hydrogen.
29. The compound or salt of claim 23 wherein: R.sup.1 is hydrogen;
R.sup.2 is hydrogen, cyano, fluoro, chloro, or bromo; R.sup.3 is
hydrogen; and R.sup.4 is hydrogen.
30. The compound or salt of claim 25 wherein: R.sup.1 is hydrogen,
unsubstituted lower alkyl, --C(O)NR.sup.8R.sup.9, unsubstituted
cycloalkyl or aryl; R.sup.2 is hydrogen, halo, lower alkoxy, cyano,
aryl, --SO.sub.2R20, or --S(O).sub.2NR.sup.13R.sup.14 wherein
R.sup.13 is hydrogen and R.sup.14 is hydrogen, aryl or alkyl;
R.sup.3 is selected from the group consisting of hydrogen, lower
alkoxy, --C(O)R.sup.15, --NR.sup.13C(O)R.sup.14, aryl and
heteroaryl; and R.sup.4 is hydrogen.
31. The compound or salt of claim 25 wherein: R.sup.1 is hydrogen
or phenyl; R.sup.2 is hydrogen, chloro, bromo, fluoro, methoxy,
ethoxy, phenyl, dimethylaminosulfonyl, cyano, methylsulfonyl,
ethylsulfonyl, benzylsulfonyl, 3-chlorophenyl-aminosulfonyl,
carboxy, methoxy, aminosulfonyl, methylaminosulfonyl,
phenylaminosulfonyl, pyridin-3-yl-aminosulfonyl,
dimethylaminosulfonyl, or isopropylamino-sulfonyl; R.sup.3 is
hydrogen, methoxy, carboxy, phenyl, pyridin-3-yl,
3,4-dichlorophenyl, 2-methoxy-5-isopropylphenyl, 4-n-butylphenyl,
3-isopropylphenyl; and R.sup.4 is hydrogen.
32. The compound or salt of claim 25 wherein: R.sup.1 is hydrogen;
R.sup.2 is hydrogen, cyano, fluoro, chloro, or bromo; R.sup.3 is
phenyl; and R.sup.4 is hydrogen.
33. The compound or salt of claim 1 wherein: R.sup.1 is hydrogen,
unsubstituted lower alkyl, --C(O)NR.sup.8R.sup.9, unsubstituted
cycloalkyl or aryl; R.sup.2 is hydrogen, halo, lower alkoxy, cyano,
aryl or --S(O).sub.2NR.sup.13R.sup.14 wherein R.sup.13 is hydrogen
and R.sup.14 is hydrogen, aryl or alkyl; R.sup.3 is selected from
the group consisting of hydrogen, lower alkoxy, --C(O)R.sup.15,
--NR.sup.13C(O)R.sup.14, aryl, and heteroaryl; and R.sup.4 is
hydrogen.
34. The compound or salt of claim 1 wherein: R.sup.1 is hydrogen,
or methyl; R.sup.2 is hydrogen, cyano, chloro, fluoro, or bromo;
R.sup.3 is selected from the group consisting of hydrogen or
phenyl; and R.sup.4 is hydrogen.
35. The compound or salt of claim 33 or 34 wherein: R.sup.5 is
--COR.sup.10; R.sup.6 is selected from the group consisting of
hydrogen and unsubstituted lower alkyl; and R.sup.7 is selected
from the group consisting of hydrogen, alkyl, aryl, heteroaryl, and
--C(O)R.sup.17 wherein R.sup.17 is hydroxy, unsubstituted lower
alkyl or aryl.
36. The compound or salt of claim 33 or 34 wherein: R.sup.6 is
--COR.sup.10; R.sup.5 is selected from the group consisting of
hydrogen and unsubstituted lower alkyl; and R.sup.7 is selected
from the group consisting of hydrogen, alkyl, aryl, heteroaryl, and
--C(O)R.sup.17 wherein R.sup.17 is hydroxy, unsubstituted lower
alkyl or aryl.
37. The compound or salt of claim 1 wherein R.sup.5 is --COR.sup.10
wherein R.sup.10 is --NR.sup.13R.sup.14 wherein R.sup.13 is
hydrogen and R.sup.14 is lower alkyl substituted with hydroxy,
lower alkyl substituted with hydroxyalkylamino, carboxy, or
--NR.sup.18R.sup.19 wherein R.sup.18 and R.sup.19 are independently
hydrogen or lower unsubstituted alkyl.
38. The compound or salt of claim 11 wherein R.sup.5 is
2-[(diethylamino)-2-hydroxyethyl]aminocarbonyl,
2-(N-ethyl-N-2-hydroxyeth- ylamino)ethylaminocarbonyl,
carboxymethylamino-carbonyl, or 2-hydroxyethylaminocarbonyl.
39. The compound or salt of claim 1 wherein R.sup.6 is --COR.sup.10
wherein R.sup.10 is --NR.sup.13R.sup.14 wherein R.sup.13 is
hydrogen and R.sup.14 is lower alkyl substituted with hydroxy,
lower alkyl substituted with hydroxyalkylamino, carboxy, or
--NR.sup.18R.sup.19 wherein R.sup.18 and R.sup.19 are independently
hydrogen or lower unsubstituted alkyl.
40. The compound or salt of claim 1 wherein R.sup.6 is
[2-(diethylamino)-2-hydroxy]ethylaminocarbonyl,
2-(N-ethyl-N-2-hydroxyeth- ylamino)ethylaminocarbonyl,
carboxymethylaminocarbonyl, or 2-hydroxyethylaminocarbonyl.
41. The compound of claim 1 wherein R.sup.5 is --COR.sup.10 wherein
R.sup.10 is --NR.sup.11(CH.sub.2).sub.nR.sup.12 wherein R.sup.12 is
--N.sup.+(O.sup.-)NR.sup.13R.sup.14 or --N(OH)R.sup.13 wherein
R.sup.13 and R.sup.14 are independently selected from the group
consisting of unsubstituted lower alkyl.
42. The compound of claim 1 wherein R.sup.5 is
2-(N-hydroxy-N-ethylamino)e- thylaminocarbonyl or
2-[N.sup.+(O.sup.-)(C.sub.2H.sub.5).sub.2]ethylaminoc- arbonyl
43. The compound of claim 1 wherein R.sup.6 is --COR.sup.10 wherein
R.sup.10 is --NR.sup.11(CH.sub.2).sub.nR.sup.12 wherein R.sup.12 is
--N.sup.+(O.sup.-)NR.sup.13R.sup.14 or --N(OH)R.sup.13 wherein
R.sup.13 and R.sup.14 are independently selected from the group
consisting of unsubstituted lower alkyl.
44. The compound of claim 1 wherein R.sup.6 is
2-(N-hydroxy-N-ethylamino)e- thylaminocarbonyl or
2-[N.sup.+(O.sup.-)(C.sub.2H.sub.5).sub.2]ethylaminoc- arbonyl.
45. The compound or salt of claim 37, 38, 41 or 42 wherein: R.sup.6
is selected from the group consisting of hydrogen, or methyl; and
R.sup.7 is selected from the group consisting of methyl, hydrogen
or phenyl.
46. The compound or salt of any of the claims 39, 40, 43, 44 or
20-22 wherein: R.sup.5 is selected from the group consisting of
hydrogen, or methyl; and R.sup.7 is selected from the group
consisting of methyl, hydrogen or phenyl.
47. The compound or salt of claim 45 wherein: R.sup.1 is hydrogen;
R.sup.2 is hydrogen, cyano, chloro, fluoro, or bromo; R.sup.3 is
hydrogen; and R.sup.4 is hydrogen.
48. The compound or salt of claim 46 wherein: R.sup.1 is hydrogen;
R.sup.2 is cyano, chloro, fluoro, or bromo; R.sup.3 is hydrogen;
and R.sup.4 is hydrogen.
49. The compound or salt of claim 1, wherein the compound is
selected from the group consisting of: 206or an L-malate salt
thereof.
50. A pharmaceutical composition, comprising a compound or salt of
claim 1 and, a pharmaceutically acceptable carrier or
excipient.
51. A pharmaceutical composition, comprising a compound or salt of
claim 49 and, a pharmaceutically acceptable carrier or
excipient.
52. A method for the modulation of the catalytic activity of a
protein kinase comprising contacting said protein kinase with a
compound or salt of claim 1 or 49.
53. The method of claim 52 wherein said protein kinase is selected
from the group consisting of a receptor tyrosine kinase, a
non-receptor tyrosine kinase and a serine-threonine kinase.
54. A method for treating or preventing a protein kinase related
disorder in an organism comprising administering a therapeutically
effective amount of a pharmaceutical composition comprising a
compound or salt of claim 50 or claim 51 and, a pharmaceutically
acceptable carrier or excipient to said organism.
55. The method of claim 54 wherein said protein kinase related
disorder is selected from the group consisting of a receptor
tyrosine kinase related disorder, a non-receptor tyrosine kinase
related disorder and a serine-threonine kinase related
disorder.
56. The method of claim 54 wherein said protein kinase related
disorder is selected from the group consisting of an EGFR related
disorder, a PDGFR related disorder, an IGFR related disorder and a
flk related disorder.
57. The method of claim 54 wherein said protein kinase related
disorder is a cancer selected from the group consisting of squamous
cell carcinoma, astrocytoma, Kaposi's sarcoma, glioblastoma, lung
cancer, bladder cancer, head and neck cancer, melanoma, ovarian
cancer, prostate cancer, breast cancer, small-cell lung cancer,
glioma, colorectal cancer, genitourinary cancer and
gastrointestinal cancer.
58. The method of claim m 54 wherein said protein kinase related
disorder is selected from the group consisting, of diabetes, an
autoimmune disorder, a hyperproliferation disorder, restenosis,
fibrosis, psoriasis, von Heppel-Lindau disease, osteoarthritis,
rheumatoid arthritis, angiogenesis, an inflammatory disorder, an
immunological disorder and a cardiovascular disorder.
59. The method of claim 54 wherein said organism is a human.
60. An intermediate of Formula (II): 207wherein: R.sup.5 is
selected from the group consisting of hydrogen, alkyl and
--C(O)R.sup.10; R.sup.6 is selected from the group consisting of
hydrogen, alkyl and --C(O)R.sup.10; R.sup.7 is selected from the
group consisting of hydrogen, alkyl, aryl, heteroaryl,
--C(O)R.sup.17 and --C(O)R.sup.10; R.sup.6 and R.sup.7 may combine
to form a group selected from the group consisting of
--(CH.sub.2).sub.4--, --(CH.sub.2).sub.5-- and
--(CH.sub.2).sub.6--; with the proviso that at least one of
R.sup.5, R.sup.6 or R.sup.7 must be --C(O)R.sup.10; R.sup.10 is
selected from the group consisting of hydroxy, alkoxy, aryloxy,
--N(R.sup.11)(CH.sub.2).sub.nR.sup.12 and --NR.sup.13R.sup.14;
R.sup.11 is selected from the group consisting of hydrogen and
alkyl; R.sup.12 is selected from the group consisting of
--NR.sup.13 R.sup.14, hydroxy, --C(O)R.sup.15, aryl and heteroaryl;
R.sup.13 and R.sup.14 are independently selected from the group
consisting of hydrogen, alkyl, cyanoalkyl, cycloalkyl, aryl and
heteroaryl; or R.sup.13 and R.sup.14 may combine to form a
heterocyclo group; R.sup.15 is selected from the group consisting
of hydrogen, hydroxy, alkoxy and aryloxy; R.sup.17 is selected from
the group consisting of alkyl, cycloalkyl, aryl and heteroaryl; and
n is 1, 2, 3, or 4.
Description
CROSS-REFERENCE INFORMATION
[0001] This application claims priority under 35 U.S.C. 119(e) to
U.S. Provisional Application Serial No. 60/182,710, filed Feb. 15,
2000, No. 60/216,422 filed on Jul. 6, 2000 and Serial No.
60/243,532, filed Oct. 27, 2000, the disclosures of which are
incorporated by reference herein in their entirety.
BACKGROUND OF THE INVENTION
[0002] 1. Field of Invention
[0003] The present invention relates to certain 3-pyrrole 150
substituted 2-indolinone compounds which modulate the activity of
protein kinases ("PKs"). The compounds of this invention are
therefore useful in treating disorders related to abnormal PK
activity. Pharmaceutical compositions comprising these compounds,
methods of treating diseases utilizing pharmaceutical compositions
comprising these compounds and methods of preparing them are also
disclosed.
[0004] 2. State of the Art
[0005] The following is offered as background information only and
is not admitted to be prior art to the present invention.
[0006] PKs are enzymes that catalyze the phosphorylation of,
hydroxy groups on tyrosine, serine and threonine residues of
proteins. The consequences of this seemingly simple activity are
staggering; cell growth, differentiation and proliferation, i.e.,
virtually all aspects of cell life in one way or another depend on
PK activity. Furthermore, abnormal PK activity has been related to
a host of disorders, ranging from relatively non-life threatening
diseases such as psoriasis to extremely virulent diseases such as
glioblastoma (brain cancer)
[0007] The PKs can be conveniently broken down into two classes,
the protein tyrosine kinases (PTKs) and the serine-threonine
kinases (STKs).
[0008] One of the prime aspects of PTK activity is their
involvement with growth factor receptors. Growth factor receptors
are cell-surface proteins. When bound by a growth factor ligand,
growth factor receptors are converted to an active form which
interacts with proteins on the inner surface of a cell membrane.
This leads to phosphorylation on tyrosine, residues of the receptor
and other proteins and to the formation inside the cell of
complexes with a variety of cytoplasmic signaling molecules that,
in turn, effect numerous cellular responses such as cell division
(proliferation), cell differentiation, cell growth, expression of
metabolic effects the extracellular microenvironment, etc. For a
more complete discussion, see Schletssinger and Ullrich, Neuron,
9:303-391 (1992) which is incorporated by reference, including any
drawings, as if fully set forth herein.
[0009] Growth factor receptors with PTK activity are known as
receptor tyrosine kinases ("RTKs"). They comprise a large family of
transmembrane receptors with diverse biological activity. At
present, at least nineteen (19) distinct subfamilies of RTKs have
been identified. An example of these is the subfamily designated
the "HER" RTKs, which include EGFR (epithelial growth factor
receptor), HER2, HER3 and HER4. These RTKs consist of an
extracellular glycosylated ligand binding domain, a transmembrane
domain and an intracellular cytoplasmic catalytic domain that can
phosphorylate tyrosine residues on proteins.
[0010] Another RTK subfamily consists of insulin receptor (1R),
insulin-like growth factor I receptor:(IGF-1R) and insulin *
receptor related receptor (IRR). IR and IGF-1R interact with
insulin, IGF-I and IGF-II to form a heterotetramer of two entirely
extracellular glycosylated .alpha. subunits and two .beta. subunits
which cross the cell membrane and which contain the tyrosine kinase
domain.
[0011] A third RTK subfamily is referred to as the platelet derived
growth factor receptor ("PDGFR") group, which includes
PDGFR.alpha., PDGFR.beta., CSFIR, c-kit and c-fms. These receptors
consist of glycosylated extracellular domains composed of variable
numbers of immunoglobin-like loops and an intracellular domain
wherein the tyrosine kinase domain is interrupted by unrelated
amino acid sequences.
[0012] Another group which, because of its similarity to the PDGFR
subfamily, is sometimes subsumed into the later group is the fetus
liver kinase ("flk") receptor subfamily. This group is believed to
be made up of kinase insert domain-receptor fetal liver kinase-1
(KDR/FLK-1, VEGF-R2), flk-1R, flk-4 and fms-like tyrosine kinase 1
(flt-1).
[0013] A further member of the tyrosine kinase growth factor
receptor family is the fibroblast growth factor ("FGF") receptor
subgroup. This group consists of four receptors, FGFR1-4, and seven
ligands, FGF1-7. While not yet well defined, it appears that the
receptors consist of a glycosylated extracellular domain containing
a variable number of immunoglobin-like loops and an intracellular
domain in which the tyrosine kinase sequence is interrupted by
regions of unrelated amino acid sequences.
[0014] Still another member of the tyrosine kinase growth factor
receptor family is the vascular endothelial growth factor (VEGF")
receptor subgroup. VEGF is a dimeric glycoprotein similar to PDGF
but has different biological functions and target cell specificity
in vivo. In particular, VEGF is presently thought to play an
essential role is vasculogenesis and angiogenesis.
[0015] A more complete listing of the known RTK subfamilies is
described in Plowman et al., DN&P, 7(6):334-339 (1994) which is
incorporated by reference, including any drawings, as if fully set
forth herein.
[0016] In addition to the RTKs, there also exists a family of
entirely intracellular PTKs called "non-receptor tyrosine kinases"
or "cellular tyrosine kinases." This latter designation,
abbreviated "CTK," will be used herein. CTKs do not contain
extracellular and transmembrane domains. At present, over 24 CTKs
in 11 subfamilies (Src, Frk, Btk, Csk, Abl, Zap70, Fes, Fps, Fak,
Jak and Ack) have been identified. The Src subfamily appear so far
to be the largest group of CTKs and includes Src, Yes, Fyn, Lyn,
Lck, Blk, Hck, Fgr and Yrk. For a more detailed discussion of CTKs,
see Bolen, Oncogene, 8:2025-2031 (1993), which is incorporated by
reference, including any drawings, as if fully set forth
herein.
[0017] The serine/threonine kinases, STKs, like the CTKs, are
predominantly intracellular although there are a few receptor
kinases of the STK type. STKs are the most common of the cytosolic
kinases; i.e., kinases that perform their function in that part of
the cytoplasm other than the cytoplasmic organelles and
cytoskelton. The cytosol is the region within the cell where much
of the cell's intermediary metabolic and biosynthetic activity
occurs; e.g., it is in the cytosol that proteins are synthesized on
ribosomes.
[0018] RTKs, CTKs and STKs have all been implicated in a host of
pathogenic conditions including, significantly, cancer. Other
pathogenic conditions which have been associated with PTKs include,
without limitation, psoriasis, hepatic cirrhosis, diabetes,
angiogenesis, restenosis, ocular diseases, rheumatoid arthritis and
other inflammatory disorders, immunological disorders such as
autoimmune disease, cardiovascular disease such as atherosclerosis
and a variety of renal disorders.
[0019] With regard to cancer, two of the major hypotheses advanced
to explain the excessive cellular proliferation that drives tumor
development relate to functions known to be PK regulated. That is,
it has been suggested that malignant cell growth results from a
breakdown in the mechanisms that control cell division and/or
differentiation. It has been shown that the protein products of a
number of proto-oncogenes are involved in the signal transduction
pathways that regulate cell growth and differentiation. These
protein products of proto-oncogenes include the extracellular
growth factors, transmembrane growth factor PTK receptors (RTKs),
cytoplasmic PTKs,(CTKs) and cytosolic STKs, discussed above.
[0020] In view of the apparent link between PK-related cellular
activities and wide variety of human disorders, it is no surprise
that a great deal of effort is being expended in an attempt to
identify ways to modulate PK activity. Some of this effort has
involved biomimetic approaches using large molecules patterned on
those involved in the actual cellular processes (e.g., mutant
ligands (U.S. Pat. No. 4,966,849); soluble receptors and antibodies
(App. No. WO 94/10202, Kendall and Thomas, Proc. Nat'l Acad. Sci.,
90:10705-09 (1994), Kim, et al., Nature, 362:841-844 (1993)); RNA
ligands (Jelinek, et al., Biochemistry, 33:10450-56); Takano, et
al., Mol. Bio. Cell 4:358A (1993); Kinsella, et al., Exp. Cell Res.
199:56-62 (1992); Wright, et al., J. Cellular Phys., 152:448-57)
and tyrosine kinase inhibitors (WO 94/03427; WO 92/21660; WO
91/15495; WO 94/14808; U.S. Pat. No. 5,330,992; Mariani, et al.,
Proc. Am. Assoc. Cancer Res., 35:2268 (1994)).
[0021] In addition to the above, attempts have been made to
identify small molecules which act as PK inhibitors. For example,
bis-monocylic, bicyclic and heterocyclic aryl compounds (PCT WO
92/20642), vinyleneazaindole derivatives (PCT WO 94/14808) and
1-cyclopropyl-4-pyridylquinolones (U.S. Pat. No. 5,330,992) have
been described as tyrosine kinase inhibitors. Styryl compounds
(U.S. Pat. No. 5,217,999), styryl-substituted pyridyl compounds
(U.S. Pat. No. 5,302,606), quinazoline derivatives (EP App. No.0
566 266 A1), selenaindoles and selenides (PCT WO 94/03427),
tricyclic polyhydroxylic compounds (PCT WO 92/21660) and
benzylphosphonic acid compounds (PCT WO 91/15495) have all been
described as PTK inhibitors useful in the treatment of cancer.
SUMMARY OF THE INVENTION
[0022] The present invention is directed to certain 3-pyrrole
substituted 2-indolinone compounds which exhibit PK modulating
ability and are therefore useful in treating disorders related to
abnormal PK activity.
[0023] Accordingly, in one aspect, the present invention relates to
3-pyrrole substituted 2-indolinones of Formula (I): 1
[0024] wherein:
[0025] R.sup.1 is selected from the group consisting of hydrogen,
halo, alkyl, cyclkoalkyl, aryl, heteroaryl, heteroalicyclic,
hydroxy, alkoxy, --(CO)R.sup.15, --NR.sup.13R.sup.14,
--(CH.sub.2).sub.rR.sup.16 and --C(O)NR.sup.8R.sup.9;
[0026] R.sup.2 is selected from the group consisting of hydrogen,
halo, alkyl, trihalomethyl, hydroxy, alkoxy, cyano,
--NR.sup.13R.sup.14, --NR.sup.13C(O)R.sup.14, --C(O)R.sup.15, aryl,
heteroaryl, --S(O).sub.2NR.sup.13R.sup.14 and --SO.sub.2R.sup.20
(wherein R.sup.20 is alkyl, aryl, aralkyl, heteroaryl and
heteroaralkyl);
[0027] R.sup.3 is selected from the group consisting of hydrogen,
halogen, alkyl, trihalomethyl, hydroxy, alkoxy, --(CO)R.sup.15,
--NR.sup.13R.sup.14, aryl, heteroaryl,
--S(O).sub.2NR.sup.13R.sup.14, --NR.sup.13C(O)R.sup.14,
[0028] --NR.sup.13C(O)OR.sup.14 and --SO.sub.2R.sup.20 (wherein
R.sup.20 is alkyl, aryl, aralkyl, heteroaryl and
heteroaralkyl);
[0029] R.sup.4 is selected from the group consisting of hydrogen,
halogen, alkyl, hydroxy, alkoxy, and --NR.sup.13R.sup.14;
[0030] R.sup.5 is selected from the group consisting of hydrogen,
alkyl and --C(O)R.sup.10,
[0031] R.sup.6 is selected from the group consisting of hydrogen,
alkyl and --C(O)R.sup.10.
[0032] R.sup.7 is selected from the group consisting of hydrogen,
alkyl, aryl, heteroaryl, --C(O)R.sup.17 and --C(O)R.sup.10; or
[0033] R.sup.6 and R.sup.7 may combine to form a group, selected
from the group consisting of --(CH.sub.2).sub.4--,
--(CH.sub.2).sub.5-- and --(CH.sub.2).sub.6--;
[0034] with the proviso that at least one of R.sup.5, R.sup.6 or
R.sup.7 must be:
[0035] R.sup.8 and R.sup.9 are independently selected from the
group consisting of hydrogen, alkyl and aryl;
[0036] R.sup.10 is selected from the group consisting of hydroxy,
alkoxy, aryloxy, --N(R.sup.11)(CH.sub.2).sub.nR.sup.12, and
--NR.sup.13R.sup.14,
[0037] R.sup.11 is selected from the group consisting of hydrogen
and alkyl;
[0038] R.sup.12 is selected from the group consisting of
--NR.sup.13R.sup.14, hydroxy, --C(O)R.sup.15, aryl, heteroaryl,
--N.sup.+(O.sup.-)R.sup.13R.sup.14, --N(OH)R.sup.13, and
--NHC(O)R.sup.a (wherein R.sup.a is unsubstituted alkyl, haloalkyl,
or aralkyl);
[0039] R.sup.13 and R.sup.14 are independently selected from the
group consisting of hydrogen, alkyl, cyanoalkyl, cycloalkyl, aryl
and heteroaryl; or
[0040] R.sup.13 and R.sup.14 may combine to form a heterocyclo
group;
[0041] R.sup.15 is selected from the group consisting of hydrogen,
hydroxy, alkoxy and aryloxy;
[0042] R.sup.16 is selected from the group consisting of hydroxy,
--C(O)R.sup.15, --NR.sup.13R.sup.14 and
--C(O)NR.sup.13R.sup.14;
[0043] R.sup.17 is selected from the group consisting of alkyl,
cycloalkyl, aryl and heteroaryl;
[0044] R.sup.20 is alkyl, aryl, aralkyl or heteroaryl; and
[0045] n and r are independently 1, 2, 3, or 4;
[0046] or a pharmaceutically acceptable salt thereof.
[0047] Preferably, R.sup.1 is selected from the group consisting of
hydrogen, halo, alkyl, cyclkoalkyl, aryl, heteroaryl,
heteroalicyclic, hydroxy, alkoxy, --C(O)R.sup.15,
--NR.sup.13R.sup.14, --(CH.sub.2).sub.rR.sup.16 and
--C(O)NR.sup.8R.sup.9;
[0048] R.sup.2 is selected from the group consisting of hydrogen,
halo, alkyl, trihalomethyl hydroxy, alkoxy, --NR.sup.13R.sup.14,
NR.sup.13C(O)R.sup.14, --C(O)R.sup.15 aryl, heteroaryl, and
--S(O).sub.2NR.sup.13R.sup.14;
[0049] R.sup.3 is selected from the group consisting of hydrogen,
halogen, alkyl, trihalomethyl, hydroxy, alkoxy, --(CO)R.sup.15,
--NR.sup.13R.sup.14, aryl, heteroaryl,
--NR.sup.13S(O).sub.2R.sup.14, --S(O).sub.2NR.sup.13R.sup.14,
[0050] R.sup.4 is selected from the group consisting of hydrogen,
halogen, alkyl, hydroxy, alkoxy and --NR.sup.13R.sup.14;
[0051] R.sup.5 is selected from the group consisting of hydrogen,
alkyl and --C(O)R.sup.10;
[0052] R.sup.6 is selected from the group consisting of hydrogen,
alkyl and --C(O)R.sup.10;
[0053] R.sup.7 is selected from the group consisting of hydrogen,
alkyl, aryl, heteroaryl, --C(O)R.sup.17 and --C(O)R.sup.10;
[0054] R.sup.6 and R.sup.7 may combine to form a group selected
from the group consisting of --(CH.sub.2).sub.4--,
--(CH.sub.2).sub.5-- and --(CH.sub.2).sub.6--;
[0055] with the proviso that at least one of R.sup.5, R.sup.6 or
R.sup.7 must be --C(O)R.sup.10;
[0056] R.sup.8 and R.sup.9 are independently selected from the
group consisting of hydrogen, alkyl and aryl;
[0057] R.sup.10 is selected from the group consisting of hydroxy,
alkoxy, aryloxy, --N(R.sup.11)(CH.sub.2).sub.nR.sup.12 and
--NR.sup.13R.sup.14;
[0058] R.sup.11 is selected from the group consisting of hydrogen
and alkyl;
[0059] R.sup.12 is selected from the group consisting of
--NR.sup.13R.sup.14, hydroxy, --C(O)R.sup.15, aryl and
heteroaryl;
[0060] R.sup.13 and R.sup.14 are independently selected from the
group consisting of hydrogen, alkyl, cycloalkyl, aryl and
heteroaryl;
[0061] R.sup.13 and R.sup.14 may combine to form a group selected
from the group consisting of --(CH.sub.2).sub.4--,
--(CH.sub.2).sub.5--, --(CH.sub.2).sub.2O(CH.sub.2).sub.2--, and
--(CH.sub.2).sub.2N(CH.sub.3)(- CH.sub.2).sub.2--;
[0062] R.sup.15 is selected from the group consisting of hydrogen,
hydroxy, alkoxy and aryloxy;
[0063] R.sup.16 is selected from the group consisting of hydroxy,
--C(O)R.sup.15, --NR.sup.13R.sup.14 and
--C(O)NR.sup.13R.sup.14;
[0064] R.sup.17 is selected from the group consisting of alkyl,
cycloalkyl, aryl and heteroaryl; and
[0065] n and r are independently 1, 2, 3, or 4;
[0066] or a pharmaceutically acceptable salt thereof.
[0067] In a second aspect this invention is directed to a
pharmaceutical composition comprising one or more compound(s) of
Formula (I) or a pharmaceutically acceptable salt thereof and a
pharmaceutically acceptable excipient.
[0068] In a third aspect, this invention is directed to a method of
treating diseases mediated by abnormal protein kinase activity, in
particular, receptor tyrosine kinases (RTKs), non-receptor protein
tyrosine kinases (CTKs) and serine/threonine protein kinases
(STKs), in an organism, in particular humans, which method
comprises administering to said organism a pharmaceutical
composition comprising a compound of Formula (I). Such diseases
include by way of example and not limitation, cancer, diabetes,
hepatic cirrhosis, cardiovasacular disease such as atherosclerosis,
angiogenesis, immunological disease such as autoimmune disease and
renal disease.
[0069] In a fourth aspect, this invention is directed to a method
of modulating of the catalytic activity of PKs, in particular,
receptor tyrosine kinases (RTKs), non-receptor protein tyrosine
kinases (CTKs) and serine/threonine protein kinases (STKs), using a
compound of this invention which may be carried out in vitro or in
vivo. In particular, the receptor protein kinase whose catalytic
activity is modulated by a compound of this invention is selected
from the group consisting of EGF, HER2, HER3, HER4, IR, IGF-1R,
IRR, PDGFR.alpha., PDGFR.beta., CSFIR, C-Kit, C-fms, Flk-1R, Flk4,
KDR/Flk-1, Flt-1, FGFR-1R, FGFR-2R, FGFR-3R and FGFR-4R. The
cellular tyrosine kinase whose catalytic activity is modulated by a
compound of this invention is selected from the group consisting of
Src, Frk, Btk, Csk, Abl, ZAP70, Fes/Fps, Fak, Jak, Ack, Yes, Fyn,
Lyn, Lck, Blk, Hck, Fgr and Yrk. The serine-threonine protein
kinase whose catalytic activity is modulated by a compound of this
invention is selected from the group consisting of CDK2 and
Raf.
[0070] In a fifth aspect, this invention is directed to the use of
a compound of Formula (I) in the preparation of a medicament which
is useful in the treatment of a disease mediated by abnormal PK
activity.
[0071] In a sixth aspect, this invention is directed to an
intermediate of Formula (II) 2
[0072] wherein:
[0073] R.sup.5 is selected from the group consisting of hydrogen,
alkyl and --C(O)R.sup.10;
[0074] R.sup.6 is selected from the group consisting of hydrogen,
alkyl and --C(O)R.sup.10;
[0075] R.sup.7 is selected from the group consisting of hydrogen,
alkyl, aryl, heteroaryl, --C(O)R.sup.17 and --C(O)R.sup.10;
[0076] R.sup.6 and R.sup.7 may combine to form a group selected
from the group consisting of --(CH.sub.2).sub.4--,
--(CH.sub.2).sub.5-- and --(CH.sub.2).sub.6--;
[0077] with the proviso that at least one of R.sup.5, R.sup.6 or
R.sup.7 must be --C(O)R.sup.10;
[0078] R.sup.10 is selected from the group consisting of hydroxy,
alkoxy, aryloxy, --N(R.sup.11)(CH.sub.2).sub.nR.sup.12 and
--NR.sup.13R.sup.14;
[0079] R.sup.11 is selected from the group consisting of hydrogen
and alkyl;
[0080] R.sup.12 is selected from the group consisting of,
--NR.sup.13R.sup.14, hydroxy, --C(O)R.sup.15 aryl and
heteroaryl;
[0081] R.sup.13 and R.sup.14 are independently selected from the
group consisting of hydrogen, alkyl, cyanoalkyl, cycloalkyl, aryl
and heteroaryl; or
[0082] R.sup.13 and R.sup.14 may combine to form a heterocyclo
group;
[0083] R.sup.15 is selected from the group consisting of hydrogen,
hydroxy, alkoxy and aryloxy;
[0084] R.sup.17 is selected from the group consisting of alkyl,
cycloalkyl, aryl and heteroaryl; and
[0085] n is 1, 2, 3, or 4.
[0086] Preferaby, R.sup.5 or R.sup.6, in the compound of formula
II, is --C(O)R.sup.10;
[0087] R.sup.6 is selected from the group consisting of hydrogen,
and alkyl more preferably hydrogen or methyl;
[0088] R.sup.5 is selected from the group consisting of hydrogen,
and alkyl, more preferably hydrogen or methyl when R.sup.6 is
--COR.sup.10;
[0089] R.sup.6 is selected from the group consisting of hydrogen,
and alkyl, more preferably hydrogen or methyl when R.sup.5 is
--COR.sup.10;
[0090] R.sup.7 is selected from the group consisting of hydrogen,
alkyl, and aryl, more preferably hydrogen, methyl or phenyl;
[0091] R.sup.10 is selected from the group consisting of hydroxy,
alkoxy, --N(R.sup.11)(CH.sub.2).sub.nR.sup.12 and
--NR.sup.13R.sup.14;
[0092] R.sup.11 is selected from the group consisting of hydrogen
and alkyl, more preferably hydrogen or methyl;
[0093] R.sup.12 is selected from the group consisting of
--NR.sup.13R.sup.14;
[0094] R.sup.13 and R.sup.14 are independently selected from the
group, consisting of hydrogen, or alkyl; or
[0095] R.sup.13 and R.sup.14 may combine to form a heterocyclo
group; and
[0096] n is 1, 2 or 3.
[0097] Within the above preferred groups, more preferred groups of
intermediate compounds are those wherein R.sup.5, R.sup.6,
R.sup.11, R.sup.12, R.sup.13 or R.sup.14 are independently groups
described in the section titled "preferred embodiments" herein
below.
[0098] In a seventh aspect, this invention is directed to methods
of preparing compounds of Formula (I).
[0099] Lastly, this invention is also directed to identifying a
chemical compound that modulates the catalytic activity of a
protein kinase by contacting cells expressing said-protein kinase
with a compound or a salt of the present invention and then
monitoring said cells for an effect.
DETAILED DESCRIPTION OF THE INVENTION
Definitions
[0100] Unless otherwise stated the following terms used in the
specification and claims have the meanings discussed below:
[0101] "Alkyl" refers to a saturated aliphatic hydrocarbon radical
including straight chain and branched chain groups of 1 to 20
carbon atoms (whenever a numerical range; e.g. "1-20", is stated
herein, it means that the group in this case the alkyl group, may
contain 1 carbon atom, 2 carbon atoms, 3 carbon atoms, etc. up to
and including 20 carbon atoms).
[0102] Alkyl groups containing from 1 to 4 carbon atoms are refered
to as lower alkyl groups. When said lower alkyl groups lack
substituents, they are referred to as unsubstituted lower alkyl
groups. More preferably, an alkyl group is a medium size alkyl
having 1 to 10 carbon atoms e.g., methyl, ethyl, propyl, 2-propyl,
n-butyl; iso-butyl, tert-butyl, pentyl, and the like. Most
preferably, it is a lower alkyl having 1 to 4 carbon atoms e.g.,
methyl, ethyl, propyl, 2-propyl, n-butyl, iso-butyl, or tert-butyl,
and the like. The alkyl group may be substituted or unsubstituted.
When substituted, the substituent group(s) is preferably one or
more, more preferably one to three, even more preferably one or two
substituent(s) independently selected from the group consisting of
halo, hydroxy, unsubstituted lower alkoxy, aryl optionally
substituted with one or more groups, preferably one, two or three
groups which are independently of each other halo, hydroxy,
unsubstituted lower alkyl or unsubstituted lower alkoxy groups,
aryloxy optionally substituted with one or more groups, preferably
one, two or three groups which are independently of each other
halo, hydroxy, unsubstituted lower alkyl or unsubstituted lower
alkoxy groups, 6-member heteroaryl having from 1 to 3 nitrogen
atoms in the ring, the carbons in the ring being optionally
substituted with one or more groups, preferably one, two or three
groups which are independently of each other halo, hydroxy,
unsubstituted lower alkyl or unsubstituted lower alkoxy groups,
5-member heteroaryl having from 1 to 3 heteroatoms selected from
the group consisting of nitrogen, oxygen and sulfur, the carbon and
the nitrogen atoms in the group being optionally substituted with
one or more groups, preferably one, two or three groups which are
independently of each other halo, hydroxy, unsubstituted lower
alkyl or unsubstituted lower alkoxy groups, 5- or 6-member
heteroalicyclic group having from 1 to 3 heteroatoms selected from
the group consisting of nitrogen, oxygen and sulfur, the carbon and
nitrogen (if present) atoms in the group being optionally
substituted with one or more groups, preferably one, two or three
groups which are independently of each other halo, hydroxy,
unsubstituted lower alkyl or unsubstituted lower alkoxy groups,
mercapto, (unsubstituted lower alkyl)thio, arylthio optionally
substituted with one or more groups, preferably one, two or three
groups which are independently of each other halo, hydroxy,
unsubstituted lower alkyl or unsubstituted lower alkoxy groups,
cyano, acyl, thioacyl, O-carbamyl, N-carbamyl, O-thiocarbamyl,
N-thiocarbamyl, C-amido, N-amido, nitro, N-sulfonamido,
S-sulfonamido, R.sup.18S(O)--, R.sup.18S(O).sub.2--,
--C(O)OR.sup.18, R.sup.18C(O)O--, and --NR.sup.18R.sup.19, wherein
R.sup.18 and R.sup.19 are independently selected from the group
consisting of hydrogen, unsubstituted lower alkyl, trihalomethyl,
unsubstituted (C.sub.3-C.sub.6)cycloalkyl, unsubstituted lower
alkenyl, unsubstituted lower alkynyl and aryl optionally
substituted with one or more, groups, preferably one, two or three
groups which are independently of each other halo, hydroxy,
unsubstituted lower alkyl or unsubstituted lower alkoxy groups.
[0103] Preferably, the alkyl group is substituted with one or two
substituents independently selected from the group consisting of
hydroxy, 5- or 6-member heteroalicyclic group having from 1 to 3
heteroatoms selected from the group consisting of nitrogen, oxygen
and sulfur, the carbon and nitrogen (if present) atoms in the group
being optionally substituted with one or more groups, preferably
one, two or three groups which are independently of each other
halo, hydroxy, unsubstituted lower alkyl or unsubstituted lower
alkoxy groups, 5-member heteroaryl having from 1 to 3 heteroatoms
selected from the group consisting of nitrogen, oxygen and sulfur,
the carbon and the nitrogen atoms in the. group being optionally
substituted with one or more groups, preferably one, two or three
groups which are independently of each other halo, hydroxy,
unsubstituted lower alkyl or unsubstituted lower alkoxy groups,
6-member heteroaryl having from 1 to 3 nitrogen atoms in the ring,
the carbons in the ring being optionally substituted with one or
more groups, preferably one, two or three groups which are
independently of each other halo, hydroxy, unsubstituted lower
alkyl or unsubstituted lower alkoxy groups, or --NR.sup.18R.sup.19,
wherein R.sup.18 and R.sup.19 are independently selected from the
group consisting of hydrogen, unsubstituted lower alkyl. Even more
preferably the alkyl group is substituted with one or two
substituents which are independently of each other hydroxy,
dimethylamino, ethylamino, diethylamino, dipropylamino,
pyrrolidino, piperidino, morpholino, piperazino, 4-lower
alkylpiperazino, phenyl, imidazolyl, pyridinyl, pyridazinyl,
pyrimidinyl, oxazolyl, triazinyl, and the like.
[0104] "Cycloalkyl" refers to a 3 to 8 member all-carbon monocyclic
ring, an all-carbon 5-member/6-member or 6-member/6-member fused
bicyclic ring or a multicyclic fused ring (a "fused" ring system
means that each ring in the system shares an adjacent pair of
carbon atoms with each other ring in the system) group wherein one
or more of the rings may contain one or more double bonds but none
of the rings has a completely conjugated pi-electron system.
[0105] Examples, without limitation, of cycloalkyl groups are
cyclopropane, cyclobutane, cyclopentane, cyclopentene, cyclohexane,
cyclohexadiene, adamantane, cycloheptane, cycloheptatriene, and the
like. A cycloalkyl group may be substituted or unsubstituted. When
substituted, the substituent group(s) is preferably one or more,
more preferably one or two substituents, independently selected
from the group consisting of unsubstituted lower alkyl,
trihaloalkyl, halo, hydroxy, unsubstituted lower alkoxy, aryl
optionally substituted with one or more, preferably one or two
groups independently of each other halo, hydroxy, unsubstituted
lower alkyl or unsubstituted lower alkoxy groups, aryloxy
optionally substituted with one or more, preferably one or two
groups independently of each other halo, hydroxy, unsubstituted
lower alkyl or unsubstituted lower alkoxy groups, 6-member
heteroaryl having from 1 to 3 nitrogen atoms in the ring, the
carbons in the ring being optionally substituted with one or more,
preferably one or two-groups independently of each other halo,
hydroxy, unsubstituted lower alkyl or unsubstituted lower alkoxy
groups, 5-member heteroaryl having from 1 to 3 heteroatoms selected
from the group consisting of nitrogen, oxygen and sulfur, the
carbon and nitrogen atoms of the group being optionally substituted
with one or more, preferably one or two groups independently of
each other halo, hydroxy, unsubstituted lower alkyl or
unsubstituted lower alkoxy groups, 5- or 6-member heteroalicyclic
group having from 1 to 3 heteroatoms selected from the group
consisting of nitrogen, oxygen and sulfur, the carbon and nitrogen
(if present) atoms in the group being optionally substituted with
one or more, preferably one or two groups independently of each
other halo, hydroxy, unsubstituted lower alkyl or unsubstituted
lower alkoxy groups, mercapto, (unsubstituted lower alkyl)thio,
arylthio optionally substituted with one or more, preferably one or
two groups independently of each other halo, hydroxy, unsubstituted
lower alkyl or unsubstituted lower alkoxy groups, cyano, acyl,
thioacyl, O-carbamyl, N-carbamyl, O- thiocarbamyl, N-thiocarbamyl,
C-amido, N-amido, nitro, N-sulfonamido, S-sulfonamido,
R.sup.18S(O)--, R.sup.18S(O).sub.2--, --C(O)OR.sup.18,
R.sup.18C(O)O--, and --NR.sup.18R.sup.19 are as defined above.
[0106] "Alkenyl" refers to a lower alkyl group, as defined herein,
consisting of at least two carbon atoms and at least one
carbon-carbon double bond. Representative examples include, but are
not limited to, ethenyl, 1-propenyl, 2-propenyl, 1-, 2-, or
3-butenyl, and the like.
[0107] "Alkynyl" refers to a lower alkyl group, as defined herein,
consisting of at least two carbon atoms and at least one
carbon-carbon triple bond. Representative examples include, but are
not limited to, ethynyl, 1-propynyl, 2-propynyl, 1-, 2-, or
3-butynyl, and the like.
[0108] "Aryl" refers to an all-carbon monocyclic or fused-ring
polycyclic (i.e., rings which share adjacent pairs of carbon atoms)
groups of 1 to 12 carbon atoms having a completely: conjugated
pi-electron system. Examples, without limitation, of aryl groups
are phenyl, naphthalenyl and anthracenyl. The aryl, group may be
substituted or unsubstituted. When substituted, the substituted
group(s) is preferably one or more, more preferably one, two or
three, even more preferably one or two, independently selected from
the group consisting of unsubstituted lower alkyl, trihaloalkyl,
halo, hydroxy, unsubstituted lower alkoxy, mercapto, (unsubstituted
lower alkyl)thio, cyano, acyl, thioacyl, O-carbamyl, N-carbamyl,
O-thiocarbamyl, N-thiocarbamyl, C-amido, N-amido, nitro,
N-sulfonamido, S-sulfonamido, R.sup.18S(O)--, R.sup.18S(O).sub.2--,
--C(O)OR.sup.18, R.sup.18C(O)O-- and --NR.sup.18R.sup.19, with
R.sup.18 and R.sup.19 as defined above. Preferably, the aryl group
is optionally substituted with one or two substituents
independently selected from halo, unsubstituted lower alkyl,
trihaloalkyl, hydroxy, mercapto, cyano, N-amido, mono or
dialkylamino, carboxy, or N-sulfonamido.
[0109] "Heteroaryl" refers to a monocyclic or fused ring (i.e.,
rings which share an adjacent pair of atoms) group of 5 to 12 ring
atoms containing one, two, or three ring heteroatoms selected from
N, O., or S, the remaining ring atoms being C, and, in addition,
having a completely conjugated pi-electron system. Examples,
without limitation, of unsubstituted heteroaryl groups are pyrrole,
furan, thiophene, imidazole, oxazole, thiazole, pyrazole, pyridine,
pyrimidine, quinoline, isoquinoline, purine and carbazole. The
heteroaryl group may be substituted or unsubstituted. When
substituted, the substituted group(s) is preferably one or more,
more preferably one, two, or three, even more preferably one or
two, independently selected from the group consisting of
unsubstituted lower alkyl, trihaloalkyl, halo, hydroxy,
unsubstituted lower alkoxy, mercapto, (unsubstituted lower
alkyl)thio, cyano, acyl, thioacyl, O-carbamyl, N-carbamyl,
O-thiocarbamyl, N-thiocarbamyl, C-amido, N-amido, nitro,
N-sulfonamido, S-sulfonamido, R.sup.18S(O)--, R.sup.18O).sub.2--,
C(O)OR.sup.18, R.sup.18C(O)O--, and --NR.sup.18R.sup.19, with
R.sup.18 and R.sup.19 as defined above. Preferably, the heteroaryl
group is optionally substituted with one or two substituents
independently selected from halo, unsubstituted lower alkyl,
trihaloalkyl, hydroxy, mercapto, cyano, N-amido, mono or
dialkylamino, carboxy, or N-sulfonamido.
[0110] "Heteroalicyclic" refers to a monocyclic or fused ring group
having in the ring(s) of 5 to 9 ring atoms in which one or two ring
atoms are heteroatoms selected from N, O, or S(O).sub.n (where n is
an integer from 0 to 2), the remaining ring atoms being C. The
rings may also have one or more double bonds. However, the rings do
not have a completely conjugated pi- electron system. Examples,
without limitation, of unsubstituted heteroalicyclic groups are
pyrrolidino, piperidino, piperazino, morpholino, thiomorpholino,
homopiperazino, and the like. The heteroalicyclic ring may bed
substituted or unsubstituted. When substituted, the substituted
group(s) is preferably one or more, more preferably one, two or
three, even more preferably one or two, independently selected from
the group consisting of unsubstituted lower alkyl, trihaloalkyl,
halo, hydroxy, unsubstituted lower alkoxy, mercapto, (unsubstituted
lower alkyl)thio, cyano, acyl, thioacyl, O-carbamyl, N-carbamyl,
O-thiocarbamyl, N-thiocarbamyl, C-amido, N-amido, nitro,
N-sulfonamido, S-sulfonamido, R.sup.18S(O)R.sup.18S(O).sub.2--,
--C(O)OR.sup.18, R.sup.18C(O)O--, and --NR.sup.18R.sup.19, with
R.sup.18 and R.sup.19 as defined above. Preferably, the
heteroalicyclic group is optionally substituted with one or two
substituents independently selected from halo, unsubstituted lower
alkyl, trihaloalkyl, hydroxy, mercapto, cyano, N-amido, mono or
dialkylamino, carboxy, or N-sulfonamido.
[0111] Preferably, the heteroalicyclic group is optionally
substituted with one or two substituents independently selected
from halo, unsubstituted lower alkyl, trihaloalkyl, hydroxy,
mercapto, cyano, N-amido, mono or dialkylamino, carboxy, or
N-sulfonamido.
[0112] "Heterocycle" means a saturated cyclic radical of 3 to 8
ring atoms in which one or two ring atoms are heteroatoms selected
from N, O, or S(O).sub.n (where n is an integer from 0 to 2), the
remaining ring atoms being C, where one or two C atoms may
optionally be replaced by a carbonyl group. The heterocyclyl ring
may be optionally substituted independently with one, two, or three
substituents selected from optionally substituted lower alkyl
(substituted with 1 or 2 substituents independently selected from
carboxy or ester), haloalkyl, cyanoalkyl, halo, nitro, cyano,
hydroxy, alkoxy, amino, monoalkylamino, dialkylamino, aralkyl,
heteroaralkyl, --COR (where R is alkyl) or COOR where R is
(hydrogen or alkyl). More specifically the term heterocyclyl
includes, but is not limited to, tetrahydropyranyl,
2,2-dimethyl-1,3-dioxolane, piperidino, N-methylpiperidin-3-yl,
piperazino, N-methylpyrrolidin-3-yl, 3-pyrrolidino, morpholino,
thiomorpholino, thiomorpholino-1-oxide, thiomorpholino-1,1-dioxide,
4-ethyloxycarbonylpiperazino, 3-oxopiperazino, 2-imidazolidone,
2-pyrrolidinone, 2-oxohomopiperazino, tetrahydropyrimidin-2-one,
and the derivatives thereof. Preferably, the heterocycle group is
optionally substituted with one or two substituents independently
selected from halo, unsubstituted lower alkyl, lower alkyl
substituted with carboxy, ester hydroxy, mono or dialkylamino.
[0113] "Hydroxy" refers to an --OH group.
[0114] "Alkoxy" refers to both an --O-(unsubstituted alkyl) and an
--O-(unsubstituted cycloalkyl) group. Representative examples
include, but are not limited to, e.g., methoxy, ethoxy, propoxy,
butoxy, cyclopropyloxy, cyclobutyloxy, cyclopentyloxy,
cyclohexyloxy, and the like.
[0115] "Aryloxy" refers to both an --O-aryl and an --O-heteroaryl
group, as defined herein. Representative examples include, but are
not limited to, phenoxy, pyridinyloxy, furanyloxy, thienyloxy,
pyrimidinyloxy, pyrazinyloxy, and the like, and derivatives
thereof.
[0116] "Mercapto" refers to an --SH group.
[0117] "Alkylthio" refers to both an --S-(unsubstituted alkyl) and
an --S-(unsubstituted cycloalkyl) group. Representative examples
include, but are not limited to, e.g., methylthio, ethylthio,
propylthio, butylthio, cyclopropylthio, cyclobutylthio,
cyclopentylthio, cyclohexylthio, and the like.
[0118] "Arylthio" refers to both an --S-aryl and an --S-heteroaryl
group, as defined herein. Representative examples include, but are
not limited to, phenylthio, pyridinylthio, furanylthio,
thientylthio, pyrimidinylthio, and the like and derivatives
thereof.
[0119] "Acyl" refers to a --C(O)--R" group, where R" is selected
from the group consisting of hydrogen, unsubstituted lower alkyl,
trihalomethyl, unsubstituted cycloalkyl, aryl optionally
substituted with one or more, preferably one, two, or three
substituents selected from the group consisting of unsubstituted
lower alkyl, trihalomethyl, unsubstituted lower alkoxy, halo and
--NR.sup.18R.sup.19 groups, heteroaryl (bonded through a ring
carbon) optionally substituted with one or more, preferably one,
two, or three substitutents selected from the group consisting of
unsubstituted lower alkyl; trihaloalkyl, unsubstituted lower
alkoxy, halo and --NR.sup.18R.sup.19 groups and heteroalicyclic
(bonded through a ring carbon) optionally substituted with one or
more, preferably one, two, or three substituents selected from the
group consisting of unsubstituted lower alkyl, trihaloalkyl,
unsubstituted lower alkoxy, halo and --NR.sup.18R.sup.19 groups.
Representative acy groups include, but are not limited to, acetyl,
trifluoroacetyl, benzoyl, and the like
[0120] "Aldehyde" refers to an acyl group in which R" is
hydrogen.
[0121] "Thioacyl" refers to a --C(S)--R" group, with R" as defined
herein.
[0122] "Ester" refers to a --C(O)O--R" group with R" as defined
herein except that R" cannot be hydrogen.
[0123] "Acetyl" group refers to a --C(O)CH.sub.3 group.
[0124] "Halo" group refers to fluorine, chlorine, bromine or
iodine, preferably fluorine or chlorine.
[0125] "Trihalomethyl" group refers to a --CX.sub.3 group wherein X
is a halo group as defined herein.
[0126] "Trihalomethanesulfonyl" group refers to a
X.sub.3CS(.dbd.O).sub.2-- - groups with X as defined above.
[0127] "Cyano" refers to a --C.ident.N group.
[0128] "Methylenedioxy" refers to a --OCH.sub.2O-- group where the
two oxygen atoms are bonded to adjacent carbon atoms.
[0129] "Ethylenedioxy" group refers to a --OCH.sub.2CH.sub.2O--
where the two oxygen atoms are bonded to adjacent carbon atoms.
[0130] "S-sulfonamido" refers to a --S(O).sub.2NR.sup.18R.sup.19
group, with R.sup.18 and R.sup.19 as defined herein.
[0131] "N-sulfonamidol" refers to a --NR.sup.18S(O).sub.2R.sup.19
group, with R.sup.18 and R.sup.19 as defined herein.
[0132] "O-carbamyl" group refers to a --OC(O)NR.sup.18R.sup.19
group with R.sup.18 and R.sup.19 as defined herein.
[0133] "N-carbamyl" refers to an R.sup.18OC(O)NR.sup.19-- group,
with R.sup.18 and R.sup.19 as defined herein.
[0134] "O-thiocarbamyl" refers to a --OC(S)NR.sup.18R.sup.19 group
with R.sup.18 and R.sup.19 as defined herein.
[0135] "N-thiocarbamyl" refers to a R.sup.18OC(S)NR.sup.19-- group,
with R.sup.18 and R.sup.19 as defined herein.
[0136] "Amino" refers to an --NR.sup.18R.sup.19 group, wherein
R.sup.18 and R.sup.19 are both hydrogen.
[0137] "C-amido" refers to a --C(O)NR.sup.18R group with R.sup.18
and R.sup.19 as defined herein.
[0138] "N-amido" refers to a R.sup.18C(O)NR.sup.19-- group, with
R.sup.18 and R.sup.19 as defined herein.
[0139] "Nitro" refers to a, --NO.sub.2 group.
[0140] "Haloalkyl" means an unsubstituted alkyl, preferably
unsubstituted lower alkyl as defined above that is substituted with
one or more same or different halo atoms, e.g., --CH.sub.2Cl,
--CF.sub.3, --CH.sub.2CF.sub.3, --CH.sub.2CCl.sub.3, and the
like.
[0141] "Aralkyl" means unsubstituted alkyl, preferably
unsubstituted lower alkyl as defined above which is substituted
with an aryl group as defined above, e.g., --CH.sub.2phenyl,
--(CH.sub.2).sub.2phenyl, --(CH.sub.2).sub.3phenyl,
CH.sub.3CH(CH.sub.3)CH.sub.2phenyl, and the like and derivatives
thereof.
[0142] "Heteroaralkyl" group means unsubstituted alkyl, preferably
unsubstituted lower alkyl as defined above which is substituted
with a heteroaryl group, e.g., --CH.sub.2pyridinyl,
--(CH.sub.2).sub.2pyrimidiny- l, --(CH.sub.2).sub.3imidazolyl, and
the like, and derivatives thereof.
[0143] "Monoalkylamino" means a radical --NHR where R is an
unsubstitued alkyl or unsubstituted cycloalkyl group as defined
above, e.g., methylamino, (1-methylethyl)amino, cyclohexylamino,
and the like.
[0144] "Dialkylamino" means a radical --NRR where each R is
independently an unsubstitued alkyl or unsubstituted cycloalkyl
group as defined above, e.g., dimethylamino, diethylamino,
(1-methylethyl)-ethylamino, cyclohexylmethylamino,
cyclopentylmethylamino, and the like.
[0145] "Cyanoalkyl" means unsubstituted alkyl, preferably
unsubstituted lower alkyl as defined above, which is substituted
with 1 or 2 cyano groups.
[0146] "Optional" or "optionally" means that the subsequently
described event or circumstance may but need not occur, and that
the description includes instances where the event or circumstance
occurs and instances in which it does not. For example,
"heterocycle group optionally substituted with an alkyl group"
means that the alkyl may but need not be present, and the
description includes situations where the heterocycle group is
substituted with an alkyl group and situations where the
heterocyclo group is not substituted with the alkyl group.
[0147] The terms "2-indolinone", "indolin-2-one" and "2-oxindole"
are used interchangeably herein to refer to a molecule having the
chemical structure: 3
[0148] The term "pyrrole" refers to a molecule having the chemical
structure: 4
[0149] The term "pyrrole substituted 2-indolinone" and
"3-pyrrolidenyl-2-indolinone" are used interchangeably herein to
refer to a chemical compound having the general structure shown in
Formula (I).
[0150] Compounds that have the same molecular formula but differ in
the nature or sequence of bonding of their atoms or the arrangement
of their atoms in space are termed "isomers". Isomers that differ
in the arrangement of their atoms in space are termed
"stereoisomers". Stereoisomers that are not mirror images of one
another are termed "diastereomers" and those that are
non-superimposable mirror images of each other are termed
"enantiomers". When a compound has an asymmetric center, for
example it is bonded to four different groups, a pair of
enantiomers is possible. An enantiomer can be characterized by the
absolute configuration of its asymmetric center and is described by
the R- and S-sequencing rules of Cahn and Prelog, or by the manner
in which the molecule rotates the plane of polarized light and
designated as dextrorotatory or levorotatory (i.e., as (+) or
(-)-isomers respectively). A chiral compound can exist as either
individual enantiomer or as a mixture thereof. A mixture containing
equal proportions of the enantiomers is called a "racemic
mixture".
[0151] The compounds of this invention may possess one or more
asymmetric centers; such compounds can therefore be produced as
individual (R)- or (S)-stereoisomers or as mixtures thereof. For
example, if the R.sup.6 substituent in a compound of formula (I) is
2-hydroxyethyl, then the carbon to which them hydroxy group is
attached is an asymmetric center and therefore the compound of
Formula (I) can exist as an (R)- or (S)-stereoisomer. Unless
indicated otherwise, the description or naming of a particular
compound in the specification and claims is intended to include
both individual enantiomers and mixtures, racemic or otherwise,
thereof. The methods for the determination of stereochemistry and
the separation of stereoisomers are well-known in the art (see
discussion in. Chapter 4 of "Advanced Organic Chemistry", 4th
edition J., March, John Wiley and Sons, New York, 1992).
[0152] The compounds of Formula (I) may exhibit the phenomena of
tautomerism and structural isomerism. For example, the compounds
described herein may adopt an E or a Z configuration about the
double bond connecting the 2-indolinone moiety to the pyrrole
moiety or they may be a mixture of E and Z. This invention
encompasses any tautomeric or structural isomeric, form and
mixtures thereof which possess the ability to modulate RTK, CTK
and/or, STK activity and is not limited to any one tautomeric or
structural isomeric form.
[0153] A "pharmaceutical composition" refers to a mixture of one or
more of the compounds described herein, or
physiologically/pharmaceutically acceptable salts or prodrugs
thereof, with other chemical components, such as
physiologically/pharmaceutically acceptable carriers and
excipients. The purpose of a pharmaceutical composition is to
facilitate administration of a compound to an organism.
[0154] The compound of Formula (I) may also act as a prodrug. A
"prodrug" refers to an agent which is converted into the: parent
drug in vivo. Prodrugs are often useful because, in some
situations, they may be easier to administer than the parent drug.
They may, for instance, be bioavailable by oral administration
whereas the parent drug is not. The prodrug may also have improved
solubility in pharmaceutical compositions; over the parent drug. An
example, without limitation, of a prodrug would be a compound of
the present invention which is administered as an ester (the
"prodrug") to facilitate transmittal across a cell membrane where
water solubility is detrimental to mobility but then is
metabolically hydrolyzed to the carboxylic acid, the active entity,
once inside the cell where water solubility is beneficial.
[0155] A further example of a prodrug might be a short polypeptide,
for example, without limitation, a 2-10 amino, acid polypeptide,
bonded through a terminal amino group to a carboxy group of a
compound of this invention wherein the X polypeptide is hydrolyzed
or metabolized in vivo to release the active molecule. The prodrugs
of a compound of Formula (I) are within the scope of this
invention.
[0156] Additionally, it is contemplated that a compound of Formula
(I) would be metabolized by enzymes in the body of the organism
such as human being to generate a metabolite that can modulate the
activity of the protein kinases. Such metabolites are within the
scope of the present invention.
[0157] As used herein, a "physiologically/pharmaceutically
acceptable carrier" refers to a carrier or diluent that does not
cause significant-irritation to an organism and does not abrogate
the biological activity and properties of the administered
compound.
[0158] An "pharmaceutically acceptable excipient" refers to an
inert substance added to a pharmaceutical composition to further
facilitate administration of a compound. Examples, without
limitation, of excipients include calcium carbonate, calcium
phosphate, various sugars and types of starch, cellulose
derivatives, gelatin, vegetable oils and polyethylene glycols.
[0159] As used herein, the term "pharmaceutically acceptable salt"
refers to those salts which retain the biological effectiveness and
properties of the parent compound. Such salts include:
[0160] (i) acid addition salt which is obtained by reaction of the
free base of the parent compound with inorganic acids such as
hydrochloric acid, hydrobromic acid, nitric acid, phosphoric acid,
sulfuric acid, and perhcloric acid and the like, or with organic
acids such as acetic acid, oxalic acid, (D) or (L) malic acid,
maleic acid, methanesulfonic acid, ethanesulfonic acid,
p-toluenesulfonic acid, salicylic acid, tartaric acid, citric acid,
succinic acid or malonic acid and the like, preferably hydrochloric
acid or (L)-malic acid such as the L-malate salt of
5-(5-fluoro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrro-
le-3-carboxylic acid (2-diethylaminoethyl)amide; or
[0161] (2) salts formed when an acidic proton present in the parent
compound either is replaced by a metal ion, e.g., an alkali metal
ion, an alkaline earth ion, or an aluminum ion; or coordinates with
an organic base such as ethanolamine, diethanolamine,
triethanolamine, tromethamine, N-methylglucamine, and the like.
[0162] "PK" refers to receptor protein tyrosine kinase (RTKs),
non-receptor or "cellular" tyrosine kinase (CTKs) and
serine-threonine kinases (STKs).
[0163] "Method" refers to manners, means, techniques and procedures
for accomplishing a given task including, but not limited to, those
manners, means, techniques and procedures either known to, or
readily developed from known manners, means, techniques and
procedures by, practitioners of the chemical, pharmaceutical,
biological, biochemical and medical arts.
[0164] "Modulation" or "modulating" refers to the alteration of the
catalytic activity of RTKs, CTKs and STKs. In particular,
modulating refers to the activation of the catalytic activity of
RTKs, CTKs and STKs, preferably the activation or inhibition of the
catalytic activity of RTKs, CTKs and STKs, depending on the
concentration of the compound or salt to which the RTK, CTK or STK
is exposed or, more preferably, the inhibition of the catalytic
activity of RTKs, CTKs and STKs.
[0165] "Catalytic activity" refers to the rate of phosphorylation
of tyrosine under the influence, direct or indirect, of RTKs and/or
CTKs or the phosphorylation of serine and threonine under the
influence, direct or indirect, of STKs.
[0166] "Contacting" refers to bringing a compound of this invention
and a target PK together in such a manner that the compound can
affect the catalytic activity of the PK, either directly, i.e., by
interacting with the kinase itself, or indirectly, i.e., by
interacting with another molecule on which the catalytic activity
of the kinase is dependent. Such "contacting" can be accomplished
"in vitro," i.e., in a test tube, a petri dish or the like. In a
test tube, contacting may involve only a compound and a PK of
interest or it may involve whole cells. Cells may also be
maintained or grown in cell culture dishes and contacted with a
compound in that environment. In this context, the ability of a
particular compound to affect a PK related disorder, i.e., the
IC.sub.50 of the compound, defined below, can be determined before
use of the compounds in vivo with more complex living organisms is
attempted. For cells outside the organism, multiple methods exist,
and are well-known to those skilled in the art, to get the PKs in
contact with the compounds including, but not limited to, direct
cell microinjection and numerous transmembrane carrier
techniques.
[0167] "In vitro" refers to procedures performed in an artificial
environment such as, e.g., without limitation, in a test tube or
culture medium.
[0168] "In vivo" refers to procedures performed within a living
organism such as, without limitation, a mouse, rat or rabbit.
[0169] "PK related disorder," "PK driven disorder," and "abnormal
PK activity" all refer to a condition characterized by
inappropriate, i.e., under or, more commonly, over, PK catalytic
activity, where the particular PK can be an RTK, a CTK or an STK.
Inappropriate catalytic activity can arise as the result of either:
(1) PK expression in cells which normally do not express PKs, (2)
increased PK expression leading to unwanted cell proliferation,
differentiation and/or growth, or, (3) decreased PK expression
leading to unwanted reductions in cell proliferation,
differentiation and/or, growth. Over-activity of a PK refers to
either amplification of the gene encoding a particular PK or
production of a level of PK activity which can correlate with a
cell proliferation, differentiation and/or growth disorder (that
is, as the level of the PK increases, the severity of one or more
of the symptoms of the cellular disorder increases). Under-activity
is, of course, the converse, wherein the severity of one or more
symptoms of a cellular disorder increase as the level of the PK
activity decreases.
[0170] "Treat", "treating" and "treatment" refer to a method of
alleviating or abrogating a PK mediated cellular disorder and/or,
its attendant symptoms. With regard particularly to cancer, these
terms simply mean that the life: expectancy of an individual
affected with a cancer will be increased or that one or more of the
symptoms of the disease will be reduced.
[0171] "Organism" refers to any living entity comprised of at least
one cell. A living organism can be as simple as, for example, a
single eukariotic cell or as complex as a mammal, including a human
being.
[0172] "Therapeutically effective amount" refers to that amount of
the compound being administered which will relieve to some extent
one or more of the symptoms of the disorder being treated. In
reference to the treatment of cancer, a therapeutically effective
amount refers to that amount which has the effect of: *
[0173] (1) reducing the size of the tumor;
[0174] (2) inhibiting (that is, slowing to some extent, preferably
stopping) tumor metastasis;
[0175] (3) inhibiting to some extent (that is, slowing to some
extent, preferably stopping) tumor growth, and/or,
[0176] (4) relieving to some extent (or, preferably, eliminating)
one or more symptoms associated with the cancer.
[0177] "Monitoring" means observing or detecting the effect of
contacting a compound with a cell expressing a particular PK. The
observed or detected effect can be a change in cell phenotype, in
the catalytic activity of a PK or a change in the interaction of a
PK with a natural binding partner. Techniques for observing or
detecting such effects are well-known in the art.
[0178] The above-referenced effect is selected from a change or an
absence of change in a cell phenotype, a change or absence of
change in the catalytic activity of said protein kinase or a change
or absence of change in the interaction of said protein kinase with
a natural binding partner in a final aspect of this invention.
[0179] "Cell phenotype" refers to the outward appearance of a cell
or tissue or the biological function of the cell or tissue.
Examples, without limitation, of a cell phenotype are cell size,
cell growth, cell proliferation, cell differentiation, cell
survival, apoptosis, and nutrient uptake and use. Such phenotypic
characteristics are measurable by techniques well-known in the
art.
[0180] "Natural binding partner" refers to a polypeptide that binds
to a particular PK in a cell. Natural binding partners can play a
role in propagating a signal in a PK-mediated signal transduction
process. A change in the interaction of the natural binding partner
with the PK can manifest itself as an increased or decreased
concentration of the PK/natural binding partner complex and, as a
result, in an observable change in the ability of the PK to mediate
signal transduction.
[0181] Representative compounds of the present invention are shown
in Table I below.
1TABLE 1 Ex- am- ple Structure Name 1 5
4-Methyl-5-(2-oxo-1,2-dihydroindol-- 3-
ylidenemethyl)-1H-pyrrole-2- carboxylic acid 2 6
4-Methyl-5-(1-methyl-2-oxo-1,2-dihydro-
indol-3-ylidenemethyl)-1H-pyrrole- -2- carboxylic acid 3 7
4-Methyl-5-(2-oxo-1,2-dihydro- indol-3-ylidenemethyl)-1H-pyrrole-2-
carboxylic acid methyl ester 4 8 5-(5-Chloro-2-oxo-1,2-dihydro-
indol-3-ylidenemethyl)-4-methy- l-1H-pyrrole-2- carboxylic acid
ethyl ester 5 9 5-(5-Chloro-2-oxo-1,2-dihydro-
indol-3-ylidenemethyl)-4-methyl-1H-pyrrole- -2- carboxylic acid 6
10 5-(5-Bromo-2-oxo-1,2-dihydro-
indol-3-ylidenemethyl)-4-methyl-1H-pyrrole-2- carboxylic acid
(3-pyrrolidin-1-ylpropyl)amided 7 11 5-(5-Bromo-2-oxo-1,2-dihydro-
indol-3-ylidenemethyl)-4-methyl-1H-pyrrole-- 2- carboxylic acid
(3-diethylaminopropyl)amide 8 12 5-(5-Bromo-2-oxo-1,2-dihydro-
indol-3-ylidenemethyl)-1H-pyrrole-2- caboxylic acid
(2-diethylaminoelhyl)amide 9 13 5-(2-Oxo-6-phenyl-1,2-dihydro-
indol-3-ylidenemethyl)-1H-pyrrole-2- carboxylic acid
(2-diethytaminoethyl)amide 10 14 5-(5-Bromo-2-oxo-1,2-dihydro-
indol-3-ylidenemethyl)-1H-pyrrole-2- carboxylic acid
(2-diethylaminoethyl)methylamide 11 15
5-(2-Oxo-6-phenyl-1,2-dihydro- indol-3-ylidenemethyl)-1H-pyrrole-2-
carboxylic acid (2-diethylaminoetliyI)methylamide 12 16
3-Methyl-5-(2-oxo-1,2-dihydro- indol-3-ylidenemethyl)-1H-pyrrole-2-
carboxylic acid (3-diethylaminopropyl)amide 13 17
5-(5-Bromo-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-3-methyl-1H-pyrrole-2-
- carboxylic acid (3-diethylamsnopropyl)amide 14 18
3-Methyl-5-(2-oxo-6-phenyl-1,2-dihydro-
indol-3-ylidenemethyl)-1H-pyrrole- -2- carboxylic acid
(3-diethylaminapropyt)amide 15 19 5-(5-Methoxy-2-oxo-1,2-dihydro-
indol-3-ylidenemethyl)-3-methyl-1H-pyrrol- e 2-carboxylic acid
(3-diethylaminopropyl)amide 16 20 5-(6-Methoxy-2-oxo-1,2-dihydro-
indol-3-ylidenemethyl)-3-methyl-1H-pyrrol- e 2-carboxylic acid
(3-diethylaminopropyl)amide 17 21 3-(5-Bromo-2-oxo-1,2-dihydro-
indol-3-ylidenemethyl)-4,5,6,7-tetrahydro-2- H-
isoindole-1-carboxylic acid (2-diethylaminoethyl)amide 18 22
3-(5-Bromo-2-oxo-1,2-dihydro-
indol-3-ylidenemethyl)-4,5,6,7-tetrah- ydro-2H-
isoindole-1-carboxylic acid (3-diethylaminopropyl)amide 19 23
3-(5-Bromo-2-oxo-1,2-dihydro- indol-3-ylidenemethyl)-4,5,6,7-
-tetrahydro-2H- isoindole-1-carboxylic acid
(3-pyrrolidin-1-ylpropyl)amide 20 24
3-(2-Oxo-6-pyridin-3-yl-1,2-dihydro- indol-3-ylidenemethyl)4,5,6,7-
tetrahydro-2H-isoindole-1-carboxylic acid
(2-diethylaminoethyl)amide 21 25 4-Benzoyl-5-(5-bromo-2-o-
xo-1,2-dihydro- indol-3-ylidenemethyl)-3-methyl-
1H-pyrrole-2-carboxylic acid (3-diethylaminopropyl)amide 22 26
4-Benzoyl-5-(5-bromo-2-oxo-1,2-dihydro-
indol-3-ylidenemethyl)-3-methyl- 1H-pyrrole-2-carboxylic acid
(3-morpholin-4-ylpropyl)amide 23 27
4-Benzoyl-3-methyl-5-(2-oxo-1,2-dihydro- indol-3-ylidenemethyl)-1H-
-pyrrole- 2-carboxyiic acid (3-pyrrolidin-1-ylpropyl)amide 24 28
4-Benzoyl-5-(5-bromo-2-oxo-1,2-dihydro-
indol-3-ylidenemethyl)-3-me- thyl- 1H-pyrrole-2-carboxylic acid
(3-pyrrolidine-1-ylpropyl)amide 25 29
4-Benzoyl-3-methyl-5-(2-oxo-6-phenyl-1,2-dihydro-
indol-3-ylidenemethyl)- 1H-pyrrole-2-carboxylic acid
(3-pyrrolidin-1-ylpropyl)amide 26 30
4-Benzoyl-5-(6-methoxy-2-oxo-1,2-dihydro-
indol-3-ylidenemethyl)-3-methyl- - 1H-pyrrole-2-carboxylic acid
(3-pyrrolidin-1-ylpropyl)amide 27 31
4-BenzoyI-5-(5-methoxy-2-oxo-1,2-dihydro-
indol-3-ylidenemethyl)-3-methyl- 1H-pyrrole-2-carboxylic acid
(3-pyrrolidin-1-ylpropyl)amide 28 32
4-BenzoyI-5-(5-fluoro-2-oxo-1,2-dihydro-
indol-3-ylidenemethyl)-3-methyl- 1H-pyrrole-2-carboxylic acid
(3-pyrrolidin-1-ylpropyl)amide 29 33
4-Acetyl-5-(5-bromo-2-oxo-1,2-dihydro- indol-3-ylidenemethyl)-3-m-
ethyl- 1H-pyrrole-2-carboxylic acid (3-diethylaminopmpyl)amide 30
34 4-Acetyl-5-(5-bromo-2-oxo-1,2-dihydro- indol-3-ylidenemethyl)-3-
-methyl- 1H-pyrrole-2-carboxylic acid
(3-pyrrolidin-1-ylpropyl)amide 31 35
4-Acetyl-5-(5-bromo-2-oxo-1,2-dihydro-
indol-3-ylidenemethyl)-3-methyl- 1H-pyrrole-2-carboxylic acid
(3-morpholin-4-ylpropyl)amide 32 36
4-Acetyl-5-(5-bromo-2-oxo-1,2-dihydro-
indol-3-ylidenemethyl)-3-methyl- 1H-pyrrole-2-carboxylic acid
(3-hydroxy-propyl)amide 33 37
4-Acetyl-5-(5-bromo-2-oxo-1,2-dihydro-
indol-3-ylidenemethyl)-3-methyl- - 1H-pyrrole-2-carboxylic acid
(2-hydroxy-ethyl)amide 34 38 4-Acetyl-5-(5-bromo-2-oxo-1,2-dihydro-
indol-3-ylidenemethyl)-3-methyl- - 1H-pyrrole-2-carboxylic acid
(2-morpholin-4-yl-ethyl)amide 35 39
4-Acetyl-5-(5-bromo-2-oxo-1,2-dihydro- indol-3-ylidenemethyl)-3-m-
ethyl- 1H-pyrrole-2-carboxylic acid (2-morpholin-4-yl-ethyl)amide
36 40 4-Acetyl-5-(5-bromo-2-oxo-1,2-dihydro-
indol-3-ylidenemethyl)-3-methyl- 1H-pyrrole-2-carboxylic acid
[(2-(4-hydroxy-phenyl)-ethyl]amide 37 41
5-(5-Bromo-2-oxo-1,2-dihydro-
indol-3-ylidenemethyl)-2-isopropyl-4-phenyl- -
1H-pyrrole-3-carboxylic acid (3-diethylaminopropyl)amide 38 42
5-(5-Bromo-2-oxo-1,2-dihydro-
indol-3-ylidenemethyl)-2-isopropyl-4-- phenyl-
1H-pyrrole-3-carboxylic acid (3-pyrrolidin-1-ylpropyl)amide 39 43
5-(5-Bromo-2-oxo-1,2-dihydro- indol-3-ylidenemethyl)-2-iso-
propyl-4-phenyl- 1H-pyrrole-3-carboxylic acid
(2-(diethylaminoethyl)amide 40 44 5-(5-Bromo-2-oxo-1,2-dihydro-
indol-3-ylidenenethyl)-2-isopropyl-4-phenyl-
1H-pyrrole-3-carboxylic acid 41 45 5-(5-Bromo-2-oxo-1,2-dihydro-
indol-3-ylidenemethyl)-2-isopropyl-4-phenyl-
1H-pyrrole-3-carboxylic acid 42 46 5-(5-Bromo-2-oxo-1,2-dihydro-
indol-3-ylidenemethyl)-2-methyl-4-phenyl-1H- pyrrole-3-carboxylic
acid (2-pyrrolidin-1-yl-ethyl)amide 43 47
5-[6-(2-Metoxy-phenyl)-2-oxo-1,2-dihydro-
indol-3-ylidenemethyl]-2-methyl- - 4-phenyl-1H-pyrrole-3-carboxylic
acid (2-pyrrolidin-1-yl-ethyl)amide 44 48
5-(5-Bromo-2-oxo-1,2-dihydro- indol-3-ylidenemethyl)-2--
methyl-phenyl-1H- pyrrole-3-carboxylic acid
(2-dimethylamino-ethyl)amide 45 49
5-[6-(2-Methoxy-phenyl)-2-oxo-1,2-dihydro-
indol-3-ylidenemethyl]-2-methyl- 4-phenyl-1H-pyrrole-3-carboxylic
acid (2-dimethylamino-ethyl]amide 46 50
5-(5-Bromo-2-oxo-1,2-dihydro-
indol-3-ylidenemethyl)-2-methyl-4-phenyl-1H- - pyrrole-3-carboxylic
acid ethyl ester 47 51 5-(5-Bromo-2-oxo-1,2-dihydro-
indol-3-ylidenemethyl)-2-methyl-4-phenyl-1H- - pyrrole-3-carboxylic
acid (3-diethylaminopropyl)amide 48 52
5-(5-Bromo-2-oxo-1,2-dihydro-
indol-3-ylidenemethyl)-2,4-dimethyl-1H- pyrrole-3-carboxylic acid
(2-dimethylamimo-ethyl)amide 49 53
2,4-Dimethyl-5-(2-oxo-6-phenyl-1,2-dihydro-
indol-3-ylidenemethyl)-1H- pyrrole-3-carboxylic acid
(2-dimethylamino-ethyl)amide 50 54 5-(5-Chloro-2-oxo-1,2-dihydro-
indol-3-ylidenemethyl)-2,4-dimethyl-1H- pyrrole-3-carboxylic acid
(2-dimethylamino-ethyl)amide 51 55 5-(5-Bromo-2-oxo-1,2-dihydro-
indol-3-ylidenemethyl)-2,4-dimethyl-1H- pyrrole-3-carboxylic acid
(2-diethylaminoethyl)amide 52 56 5-(5-Bromo-2-oxo-1,2-dihydro-
indol-3-ylidenemethyl)-2,4-dimethyl-1H- pyrrole-3-carboxylic acid
(2-pyrrolidin-1-yl-ethyl)amide 53 57 5-(5-Bromo-2-oxo-1,2-dihydro-
indol-3-ylidenemethyl)-2,4-dimethyl-1- H- pyrrole-3-carboxylic acid
(3-imidazol-1-ylpropyl)amide 54 58
5-[6-(2-Methoxy-phenyl)-2-oxo-1,2-dihydro-
indol-3-ylidenemethyl]-2- ,4- dimethyl-1H-pyrrole-3-carboxylic acid
(2-dimethylamino-ethyl)amide 55 59
5-[6-(3-Methoxy-phenyl)-2-oxo-1,2-dihydro-
indol-3-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid
(2-dimethylamino-ethyl]amide 56 60
2,4-Dimethyl-5-(2-oxo-5-phenyl-1,2-dihydro-
indol-3-ylidenemethyl)-1H- pyrrole-3-carboxylic acid
(2-diethylaminoethyl)amide 57 61
2,4-Dimethyl-5-(2-oxo-5-phenyl-1,2-dihydro-
indol-3-ylidenemethyl)-1H- pyrrole-3-carboxylic acid
(2-pyrrolidin-1-yl-ethyl)amide 58 62
2,4-Dimethyl-5-(2-oxo-5-phenyl-1,2-dihydro-
indol-3-ylidenemethyl)-- 1H- pyrrole-3-carboxylic acid
(3-imidazol-1-ylpopyl)amide 59 63
2,4-Dimethyl-5-(2-oxo-6-phenyl-1,2-dihydro-
indol-3-ylidenemethyl)-- 1H- pyrrole-3-carboxylic acid
(2-diethylaminoethyl)amide 60 64
2,4-Dimethyl-5-(2-oxo-6-phenyl-1,2-dihydro-
indol-3-ylidenemethyl)-- 1H- pyrrole-3-carboxylic acid
(2-pyrrolidin-1-yl-ethyl)amide 61 65
2,4-Dimethyl-5-(2-oxo-6-phenyl-1,2-dihydro-
indol-3-ylidenemethyl)-1H- pyrrole-3-carboxylic acid
(3-imidazol-1-ylpropyl)amide 62 66
5[6-(3,5-Dichloro-phenyl)-2-oxo-1,2-dihydro-
indol-3-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid
(2-diethylaminoethyl)amide 63 67
2,4-Dimethyl-5-(2-oxo-6-pyridin-3-yl-1,2-dihydro-
indol-3-ylidenemethyl)-1H- pyrrole-3-carboxylic acid
(2-diethylaminoethyl)amide 64 68 2,4-Dimethyl-5-(2-oxo-6--
pyridin-3-yl-1,2-dihydro- indol-3-ylidenemethyl)-1H-
pyrrole-3-carboxylic acid (2-pyrrolidin-1-yl-ethyl)amide 65 69
2,4-Dimethyl-5-(2-oxo-6-pyridin-3-yl-1,2-dihydro-
indol-3-ylidenemethyl)-- 1H- pyrrole-3-carboxylic acid
(3-dimethylamino-propyl)amide 66 70
2,4-Dimethyl-5-(2-oxo-5-phenyl-1,2-dihydro-
indol-3-ylidenemethyl)-1H- pyrrole-3-carboxylic acid
(3-dimethylamino-propyl)amide 67 71
2,4-Dimethyl-5-(2-oxo-5-phenyl-1,2-dihydro-
indol-3-ylidenemethyl)-1H- pyrrole-3-carboxylic acid
(3-diethylaminopropyl)amide 68 72
2,4-Dimethyl-5-(2-oxo-6-phenyl-1,2-dihydro-
indol-3-ylidenemethyl)-1H- pyrrole-3-carboxylic acid
(3-diethylaminopropyl)amide 69 73
3-[4-(3-Diethylamino-propylcarbamoyl)-3,5-dimethyl-1H-pyrrol-2-
ylmethylene]-2-oxo-2,3-dihydro-1H-indole-4-carboxylic acid
(3-chloro-4-methoxy-phenyl)amide 70 74
5-(5-Bromo-2-oxo-1,2-dihydro-
indol-3-ylidenemethyl)-2,4-dimethyl-1H- pyrrol-3-carboxylic
acid(3-diethylaminopropyl)amide 71 75 5-(5-Bromo-2-oxo-1,2-dihydro-
indol-3-ylidenemethyl)-2,4-diisopropyl-1H- pyrrole-3-carboxylic
acid (2-diethylaminoethyl)amide 72 76 5-(5-Bromo-2-oxo-1,2-dihydro-
indol-3-ylidenemethyl)-2,4-diisopropyl-1- H- pyrrole-3-carboxylic
acid (3-diethylaminopropyl)amide 73 77
5-(5-Bromo-2-oxo-1,2-dihydro-
indol-3-ylidenemethyl)-2,4-diisopropy- l-1H- pyrrole-3-carboxylic
acid (3-pyridin-1-ylpropyl)amide 74 78
5-(5-Bromo-2-oxo-1,2-dihydro- indol-3-ylidenemethyl)-2,4-dimethyl--
1H- pyrrole-3-carboxylic acid (pyridin-4-yl-methyl)amide 75 79
5-[6-(4-Butyl-phenyl)-2-oxo-1,2-dihydro-
indol-3-ylidenemethyl]-2,3- 4-dimethyl- 1H-pyrrole-3-carboxylic
acid (2-pyrrolidin-1-ylethylene)amide 76 80
5-[6-(5-Isopropyl-2-methoxy-phenyl)-2-oxo-1,2-dihyd- roindol-3-
ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3- carboxylic acid
(2-pyrrolidin-1-yl-ethyl]amide 77 81
5-[6-(4-Ethyl-phenyl)-2-oxo-1,2-dihydroindol-3-
ylidenemethyl]-2,4-dimeth- yl- 1H-pyrrole-3-carboxylic acid
(2-pyrrolidin-1-yl-ethyl)amide 78 82
5-[6-(2,4-Dimethoxy-phenyl)-2-oxo-1,2-dihydro-
indol-3-yldenemethyl]-2,4- dimetyl-1H-pyrrole-3-carboxylic acid
(2-pyrrolidin-1-yl-ethyl)amide 79 83
5-[6-(3-Isopropyl-phenyl)-2-oxo-1,2-dihydro-
indol-3-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid
(2-pyrridine-1-yl-ethyl)amide 80 84
5-(5-Fluoro-2-oxo-1,2-dihydroindol-3-
ylidenemethyl)-2,4-dimethyl-1H- pyrrole-3-carboxylic acid
(2-diethylaminoethyl)amide 81 85 3-[4-(2-diethylamninoeth-
ylcabamoyl)-3,5- dimethyl-1H-pyrrol-2-ylmethylene]-
2-oxo-2,3-dihydro-1H-indole-6-carboxylic acid 82 86
5-(5-Dimethylsurfamoyl-2-oxo-1,2-dihydroindol-3-
ylidenemethyl)-2,4-dimet- hyl-1H-pyrrole-3- carboxylic acid
(2-pyrrolidin-1-yl-ethyl)amide 83 87
5-[5-(3-Chloro-phenylsulfamoyl)-2-oxo-1,2-dihydro-
indol-3-ylidenemethyl]-2,4-dimethyl-1H- pyrrola-3-carboxylic acid
(2-pyrrolidin-1-yl-ethyl]amide 84 88
2,4-Dimethyl-5-[2-oxo-5-(pyridin-3-ylsulfamoyl)-
1,2-dihydroindol-3-yldie- nemethyl]-1H-pyrrole-3-carboxy acid
(2-pyridin-1-yl-ethyl]amide 85 89
3-[3,5-Dimethyl-4-(4-methyl-piperazine-1-cabonyl)-1H-pyrrol-2-
ylmethylene]-4-(2-hydroxy-ethyl)- 1,3-dihydroindol-2-one 86 90
3-[(3,5-Dimethyl-4-(4-methyl-piperazine-1-carbonyl)-1H-pyrrol-2-
ylmethylene]-2-oxo-2,3-dihydro-1H-indole-5- sulfonic acid
phenylamide 87 91 5-(5-Dimethylsulfamoyl-2-oxo-1,2-dihy-
droindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid
(2-diethylaminoethyl)amide 88 92 5-[5-(3-Chloro-phenylsul-
famoyl)-2-oxo-1,2-dihydroindol-3-ylidenemethyl]-
2,4-dimethyl-1H-pyrrole-3- -carboxylic acid
(2-diethylaminoethyl)amide 89 93
3-(5-Bromo-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-
4,5,6,7-tetrahydro-2H-isoindole-1-carboxylic acid
(2-dimethylamino-ethyl)- -amide 90 94
3-(2-Oxo-1,2-dihydro-indol-3-ylidenemethyl)-4-
,5,6,7-tetrahydro-2H- isoindole-1-carboxylic acid ethyl ester 91 95
3-(4-Methyl-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-
4,5,6,7-tetrahydro-2H-isoindole-1-carboxylic acid ethyl ester 92 96
3-(5-Bromo-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-
4,5,6,7-tetrahydro-2H-isoindole-1- carboxylic acid ethyl ester 93
97 3-(3-Ethoxycarbonyl-4,5,6,7-tetrahydro-2H-isoindol-1-ylmethyle-
ne)-2-oxo- 2,3-dihydro-1H-indole-5-carboxylic acid 94 98
3-(5-Methoxy-2-oxo-1,2-dihydro-indol-3-ylidenenethyl)-
4,5,6,7-tetrahydro-2H-isoindole-1- carboxylic acid ethyl ester 95
99 3-(2-Oxo-5-phenyl-1,2-dihydro-indol-3-ylidenenethyl)-
4,5,6,7-tetrahydro-2H-isoindole-1- carboxylic acid ethyl ester 96
100 3-(2-Oxo-5-sulfamoyl-1,2-dihydro-indol-3-ylidenemethyl)-
4,5,6,7-tetrahydro 2H-isoindole-1-carboxylic acid ethyl ester 97
101 3-(5-Methylsulfamoyl-2-oxo-1,2-dihydro-indol-3-
ylidenemethyl)-4,5,6,7- tetrahydro-2H-isoindole-1-carboxylic acid
ethyl ester 98 102 3-(5-Dimethylsulfamoyl-2-oxo-1,2-dihydro-ind-
ol-3- ylidenemethyl)-4,5,6,7- tetrahydro-2H-isoindole-1-carboxylic
acid ethyl ester 99 103 3-(2-Oxo-5-phenylsulfanoyl-1,2-dihydro-
-indol-3- ylidenemethyl)-4,5,6,7-
tetrahydro-2H-isoindole-1-carboxylic acid ethyl ester 100 104
3-(6-Bromo-2-oxo-1,2-dihydro-ind- ol-3-ylidenemethyl)-
4,5,6,7-tetrahydro-2H-isoindole-1-carboxylic acid ethyl ester 101
105 3-(2-Oxo-6-phenyl-1,2-dihydro-indol-3- -ylidenemethyl)-
4,5,6,7-tetrahydro-2H-isoindole-1-carboxylic acid ethyl ester 102
106 3-(3-Ethoxycarbonyl-4,5,6,7-tetrahydro-2H-
isoindol-1-ylmethylene)-2-oxo- 2,3-dihydro-1H-indole-6-carboxylic
acid 103 107 3-(6-Methoxy-2-oxo-1,2-dihydro-indol-3-ylidenemethyl-
)-4,5,6,7-tetrahydro- 2H-isoindole-1-carboxylic acid ethyl ester
104 108 3-(5-Isopropylsulfamoyl-2-oxo-1,2-dihydro-indol-3-ylidenem-
ethyt)-4,5,6,7- tetrahydro-2H-isoindole-1-carboxylic acid ethyl
ester 105 109
3-(3-Methylcarbamoyl-4,5,6,7-tetrahydro-2H-isoindol-1--
ylmethylene)-2- oxo-2,3-dihydro-1H-indole-5-carboxylic acid 106 110
3-(3-Dimethylcarbamoyl-4,5,6,7-tetrahydra-2H-isoindol-1-
ylmethylene)-2-oxo-2,3-dihydro- 1H-indole-5-carboxylic acid 107 111
2-Oxo-3-[3-(pyrrolidine-1-carbonyl)-4,5,6,7-tetrahydro-2H-iso-
indol-1-ylmethylene]-2,3-dihydro-1H-indole-5-carboxylic acid 108
112 3-[3-(Morpholine-4-carbonyl)-4,5,6,7-tetrahydro-2H-iso-
indol-1-ylmethylene]-2-oxo-2,3-dihydro-1H- indole-5-carboxylic acid
109 113 3-[3-(Morpholine-4-carbonyl)-4,5,8,7-tetrahydro-2H-iso-
indol-1-ylmethylene]-2-oxo-2,3-dihydro-1H- indole-6-carboxylic acid
110 114 3-(5-Bromo-2-oxo-1,2-dihydro-indol-3-
ylidenemethyl)-4,5,6,7-tetrahydro- 2H-isoindole-1-carboxylic acid
methylamide 111 115 3-(5-Bromo-2-oxo-1,2-dihydro-indol-3-
ylidenemethyl)-4,5,6,7-tetrahydro- 2H-isoindole-1-carboxylic acid
methylamide 112 116 5-Bromo-3-[3-(pyrrolidine-1-carbonyl)-
-4,5,6,7-tetrahydro-2H-isoindol-1-
ylmethylene]-1,3-dihydro-indol-2-one 113 117
5-Bromo-3-[3-(morpholine-4-carbonyl)-4,5,6,7-tetrahy-
dro-2H-isoindol-1- ylmethylene]-1,3-dihydro-indol-2-one 114 118
3-(3-Dimethylcarbamoyl-4,5,6,7-tetrahydro-2H-1-isodol-1-
ylmethylene)-2-oxo-2,3- dihydro-1H-6-indole-6-carboxylic acid 115
119 4-Methyl-5-(5-methylsulfamoyl-2-oxo-1,2-dihydro-indo-
3-ylidenemethyl)-1H-pyrrolle-3- carboxylic acid 116 120
{[4-Methyl-5-(4-methyl-5-methylsulfamoyl-2-oxo-1,2-
dihydro-indol-3-ylidenemethyl)-1H-pyrrole-3-carbonyl]-
amino}-acetic acid ethyl ester 117 121
{[4-Methyl-5-(5-methylsulfamoyl-2-axo- -1,2-dihydro-
indol-3-ylidenemethyl)-1H-pyrrole-3-carbonyl]- amino}-acetic
acid ethyl ester 118 122 {[4-Methyl-5-(5-methylsulfamoyl--
2-oxo-1,2-dihydro- indol-3-ylidenemethyl)-1H-pyrrole-3-carbonyl]-
amino}-acetic acid 119 123 3-[3-Methyl-4-(piperidine-1-ca-
rbonyl)-1H-pyrrol-2-ylmethylene]-
2-oxo-2,3-dihydro-1H-indole-5-sulfonic acid methylamide 120 124
5-Methyl-2-(2-oxo-1,2-dihydro-in- dol-3-ylidenemethyl)-
1H-pyrrole-3-carboxylic acid 121 125
5-Methyl-2-(2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-
1H-pyrrole-3-carboxylic acid ethyl ester 122 126
2-(5-Bromo-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-5-
methyl-1H-pyrrole-3-carboxylic acid ethyl ester 123 127
2-(5-Bromo-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-5-
methyl-1H-pyrrole-. 3-carboxylic acid 124 128
2-(5-Bromo-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-5-
methyl-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-yl-ethyl)-amide
125 129 2-(5-Bromo-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-5-
methyl-1H-pyrrole-3-carboxylic acid (2-diethylamino-ethyl)-amide
126 130 2,4-Dimethyl-5-[2-oxo-1,2- dihydro-indol-(3Z)-ylidenemethy-
l]- 1H-pyrrole-3-carboxylic acid (2- diethylaminoethyl)-amide 381
[M + 1] 127 131 5-[5-Chloro-2-oxo-1,2-dihydro-
indol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic
acid (2-diethylaminoethyl)-amide 415 [M + 1] 128 132
2,4-Dimethyl-5-[2-oxo-1,2- dihydro-indol-(3Z)-ylidenemethyl]-
2,4-dimethyl-1H-pyrrole-3- carboxylic acid (2-pyrrolidin-1-
ylethyl)-amide 379 [M + 1] 129 133 5-[5-Fluoro-2-oxo-1,2-dihydro-
indol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic
acid (2-pyrrolidin-1-ylethyl)-amide 397 [M + 1] 130 134
5-[5-Chloro-2-oxo-1,2-dihydro- indol-(3Z)-ylidenemethyl]-1H-
pyrrole-3-carboxylic (2- pyrrolidin-1-ylethyl)-amide 413 [M + 1]
131 135 2,4-Dimethyl-5-[2-oxo-1,2-
dihydro-indol-(3Z)-ylidenemethyl]- 2,4-dimethyl-1H-pyrrole-3-
carboxylic acid (2- dimethylaminoethyl)-amide 353 [M + 1] 132 136
5-[5-Fluoro-2-oxo-1,2-dihydro- indol-(3Z)-ylidenemethyl]-2,4-
dimethyl-1H-pyrrole-3-carboxylic acid (2-dimethylaminoethyl)- amide
371 [M + 1] 133 137 5-[5-Chloro-2-oxo-1,2-dihydro-indol-(3Z)-
ylidenemethyl]-2,4-dimethyl-1H-- pyrrole- 3-carboxylic acid
(2-acetylamino-ethyl)- amide 399 [M + 1] 134 138
5-[5-Fluoro-2-oxo-1,2-dihydro-indol-(3Z)-
ylidenemethyl]-2,4-dimethyl-1H-pyrrole- 3-carboxylic acid
(2-acetylamino-ethyl)- amide 383 [M + 1] 135 139
2,4-Dimethyl-5-[2-oxo-1,2-dihydro- indol-(3Z)-ylidenemethyl]-1H-
pyrrole-3-carboxylic acid (2-acetylamino-ethyl)-amide 365 [M + 1]
136 140 5-[5-Bromo-2-oxo-1,2-dihydro-indol-
(3Z)-ylidenemethyl]-2,4-dimethyl-1H- pyrrole-3-carboxylic acid
[-(2-oxo-tetrahydro-pyrimidin-1- yl)propyl]-amide 500 [M + 1]502 [M
+ 1] 137 141 5-[5-Chloro-2-oxo-1,2-dihydro-indol-
(3Z)-ylidenemethyl]-2,4-dimethyl-1H- pyrrole-3-carboxylic acid
[3-(2-oxo-tetrahydro- pyrimidin-1-yl)-propyl]-amide 454 [M - 1] 138
142 5-[5-Fluoro-2-oxo-1,2-dihydro-indol-
(3Z)-ylidenemethyl]-2,4-dimethyl-1H- pyrrole-3-carboxylic acid
[3-(2-oxo-tetrahydro-nl pyrimidin-1-yl)-propyl]-amide 438 [M - 1]
139 143 2,4-Dimethyl-5-[2-oxo-1,2-dihydro-
indol-(3Z)-ylidenemethyl]-1H- pyrrole-3-carboxylic acid
[3-(2-oxo-tetrahydro-nl pyrimidin-1-yl)-propyl]-amide 422 [M + 1]
140 144 5-[5-Cyano-2-oxo-1,2-dihydro-indol-
(3Z)-ylidenemethyl]-2,4-dimethyl- 1H-pyrrole-3-carboxylic acid
[3-(2-oxo-tetrahydro-nl pyrimidin-1-yl)-propyl]-amide 447 [M + 1]
141 145 Trifluoro-acetate-[2-({5-[5-bromo-
2-oxo-1,2-dihydro-indol-(3Z)- ylidenemethyl]-1H-
pyrrole-3-carbonyl)-amin- o)- ethyl]-2-oxo-piperazin-1-ium; 486 [M
+ 1]488 [M + 1] 142 146 5-[5-Cyano-2-oxo-1,2-dihydro-indol-
(3Z)-ylidenemethyl]-2,4-dimet- hyl-1H pyrrole-3-carboxylic
acid[3-(2-oxo- pyrrolidin-1-yl)-propyl]-amide 430 [M + 1] 143 147
5-[5-Bromo-2-oxo-1,2-dihydro-indol- (3Z)-
ylidenemethyl]-2,4-dimethyl-1H pyrrole-3-carboxylic acid
[2-(2-oxo-imidazolin-1-yl)-ethyl]-amide 470 [M - 1]472 [M - 1] 488
[M + 1] 144 148 5-[5-Chloro-2-oxo-1,2-dihydro-indol- (3Z)-
ylidenemethyl]-2,4-dimethyl-1H pyrrole-3-carboxylic acid
[2-(2-oxo-imidazolin-1-yl)-ethyl]-amide 428 [M + 1] 145 149
5-[5-Fluoro-2-oxo-1,2-dihydro-indol- (3Z)-
ylidenemethyl]-2,4-dimethy- l-1H pyrrole-3-carboxylic acid
[2-(2-oxo-imidazolin-1-yl)-ethyl]-amide 412 [M + 1] 146 150
2,4-Dimethyl-5-[2-oxo-1,2-dihydro- indol-(3Z)-
ylidenemethyl]-2,4-dimethyl-1H pyrrole-3-carboxylic acid
[2-(2-oxo-imidazolin-1-yl)-ethyl]-amide 392 [M + 1] 147 151
5-[5-Cyano-2-oxo-1,2-dihydro-indol- (3Z)-
ylidenemethyl]-2,4-dimethyl- -1H pyrrole-3-carboxylic acid
[2-(2-oxo-imidazolin-1-yl)-ethyl]-amide 419 [M + 1] 148 152
{4-[2-({5-Bromo-2-oxo-1,2- dihydro-indol-(3Z)-ylidenemethyl]-
2,4-dimethyl-1H-pyrrole-3-carbonyl}ami- no)-ethyl]-piperazin-1-
yl}-acetic acid ethyl ester 558 [M + 1]560 [M + 1] 149 153
{4-[2-({5-Bromo-2-oxo-1,2- dihydro-indol-(3Z)-ylidenemethyl]-
2,4-dimethyl-1H-pyrrole-3-carbonyl}ami- no)-ethyl]-piperazin-1-
yl}-acetic acid ethyl ester 514 [M + 1] 150 154
{4-[2-({5-[5-Chloro-2-oxo-1,2- dihydro-indol-(3Z)-ylidenemet- hyl]-
2,4-dimethyl-1H-pyrrole-3-carbonyl}amino)-ethyl]-piperazin-1-
yl}-acetic acid ethyl ester 514 [M + 1] 153 155
2,4-Dimethyl-5-[2-oxo-1,2- dihydro-indol-(3Z)-ylidenemethyl]-
1H-pyrrole-3-carboxylic acid[(cyanomethyl-amino)- ethyl]-amide 362
[M - 1] 154 156 5-[5-Bromo-2-oxo-1,2- dihydro-indol-(3Z)-ylide-
nemethyl]- 1H-pyrrole-3-carboxylic acid [3-(2-oxo-azepan-1-yl)-
propyl]-amide 511 [M - 1]513 [M - 1] 155 157 5-[5-Chloro-2-oxo-1,2-
dihydro-indol-(3Z)-ylidenemethyl]- 1H-pyrrole-3-carboxylic acid
[3-(2-oxo-azepan-1-yl)- propyl]-amide 469 [M + 1] 156 158
5-[5-Fluoro-2-oxo-1,2- dihydro-indol-(3Z)-ylidenemethyl]-
1H-pyrrole-3-carboxylic acid [3-(2-oxo-azepan-1-yl)- propyl]-amide
453 [M + 1] 157 159 2,4-Dimethyl-5-[2-oxo-1,2-
dihydro-indol-(3Z)-ylidenemethyl]- 1H-pyrrole-3-carboxylic acid
[3-(2-oxo-azepan-1-yl)- propyl]-amide 435 [M + 1] 158 160
5-[5-Cyano-2-oxo-1,2- dihydro-indol-(3Z)-ylidenemethyl]-
1H-pyrrole-3-carboxylic acid [3-(2-oxo-azepan-1-yl)- propyl]-amide
460 [M + 1] 156 161 5-[5-Bromo-2-oxo-1,2-
dihydro-indol-(3Z)-ylidenemethyl]- 1H-pyrrole-3-carboxylic acid
[3-(2-oxo-azepan-1-yl)- propyl]-amide 443 [M - 1]445 [M - 1] 160
162 Trifluoro-acetate4-[2-({5-[5-fluo- ro-2-
oxo-1,2-dihydro-indol-(3Z)- ylidenemethyl]-2,4-
dimethyl-1H-pyrrole-3-carboxnyl}-
amino)ethyl]-2-oxo-piperazin-1-ium; 426 [M + 1] 161 163
Trifluoro-acetate4-[2-({5-[5-fluoro-2- oxo-1,2-dihydro-indol-(3Z)-
ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-car- boxnyl}-
amino)ethyl]-2-oxo-piperazin-1-ium; 408 [M + 1] 162 164
Trifluoro-acetate4-[2-({5-[5-fluoro-2- oxo-1,2-dihydro-indol-(3Z)-
- ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxnyl}-
amino)ethyl]-2-oxo-piperazin-1-ium; 433 [M + 1] 163 165
5-[5-Bromo-2-oxo-1,2- dihydro-indol-(3Z)-ylidenemethyl]-2,4-
dimethyl-1H-pyrrole-3-carboxylic acid
[2-(2-cyanoethylamino)-ethyl]-amide 454 [M - 1]456 [M - 1] 164 166
5-(5-Chloro-2-oxo-1,2- dihydro-indol-(3Z)-ylidenemethyl]-2,4-
dimethyl-1H-pyrrole-3-carboxylic
acid[2-(2-cyanoethylamino)-ethyl]-amide 410 [M - 1]456 [M - 1] 165
167 5-[5-Fluoro-2-oxo-1,2- dihydro-indol-(3Z)-ylidenemethyl]-2,4- -
dimethyl-1H-pyrrole-3-carboxylic acid
[2-(2-cyanoethylamino)-ethyl]-amid- e 454 [M - 1]394 [M - 1] 166
168 2,4-Dimethyl-5-[2-oxo-1,2- - dihydro-indol-(3Z)-ylidenemethyl]-
1H-pyrrole-3-carboxylic acid [2-(2-cyanoethylamino)-ethyl]-amide
454 [M - 1]376 [M - 1] 167 169 5-[5-Cyano-2-oxo-1,2-
dihydro-indol-(3Z)-ylidenemethyl]-2,4-
dimethyl-1H-pyrrole-3-carboxylic acid
[2-(2-cyanoethylamino)-ethyl]-amide 454 [M - 1]401 [M - 1] 168 170
Trifluoro-acetate4-[2-({5-- [5-chloro-2-
oxo-1,2-dihydro-indol-(3Z)- ylidenemethyl]-2,4-dimethyl-1H-
pyrrole-3-carbonyl)- amino-ethyl]-2-oxo- piperazin-1-ium; 440 [M -
1] 168 171 5-[5-Fluoro-2-oxo-1,2- dihydro-indol-(3Z)-ylidenemeth-
yl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid
[2-(2-cyanoethylamino)-ethy- l]-amide 454 [M - 1]424 [M - 1] 169
172 5-[5-Chloro-2-oxo-1,2- dihydro-indol-(3Z)-ylidenemethyl]-2,4-
dimethyl-1H-pyrrole-3-carboxylic acid
[2-(2-cyanoethylamino)-ethyl]-amide 454 [M - 1]440 [M - 1] 170 173
5-[5-Bromo-2-oxo-1,2- dihydro-indol-(3Z)-ylidenemethyl]-2,4-
dimethyl-1H-pyrrole-3-carboxylic acid
[2-(2-cyanoethylamino)-ethyl]-amide 454 [M - 1]484 [M - 1]486 [M -
1] 171 174 2,4-Dimethyl-5-[2-oxo-1,2-
dihydro-indol-(3Z)-ylidenemethyl]-2,4-
dimethyl-1H-pyrrole-3-carboxylic acid
[2-(2-cyanoethylamino)-ethyl]-amide 406 [M - 1] 172 175
2,4-Dimethyl-5-[2-oxo-1,2- dihydro-indol-(3Z)-ylidenemethyl]-2,4-
dimethyl-1H-pyrrole-3-carboxylic acid
[2-(2-cyanoethylamino)-ethyl]-amide 422 [M + 1] 173 176
5-[5-Fluoro-2-oxo-1,2- dihydro-indol-(3Z)-ylidenemethyl]-2,4-
dimethyl-1H-pyrrole-3-carboxylic acid
[2-(2-cyanoethylamino)-ethyl]-amide 438 [M - 1] 174 177
5-[5-Chloro-2-oxo-1,2- dihydro-indol-(3Z)-ylidenemethyl]-2,4-
dimethyl-1H-pyrrole-3-carboxylic acid
[2-(2-cyanoethylamino)-ethyl]-amide 456 [M + 1] 175 178
5-[5-Bromo-2-oxo-1,2- dihydro-indol-(3Z)-ylidenemethyl]-2,4-
dimethyl-1H-pyrrole-3-carboxylic acid
[2-(2-cyanoethylamino)-ethyl]-amide 498 [M - 1]500 [M - 1] 176 179
2,4-Dimethyl-5-[2-oxo-1,2- dihydro-indol-(3Z)-ylidenemethy- l]-
1H-pyrrole-3-carboxylic acid[3- (4-methyl-piperazin-1-yl-propyl]-
amide 422 [M + 1] 177 180 5-[5-Fluoro-2-oxo-1,2-dihydro-
indol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic
acid[3-(4-methyl-piperazin-1-yl)- propyl]-amide 438 [M - 1] 178 181
5-[5-Chloro-2-oxo-1,2-dihydro- indol-(3Z)-ylidenemethyl]-2,4-
dimethyl-1H-pyrrole-3-carboxylic acid[3-(4-methyl-piperazin-1-yl)-
propyl]-amide 454 [M - 1] 179 182 5-[5-Bromo-2-oxo-1,2-di- hydro-
indol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic
acid[3-(4-methyl-piperazin-1-yl)- propyl]-amide 498 [M - 1]500 [M -
1] 180 183 2,4-Dimethyl-5-[2-oxo-1,2- dihydro-indol-(3Z)-yliden-
emethyl]- 1H-pyrrole-3-carboxylic acid[2-
(4-benzyl-piperazin-1-yl)-ethyl]- - amide 482 [M - 1] 181 184
5-[5-Fluoro-2-oxo-1,2-dihydro- indol-(3Z)-ylidenemethyl]-2,4-
dimethyl-1H-pyrrole-3-carboxylic acid[2-(4-benzyl-piperazin-1-yl)-
ethyl]-amide 500 [M - 1] 182 185 5-[5-Chloro-2-oxo-1,2-dihydro-
indol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic
acid [2-(4-benzyl-piperazin-1-yl)- ethyl]-amide 517 [M - 1] 183 186
5-[5-Bromo-2-oxo-1,2-dih- ydro- indol-(3Z)-ylidenemethyl]-2,4-
dimethyl-1H-pyrrole-3-carboxylic acid[2-(4-benzyl-piperazin-1-yl)-
ethyl]-amide 560 [M - 1]562 [M - 1] 184 187
5-[5-Chloro-2-oxo-1,2-dihydro-indol-(3Z)-
ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3- carboxylic
acid(3-pyrrolidin-1yl-2-one)- amide 480 [M + 1] 185 188
Trifluoroacetate 4-[({5-[5-Chloro-2-oxo-1,2-
dihydro-indol-(3Z)-ylideneme- thyl]-2,4-
dimethyl-1H-pyrrole-3-carbonyl}amino)-ethyl]2-oxo-piperazin-1-i- um
440 [M - 1] 186 189 5-[5-Chloro-2-oxo-1,2-
dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-
carboxylic acid(3-pyrrolidin-1yl-2-one)- amide 187 190
5-[5-Fluoro-2-oxo-1,2-dihydro-indol-(3Z)-
ylidenemethyl]-2,4-dimethyl-1H-- pyrrole-3- carboxylic
acid(3-pyrrolidin-1yl-2-one)- amide 188 191
5-[2-oxo-1,2-dihydro-indol-(3Z)- ylidenemethyl]-2,4-dimethyl-1H-p-
yrrole-3- carboxylic acid(3-pyrrolidin-1yl-2-one)- amide 189 192
5-[5-Chloro-2-oxo-1,2-dihydro-indol-(3Z)- ylidenemethyl]-2,4-dime-
thyl-1H-pyrrole-3- carboxylic acid(2-pyridin-2-ylethyl)-amide 190
193 5-[5-Fluoro-2-oxo-1,2-dihydro-indol-(3Z)-
ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3- carboxylic
acid(2-pyridin-2-ylethyl)-amide trifluoroacetate salt 191 194
5-[2-oxo-1,2-dihydro-indol-(3Z)-
ylidenemethyl]-2,4-dimethyl-1H-pyrro- le-3- carboxylic
acid(2-pyridin-2-ylethyl)-amide hydrochloride salt 192 195
5-[5-Bromo-2-oxo-1,2-dihydro-indol-(3Z)-
ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3- carboxylic
acid(2-pyridin-2-ylethyl)-amide trifluoroacetate salt 193 196
5-[5-Fluoro-2-oxo-1,2-dihydro-indol-(3Z)-
ylidenemethyl]-2,4-dimethyl- -1H-pyrrole-3- carboxylic
acid(2-ethylaminoethyl)-amide 194 197
5-[5-Fluoro-2-oxo-1,2-dihydro-indol-(3Z)- ylidenemethyl]-2,4-dime-
thyl-1H-pyrrole-3- carboxylic acid(2-aminoethyl)-amide 195 198
5-[5-Fluoro-2-oxo-1,2-dihydro-indol-(3Z)-
ylidenemethyl]-2,4-dimethyl- -2,4-dimethyl- 1H-pyrrole-3-carboxylic
acid(2-diethyl-N- oxoaminoethyl)-amide 196 199
5-[5-Fluoro-2-oxo-1,2-dihydr- o-indol-(3Z)-
ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3- carboxylic
acid(2-ethyl-N-hydroxy- aminoethyl)-amide 197 200
5-[5-Fluoro-2-oxo-1,2-dihydro-indol-(3Z)-
ylidenemethyl]-1H-pyrrole-3-car- boxylic
acid(2-diethylamino-2-hydroxyethyl)- amide 198 201
5-[5-Fluoro-2-oxo-1,2-dihydro-indol-(3Z)-
ylidenemethyl]-2,4-dimethyl-1H-- pyrrole-3- carboxylic
acid[2-ethyl-2-(2- hydroxyethyl)aminoethyl]-amide 199 202
5-[5-Fluoro-2-oxo-1,2-dihydro-indol-(3Z)-
ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3- carboxylic
acid[2-ethyl-2-(1- hydroxyethyl)aminoethyl]-amide 200 203
5-[5-Cyano-2-oxo-1,2-dihydro-indol-(3Z)-
ylidenemethyl]-2,4-dimethyl-1H-p- yrrole-3- carboxylic
acid(2-N-acetylaminoethyl)- amide 201 204
5-[5-Fluoro-2-oxo-1,2-dihydro-indol-(3Z)-
ylidenemethyl]-2,4-dimethyl- -1H-pyrrole-3- carboxylic
acid(carboxymethyl)-amide
[0182] The compound numbers correspond to the Example numbers in
the Examples section. That is, the synthesis of Compound 1 in Table
1 is described in Example 1. The compounds presented in Table 1 are
exemplary only and are not to be construed as limiting the scope of
this invention in any manner.
Preferred Embodiments
[0183] While the broadest definition is set forth in the Summary of
the Invention, certain compounds of Formula (I) set forth below are
preferred.
[0184] (1) A preferred group of compounds of Formula (I) is that
wherein R.sup.1, R.sup.3, and R.sup.4 are hydrogen.
[0185] (2) Another preferred group of compounds of Formula (I) is
that wherein R.sup.1, R.sup.2, and R.sup.4 are hydrogen.
[0186] (3) Another preferred group of compounds of Formula (I) is
that wherein R.sup.1, R.sup.2, and R.sup.3 are hydrogen.
[0187] (4) Another preferred group of compounds of Formula (I) is
that wherein R.sup.2, R.sup.3, and R.sup.4 are hydrogen.
[0188] (5) Another preferred group of compounds of Formula (I) is
that wherein R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are
hydrogen.
[0189] (6) Yet another preferred group of compounds of Formula (I)
is that wherein R.sup.5, R.sup.6 or R.sup.7, preferably R.sup.5 or
R.sup.6, more preferably R.sup.6 is --COR.sup.10 wherein R.sup.10
is --NR.sup.11(CH.sub.2).sub.nR.sup.12 wherein:
[0190] R.sup.1 is hydrogen or lower unsubstituted alkyl, preferably
hydrogen or methyl;
[0191] n is 2, 3 or 4, preferably 2 or 3; and
[0192] R.sup.12 is --NR.sup.13R.sup.14 wherein R.sup.13 and
R.sup.14 are independently alkyl, more preferably lower
unsubstituted lower alkyl or R.sup.13 and R.sup.14 combine to form
a group selected from --(CH.sub.2).sub.4--, --(CH.sub.2).sub.5--,
--(CH.sub.2).sub.2--O--(CH.su- b.2).sub.2-- or,
--(CH.sub.2).sub.2N(CH.sub.3)(CH.sub.2).sub.2--, preferably
R.sup.13 and R.sup.14 are independently hydrogen, methyl, ethyl, or
combine to form morpholin-4-yl, pyrrolidin-1-yl, piperazin-1-yl, or
4-methylpiperazin-1-yl.
[0193] More preferably, R.sup.5 or R.sup.6 in (6) above is
N-(2-dimethylaminoethyl-)aminocarbonyl,
N-(2-ethylaminoethyl)-N-methylami- nocarbonyl,
N-(3-dimethylaminopropyl)aminocarbonyl,
N-(2-diethylaminoethyl)aminocarbonyl,
N-(3-ethylaminopropyl)aminocarbonyl- ,
N-(3-diethylaminopropyl)aminocarbonyl,
3-pyrrolidin-1-ylpropylaminocarbo- nyl,
3-morpholin-4-ylpropylaminocarbonyl,
2-pyrrolidin-1-ylethylaminocarbo- nyl,
2-morpholin-4-ylethylaminocarbonyl,
2-(4-methylpiperazin-1-yl)ethylam- inocarbonyl,
2-(4-methylpiperazin-1-yl)propylaminocarbonyl;
2-(3,5-dimethylpiperazin-1-y)ethylaminocarbonyl or
2-(3,5-dimethylpiperazin-1-y)propylaminocarbonyl, even more
preferably N-(2-diethylaminoethyl)aminocarbonyl or
N-(2-ethylaminoethyl)aminocarbony- l.,
[0194] (7) Yet another preferred group of compounds of Formula (I)
is that wherein R.sup.5, R.sup.6 or R.sup.7, preferably R.sup.5 or
R.sup.6, more preferably R.sup.6 is --COR.sup.10 wherein R.sup.10
is --NR.sup.13R.sup.14 wherein R.sup.13 is hydrogen and R.sup.14 is
alkyl, preferably lower alkyl substituted with hydroxy, aryl,
heteroaryl, heteroalicyclic, or carboxy, more preferably methyl,
ethyl, propyl or butyl substituted with hydroxy, aryl,
heteroalicyclic such as piperidine, piperazine, morpholine and the
like, heteroaryl, or carboxy. Even more preferably within this
group (7), R.sup.5 or R.sup.6 is
2-ethoxycarbonylmethyl-aminocarbonyl, carboxymethylaminocarbonyl,
3-hydroxypropyl-aminocarbonyl, 2-hydroxyethylaminocarbonyl,
3-triazin-1-ylprpopylaminocarbonyl, triazin-1-ylethylaminocarbonyl,
4-hydroxyphenylethylaminocarbonyl,
3-imidazol-1-ylpropylaminocarbonyl,
pyridin-4-ylmethylaminocarbonyl, 2-pyridin-2-ylethylaminocarbonyl
or 2-imidazol-1-ylethylaminocarbonyl.
[0195] (8) Yet another preferred group of compounds of Formula (I)
is that wherein R.sup.5, R.sup.6 or R.sup.7, preferably R.sup.5 or
R.sup.6, more preferably R.sup.6 is --COR.sup.10 wherein R.sup.10
is --NR.sup.11(CH.sub.2).sub.nR.sup.12 wherein:
[0196] R.sup.11 is hydrogen or alkyl, preferably hydrogen or
methyl;
[0197] n is 2, 3 or 4, preferably 2 or 3; and
[0198] R.sup.12 is --NR.sup.13R.sup.14 wherein R.sup.13 and
R.sup.14 together combine to form a heterocycle, preferably a 5, 6
or 7 membered heterocycle containing a carbonyl group and 1 or 2
nitrogen atoms. Preferably, R.sup.5 or R.sup.6 is
2-(3-ethoxycarbonylmethylpiperazin-1-yl- )ethylaminocarbonyl,
2-(3-oxopiperazin-1-yl)ethylaminocarbonyl,
2-(imidazolidin-1-yl-2-one)ethylaminocarbonyl,
2-(tetrahydropyrimidin-1-y- l-2-one)ethylaminocarbonyl,
2-(2-oxopyrrolidin-1-yl)-ethylaminocarbonyl,
3-(4-methylpiperazin-1-yl)propylaminocarbonyl,
3-(3-ethoxycarbonylmethylp- iperazin-1-yl)-propylaminocarbonyl,
3-(3-oxopiperazin-1-yl)propylaminocarb- onyl,
3-(imidazolidin-1-yl-2-one)propylaminocarbonyl,
3-(tetrahydropyrimidin-1-yl-2-one)-propylaminocarbonyl,
3-(2-oxopyrrolidin-1-yl)propylaminocarbonyl,
2-(2-oxohomopiperidin-1-yl) ethylaminocarbonyl or
3-(2-oxohomopiperidin-1-yl)propylaminocarbonyl.
[0199] (9) Yet another preferred group of compounds of Formula (I)
is that wherein R.sup.5, R.sup.6 or R.sup.7, preferably R.sup.5 or
R.sup.6, more preferably R.sup.6 is --COR.sup.10 wherein:
[0200] (a) R.sup.10 is --NR.sup.11(CH.sub.2).sub.nR.sup.12
wherein:
[0201] R.sup.11 is hydrogen or alkyl, preferably hydrogen or
methyl;
[0202] n is 2, 3 or 4, preferably 2 or 3; and
[0203] R.sup.2 is --NR.sup.13R.sup.14 wherein R.sup.13 is hydrogen
and R.sup.14 is cyanoalkyl or --NHCOR.sup.a where R.sup.a is alkyl;
or
[0204] (b) R.sup.10 is --NR.sup.13R.sup.14 wherein R.sup.13 and
R.sup.14 together combine to form a heterocycle not containing a
carbonyl group within the ring. Preferably, R.sup.5 or R.sup.6 is
2-(2-cyanoethylamino)ethylaminocarbonyl,
2-(acetylamino)ethylaminocarbony- l, morpholinocarbonyl,
piperidin-1-ylcarbonyl, 2-cyanomethylaminoethylamin- ocarbonyl or
piperidin-1-ylcarbonyl.
[0205] (10) Another preferred group of compouds of Formula (I) is
that wherein R.sup.5 is --COR.sup.10 wherein R.sup.10 is
--NR.sup.13R.sup.14 wherein R.sup.13 is hydrogen and R.sup.14 is
lower alkyl substituted with hydroxy, lower alkyl substituted with
hydroxyalkylamino, carboxy, or --NR.sup.18R.sup.9 wherein R.sup.18
and R.sup.19 are independently hydrogen or lower unsubstituted
alkyl, more preferably R.sup.5 is
2-[(diethylamino)-2-hydroxyethyl]aminocarbonyl,
2-(N-ethyl-N-2-hydroxyeth- ylamino)ethylaminocarbonyl,
carboxymethylamino-carbonyl, or
2-(2-hydroxyethylamino)ethylamino-carbonyl.
[0206] (11) Yet another preferred group of compounds of Formula
(I), is that wherein R.sup.5 is --COR.sup.10 wherein R.sup.10 is
--NR.sup.13R.sup.14 wherein R.sup.13 is hydrogen and R.sup.14 is
lower alkyl substituted with hydroxy, lower alkyl substituted with
hydroxyalkylamino, carboxy, or --NR.sup.18R.sup.19 wherein R.sup.18
and R.sup.19 are independently hydrogen or lower unsubstituted
alkyl; more preferably R.sup.6 is
[2-(diethylamino)-2-hydroxy]ethylaminocarbonyl,
2-(N-ethyl-N-2-hydroxyethyl-amino)ethylaminocarbonyl,
carboxymethylaminocarbonyl, or
2-(2-hydroxyethylamino)ethylamino-carbonyl- .
[0207] (12) Yet another preferred group of compounds of Formula (I)
is that wherein R.sup.5 is --COR.sup.10 wherein R.sup.10 is
--NR.sup.11(CH.sub.2).sub.nR.sup.12 wherein R.sup.12 is
--N.sup.+(O.sup.-)NR.sup.13R.sup.14 or --N(OH)R.sup.13 wherein
R.sup.13 and R.sup.14 are independently selected from the group
consisting of hydrogen and unsubstituted lower alkyl, preferably
R.sup.5 is 2-(N-hydroxy-N-ethylamino)ethylaminocarbonyl or
2-[N.sup.+(O.sup.-)(C.sub- .2H.sub.5).sub.2]ethyl-aminocarbonyl
[0208] (13) Yet another preferred group of compounds of Formula (I)
is that wherein R.sup.6 is --COR.sup.10 wherein R.sup.10 is
--NR.sup.11(CH.sub.2).sub.nR.sup.12 wherein R.sup.12 is
--N.sup.+(O.sup.-)NR.sup.13R.sup.14 or --N(OH)R.sup.13 wherein
R.sup.13 and R.sup.14 are independently selected from the group
consisting of hydrogen and unsubstituted lower alkyl, preferably RE
is 2-(N-hydroxy-N-ethylamino)ethylaminocarbonyl or
2-[N.sup.+(O.sup.-)(C.sub- .2H.sub.5).sub.2]ethylaminocarbonyl.
[0209] (14) In the above preferred groups (6)-(13) when R.sup.5 is
--COR.sup.10, then a more preferred group of compounds is that
wherein:
[0210] R.sup.6 is selected from the group consisting of hydrogen
and alkyl, preferably hydrogen, methyl, ethyl, isopropyl,
tert-butyl, isobutyl, or n-butyl, more preferably hydrogen or
methyl; and
[0211] R.sup.7 is selected from the group consisting of hydrogen,
alkyl, aryl, heteroaryl, and --C(O)R.sup.17 wherein R.sup.17 is
hydroxy, alkyl or aryl, more preferably hydrogen, methyl, ethyl,
isopropyl, n-, iso or tert-butyl, phenyl, benzoyl, acetyl or
carboxy, even more preferably methyl, hydrogen or phenyl.
[0212] (15) In the above preferred groups (6)-(13) when R.sup.5 is
--COR.sup.10, then another more preferred group of compounds is
that wherein R.sup.6 and R.sup.7 combine to form
--(CH.sub.2).sub.4--.
[0213] (16) In the above preferred groups (6)-(13) when R.sup.6 is
--COR.sup.10, then a more preferred group of compounds is that
wherein:
[0214] R.sup.5 is selected from the group consisting of hydrogen
and alkyl, preferably hydrogen, methyl, ethyl, isopropyl,
tert-butyl, isobutyl, or n-butyl, more preferably hydrogen or
methyl; and
[0215] R.sup.7 is selected from the group consisting of hydrogen,
alkyl, aryl, heteroaryl, and --C(O)R.sup.17, wherein R.sup.17 is
hydroxy, alkyl or aryl, more preferably hydrogen, methyl, ethyl,
isopropyl, n-, iso or tert-butyl, phenyl, benzoyl, acetyl or
carboxy, even more preferably methyl, hydrogen or phenyl.
[0216] (17) Within the above preferred and more preferred groups
(6)-(16), an even more preferred group of compounds is that
wherein:
[0217] R.sup.1 is hydrogen, alkyl, --C(O)NR.sup.8R.sup.9,
unsubstituted cycloalkyl or aryl, preferably hydrogen, phenyl,
3,4-dimethoxyphenylamino- carbonyl,
4-methoxy-3-chlorophenylaminocarbonyl, even more preferably
hydrogen or methyl, most preferably hydrogen;
[0218] R.sup.2 is cyano, hydrogen, halo, lower alkoxy, aryl or
--S(O).sub.2NR.sup.13R.sup.14 wherein R.sup.13 is hydrogen and
R.sup.14 is hydrogen, aryl, or alkyl, preferably R.sup.2 is
hydrogen, chloro, bromo, fluoro, methoxy, ethoxy, phenyl,
dimethylaminosulfonyl, 3-chlorophenyl-aminosulfonyl, carboxy,
methoxy, aminosulfonyl, methylaminosulfonyl, phenylaminosulfonyl,
pyridin-3-yl-aminosulfonyl, dimethylaminosulfonyl,
isopropylamino-sulfonyl, more preferably hydrogen, fluoro, or
bromo;
[0219] R.sup.3 is selected from the group consisting of hydrogen,
lower alkoxy, --C(O)R.sup.5, --NR.sup.13C(O)R.sup.4, aryl
preferably aryl optionally substituted with one or two
substitutents selected from the group consisting of lower alkyl,
halo, or lower alkoxy, and heteroaryl, preferably heteroaryl
optionally substituted with one or two substitutents selected from
the group consisting of lower alkyl, halo, or lower alkoxy,
preferably hydrogen, methoxy, carboxy, phenyl, pyridin-3-yl,
3,4-dichlorophenyl, 2-methoxy-5 isopropylphenyl, 4-n-butylphenyl,
3-isopropylphenyl, more preferably hydrogen or phenyl; and
[0220] R.sup.4 is hydrogen.
[0221] (18) Another more preferred group of compounds of Formula
(I) is that wherein:
[0222] R.sup.1 is hydrogen, alkyl, --C(O)NR.sup.8R.sup.9,
unsubstituted cycloalkyl or aryl, preferably hydrogen,
3,4-dimethoxyphenyl-aminocarbony- l;
4-methoxy-3-chlorophenylaminocarbonyl, even more preferably
hydrogen or methyl, particularly hydrogen;
[0223] R.sup.2 is cyano, hydrogen, halo, lower alkoxy, aryl or
--S(O).sub.2NR.sup.13R.sup.14 wherein R.sup.13 is hydrogen and
R.sup.14 is hydrogen, aryl or alkyl, preferably R.sup.2 is
hydrogen, chloro, bromo, fluoro, methoxy, ethoxy, phenyl,
dimethylaminosulfonyl, 3-chlorophenyl-aminosulfonyl, carboxy,
methoxy, aminosulfonyl, methylaminosulfonyl, phenylaminosulfonyl,
pyridin-3-yl-aminosulfonyl, dimethylaminosulfonyl,
isopropylamino-sulfonyl, more preferably hydrogen, fluoro, or
bromo;
[0224] R.sup.3 is selected from the group consisting of hydrogen,
lower alkoxy, --C(O)R.sup.15, --NR.sup.13C(O)R.sup.14, aryl
preferably aryl* optionally substituted with one or two
substitutents selected from the group consisting of lower alkyl,
halo, or lower alkoxy, and heteroaryl, preferably heteroaryl
optionally substituted with one or two substitutents selected from
the group consisting of lower alkyl, halo, or lower alkoxy,
preferably hydrogen, methoxy, carboxy, phenyl, pyridin-3-yl,
3,4-dichlorophenyl, 2-methoxy-5-isopropylphenyl, 4-n-butylphenyl,
3-isopropylphenyl, more preferably hydrogen or phenyl; and
[0225] R.sup.4 is hydrogen.
[0226] Within the above preferred group (18) a more preferred group
of compounds is wherein:
[0227] R.sup.5 is --COR.sup.10 where R.sup.10 is as defined in the
Summary of the Invention, preferably
--NR.sup.11(CH.sub.2).sub.nR.sup.12 or --NR.sup.13R.sup.14 as
defined in the Summary of the Invention.
[0228] R.sup.6 is selected from the group consisting of hydrogen
and alkyl, preferably hydrogen, methyl, ethyl, isopropyl,
tert-butyl, isobutyl, or n-butyl, more preferably hydrogen or
methyl; and
[0229] R.sup.7 is selected from the group consisting of hydrogen,
alkyl, aryl, heteroaryl, and --C(O)R.sup.17 wherein R.sup.17 is
hydroxy, alkyl or aryl, more preferably hydrogen, methyl, ethyl,
isopropyl, n-, iso or tert-butyl, phenyl, benzoyl, acetyl or
carboxy, even more preferably methyl, hydrogen or phenyl.
[0230] In the above preferred group (18) another more preferred
group of compounds is that wherein:
[0231] R.sup.6 is --COR.sup.10 where R.sup.10 is as defined in the
Summary of the Invention, preferably
--NR.sup.11(CH.sub.2).sub.nR.sup.12 or --NR.sup.13R.sup.14 as
defined in the Summary of the Invention.
[0232] R.sup.5 is selected from the group consisting of hydrogen
and alkyl, preferably hydrogen, methyl, ethyl, isopropyl,
tert-butyl, isobutyl, or n-butyl, more preferably hydrogen or
methyl; and
[0233] R.sup.7 is selected from the group consisting of hydrogen,
alkyl, aryl, heteroaryl, and --C(O)R.sup.17 wherein R.sup.17 is
hydroxy, alkyl or aryl, more preferably hydrogen, methyl, ethyl,
isopropyl, n-, iso or tert-butyl, phenyl, benzoyl, acetyl or
carboxy, even more preferably methyl, hydrogen or phenyl.
[0234] (19) Another more preferred group of compounds of Formula
(I) is that wherein:
[0235] R.sup.1 and R.sup.4 are hydrogen;
[0236] R.sup.2 is selected from the group consisting of hydrogen,
halo, lower, alkoxy, --C(O)R.sup.15 and
--S(O).sub.2NR.sup.13R.sup.14;
[0237] R.sup.3 is selected from the group consisting of hydrogen,
lower alkoxy, --C(O)R.sup.15, --S(O).sub.2NR.sup.13R.sup.4, aryl
and heteroaryl;
[0238] R.sup.5 is --C(O)R.sup.10;
[0239] R.sup.6 is selected from the group consisting of hydrogen
and lower alkyl; and
[0240] R.sup.7 is selected from the group consisting of hydrogen,
lower alkyl and --C(O)R.sup.17.
[0241] It is another presently preferred embodiment of this
invention that, in a compound having a structure as described in
(15):
[0242] R.sup.10 is selected from the group consisting of hydroxy,
lower alkoxy and --NR.sup.1 (CH.sub.2).sub.nR.sup.12 wherein
[0243] n is 2 or 3;
[0244] R.sup.11 is selected from the group consisting of hydrogen
and lower alkyl; and,
[0245] R.sup.12 is selected from the group consisting of aryl and
--NR.sup.13R.sup.14.
[0246] It is a further presently preferred embodiment of this
invention that, in a compound having a structure as described in
the previous two paragraphs, R.sup.13 and R.sup.14 are
independently selected from the group consisting of hydrogen, lower
alkyl, and, combined, --(CH.sub.2).sub.4--,
--(CH.sub.2).sub.5--CH.sub.2).sub.2O(CH.sub.2).sub.- 2-- or
--(CH.sub.2).sub.2N(CH.sub.3)(CH.sub.2).sub.2--.
[0247] (20) Another presently preferred embodiment of this
invention is a compound in which:
[0248] R.sup.1 is selected from the group consisting of hydrogen,
lower alkyl, --(CH.sub.2).sub.rR.sup.16 and
--C(O)NR.sup.8R.sup.9;
[0249] R.sup.2 is group consisting hydrogen, halogen, aryl and
--S(O).sub.2NR.sup.13R.sup.14;
[0250] R.sup.3 is selected from the group consisting of hydrogen,
lower alkyl, lower alkoxy, aryl, heteroaryl and --C(O)R.sup.15;
[0251] R.sup.4 is hydrogen;
[0252] R.sup.5 is selected from the group consisting of hydrogen
and lower alkyl;
[0253] R.sup.6 is --C(O)R.sup.10;
[0254] R.sup.7 is selected from the group consisting of hydorgen,
lower alkyl and aryl;
[0255] R.sup.16 is selected from the group consisting of hydroxy
and --C(O)R.sup.15; and,
[0256] r is 2 or 3.
[0257] A presently preferred embodiment of this invention is a
compound having as structure described in the paragraph just above
in which R.sup.3 is aryl optionally substituted with one or more
groups selected from the group consisting of lower alkyl, lower
alkoxy and halo.
[0258] (21) Likewise, it is a presently preferred embodiment of
this invention that, in a compound in which:
[0259] R.sup.1 is selected from the group consisting of hydrogen,
lower alkyl, --(CH.sub.2)R.sup.16 and --C(O)NR.sup.8R.sup.9;
[0260] R.sup.2 is selected from the group consisting of hydrogen,
halogen, aryl and --S(O).sub.2NR.sup.13R.sup.14;
[0261] R.sup.3 is selected from the group consisting of hydrogen,
lower alkyl, lower alkoxy, aryl, heteroaryl and --C(O)R.sup.15;
[0262] R.sup.4 is hydrogen;
[0263] R.sup.5 is selected from the group consisting of hydrogen
and lower alkyl;
[0264] R.sup.6 is --C(O)R.sup.10;
[0265] R.sup.7 is selected from the group consisting of hydorgen,
lower alkyl and aryl;
[0266] R.sup.16 is selected from the group consisting of hydroxy
and --C(O)R.sup.15; and,
[0267] r is 2 or 3,
[0268] R.sup.10 is selected from the group consisting of hydroxy,
lower alkoxy, --NR.sup.13R.sup.14 and
--NR.sup.11(CH.sub.2).sub.nR.sup.12, wherein n is 1, 2 or 3,
R.sup.11 is hydrogen and R.sup.2 is selected from the group
consisting of hydroxy, lower alkoxy, --C(O)R.sup.15, heteroaryl:
and --NR.sup.13R.sup.14.
[0269] (22) A further presently preferred embodiment: of this
invention is a compound having a structure as described in the
paragraph immediately above in which R.sup.13 and R.sup.14 are
independently selected from the group consisting of hydrogen, lower
alkyl, heteroaryl and, combined, --(CH.sub.2).sub.4--,
--(CH.sub.2).sub.5--, --(CH.sub.2).sub.2O(CH.sub.2)- .sub.2--, or
--(CH.sub.2).sub.2N(CH.sub.3)(CH.sub.2).sub.2--.
[0270] (23) Another presently preferred embodiment of this
invention is a compound in which:
[0271] R.sup.1 is --C(O)NR.sup.8R.sup.9, wherein R.sup.8 is
hydrogen and R.sup.9 is aryl optionally substituted with one or
more groups selected from the group consisting of halo, hydroxy and
lower alkoxy;
[0272] R.sup.2 is selected from the group consisting of hydrogen,
halogen, aryl and --S(O).sub.2NR.sup.13R.sup.14;
[0273] R.sup.3 is selected from the group consisting-of hydrogen,
lower alkyl, lower alkoxy, aryl, heteroaryl and --C(O)R.sup.15;
[0274] R.sup.4 is hydrogen;
[0275] R.sup.5 is selected from the group consisting of hydrogen
and lower alkyl;
[0276] R.sup.6 is --C(O)R.sup.10;
[0277] R.sup.7 is selected from the group consisting of hydorgen,
lower alkyl and aryl;
[0278] R.sup.16 is selected from the group consisting of hydroxy
and --C(O)R.sup.15; and,
[0279] r is 2 or 3,
[0280] (24) A still further presently preferred embodiment of this
invention is a compound in which:
[0281] R.sup.1 is selected from the group consisting of hydrogen
and lower alkyl;
[0282] R.sup.2 is selected from the group consisting of hydrogen,
halo, lower alkoxy, aryl, --C(O)R.sup.15 and
--S(O).sub.2NR.sup.13R.sup.14;
[0283] R.sup.3 is selected from the group consisting of hydrogen,
halo, aryl, heteroaryl and --C(O)R.sup.15;
[0284] R.sup.4 is hydrogen;
[0285] R.sup.5 is --C(O)R.sup.10; and
[0286] R.sup.6 and R.sup.7 combine to form a --(CH.sub.2).sub.4--
group.
[0287] In a compound having a structure as described in the
paragraph immediately above, it is a presently preferred embodiment
that R.sup.10 is selected from the group consisting of hydroxy,
alkoxy, --NR.sup.13R.sup.14 and
--NH(CH.sub.2).sub.nNR.sup.13R.sup.14 wherein n is 2 or 3.
[0288] It is a presently preferred embodiment of this, invention
that, in a compound having a structure as described in the two
paragraphs immediately above, R.sup.13 and R.sup.14 are
independently selected from the group consisting of hydrogen, lower
alkyl, and, combined, --(CH.sub.2).sub.4--, --(CH.sub.2).sub.5--,
--(CH.sub.2).sub.2O(CH.sub.2)- .sub.2-- or
--(CH.sub.2).sub.2N(CH.sub.3)(CH.sub.2).sub.2--.
Utility
[0289] The PKs whose catalytic activity is modulated by the
compounds of this invention include protein tyrosine kinases of
which there are two types, receptor tyrosine kinases (RTKs), and
cellular tyrosine kinases (CTKs), and serine-threonine kinases
(STKs). RTK mediated signal transduction is initiated by
extracellular interaction with a specific growth factor (ligand),
followed by receptor dimerization, transient, stimulation of the
intrinsic protein tyrosine kinase activity and phosphorylation.
Binding sites are thereby created for intracellular signal
transduction molecules and lead to the formation of complexes with
a spectrum of cytoplasmic signaling molecules that facilitate the
appropriate cellular response (e.g., cell division, metabolic
effects on the extracellular microenvironment, etc.). See,
Schlessinger and Ullrich, 1992, Neuron 9:303-391.
[0290] It has been shown that tyrosine phosphorylation sites on
growth factor receptors function as high-affinity binding sites for
SH2 (src homology) domains of signaling molecules. Fantl et al.,
1992, Cell 69:413-423, Songyang et al., 1994, Mol. Cell. Biol.
14:2777-2785), Songyang et al., 1993, Cell 72:767-778, and Koch et
al., 1991, Science 252:668-678. Several intracellular substrate
proteins that associate with RTKs have been identified. They may be
divided into two principal groups: (1) substrates that have a
catalytic domain, and (2) substrates which lack such domain but
which-serve as adapters and associate with catalytically active
molecules. Songyang et al., 1993, Cell 72:767-778. The specificity
of the interactions between receptors and SH2 domains of their
substrates is determined by the amino acid residues immediately
surrounding the phosphorylated tyrosine residue. Differences in the
binding affinities between SH2 domains and the amino acid sequences
surrounding the phosphotyrosine residues on particular receptors
are consistent with the observed differences in their substrate
phosphorylation profiles. Songyang et al., 1993, Cell 72:767-778.
These observations suggest that the function of each RTK is
determined not only by its pattern of expression and ligand
availability but also by the array of downstream signal
transduction pathways that are activated by a particular receptor.
Thus, phosphorylation provides an important regulatory step which
determines the selectivity of signaling pathways recruited by
specific growth factor receptors, as well as differentiation factor
receptors.
[0291] STKs, being primarily cytosolic, affect the internal
biochemistry of the cell, often as a down-line response to a PTK
event. STKs have been implicated in the signaling process which
initiates DNA synthesis and subsequent mitosis leading to cell
proliferation.
[0292] Thus, PK signal transduction results in, among other
responses, cell proliferation, differentiation, growth and
metabolism. Abnormal cell proliferation may result in a wide array
of disorders and diseases, including the development of neoplasia
such as carcinoma, sarcoma, glioblastoma and hemangioma, disorders
such as leukemia, psoriasis, arteriosclerosis, arthritis and
diabetic retinopathy and other disorders related to uncontrolled
angiogenesis and/or vasculogenesis.
[0293] A precise understanding of the mechanism by which the
compounds of this invention inhibit PKs is not required in order to
practice the present invention. However, while not hereby being
bound to any particular mechanism or theory, it is believed that
the compounds interact with the amino acids in the catalytic region
of PKs. PKs typically possess a bi-lobate structure wherein ATP
appears to bind in the cleft between the two lobes in a region
where the amino acids are conserved among PKs. Inhibitors of PKs
are believed to bind by non-covalent interactions such as hydrogen
bonding, van der Waals forces and ionic interactions in the same
general region where the aforesaid ATP binds to the PKs. More
specifically, it is thought that the 2-indolinone component of the
compounds of this invention binds in the general space normally
occupied by the adenine ring of ATP. Specificity of a particular
molecule for a particular PK may then arise as the result of
additional interactions between the various substituents on the
2-indolinone core and the amino acid domains specific to particular
PKs. Thus, different indolinone substituents may contribute to
preferential binding to particular PKs. The ability to select
compounds active at different ATP (or other nucleotide) binding
sites makes the compounds of this invention useful for targeting
any protein with such a site. The compounds disclosed herein thus
have utility in in vitro assays for such proteins as well as
exhibiting in vivo therapeutic effects through interaction with
such proteins.
[0294] Additionally, the compounds of the present invention provide
a therapeutic approach to the treatment of many kinds of solid
tumors, including but not limited to carcinomas, sarcomas including
Kaposi's sarcoma, erythroblastoma, glioblastoma, meningioma,
astrocytoma, melanoma and myoblastoma. Treatment or prevention of
non-solid tumor cancers such as leukemia are also contemplated by
this invention. Indications may include, but are not limited to
brain cancers, bladder cancers, ovarian cancers, gastric cancers,
pancreas cancers, colon cancers, blood cancers, lung cancers and
bone cancers.
[0295] Further examples, without limitation, of the types of
disorders related to inappropriate PK activity that the compounds
described herein may be useful in preventing, treating and
studying, are cell proliferative disorders, fibrotic disorders and
metabolic disorders.
[0296] Cell proliferative disorders, which may be prevented,
treated or further studied by the present invention include cancer,
blood vessel proliferative disorders and mesangial cell
proliferative disorders.
[0297] Blood vessel proliferative disorders refer to disorders
related to abnormal vasculogenesis (blood vessel formation) and
angiogenesis (spreading of blood vessels). While vasculogenesis and
angiogenesis play important roles in a variety of normal
physiological processes such as embryonic development, corpus
luteum formation, wound healing and organ regeneration, they also
play a pivotal role in cancer development where they result in the
formation of new capillaries needed to keep a tumor alive. Other
examples of blood vessel proliferation disorders include arthritis,
where new capillary blood vessels invade the joint and destroy
cartilage, and ocular diseases, like diabetic retinopathy, where
new capillaries in the retina invade the vitreous, bleed and cause
blindness.
[0298] Two structurally related RTKs have been identified to bind
VEGF with high affinity: the fms-like tyrosine, 1 (fit-1) receptor
(Shibuya et al., 1990, Oncogene, 5:519-524; De Vries et al., 1992,
Science, 255:989-991) and the KDR/FLK-1 receptor, also known as
VEGF-R2. Vascular endothelial growth factor (VEGF) has been
reported to be an endothelial cell specific mitogen with in vitro
endothelial cell growth promoting activity. Ferrara & Henzel,
1989, Biochein. Biophys. Res. Comm., 161:851-858; Vaisman et al.,
1990, J. Biol. Chem., 265:19461-19566. Information set forth in
U.S. application Ser. Nos. 08/193,829, 08/038,596 and 07/975,750,
strongly suggest that VEGF is not only responsible for endothelial
cell, proliferation, but also is the prime regulator of normal and
pathological angiogenesis. See generally, Klagsburn & Soker,
1993, Current Biology, 3(10)699-702; Houck, et al., 1992, J. Biol.
Chem., 267:26031-26037.
[0299] Normal vasculogenesis and angiogenesis play important roles
in a variety of physiological processes such as embryonic
development, wound healing, organ regeneration and female
reproductive processes such as follicle development in the corpus
luteum during ovulation and placental growth after pregnancy.
Folkman & Shing, 1992, J. Biological Chem., 267(16):10931-34.
Uncontrolled vasculogenesis and/or angiogenesis has been associated
with diseases such as diabetes as well as with malignant solid
tumors that rely on vascularization for growth. Klagsburn &
Soker, 1993, Current Biology, 3(10):699-702; Folkham, 1991, J.
Natl. Cancer Inst., 82:4-6; Weidner, et al., 1991, New Engl. J.
Med., 0.324:1-5.
[0300] The surmised role of VEGF in endothelial cell proliferation
and migration during angiogenesis and vasculogenesis indicates an
important role for the KDR/FLK-1 receptor in these processes.
Diseases such as diabetes mellitus (Folkman, 198, in XIth Congress
of Thrombosis and Haemostasis (Verstraeta, et al., eds.), pp.
583-596, Leuven University Press, Leuven) and arthritis, as well as
malignant tumor growth may result from uncontrolled angiogenesis.
See e.g.; Folkman, 1971, N. Engl. J. Med., 285:1182-1186. The
receptors to which VEGF specifically binds are an important and
powerful therapeutic target for the regulation and modulation of
vasculogenesis and/or angiogenesis and a variety of severe diseases
which involve abnormal cellular growth caused by such processes.
Plowman, et al., 1994, DN&P, 7(6):334-339. More particularly,
the KDR/FLK-1 receptor's highly specific role in neovascularization
make it a choice target for therapeutic approaches to the treatment
of cancer and other diseases which involve the uncontrolled
formation of blood vessels.
[0301] Thus, the present invention provides compounds capable of
regulating and/or modulating tyrosine kinase signal transduction
including KDR/FLK-1 receptor signal transduction in order to
inhibit or promote angiogenesis and/or vasculogenesis, that is,
compounds that inhibit, prevent, or interfere with the signal
transduced by KDR/FLK-1 when activated by ligands such as VEGF.
Although it is believed that the compounds of the present invention
act on a receptor or other component along the tyrosine kinase
signal transduction pathway, they may also act directly on the
tumor cells that result from uncontrolled angiogenesis.
[0302] Although the nomenclature of the human and murine
counterparts of the generic "flk-I" receptor differ, they are, in
many respects, interchangeable. The murine receptor, Flk-1, and its
human counterpart, KDR, share a sequence homology of 93.4% within
the intracellular domain. Likewise, murine FLK-1 binds human VEGF
with the same affinity as mouse VEGF, and accordingly is activated
by the ligand derived from either species. Millauer et al., 1993,
Cell, 72:835-846; Quinn et al., 1993, Proc. Natl. Acad. Sci. USA,
90:7533-7537. FLK-1 also associates with and subsequently tyrosine
phosphorylates human RTK substrates (e.g., PLC-.gamma. or p85) when
co-expressed in 293 cells (human embryonal kidney fibroblasts).
[0303] Models which rely upon the FLK-1 receptor therefore are
directly applicable to understanding the KDR receptor. For example,
use of the murine FLK-1 receptor in methods which identify
compounds that regulate the murine signal transduction pathway are
directly applicable to the, identification of compounds which may
be used to regulate the human signal transduction pathway, that is,
which regulate activity related to the KDR receptor. Thus, chemical
compounds identified as inhibitors of KDR/FLK-1 in vitro, can be
confirmed in suitable in vivo models. Both in vivo mouse and rat
animal models have been demonstrated to be of excellent value for
the examination of the clinical potential of agents acting on the
KDR/FLK-1 induced signal transduction pathway.
[0304] Thus, the present invention provides compounds that
regulate, modulate and/or inhibit vasculogenesis and/or
angiogenesis by affecting the enzymatic activity of the KDR/FLK-1
receptor and interfering with the signal transduced by KDR/FLK-1.
Thus the present invention provides a therapeutic approach to the
treatment of many kinds of solid tumors including, but not limited
to, glioblastoma, melanoma and Kaposi's sarcoma, and ovarian, lung,
mammary, prostate, pancreatic, colon and epidermoid carcinoma. In
addition, data suggests the administration of compounds which
inhibit the KDR/Flk-1 mediated signal transduction pathway may also
be used in the treatment of hemangioma, restenois and diabetic
retinopathy.
[0305] Furthermore, this invention relates to the inhibition of
vasculogenesis and angiogenesis by other receptor-mediated
pathways, including the pathway comprising the flt-1 receptor.
[0306] Receptor tyrosine kinase mediated signal transduction is
initiated by extracellular interaction with a specific growth
factor (ligand), followed by receptor dimerization, transient
stimulation of the intrinsic protein tyrosine kinase activity and
autophosphorylation. Binding sites are thereby created for
intracellular signal transduction molecules which leads to the
formation of complexes with a spectrum of cytoplasmic signalling
molecules that facilitate the appropriate cellular response, e.g.,
cell division and metabolic effects to the extracellular
microenvironment. See, Schlessinger and Ullrich, 1992, Neuron,
9:1-20.
[0307] The close homology of the intracellular regions of KDR/FLK-1
with that of the PDGF-.beta. receptor (50.3% homology) and/or the
related flt-1 receptor indicates the induction of overlapping
signal transduction pathways. For example, for the PDGF-.beta.
receptor, members of the src family (Twamley et al., 1993, Proc.
Natl. Acad. Sci. USA, 90:7696-7700), phosphatidylinositol-3'-kinase
(Hu et al. 1992, Mol. Cell. Biol., 12:981-990), phospholipase
c.gamma. (Kashishian & Cooper, 1993, Mol. Cell. Biol.,
4:49-51), ras-GTPase-activating protein, (Kashishian et al., 1992,
EMBO J., 11:1373-1382), PTP-ID/syp (Kazlauskas et al., 1993, Proc.
Natl. Acad. Sci. USA, 10 90:6939-6943), Grb2 (Arvidsson et al.,
1994, Mol. Cell. Biol., 14:6715-6726), and the adapter molecules
Shc and Nck (Nishimura et al., 1993, Mol. Cell. Biol.,
13:6889-6896), have been shown to bind to regions involving
different autophosphorylation sites. See generally, Claesson-Welsh,
1994, Prog. Growth Factor Res., 5:37-54. Thus, it is likely that
signal transduction pathways activated by KDR/FLK-1 include the ras
pathway (Rozakis et al., 1992, Nature, 360:689-692), the
PI-3'-kinase, the src-mediated and the plc.gamma.-mediated
pathways. Each of these pathways may play a critical role in the
angiogenic and/or vasculogenic effect of KDR/FLK-1 in endothelial
cells. Consequently, a still further aspect of this invention
relates to the use of the organic compounds described herein to
modulate angiogenesis and vasculogenesis as such processes are
controlled by these pathways.
[0308] Conversely, disorders related to the shrinkage, contraction
or closing of blood vessels, such as restenosis, are also
implicated and may be treated or prevented by the methods of this
invention.
[0309] Fibrotic disorders refer to the abnormal formation of
extracellular matrices. Examples of fibrotic disorders include
hepatic cirrhosis and mesangial cell proliferative disorders.
Hepatic cirrhosis is characterized by the increase in extracellular
matrix constituents resulting in the formation of a hepatic scar.
An increased extracellular matrix resulting in a hepatic scar can
also be caused by a viral infection such as hepatitis. Lipocytes
appear to play a major role in hepatic cirrhosis. Other fibrotic
disorders implicated include atherosclerosis.
[0310] Mesangial cell proliferative disorders refer to disorders
brought about by abnormal proliferation of mesangial cells.
Mesangial proliferative disorders include various human renal
diseases such as glomerulonephritis, diabetic nephropathy and
malignant nephrosclerosis as well as such disorders as thrombotic
microangiopathy syndromes, transplant rejection, and
glomerulopathies. The RTK PDGFR has been implicated in the
maintenance of mesangial cell proliferation. Floege et al., 1993,
Kidney International 43:47S-54S.
[0311] Many cancers are cell proliferative disorders and, as noted
previously, PKs have been associated with cell proliferative
disorders. Thus, it is not surprising that PKs such as, for
example, members of the RTK family have been associated with the
development of cancer. Some of these receptors, like EGFR (Tuzi et
al., 1991, Br. J. Cancer 63:227233, Torp et al., 1992, APMIS
100:713-719) HER2/neu (Slamon et al., 1989, Science 244:707-712)
and PDGF-R (Kumabe et al., 1992, Oncogene, 7:627-633) are
over-expressed in many tumors and/or persistently activated by
autocrine loops. In fact, in the most common and severe cancers
these receptor over-expressions (Akbasak and Suner-Akbasak et al.,
1992, J. Neurol. Sci., 111:119-133, Dickson et al., 1992, Cancer
Treatment Res. 61:249-273, Korc et al. 1992, J. Clin. Invest.
90:1352-1360) and autocrine loops (Lee and Donoghue, 1992, J. Cell.
Biol., 118:1057-1070, Korc et al., supra, Akbasak and Suner-Akbasak
et al., supra) have been demonstrated. For example, EGFR has been
associated with squamous cell carcinoma, astrocytoma, glioblastoma,
head and neck cancer, lung cancer and bladder cancer. HER2 has been
associated with breast, ovarian, gastric, lung, pancreas and
bladder cancer. PDGFR has been associated with glioblastoma and
melanoma as well as lung, ovarian and prostate cancer. The RTK
c-met has also been associated with malignant tumor formation. For
example, c-met has been associated with, among other cancers,
colorectal, thyroid, pancreatic, gastric and hepatocellular
carcinomas and lymphomas. Additionally c-met has been linked to
leukemia. Over-expression of the c-met gene has also been detected
in patients with Hodgkins disease and Burkitts disease.
[0312] IGF-IR, in addition to being implicated in nutritional
support and in type-II diabetes, has also been associated with
several types of cancers. For example, IGF-I has been implicated as
an autocrine growth stimulator for several tumor types, e.g. human
breast cancer carcinoma cells (Arteaga et al., 1989, J. Clin.
Invest. 84:1418-1423) and small lung tumor cells.(Macauley et al.,
1990, Cancer Res. 50:22511-2517). In addition, IGF-I, while
integrally involved in the normal growth and differentiation of the
nervous system, also appears to be an autocrine stimulator of human
gliomas. Sandberg-Nordqvist et al., 1993, Cancer Res. 53:2475-2478.
The importance of IGF-IR and its ligands in cell proliferation is
further supported by the fact that many cell types in culture
(fibroblasts, epithelial cells, smooth muscle cells, T-lymphocytes,
myeloid cells, chondrocytes and osteoblasts (the stem cells of the
bone marrow)) are stimulated to grow by IGF-I. Goldring and
Goldring, 1991, Eukaryotic Gene Expression, 1:301-326. Baserga and
Coppola suggest that IGF-IR plays a central role in the mechanism
of transformation and, as such, could be a preferred target for
therapeutic interventions for a broad spectrum of human
malignancies. Baserga, 1995, Cancer Res., 55:249-252, Baserga,
1994, Cell 79:927-930, Coppola et al., 1994, Mol. Cell. Biol.,
14:4588-4595.
[0313] STKs have-been implicated in many types of cancer including,
notably, breast cancer (Cance, et al., Int. J. Cancer, 54:571-77
(1993)).
[0314] The association between abnormal PK activity and disease is
not restricted to cancer. For example, RTKs have been associated
with diseases such as psoriasis, diabetes mellitus, endometriosis,
angiogenesis, atheromatous plaque development, Alzheimer's disease,
restenosis, von Hippel-Lindau disease, epidermal
hyperproliferation, neurodegenerative diseases, age related macular
degeneration and hemangiomas. For example, EGFR has been indicated
in corneal and dermal wound healing. Defects in Insulin-R and
IGF-1R are indicated in type-II diabetes mellitus. A more complete
correlation between specific RTKs and their therapeutic indications
is set forth in Plowman et al., 1994; DN&P 7:334-339.
[0315] As noted previously, not only RTKs but CTKs including; but
not limited to, src, abl, fps, yes, fyn, lyn, lck, blk, hck, fgr
and yrk (reviewed by Bolen et al., 1992, FASEB J., 6:3403-3409) are
involved in the proliferative and metabolic signal transduction
pathway and thus could be expected, and have been shown, to be
involved in many PTK-mediated disorders to which the present
invention is directed. For example, mutated src (v-src) has been
shown to be an oncoprotein (pp60.sup.v-src) in chicken. Moreover,
its cellular homolog, the proto-oncogene pp60.sup.c-src transmits
oncogenic signals of many receptors. Over-expression of EGFR or
HER2/neu in tumors leads to the constitutive activation of
pp60.sup.c.quadrature.src, which is characteristic of malignant
cells but absent in normal cells. On the other hand, mice deficient
in the expression of c-src exhibit an osteopetrotic phenotype,
indicating a key participation of c-src in osteoclast function and
a possible involvement in related disorders.
[0316] Similarly, Zap70 has been implicated in T-cell signaling
which may relate to autoimmune disorders.
[0317] STKs have been associated with inflamation, autoimmune
disease, immunoresponses, and hyperproliferation disorders such as
restenosis, fibrosis, psoriasis, osteoarthritis and rheumatoid
arthritis.
[0318] PKs have also been implicated in embryo implantation. Thus,
the compounds of this invention may provide an effective method of
preventing such embryo implantation and thereby be useful as birth
control agents. Additional disorders which may be treated or
prevented using the compounds of this invention are immunological
disorders such as autoimmune-disease, AIDS and cardiovasular
disorders such as atherosclerosis.
[0319] Finally, both RTKs and CTKs are currently suspected as being
involved in hyperimmune disorders.
[0320] Examples of the effect of a number of exemplary compounds of
this invention on several PTKs are shown in Table 2 below. The
compounds and data presented are not to be construed as limiting
the scope of this invention in any manner whatsoever.
Administration and Pharmaceutical Composition
[0321] A compound of the present invention or a phearmaceutically
acceptable salt thereof, can be administered as such to a human
patient or can be administered in pharmaceutical compositions in
which the foregoing materials are mixed with suitable carriers or
excipient(s). Techniques for formulation and administration of
drugs may be found in "Remington's Pharmacological Sciences," Mack
Publishing Co., Easton, Pa., latest edition.
[0322] As used herein, "administer" or "administration" refers to
the delivery of a compound of Formula (I) or a pharmaceutically
acceptable salt thereof or of a pharmaceutical composition
containing a compound of Formula (I) or a pharmaceutically
acceptable salt thereof of this invention to an organism for the
purpose of prevention or treatment of a PK-related disorder.
[0323] Suitable routes of administration may include, without
limitation, oral, rectal, transmucosal or intestinal administration
or intramuscular, subcutaneous, intramedullary, intrathecal, direct
intraventricular, intravenous, intravitreal, intraperitoneal,
intranasal, or intraocular injections. The preferred routes of
administration are oral and parenteral.
[0324] Alternatively, one may administer the compound in a local
rather than systemic manner, for example, via injection of the
compound directly into a solid tumor, often in a depot or sustained
release formulation.
[0325] Furthermore, one may administer the drug in a targeted drug
delivery system, for example, in a liposome coated with
tumor-specific antibody. The liposomes will be targeted to and
taken upselectively by the tumor.
[0326] Pharmaceutical compositions of the present invention may be
manufactured by processes well known in the art, e.g., by means of
conventional mixing, dissolving, granulating, dragee-making,
levigating, emulsifying, encapsulating, entrapping or lyophilizing
processes.
[0327] Pharmaceutical compositions for use in accordance with the
present invention may be formulated in conventional manner using
one or more physiologically acceptable carriers comprising
excipients and auxiliaries which facilitate processing of the
active compounds into preparations which can be used
pharmaceutically. Proper formulation is dependent upon the route of
administration chosen.
[0328] For injection, the compounds of the invention may be
formulated in aqueous solutions, preferably in physiologically
compatible buffers such as Hanks' solution, Ringer's solution, or
physiological saline buffer. For transmucosal administration,
penetrants appropriate to the barrier to be permeated are used in
the formulation. Such penetrants are generally known in the
art.
[0329] For oral administration, the compounds can be formulated by
combining the active compounds with pharmaceutically acceptable
carriers well known in the art. Such carriers enable the compounds
of the invention to be formulated as tablets, pills, lozenges,
dragees, capsules, liquids, gels, syrups, slurries, suspensions and
the like, for oral ingestion by a patient. Pharmaceutical
preparations for oral use can be made using a solid excipient,
optionally grinding the resulting mixture, and processing the
mixture of granules, after adding other suitable auxiliaries if
desired, to obtain tablets or dragee cores. Useful excipients are,
in particular, fillers such as sugars, including lactose, sucrose,
mannitol, or sorbitol, cellulose preparations such as, for example,
maize starch, wheat starch, rice starch and potato starch and other
materials such as gelatin, gum tragacanth, methyl cellulose,
hydroxypropylmethyl-cellulose, sodium carboxymethylcellulose,
and/or polyvinyl-pyrrolidone (PVP). If desired, disintegrating
agents may be added, such as cross-linked polyvinyl pyrrolidone,
agar, or alginic acid. A salt such as sodium alginate may also be
used.
[0330] Dragee cores are provided with suitable coatings. For this
purpose, concentrated sugar solutions may be used which may
optionally contain gum arabic, talc, polyvinyl pyrrolidone,
carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer
solutions, and suitable organic solvents or solvent mixtures.
Dyestuffs or pigments may be added to the tablets or dragee
coatings for identification or to characterize different
combinations of active compound doses.
[0331] Pharmaceutical compositions which can be used orally include
push-fit capsules made of gelatin, as well as soft, sealed capsules
made of gelatin and a plasticizer, such as glycerol or sorbitol.
The push-fit capsules can contain the active ingredients in
admixture with a filler such as lactose, a binder such as starch,
and/or a lubricant such as talc or magnesium stearate and,
optionally, stabilizers. In soft capsules, the active compounds may
be dissolved or suspended in suitable liquids, such as fatty oils,
liquid paraffin, or liquid polyethylene glycols. Stabilizers may be
added in, these formulations, also.
[0332] Pharmaceutical compositions which may also be used include
hard gelatin capsules. As a non-limiting example, the active
compound capsule oral drug product formulation may be as 50 and 200
mg dose strengths (formulation codes J-011248-AA-00 and
J-011248-AA-01, respectively). The two dose strengths are made from
the same granules by filling into different size hard gelatin
capsules; size 3 for the 50 mg capsule and size 0 for the 200 mg
capsule. The composition of the formulation may be, for example, as
indicated in Table 2.
2TABLE 2 Amount in Concentration 200 mg Ingredient in Granulation
Amount in 50 mg Capsule Name/Grade (% w/w) Capsule (mg) (mg)
Formulation Code J-011248-AA J-011248-AA-00 J-011248- AA-01 Active
Compound 65.0 50.0 200.0 NF Mannitol NF 23.5 18.1 72.4
Croscarmellose 6.0 4.6 18.4 sodium NE Povidone K 30 NF 5.0 3.8 15.2
Magnesium 0.5 0.38 1.52 stearate NE Capsule, Swedish Size 3 Size 0
yellow NF
[0333] The capsules may be packaged into brown glass or plastic
bottles to protect the active compound from light. The containers
containing the active compound capsule formulation must be stored
at controlled room temperature (15-30.degree. C.).
[0334] For administration by inhalation, the compounds for use
according to the present invention are conveniently delivered in
the form of an aerosol spray using a pressurized pack or a
nebulizer and a suitable propellant, e.g., without limitation,
dichlorodifluoromethane, trichlorofluoromethane,
dichlorotetra-fluoroethane or carbon dioxide. In the case of a
pressurized aerosol, the dosage unit may be controlled by providing
a valve to deliver a metered amount. Capsules and cartridges of,
for example, gelatin for use in an inhaler or insufflator may be
formulated containing a powder mix of the compound and a suitable
powder base such as lactose or starch.
[0335] The compounds may also be formulated for parenteral
administration, e.g., by bolus injection or continuous infusion.
Formulations for injection may be presented in unit dosage form,
e.g., in ampoules or in multi-dose containers, with an added
preservative. The compositions may take such forms as suspensions,
solutions or emulsions in oily or aqueous vehicles, and may contain
formulating materials such as suspending, stabilizing and/or
dispersing agents.
[0336] Pharmaceutical compositions for parenteral administration
include aqueous solutions of a water soluble form, such as, without
limitation, a salt, of the active compound. Additionally,
suspensions of the active compounds may be prepared in a lipophilic
vehicle. Suitable lipophilic vehicles include fatty oils such as
sesame oil, synthetic fatty acid esters such as ethyl oleate and
triglycerides, or materials such as liposomes. Aqueous injection
suspensions may contain substances which increase the viscosity of
the suspension, such as sodium carboxymethyl cellulose, sorbitol,
or dextran. Optionally, the suspension may also contain suitable
stabilizers and/or agents that increase the solubility of the
compounds to allow for the preparation of highly concentrated
solutions.
[0337] Alternatively, the active ingredient may be in powder form
for constitution with a suitable vehicle, e.g., sterile,
pyrogen-free water, before use.
[0338] The compounds may also be formulated in rectal compositions
such as suppositories or retention enemas, using, e.g.,
conventional suppository bases such as cocoa butter or other
glycerides.
[0339] In addition to the fomulations described previously, the
compounds may also be formulated as depot preparations. Such long
acting formulations may be administered by implantation (for
example, subcutaneously or intramuscularly) or by intramuscular
injection. A compound of this invention may be formulated for this
route of administration with suitable polymeric or hydrophobic
materials (for instance, in an emulsion with a pharamcologically,
acceptable oil), with ion exchange resins, or as a sparingly
soluble derivative such as, without limitation, a sparingly soluble
salt.
[0340] A non-limiting example of a pharmaceutical carrier for the
hydrophobic compounds of the invention is a cosolvent system
comprising benzyl alcohol, a nonpolar surfactant, a water-miscible
organic polymer and an aqueous phase such as the VPD co-solvent
system. VPD is a solution of 3% w/v benzyl alcohol, 8% w/v of the
nonpolar surfactant Polysorbate 80, and 65% w/v polyethylene glycol
300, made up to volume in absolute ethanol. The VPD co-solvent
system (VPD:D5W) consists of VPD diluted 1:1 with a 5% dextrose in
water solution. This cosolvent system dissolves hydrophobic
compounds well, and itself produces low toxicity upon systemic
administration. Naturally, the proportions of such a co-solvent
system may be varied considerably without destroying its solubility
and toxicity characteristics. Furthermore, the identity of the
co-solvent components may be varied: for example, other
low-toxicity nonpolar surfactants may be used instead of
Polysorbate 80, the fraction size of polyethylene glycol may be
varied, other biocompatible polymers may replace polyethylene
glycol, e.g., polyvinyl pyrrolidone, and other sugars or
polysaccharides may substitute for dextrose.
[0341] Alternatively, other delivery systems for hydrophobic
pharmaceutical compounds may be employed. Liposomes and emulsions
are well known examples of delivery vehicles or carriers for
hydrophobic drugs. In addtion, certain organic solvents such as
dimethylsulfoxide also may be employed, although often at the cost
of greater toxicity.
[0342] Additionally, the compounds may be delivered using a
sustained-release system, such as semipermeable matrices of solid
hydrophobic polymers containing the therapeutic agent. Various
sustained-release materials have been established and are well
known by those skilled in the art. Sustained-release capsules may,
depending on their chemical nature, release the compounds for a few
weeks up to over 100 days. Depending on the chemical nature and the
biological stability of the therapeutic reagent, additional
strategies for protein stabilization may be employed.
[0343] The pharmaceutical compositions herein also may comprise
suitable solid or gel phase carriers or excipients. Examples of
such carriers or excipients include, but are not limited to,
calcium carbonate, calcium phosphate, various sugars, starches,
cellulose derivatives, gelatin, and polymers such as polyethylene
glycols.
[0344] Many of the PK modulating compounds of the invention may be
provided as physiologically acceptable salts wherein the claimed
compound may form the negatively or the positively charged species.
Examples of salts in which the compound forms the positively
charged moiety include, without limitation, quaternary ammonium
(defined elsewhere herein), salts such as the hydrochloride,
sulfate, carbonate, lactate, tartrate, malate, maleate, succinate
wherein the nitrogen atom of the quaternary ammonium group is a
nitrogen of the selected compound of this invention which has
reacted with the appropriate acid. Salts in which a compound of
this invention forms the negatively charged species include,
without limitation, the sodium, potassium, calcium and magnesium
salts formed by the reaction of a carboxylic acid group in the
compound with an appropriate base (e.g. sodium hydroxide (NaOH),
potassium hydroxide (KOH), Calcium hydroxide (Ca(OH).sub.2),
etc.).
[0345] Pharmaceutical compositions suitable for use in the present
invention include compositions wherein the active ingredients are
contained in an amount sufficient to achieve the intended purpose,
e.g., the modulation of PK activity or the treatment or prevention
of a PK-related disorder.
[0346] More specifically, a therapeutically effective amount means
an amount of compound effective to prevent, alleviate or ameliorate
symptoms of disease or prolong the survival of the subject being
treated.
[0347] Determination of a therapeutically effective amount is well
within the capability of those skilled in the art, especially in
light of the detailed disclosure provided herein.
[0348] For any compound used in the methods of the invention, the
therapeutically effective amount or dose can be estimated initially
from cell culture assays. Then, the dosage can be formulated for
use in animal models so as to achieve a circulating concentrations
range that includes the IC.sub.50 as determined in cell culture
(i.e., the concentration of the test compound which achieves a
half-maximal inhibition of the PK activity). Such information can
then be used to more accurately determine useful doses in
humans.
[0349] Toxicity and therapeutic efficacy of the compounds described
herein can be determined by standard pharmaceutical procedures in
cell cultures or experimental animals, e.g., by determining the
IC.sub.50 and the LD.sub.50 (both of which are discussed elsewhere
herein) for a subject compound. The data obtained from these cell
culture assays and animal studies can be used in formulating a
range of dosage for use in humans. The dosage may vary depending
upon the dosage form employed and the route of administration
utilized. The exact formulation, route of administration and dosage
can be chosen by the individual physician in view of the patient's
condition. (See e.g., Fingl, et al., 1975, in "The Pharmacological
Basis of Therapeutics", Ch. 1 p.1).
[0350] Dosage amount and interval may be adjusted individually to
provide plasma levels of the active species which are sufficient to
maintain the kinase modulating effects. These plasma levels are
referred to as minimal effective concentrations (MECs). The MEC
will vary for each compound, but can be estimated from in vitro
data, e.g., the concentration necessary to achieve 50-90%
inhibition of a kinase may be ascertained using the assays
described herein. Dosages necessary to achieve the MEC will depend
on individual characteristics and route of administration. HPLC
assays or bioassays can be used to determine plasma
concentrations.
[0351] Dosage intervals can also be determined using MEC value.
Compounds should be administered using a regimen that it maintains
plasma levels above the MEC for 10-90% of the time, preferably
between 30-90% and most preferably between 50-90%.
[0352] At present, the therapeutically effective amounts of
compounds of Formula (I) may range from approximately 25 mg/m.sup.2
to 1500 mg/m.sup.2 per day; preferably about 3 mg/m.sup.2/day. Even
more preferably 50 mg/qm qd till 400 mg/qd.
[0353] In cases of local administration or selective uptake, the
effective local concentration of the drug may not be related to
plasma concentration and other procedures known in the art may be
employed to determine the correct dosage amount and interval.
[0354] The amount of a composition administered will, of course, be
dependent on the subject being treated, the severity of the
affliction, the manner of administration, the judgment of the
prescribing physician, etc.
[0355] The compositions may, if desired, be presented in a pack or
dispenser device, such as an FDA approved kit, which may if contain
one or more unit dosage forms containing the active ingredient. The
pack may for example comprise metal or plastic foil, such as a
blister pack. The pack or dispenser device may be accompanied by
instructions for administration. The pack or dispenser may also be
accompanied by a notice associated with the container in a form
prescribed by a governmental agency regulating the manufacture, use
or sale of pharmaceuticals, which notice is reflective of approval
by the agency of the form of the compositions or of human or
veterinary administration. Such notice, for example, may be of the
labeling approved by the U.S. Food and Drug Administration for
prescription drugs or of an approved product insert. Compositions
comprising a compound of the invention formulated in a compatible
pharmaceutical carrier may also be prepared, placed in an
appropriate container, and labeled for treatment of an indicated
condition. Suitable conditions indicated on the label may include
treatment of a tumor, inhibition of angiogenesis, treatment of
fibrosis, diabetes, and the like.
[0356] It is also an aspect of this invention that a compound
described herein, or its salt or prodrug, might be combined with
other chemotherapeutic agents for the treatment of the diseases and
disorders discussed above. For instance, a compound, salt or
prodrug of this invention might be combined with alkylating agents
such as fluorouracil (5-FU) alone or in further combination with
leukovorin; or other alkylating agents such as, without limitation,
other pyrimidine analogs such as UFT, capecitabine, gemcitabine and
cytarabine, the alkyl sulfonates, e.g., busulfan (used in the
treatment of chronic granulocytic leukemia), improsulfan and
piposulfan; aziridines e.g., benzodepa, carboquone, meturedepa and
uredepa; ethyleneimines and methylmelamines, e.g., altretamine,
triethylenemelamine, triethylenephosphoramide,
triethylenethiophosphoramide and trimethylolmelamine; and the
nitrogen mustards, e.g., chlorambucil (used in the treatment of
chronic lymphocytic leukemia, primary macroglobulinemia and
non-Hodgkin's lymphoma), cyclophosphamide (used in the treatment of
Hodgkin's disease, multiple myeloma, neuroblastoma, breast cancer,
ovarian cancer, lung cancer, Wilm's tumor and rhabdomyosarcoma),
estramustine, ifosfamide, novembrichin, prednimustine and uracil
mustard (used in the treatment of primary thrombocytosis,
non-Hodgkin's lymphoma, Hodgkin's disease and ovarian cancer); and
triazines, e.g., dacarbazine (used in the treatment of soft tissue
sarcoma).
[0357] A compound, salt or prodrug of this invention can also be
used in combination with other antimetabolite chemotherapeutic
agents such as, without limitation, folic acid analogs, e.g.
methotrexate (used in the treatment of acute lymphocytic leukemia,
choriocarcinoma, mycosis fungiodes breast cancer, head and neck
cancer and osteogenic sarcoma) and pteropterin; and the purine
analogs such as mercaptopurine; and thioguanine which find use in
the treatment of acute granulocytic, acute lymphocytic and chronic
granulocytic leukemias.
[0358] It is contemplated that a compound, salt or prodrug of this
invention can also be used in combination with natural product
based chemotherapeutic agents such as, without limitation, the
vinca alkaloids, e.g., vinblastin (used in the treatment of breast
and testicular cancer), vincristine and vindesine; the
epipodophylotoxins, e.g., etoposide and teniposide, both of which
are useful in the treatment of testicular cancer and Kaposi's
sarcoma; the antibiotic chemotherapeutic agents, e.g.,
daunorubicin, doxorubicin, epirubicin, mitomycin (used to treat
stomach, cervix, colon, breast, bladder and pancreatic cancer),
dactinomycin, temozolomide, plicamycin, bleomycin (used in the
treatment of skin, esophagus and genitourinary tract cancer); and
the enzymatic chemotherapeutic agents such as L-asparaginase.
[0359] In addition to the above, a compound, salt or prodrug of
this invention could also be used in combination with the platinum
coordination complexes (cisplatin, etc.); substituted ureas such as
hydroxyurea; methylhydrazine derivatives, e.g., procarbazine;
adrenocortical suppressants, e.g., mitotane, aminoglutethimide; and
hormone and hormone antagonists such as the adrenocorticosteriods
(e.g., prednisone), progestins (e.g., hydroxyprogesterone
caproate); estrogens (e.g., diethylstilbesterol); antiestrogens
such as tamoxifen; androgens, e.g., testosterone propionate; and
aromatase inhibitors such as anastrozole.
[0360] Finally, it is also contemplated that the combination of a
compound of this invention will be effective in combination with
mitoxantrone or paclitaxel for the treatment of solid tumor cancers
or leukemias such as, without limitation, acute myelogenous
(non-lymphocytic) leukemia.
General Synthetic Procedure
[0361] The following general methodology may be employed to prepare
the compounds of this invention:
[0362] The appropriately substituted 2-oxindole (1 equiv.), the
appropriately substituted aldehyde (1.2 equiv.) and a base (0.1
equiv.) are mixed in a solvent (1-2 ml/mmol 2-oxindole) and the
mixture is then heated for from about 2 to about 12 hours. After
cooling, the precipitate that forms is filtered, washed with cold
ethanol or ether and vacuum dried to give the solid product. If no
precipitate forms, the reaction mixture is concentrated and the
residue is triturated with dichloromethane/ether, the resulting
solid is collected by filtration and then dried. The product may
optionally be further purified by chromatography.
[0363] The base may be an organic or an inorganic base. If an
organic base is used, preferably it is a nitrogen base. Examples of
organic nitrogen bases include, but are not limited to,
diisopropylamine, trimethylamine, triethylamine, aniline, pyridine,
1,8-diazabicyclo[5.4.1]undec-7-ene, pyrrolidine and piperidine.
[0364] Examples of inorganic bases are, without limitation,
ammonia, alkali metal or alkaline earth hydroxides, phosphates,
carbonates, bicarbonates, bisulfates and amides. The alkali metals
include, lithium, sodium and potassium while the alkaline earths
include calcium, magnesium and barium.
[0365] In a presently preferred embodiment of this invention, when
the solvent is a protic solvent, such as water or alcohol, the base
is an alkali metal or an alkaline earth inorganic base, preferably,
a alkali metal or an alkaline earth hydroxide.
[0366] It will be clear to those skilled in the art, based both on
known general principles of organic synthesis and on the
disclosures herein which base would be most appropriate for the
reaction contemplated.
[0367] The solvent in which the reaction is carried out may be a
protic or an aprotic solvent, preferably it is a protic solvent. A
"protic solvent" is a solvent which has hydrogen atom(s) covalently
bonded to oxygen or nitrogen atoms which renders the hydrogen atoms
appreciably acidic and thus capable of being "shared" with a solute
through hydrogen bonding. Examples of protic solvents include,
without limitation, water and alcohols.
[0368] An "aprotic solvent" may be polar or non-polar but, in
either case, does not contain acidic hydrogens and therefore is not
capable of hydrogen bonding with solutes. Examples, without
limitation, of non-polar aprotic solvents, are pentane, hexane,
benzene, toluene, methylene chloride and carbon tetrachloride.
Examples of polar aprotic solvents are chloroform, tetrahydrofuran,
dimethylsulfoxide and dimethylformamide.
[0369] In a presently preferred embodiment of this invention, the
solvent is a protic solvent, preferably water or an alcohol such as
ethanol.
[0370] The reaction is carried out at temperatures greater than
room temperature. The temperature is generally from about
30.degree. C. to about 150.degree. C., preferably about 80.degree.
C. to about 100.degree. C., most preferable about 75.degree. C. to
about 85.degree. C., which is about the boiling point of ethanol.
By "about" is meant that the temperature range is preferably within
10 degrees Celcius of the indicated temperature, more preferably
within 5 degrees Celcius of the indicated temperature and, most
preferably, within 2 degrees Celcius of the indicated temperature.
Thus, for example, by "about 75.degree. C." is meant 75.degree.
C..+-.10.degree. C., preferably 75.degree. C..+-.5.degree. C. and
most preferably, 75.degree. C..+-.2.degree. C.
[0371] 2-Oxindoles and aldehydes, may be readily synthesized fusing
techniques well known in the chemical arts. It will be appreciated
by those skilled in the art that other synthetic pathways for
forming the compounds of the invention are available and that the
following is offered by way of example and not limitation.
EXAMPLES
[0372] The following preparations and examples are given to enable
those skilled in the art to more clearly understand and to practice
the present invention. They should not be considered as limiting
the scope of the invention, but merely as being illustrative and
representative, thereof.
SYNTHETIC EXAMPLES
[0373] Method A: Formylation of Pyrroles
[0374] POCl.sub.3 (1.1 equiv.) is added dropwise to
dimethylformamide (3 equiv.) at -10.degree. C. followed by addition
of the appropriate pyrrole dissolved in dimethylformamide. After
stirring for two hours, the reaction mixture is diluted with
H.sub.2O and basified to pH 11 with 10 N KOH. The precipitate which
forms is collected by filtration, washed with H.sub.2O and dried in
a vacuum oven to give the desired aldehyde.
[0375] Method B: Saponification of Pyrrolecarboxylic Acid
Esters
[0376] A mixture of a pyrrolecarboxylic acid ester and KOH (2-4
equiv.) in EtOH is refluxed until reaction completion is indicated
by thin layer chromatography (TLC). The cooled reaction mixtrue is
acidified to pH 3 with 1N HCl. The precipitate which forms is
collected by filtration, washed with H.sub.2O and dried in a vacuum
oven to give the desired pyrrolecarboxylic acid.
[0377] Method C: Amidation
[0378] To a stirred solution of a pyrrolecarboxylic acid dissolved
in dimethylformamide (0.3M) is added
1-ethyl-3-(3-dimethylamino-propyl)carbo- diimide (1.2 equiv.),
1-hydroxybenzotriazole (1.2 equiv.) and triethylamine (2 equiv.).
The appropriate amine is added (1 equiv.) and the reaction stirred
until completion is indicated by TLC. Ethyl acetate is then added
to the reaction mixture and the solution washed with saturated
NaHCO.sub.3 and brine (with extra salt), dried over anhydrous
MgSO.sub.4 and concentrated to afford the desired amide.
[0379] Method D: Condensation of Aldehydes and Oxindoles Containing
Carboxylic Acid Substituents
[0380] A mixture of the oxindole (1 equivalent), 1 equivalent of
the aldehyde and 1-3 equivalents of piperidine (or pyrrolidine) in
ethanol (0.4 M) is stirred at 90-100.degree. C. until reaction
completion is indicated by TLC. The mixture is then concentrated
and the residue acidified with 2N HCl. The precipitate that forms
is washed with H.sub.2O and EtOH and then dried in a vacuum oven to
give the product.
[0381] Method E: Condensation of Aldehydes and Oxindoles not
Containing Carboxylic Acid Substituents
[0382] A mixture of the oxindole (1 equivalent), 1 equivalent of
the aldehyde and 1-3 equivalents of piperidine (or pyrrolidine) in
ethanol (0.4 M), is stirred at 90-100.degree. C. until reaction
completion is indicated by TLC. The mixture is cooled to room
temperature and the solid which forms is collected by vacuum
filtration, washed with ethanol and dried to give the product. If a
precipitate does not form upon cooling of the reaction mixture, the
mixture is concentrated and purified by column chromatography.
[0383] C. Examples of Oxindole Syntheses
[0384] The following examples of the synthesis of representative
oxindoles is not to be construed as limiting the scope of this
invention in any manner whatsoever. Alternate routes to the
oxindoles shown as well as other oxindoles to be used to make the
compounds of this invention will become apparent to those skilled
in the art based on the following disclosures. Such syntheses and
oxindoles are within the scope and spirit of this invention.
[0385] 5-Amino-2-oxindole
[0386] 5-Nitro-2-oxindole (6.3 g) was hydrogenated in methanol over
10% palladium on carbon to give 3.0 g (60% yield) of the title
compound as a white solid.
[0387] 5-Bromo-2-oxindole
[0388] 2-Oxindole (1.3 g) in 20 mL acetonitrile was cooled to
10.degree. C. and 2.0 g N-bromosuccinimide was slowly added with
stirring. The reaction was stirred for 1 hour at -10.degree. C. and
2 hours at 0.degree. C. The precipitate was collected, washed with
water and dried to give 1.9 g (90% yield) of the title
compound.
[0389] 4-Methyl-2-oxindole
[0390] Diethyl oxalate (30 mL) in 20 mL of dry ether was added with
stirring to 19 g of potassium ethoxide suspended in 50 mL of dry
ether. The mixture was cooled in an ice bath and 20 mL of
3-nitro-o-xylene in 20 mL of dry ether was slowly added. The thick
dark red mixture was heated to reflux for 0.5 hr, concentrated to a
dark red solid, and treated with 10% sodium hydroxide until almost
all of the solid dissolved. The dark red mixture was treated with
30% hydrogen peroxide until the red color changed to yellow. The
mixture was treated alternately with 10% sodium hydroxide and 30%
hydrogen peroxide until the dark red color was no longer present.
The solid was filtered off and the filtrate acidified with 6N
hydrochloric acid. The resulting precipitate was collected by
vacuum filtration, washed with water, and dried under vacuum to
give 9.8 g (45% yield) of 2-methyl-6-nitrophenylacetic acid as an
off-white solid. The solid was hydrogenated in methanol over 10%
palladium on carbon to give 9.04 g of the title compound as a white
solid.
[0391] 7-Bromo-5-chloro-2-oxindole
[0392] 5-Chloro-2-oxindole (16.8 g) and 19.6 g of
N-bromosuccinimide were suspended in 140 mL of acetonitrile and
refluxed for 3 hours. Thin layer chromatography (silica, ethyl
acetate) at 2 hours of reflux showed 5-chloro-2-oxindole or
N-bromosuccinimide (Rf 0.8), product (Rf 0.85) and a second product
(Rf 0.9) whose proportions did not change after another hour of
reflux. The mixture was cooled to 10.degree. C., the precipitate
was collected by vacuum filtration, washed with 25 mL of ethanol
and sucked dry for 20 minutes in the funnel to give 14.1 g of wet
product (56% yield). The solid was suspended in 200 mL of denatured
ethanol and slurry-washed by stirring and refluxing for 10 minutes.
The mixture was cooled in an ice bath to 10.degree. C. The solid
product was collected by vacuum filtration, washed with 25 mL of
ethanol and dried, under vacuum at 40.degree. C. to give 12.7 g
(51% yield) of 7-bromo-5-chloro-2-oxindol- e.
[0393] 5-Fluoro-2-oxindole
[0394] 5-Fluoroisatin (8.2 g) was dissolved in 50 mL of hydrazine
hydrate and refluxed for 1.0 hr. The reaction mixtures were then
poured in ice water. The precipitate was then filtered, washed with
water and dried in a vacuum oven to afford the title compound.
[0395] 5-Nitro-2-oxindole
[0396] 2-Oxindole (6.5 g) was dissolved in 25 mL concentrated
sulfuric acid, and the mixture maintained at -10 to -15.degree. C.
while 2.1 mL of fuming nitric acid was added dropwise. After the
addition of the nitric acid the reaction mixture was stirred at
0.degree. C. for 0.5 hr and poured into ice-water. The precipitate
was collected by filtration, washed with water and crystallized
from 50% acetic acid. The crystalline product was then filtered,
washed with water and dried under vacuum to give 6.3 g (70%) of
5-nitro-2-oxindole.
[0397] 5-Aminosulfonyl-2-oxindole
[0398] To a 100 mL flask charged with 27 mL of chlorosulfonic acid
was added slowly 13.3 g of 2-oxindole. The reaction temperature was
maintained below 30.degree. C. during the addition. After the
addition, the reaction mixture was stirred at room temperature for
1.5 hr, heated to 68.degree. C. for 1 hr, cooled, and poured into
water. The precipitate was washed with water and dried in a vacuum
oven to give 11.0 g of 5-chlorosulfonyl-2-oxindole (50% yield)
which was used without further purification.
[0399] 5-Chlorosulfonyl-2-oxindole (2.1 g) was added to 10 mL of
ammonium hydroxide in 10 mL of ethanol and stirred at room
temperature overnight. The mixture was concentrated and the solid
collected by vacuum filtration to give 0.4 g (20% yield) of the
title compound as an off-white solid.
[0400] 5-Isopropylaminosulfonyl-2-oxindole
[0401] To a 100 mL flask charged with 27 mL chlorosulfonic acid was
slowly added 13.3 g 2-oxindole. The reaction temperature was
maintained below 30.degree. C. during the addition. The reaction
mixture was stirred at room temperature for 1.5 hour, heated to
68.degree. C. for 1 hour, cooled, and poured into water. The
precipitate which formed was filtered, washed with water and dried
in a vacuum oven to give 11.0 g (50%) of
5-chlorosulfonyl-2-oxindole which was used without further
purification.
[0402] A suspension of 3 g 5-chlorosulfonyl-2-oxindole, 1.15 g
isopropylamine and 1.2 mL of pyridine in 50 mL of dichloromethane
was stirred at room temperature for 4 hours during which time a
white solid formed. The solid was collected by vacuum filtration,
slurry-washed with hot ethanol, cooled, collected by vacuum
filtration and dried under vacuum at 40.degree. C. overnight to
give 1.5 g (45%) of 5-isopropylaminosulfonyl-2-oxindole.
[0403] .sup.1HNMR (360 MHz, DMSO-d6) .delta. 10.69 (s, br, 1H, NH),
7.63 (dd, J=2 and 8 Hz, 1H), 7.59 (d, J=2 Hz, 1H), 7.32 (d, J=7 Hz,
1H, NH--SO.sub.2--), 6.93 (d, J=8 Hz, 1H), 3.57 (s, 2H), 3.14-3.23
(m, 1H, CH--(CH.sub.3).sub.2), 0.94 (d, J=7 Hz, 6H,
2.times.CH.sub.3).
[0404] 5-Phenylaminosulfonyl-2-oxindole
[0405] A suspension of 5-chlorosulfonyl-2-oxindole (1.62 g, 7
mmol), aniline (0.782 mL, 8.4 mmol) and pyridine (1 mL) in
dichloromethane (20 ml) was stirred at room temperature for 4
hours. The reaction mixture was diluted with ethyl acetate (300 mL)
and acidified with 1N hydrochloric acid (16 mL). The organic layer
was washed with sodium bicarbonate and brine, dried and
concentrated. The residue was washed with ethanol (3 mL) and then
chromatographed on silica gel eluting with methanol/dichloromethane
1:9 to give of 5-phenylaminosulfonyl-2-oxindole.
[0406] .sup.1HNMR (360 MHz, DMSO-d6) .delta. 10.71 (s, br, 1H, NH),
10.10 (s, br, 1H, NH), 7.57-7.61 (m, 2H), 7.17-7.22 (m, 2H),
7.06-7.09 (m, 2H), 6.97-7.0 (m, 1H), 6.88 (d, J=8.4 Hz, 1H), 3.52
(s, 2H).
[0407] 2-Oxo-2,3-dihydro-1H-indole-5-sulfonic Acid
Pyridin-3-ylamide
[0408] A solution of 5-chlorosufonyl-2-oxindole (3 g) and
3-aminopyridine (1.46 g) in pyridine (15 mL) was stirred at room
temperature overnight at which time a brown solid was present. The
solid was filtered, washed with ethanol and dried under vacuum to
yield 1.4 g (38%) of 2-oxo-2,3-dihydro-1H-indole-5-sulfonic acid
pyridin-3-ylamide.
[0409] .sup.1HNMR (360 MHz, DMSO-d6) .delta. 10.74 (s, 1H, NH),
10.39 (s, 1H, SO.sub.2NH), 8.27-8.28 (d, 1H), 8.21-8.23 (m, 1H),
7.59-7.62 (m, 2H), 7.44-7.68 (m, 1H), 7.24-7.28 (m, 1H), 6.69-6.71
(d, 1H), 3.54 (s, 2H).
[0410] MS m/z (APCI+) 290.2.
[0411] 5-Phenyloxindole
[0412] 5-Bromo-2-oxindole (5 g, 23.5 mmol) was dissolved in 110 mL
toluene and 110 mL ethanol with stirring and a little heat.
Tetrakis(triphenylphosphine)palladium(0) (1.9 g, 1.6 mmol) was
added followed by 40 mL (80 mmol) 2M aqueous sodium carbonate. To
this mixture was added benzene boronic acid (3.7 g, 30.6 mmol) and
the mixture was heated in a 100.degree. C. oil bath for 12 hours.
The reaction was cooled, diluted with ethyl acetate (500 mL),
washed with saturated sodium bicarbonate (200 mL), water (200 mL),
1N HCl (200 mL) and brine (200 mL). The organic layer was dried
over magnesium sulfate and concentrated to afford a brown solid.
Trituration with dichloromethane afforded 3.8 g (77%) of
5-phenyl-2-oxindole as a tan solid.
[0413] .sup.1H NMR (360 MHz, DMSO-d6) .delta. 10.4 (br s, 1H, NH),
7.57 (dd, J=1.8 and 7.2 Hz, 1H), 7.5 to 7.35 (m, 5H), 7.29 (m, 1H),
6.89 (d, J=8.2 Hz, 1H), 3.51 (s, 2H, CH.sub.2CO).
[0414] MS m/z 209 [M.sup.+].
[0415] In similar fashion, the following oxindoles can be
prepared:
[0416] 6-(3,5-Dichlorophenyl)-1,3-dihydroindol-2-one
[0417] .sup.1H NMR (360 MHz, DMSO-d6) .delta. 10.46 (br, 1H, NH),
7.664 (d, J=1.8 Hz, 2H), 7.57 (m, 1H), 7.27 (m, 2H), 7.05 (d, J=1.1
Hz, 1H), 3.5 (s, 2H).
[0418] MS-EI m/z 277/279 [M].sup.+.
[0419] 6-(4-Butylphenyl)-1,3-dihydroindol-2-one
[0420] .sup.1H NMR (360 MHz, DMSO-d6) .delta. 10.39 (s, 1H, NH),
7.49 (d, J=8.0 Hz, 2H), 7.25 (d, J=8 Hz, 3H), 7.17 (dd, J=1.5 and
7.8 Hz, 1H), 6.99 (d, J=1.5 Hz, 1H), 3.48 (s, 2H, CH.sub.2CO), 2.60
(t, J=7.5 Hz, 2 Hz, CH.sub.2CH.sub.3), 1.57 (m, 2H, CH.sub.2), 1.32
(m, 2H, CH.sub.2), 0.9 (t, J=7.5 Hz, 3H, CH.sub.3).
[0421] 6-(5-Isopropyl-2-methoxyphenyl)-1,3-dihydroindol-2-one
[0422] .sup.1H NMR (360 MHz, DMSO-d6) .delta. 10.29 (br s, 1H, NH),
7.16-7.21 (m, 2H), 7.08 (d, J=2.4 Hz, 1H), 6.97-7.01 (m, 2H), 6.89
(d, J=0.8 Hz, 1H), 3.71 (s, 3H, OCH.sub.3), 3.47 (s, 2H,
CH.sub.2CO), 2.86 (m, 1H, CH(CH.sub.3).sub.2), 1.19 (d, J=6.8 Hz,
6H, CH(CH.sub.3).sub.2).
[0423] MS-EI m/z 281, [M].sup.+.
[0424] 6-(4-Ethylphenyl)-1,3-dihydroindol-2-one
[0425] .sup.1H NMR (360 MHz, DMSO-d6) .delta. 10.39 (br s, 1H, NH),
7.50 (d, J=8.2 Hz, 2H), 7.28 (d, J=8.2 Hz, 2H), 7.25 (d, J=7.5 Hz,
1H), 7.17 (dd, J=1.6 & 7.5 Hz, 1H), 6.99 (d, J=1.6 Hz, 1H),
3.48 (s, 2H, CH.sub.2CO), 2.63 (q, J=7.6 Hz, 2H, CH.sub.2CH.sub.3),
1.20 (t, J==7.6 Hz, 3H, CH.sub.2CH.sub.3).
[0426] MS-EI m/z 237 [M].sup.+.
[0427] 6-(3-Isopropylphenyl)-1,3-dihydroindol-2-one
[0428] .sup.1H NMR (360 MHz, DMSO-d6) .delta. 10.37 (br s, 1H, NH),
7.43 (m, 1H), 7.35-7.39 (m, 1H), 7.17-7.27 (m, 3H), 7.01 (d, J=1.8
Hz, 1H), 3.49 (s, 2H, CH.sub.2CO), 2.95 (m, 1H,
CH(CH.sub.3).sub.2), 1.24 (d, J=6.8 Hz, 6H,
CH(CH.sub.3).sub.2).
[0429] MS-EI m/z 251 [M].sup.+.
[0430] 6-(2.4-Dimethoxyphenyl)-1,3-dihydroindol-2-one
[0431] .sup.1H NMR (360 MHz, DMSO-d6) .delta. 10.28 (br s, 1H, NH),
7.17 (m, 2H), 6.93 (dd, J=1.6 & 7.6 Hz, 1H), 6.86 (d, J=1.6 Hz,
1H), 6.63 (d, J=2.4 Hz, 1H), 6.58 (dd, J=2.4 & 8.5 Hz, 1H),
3.79 (s, 3H, OCH.sub.3), 3.74 (s, 3H, OCH.sub.3), 3.45 (s, 2H,
CH.sub.2CO).
[0432] MS-EI m/z 269 [M].sup.+.
[0433] 6-Pyridin-3-yl-1,3-dihydroindol-2-one
[0434] .sup.1H NMR (360 MHz, DMSO-d6) .delta. 10.51 (s, 1H, NH),
8.81 (d, J=2.5 Hz, 1H), 8.55 (dd, J=1.8 and 5.7 Hz, 1H), 8 (m, 1H),
7.45 (dd, J=5.7 and 9.3 Hz, 1H), 7.3 (m, 2H), 7.05 (s, 1H), 3.51
(s, 2H, CH.sub.2CO).
[0435] MS m/z 210 [M].sup.+.
[0436] 2-Oxo-2,3-dihydro-1H-indole-4-carboxylic Acid
(3-chloro-4-ethoxyphenyl)-amide
[0437] To a solution of 4-carboxy-2-oxindole (200 mg, 1.13 mmol)
and 3-chloro-4-methoxyphenylamine (178 mg, 1.13 mmol) in
dimethylformamide (15 mL) at room temperature was added
benzotriazol-1-yloxytris(dimethylam- ino)phosphonium
hexafluorophosphate (BOP reagent, 997 mg, 2.26 mmol) followed by
4-dimethylaminopyridine (206 mg, 1.69 mmol). The mixture was
stirred at room temperature for 72 hours. The reaction was then
diluted with ethyl acetate (300 mL), washed with saturated sodium
bicarbonate (100 mL), water, 2N hydrochloric acid (100 mL), water
(3.times.200 mL) and brine. It was then dried over magnesium
sulfate and concentrated. The residue was triturated with ethyl
acetate to give 2-oxo-2,3-dihydro-1H-in- dole-4-carboxylic acid
(3-chloro-4-methoxyphenyl)-amide as a pink solid.
[0438] .sup.1HNMR (360 MHz, DMSO-d6) .delta. 10.50 (s, br, 1H, NH),
10.12 (s, br, 1H, NH), 7.9 (s, J=2.5 Hz, 1H), 7.62 (dd, J=2.5 &
9 Hz, 1H), 7.38 (d, J=7.6 Hz, 1H), 7.32 (t, J=7.6 Hz, 1H), 7.13 (d,
J=9 Hz, 1H), 6.98 (d, J=7.6 Hz, 1H), 3.83 (s, 3H, OCH.sub.3), 3.69
(s, 2H, CH.sub.2).
[0439] MS-EI m/z 316 [M].sup.+.
[0440] 4-Carboxy-2-oxindole
[0441] A solution of trimethylsilyldiazomethane in hexane (2 M) was
added dropwise to a solution of 2.01 g
2-chloro-3-carboxynitrobenzene in 20 mL methanol at room
temperature until no further gas evolution occurred. Acetic acid
was then added to quench excess trimethylsilyldiazomethane. The
reaction mixture was evaporated under vacuum and the residue was
dried in an oven overnight. The
2-chloro-3-methoxycarbonylnitrobenzene obtained was pure enough for
the following reaction.
[0442] Dimethyl malonate (6.0 mL) was added to an ice-cold
suspension of 2.1 g sodium hydride in 15 mL DMSO. The reaction
mixture was stirred at 100.degree. C. for 1 hour and then cooled to
room temperature. 2-Chloro-3-methoxycarbonylnitrobenzene (2.15 g)
was added in one portion and the mixture was heated to 100.degree.
C. for 1.5 hours. The reaction mixture was then cooled to room
temperature, poured into ice water, acidified to pH 5 and extracted
with ethyl acetate. The organic layer was washed with brine, dried
over anhydrous sodium sulfate and concentrated to give 3.0 g of the
dimethyl 2-methoxycarbonyl-6-nitrophenyl-malonate.
[0443] Dimethyl 2-methoxycarbonyl-6-nitrophenylmalonate (3.0 g) was
refluxed in 50 mL of 6 N hydrochloric acid overnight. The mixture
was concentrated to dryness, 20 mL ethanol and 1.1 g of tin(II)
chloride were added and the mixture was refluxed for 2 hours. The
mixture was filtered through Celite, concentrated and
chromatographed on silica gel using ethyl acetate:hexane:acetic
acid as eluent to give 0.65 g (37%) of 4-carboxy-2-oxindole as a
white solid.
[0444] .sup.1HNMR (360 MHz, DMSO-d6) .delta. 12.96 (s, br, 1H,
COOH), 10.74 (s, br, 1H, NH), 7.53 (d, J=8 Hz, 1H), 7.39 (t, J=8
Hz, 1H), 7.12 (d, J=8 Hz, 1H), 3.67 (s, 2H).
[0445] D. Synthesis of Pyrrole Substituted 2-indolinones.
Example 1
[0446]
4-Methyl-5-(2-oxo-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-2-ca-
rboxylic Acid
[0447] 4-Methyl-2-pyrrolecarboxylic acid ethyl ester (commercially
available) was formylated using method A to give (73%) of
5-formyl-4-methyl-2-pyrrolecarboxylic acid ethyl ester. It was then
hydrolysed using method B to give
5-formyl-4-methyl-1H-pyrrole-2-carboxyl- ic acid (58%).
[0448] Oxindole (133 mg, 1 mmol), was condensed with
5-formyl-4-methyl-1H-pyrrole-2-carboxylic acid (153 mg) using
method D to give 268 mg (100%) of the title compound as an
orange-red solid.
[0449] .sup.1HNMR (360 MHz, DMSO-d6) .delta. 13.84 (s, br, 1H, NH),
12.84 (s, br, 1H, COOH), 10.98 (s, br, 1H, NH), 7.82 (d, J=7.5 Hz,
1H), 7.67 (s, 1H, H-vinyl), 7.18 (t, J=7.5 Hz, 1H), 7.01 (t, J=7.5
Hz, 1H), 6.88 (d, J=7.5 Hz, 1H), 6.71 (d, J=2.2 Hz, 1H), 2.32 (s,
3H, CH.sub.3).
[0450] MS (negative mode) 266.8 [M-1].sup.+.
Example 2
[0451]
4-Methyl-5-(1-methyl-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-1H-pyr-
role-2-carboxylic Acid
[0452] 1-Methyl-1,3-dihydroindol-2-one (147 mg, 11 mmol) was
condensed with 5-formyl-4-methyl-1H-pyrrole-2-carboxylic acid (153
mg) using method D to give 250 mg (86%) of the title compound.
[0453] .sup.1HNMR (360 MHz, DMSO-d6) .delta. 13.82 (s, br, 1H, NH),
12.88 (s, br, 1H, 7.83 (d, J=7.5 Hz, 1H), 7.65 (s, 1H, H-vinyl),
7.26 (t, J=7.5 Hz, 1H), 7.02-7.09 (m, 2H), 6.70 (d, J=2.2 Hz, 1H),
2.32 (s, 3H, CH.sub.3).
[0454] MS m/z 283.0 [M+1].sup.+.
Example 3
[0455]
4-Methyl-5-(2-oxo-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-2-ca-
rboxylic Acid Methyl Ester
[0456] Oxindole (105 mg, 0.79 mmol) was condensed with
5-formyl-4-methyl-1H-pyrrole-2-carboxylic acid methyl ester (110
mg, 0.67 mmol) using method E to give 153.2 mg (81%) of the title
compound.
[0457] .sup.1HNMR (360 MHz, DMSO-d6) .delta. 13.98 (s, br, 1H, NH),
10.97 (s, br, 1H, NH), 7.82 (d, J=7.6 Hz, 1H), 7.67 (s, 1H,
H-vinyl), 7.2 (dt, J=1.2 & 7.7 Hz, 1H), 7.01 (dt, J=1.2, 7.7
Hz, 1H), 6.90 (d, J=7.6 Hz, 1H), 6.77 (d, J=0.2 Hz, 1H).
[0458] MS (ES) m/z 283 [M.sup.++1].
Example 4
[0459]
5-(5-Chloro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-4-methyl-1H-pyr-
role-2-carboxylic Acid Ethyl Ester
[0460] 5-chloro-1,3-dihydroindol-2-one (2.22 g, 13.2 mmol) was
condensed with 5-formyl-4-methyl-1H-pyrrole-2-carboxylic acid ethyl
ester (2.43 g) using method E to give 4.1 g (94%) of the title
compound as an orange solid.
[0461] .sup.1HNMR (360 MHz, DMSO-d6) .delta. 13.95 (s, br, 1H, NH),
7.98 (d, J=2.2 Hz, 1H, H-4), 7.78 (s, 1H, H-vinyl), 7.18 (dd, J=2.2
& 8.3 Hz, 1H, H-6), 6.87 (d, J.beta.8.3 Hz, 1H, H-7), 7.34 (d,
J=1.8 Hz, 1H, H-3'), 4.27 (q, J=7.2 Hz, 2H, OCH.sub.2CH.sub.3),
2.33 (s, 3H, CH.sub.3), 1.29 (t, J=7.2, Hz, 3H,
OCH.sub.2CH.sub.3).
[0462] MS-EI m/z: 330 [M.sup.+].
Example 5
[0463]
5-(5-Chloro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-4-methyl-1H-pyr-
role-2-carboxylic Acid
[0464] A mixture of
5-(5-chloro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-4--
methyl-1H-pyrrole-2-carboxylic acid ethyl ester (1.3 g, 4 mmol) and
potassium, hydroxide in methanol (25 mL) and ethanol (25 mL) was
heated to reflux for overnight. Insoluble materials were removed by
filtration and the mixture was neutralized with 6N hydrochloric
acid to give 0.876 g (70%) of the title compound.
[0465] .sup.1HNMR (360 MHz, DMSO-d6) .delta. 13.80 (s, br, 1H NH),
12.90 (s br, 1H, COOH), 11.06 (s, br, 1H, NH), 8.02 (d, J=1.8 Hz,
1H, H-4), 7.81 (s, 1H, H-vinyl), 7.20 (dd, J=1.8 & 8.3 Hz 1H,
H-6), 6.89 (d, J=8.3 Hz, 1H, H-7), 6.72 (d, J=1.8 Hz, 1H, H-3'),
2.35 (s, 3H, CH.sub.3).
[0466] MS-EI m/z 302 [M.sup.+].
Example 6
[0467]
5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-4-methyl-1H-pyrr-
ole-2-carboxylic Acid (3-pyrrolidin-1-yl-propyl)amide
[0468] 5-Bromo-1,3-dihydroindol-2-one (0.16 g, 0.76 mmol) was,
condensed with 5-formyl-4-methyl-1H-pyrrole-2-carboxylic acid
(3-pyrrolidin-1-ylpropyl)amide (0.2 g, prepared by method C) to
give 60 mg (17%) of the title compound as an orange solid.
[0469] .sup.1HNMR (300 MHz, DMSO-d6) .delta. 13.61 (s, br, 1H, NH),
11.02 (s, br, 1H, NH), 8.42 (t, J=50.8 Hz, 1H, CONHCH.sub.2), 8.12
(d, J=1.8 Hz, 1H, H-4), 7.78 (s, 1H, H-vinyl), 7.30 (dd, J=1.8
& 8.4 Hz, 1H, H-6), 6.82 (d, J=8.4 Hz, 1H, H-7), 6.77 (d, J=2.4
Hz, 1H, H-3'), 3.22-3.1 (m, 2H, CH.sub.2), 2.38-2.43 (m, 6H,
3.times.CH.sub.2), 2.35 (s, 3H, CH.sub.3), 1.62-1.71 (m, 6H,
3.times.CH.sub.2).
[0470] MS-EI m/z 456 and 458 [M.sup.+-1 and M.sup.++2].
Example 7
[0471]
5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-4-methyl-1H-pyrr-
ole-2-carboxylic Acid (3-diethylamino-propyl)amide
[0472] 5-Bromo-1,3-dihydroindol-2-one (0.16 g, 0.75 mmol) was
condensed with 5-formyl-4-methyl-1H-pyrrole-2-carboxylic acid
(3-diethylaminopropyl)amide (0.2 g, prepared by method C) to give
30 mg (8%) of the title compound as an orange solid.
[0473] .sup.1HNMR (300 MHz, DMSO-d6) .delta. 13.61 (s, br, 1H, NH),
11.02 (s, br, 1H, NH), 8.40 (m, 1H, CONHCH.sub.2), 8.12 (d, J=1.5
Hz, 1H, H-4), 7.78 (s, 1H, H-vinyl), 7.30 (dd, J=1.5 & 8.2 Hz,
1H, H-6), 6.82 (d, J=8.2 Hz, 1H, H-7), 6.78 (d, J=2.4 Hz, 1H,
H-3'), 3.23 (m, 2H, CH.sub.2), 2.38-2.45 (m, 6H, CH.sub.2 &
N(CH.sub.2CH.sub.3).sub.2), 2.35 (s, 3H, CH.sub.3), 1.61 (m, 2H,
CH.sub.2), 0.93 (t, J=7.1 Hz, 6H, N(CH.sub.2CH.sub.3).sub.2).
[0474] MS-EI m/z 458 and 460 [M.sup.+-1 and M.sup.++2].
Example 8
[0475]
5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-2-car-
boxylic Acid (2-diethylaminoethyl)amide
[0476] 5-Bromo-1,3-dihydroindol-2-one (212 mg, 1 mmol) was
condensed with 5-formyl-1H-pyrrole-2-carboxylic acid
(2-diethylaminoethyl)amide (prepared from ethyl
pyrrole-2-carboxylate by method A, B and then C) to give 162 mg
(38%) of the title compound.
[0477] .sup.1H NMR (300 MHz, DMSO-d6) .delta. 13.53 (s, br, 1H,
NH), 11.06 (s, br, 1H, NH), 8.37 (t, 1H, CONHCH.sub.2), 7.89 (m,
2H), 7.32 (dd, J=2.0 Hz, 1H), 6.96 (s, 1H), 6.80-6.84 (m, 2H), 3.3
(m, 2H, CH.sub.2), 2.45-2.55 (m, 6H, N(CH.sub.2CH.sub.3).sub.2
& CH.sub.2), 0.95 (t, J=7.2 Hz, 6H,
N(CH.sub.2CH.sub.3).sub.2).
[0478] MS-EI m/z 430 and 432 [M.sup.+-1 and M.sup.++1].
Example 9
[0479]
5-(2-Oxo-6-phenyl-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-2-ca-
rboxylic Acid (2-diethylaminoethyl)amide
[0480] 6-Phenyl-1,3-dihydroindol-2-one (209 mg, 1 mmol) was
condensed with 5-formyl-1H-pyrrole-2-carboxylic acid
(2-diethylaminoethyl)amide to give 182 mg (42%) of the title
compound.
[0481] .sup.1H NMR (300 MHz, DMSO-d6) .delta. 13.56 (s, br, 1H,
NH), 11.06 (s, br, 1H, NH), 8.36 (t, 1H, CONHCH.sub.2), 7.77 (s,
1H, H-vinyl), 7.73 (d, J=7.8 Hz, 1H), 7.64 (d, J=7.2 Hz, 0.2H),
7.46 (m, 2H), 7.32 (m, 2H), 7.11 (s, 1H), 6.96 (m, 1H), 6.80 (m,
1H), 3.31-3.32 (m, 2H, CH.sub.2), 2.46-2.53 (m, 6H,
N(CH.sub.2CH.sub.3).sub.2 & CH.sub.2), 0.96 (t, J=6.9 Hz, 6H,
N(CH.sub.2CH.sub.3).sub.2).
[0482] MS-EI m/z 428 [M.sup.+].
Example 10
[0483]
5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-2-car-
boxylic Acid (2-diethylaminoethyl)-methyl-amide
[0484] 5-Bromo-1,3-dihydroindol-2-one (212 mg, 1 mmol) was
condensed with 5-formyl-1H-pyrrole-2-carboxylic acid
(2-diethylaminoethyl)methylamide to give 246 mg (55%) of the title
compound.
[0485] .sup.1H NMR (360 MHz, DMSO-d6) .delta.13.54 (s, br, 1H, NH),
11.06 (s, br, 1H, NH), 7.90 (m, 2H), 7.33 (dd, J=1.8 & 8.4 Hz,
1H), 6.82-6.85 (m, 3H), 3.55 (s, br, 2H, CH.sub.2), 3.25 (s, br,
3H, NCH.sub.3), 2.57 (t, J=6.5 Hz, 2H, CH.sub.2), 2.45 (m, 4H,
N(CH.sub.2CH.sub.3).sub.2), 0.91 (m, 6H,
N(CH.sub.2CH.sub.3).sub.2).
[0486] MS-EI m/z 444 and 446 [M.sup.+-1 and M.sup.++1].
Example 11
[0487]
5-(2-Oxo-6-phenyl-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-2-ca-
rboxylic Acid (2-diethylaminoethyl)methylamide
[0488] 6-Phenyl-1,3-dihydroindol-2-one (209 mg, 1 mmol) was
condensed with 5-formyl-1H-pyrrole-2-carboxylic acid
(2-diethylaminoethyl)methylamide to give 277 mg (63%) of the title
compound.
[0489] .sup.1H NMR (360 MHz, DMSO-d6) .delta. 13.58 (s, br, 1H,
NH), 11.04 (s, br, 1H, NH), 7.78 (s, 1H, H-vinyl), 7.73 (d, J=7.8
Hz, 1H), 7.64 (d, J=7.5 Hz, 2H), 7.46 (m, 2H), 7.33-7.36 (m, 2H),
7.11 (s, 1H), 6.84 (m, 1H), 6.78 (m, 1H), 3.55 (s, br, 2H,
CH.sub.2), 3.25 (s, br, 3H, NCH.sub.3), 2.58 (t, 2H, CH.sub.2),
2.44 (m, 4H, N(CH.sub.2CH.sub.3).sub.- 2), 0.92 (m, 6H,
N(CH.sub.2CH.sub.3).sub.2).
Example 12
[0490]
3-Methyl-5-(2-oxo-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-2-ca-
rboxylic Acid (3-diethylaminopropyl)amide
[0491] Oxindole (66.5 mg, 0.5 mmol) was condensed with
5-formyl-3-methyl-1H-pyrrole-2-carboxylic acid
(3-diethylaminopropyl) amide (prepared from
3-formyl-3-methyl-1H-pyrrole-2-carboxylic acid ethyl ester by
method B then C) to give 39 mg (21%) of the title compound.
[0492] .sup.1H NMR (300 MHz, DMSO-d6) .delta. 13.34 (s, br, 1H,
NH), 10.88 (s, br, 1H, NH), 7.62-7.67 (m, 3H), 7.17 (m, 1H), 6.99
(m, 1H), 6.87 (d, J=7.6 Hz, 1H), 6.63 (d, J=1 Hz, 1H), 3.26-3.32
(m, 2H, CH.sub.2), 2.41-2.48 (m, 6H, CH.sub.2 &
N(CH.sub.2CH.sub.3).sub.2), 2.29 (s, 3H, CH.sub.3), 1.63 (m, 2H,
CH.sub.2), 0.93 (t, J=7.2 Hz, 6H, N(CH.sub.2CH.sub.3).sub.2).
[0493] MS-EI m/z 380 [M.sup.+].
Example 13
[0494]
5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-3-methyl-1H-pyrr-
ole-2-carboxylic Acid (3-diethylamino-propyl)amide
[0495] 5-Bromo-1,3-dihydroindol-2-one (106 mg, 0.5 mmol) was
condensed with 5-formyl-3-methyl-1H-pyrrole-2-carboxylic acid
(3-diethylaminopropyl)amide to give 35 mg (15%) of the title
compound.
[0496] .sup.1H NMR (300 MHz, DMSO-d6) .delta. 13.35 (s, br, 1H,
NH), 11.00 (s, br, 1H, NH), 7.89 (d, J=1.9 Hz, 1H, H-4), 7.80 (s,
1H, H-vinyl), 7.74 (t, J=5.3 Hz, 1H, CONHCH.sub.2), 7.31 (dd, J=1.9
& 8.4 Hz, 1H, H-6), 6.83 (d, J=8.4 Hz, 1H, H-7), 6.63 (s, 1H,
H-3'), 3.26 (m, 2H, CH.sub.2), 2.41-2.48 (m, 6H, CH.sub.2 &
N(CH.sub.2CH.sub.3).sub.2), 2.29 (s, 3H, CH.sub.3), 1.63 (m, 2H,
CH.sub.2), 0.93 (t, J=7.1 Hz, 6H, N(CH.sub.2CH.sub.3).sub.2).
[0497] MS-EI m/z 458 and 460 [M.sup.+-1 and M.sup.++1].
Example 14
[0498]
3-Methyl-5-(2-oxo-6-phenyl-1,2-dihydroindol-3-ylidenemethyl)-1H-pyr-
role-2-carboxylic Acid (3-diethylaminopropyl)amide
[0499] 6-Phenyl-1,3-dihydroindol-2-one (105 mg, 0.5 mmol) was
condensed with 5-formyl-3-methyl-1H-pyrrole-2-carboxylic acid
(3-diethylaminopropyl)amide to give 67.8 (30%) of the title
compound.
[0500] .sup.1H NMR (300 MHz, DMSO-d6) .delta. 13.37 (s, br, 1H,
NH), 11.02 (s, br, 1H, NH), 7.23-7.73 (m, 1H), 3.29 (m, 2H,
CH.sub.2), 2.41-2.48 (m, 6H, CH.sub.2 &
N(CH.sub.2CH.sub.3).sub.2), 2.29 (s, 3H, CH.sub.3), 1.64 (m, 2H,
CH.sub.2), 0.94 (t, J=7.0 Hz, 6H, N(CH.sub.2CH.sub.3).sub.2).
[0501] MS-EI m/z 456 [M.sup.+].
Example 15
[0502]
5-(5-Methoxy-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-3-methyl-1H-py-
rrole-2-carboxylic Acid (3-diethylamino-propyl)amide
[0503] 5-Methoxy-1,3-dihydroindol-2-one (82.5 mg, 0.5 mmol) was
condensed with 5-formyl-3-methyl-1H-pyrrole-2-carboxylic acid
(3-diethylaminopropyl)amide to give 80 mg (39%) of the title
compound.
[0504] .sup.1H NMR (300 MHz, DMSO-d6) .delta. 13.45 (s, br, 1H,
NH), 10.70 (s, br, 1H, NH), 7.68-7.70 (m, 2H), 7.32 (d, J=1.8 Hz,
1H), 6.72-6.79 (m, 2H), 6.60 (s, 1H), 3.73 (s, 3H, OCH.sub.3), 3.28
(m, 2H, CH.sub.2), 2.41-2.48 (m, 6H, CH.sub.2 &
N(CH.sub.2CH.sub.3).sub.2), 2.29 (s, 3H, CH.sub.3), 1.63 (m, 2H,
CH.sub.2), 0.93 (t, J=7.0 Hz, 6H, N(CH.sub.2CH.sub.3).sub.2).
[0505] MS m/z 410 [M.sup.+].
Example 16
[0506]
5-(6-Methoxy-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-3-methyl-1H-py-
rrole-2-carboxylic Acid (3-diethylamino-propyl)amide
[0507] 6-Methoxy-1,3-dihydroindol-2-one (82.5 mg, 0.5 mmol) was
condensed with 5-formyl-3-methyl-1H-pyrrole-2-carboxylic acid
(3-diethylaminopropyl)amide to give 63 mg (31%) of the title
compound.
[0508] .sup.1H NMR (300 MHz, DMSO-d6) .delta. 13.22 (s, br, 1H,
NH), 10.86 (s, br, 1H, NH), 7.39-7.63 and 6.37-6.55 (m, 6H), 3.73
(s, 3H, OCH.sub.3), 3.3 (m, 2H, CH.sub.2), 2.45 (m, 6H, CH.sub.2
& N(CH.sub.2CH.sub.3).sub.2), 2.28 (s, 3H, CH.sub.3), 1.63 (m,
2H, CH.sub.2), 0.93 (m, 6H, N(CH.sub.2CH.sub.3).sub.2).
[0509] MS m/z 410 [M.sup.+].
Example 17
[0510]
3-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-4,5,6,7-tetrahyd-
ro-2H-isoindole-1-carboxylic Acid (2-diethylaminoethyl)amide
[0511] 4,5,6,7-Tetrahydro-2H-isoindole-1-carboxylic acid ethyl
ester (May, Donald A.; Lash, Timothy D.; J. Org. Chem., 1992,
57:18, 4820-4828) was formylated using method A then B to give
3-formyl-4,5,6,7-tetrahydro-2H-i- soindole-1-carboxylic acid.
[0512] 5-Bromo-1,3-dihydroindol-2-one (1.43 g, 6.8 mmol) was
condensed with
3-formyl-4,5,6,7-tetrahydro-2H-isoindole-1-carboxylic acid
(2-diethylaminoethyl)amide (1.97 g) to give 2.2 g (67%) of the
title compound as a yellow-orange solid.
[0513] .sup.1H NMR (360 MHz, DMSO-d6) .delta. 13.47 (s, 1H, NH),
11.0 (s, 1H, NH), 8.0 (d, 1H, NH), 7.70 (s, 1H, CH), 7.28 (dd,
J=2.1 and 8.2 Hz, 1H, ArH), 7.16 (m, 1H, ArH), 6.8 (d, J=8.3 Hz,
1H, ArH), 3.3 (s, 2H, CONH), 2.5 (m, 6H, 3.times.NCH.sub.2), 2.78
(br m, 2H, pyrrole CH.sub.2), 29.72 (br m, 2H, pyrroleCH.sub.2),
1.7 (br m, 4H, N(CH.sub.2CH.sub.3).sub- .2), 1.74 (br s, 4H,
CH.sub.2CH.sub.2CH.sub.2CH.sub.2), 0.96 (t, J=7.4 Hz, 6H,
N(CH.sub.2CH.sub.3).sub.2).
[0514] MS-EI m/z 484 and 486 [M.sup.+-1 and M.sup.++1].
Example 18
[0515]
3-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-4,5,6,7-tetrahyd-
ro-2H-isoindole-1-carboxylic Acid (3-diethylaminopropyl)amide
[0516] 5-Bromo-1,3-dihydroindol-2-one (20 mg, 0.1 mmol) was
condensed with
3-formyl-4,5,6,7-tetrahydro-2H-isoindole-1-carboxylic acid
(3-diethylaminopropyl)amide (30 mg) to give 33 mg (46%) of the
title compound as an orange solid.
[0517] .sup.1H NMR (360 MHz, DMSO-d6) .delta. 10.9 (s, 1H, NH), 8.0
(m, 1H, NH), 7.68 (m, 1H, ArH), 7.4 (m, 1H, ArH), 7.29 (d, J=1.9
and 8.5 Hz, 1H, ArH), 6.8 (d, J=8 Hz, 1H, ArH), 2.7 (br m, 4H,
2.times.NCH.sub.2), 2.4 (m, 8H, 4.times.NCH.sub.2), 1.7 (br m, 4H,
N(CH.sub.2CH.sub.3).sub.2)- , 1.6 (br m, 2H,
CH.sub.2CH.sub.2CH.sub.2), 0.93 (t, J=7.4 Hz, 6H,
N(CH.sub.2CH.sub.3) 2).
[0518] MS-EI m/z 499 and 501 [M.sup.+ and M.sup.+.sub.+2].
Example 19
[0519]
3-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-4,5,6,7-tetrahyd-
ro-2H-isoindole-1-carboxylic Acid
(3-pyrrolidin-1-ylpropyl)amide
[0520] 5-Bromo-1,3-dihydroindol-2-one (80 mg, 0.4 mmol) was
condensed with
3-formyl-4,5,6,7-tetrahydro-2H-isoindole-1-carboxylic acid
(3-pyrrolidin-1-ylpropyl)amide (120 mg) to give 43 mg (22%) of the
title compound as a tan-orange solid.
[0521] .sup.1H NMR (360 MHz, DMSO-d6) .delta. 13.4 (s, 1H, NH),
10.9 (s, 1H, NH), 8.0 (m, 1H, NH), 7.69 (m, 1H, ArH), 7.49 (m, 1H,
ArH), 7.28 (d, J=1.7 and 7.8 Hz, 1H, ArH), 6.8 (d, J=8 Hz, 1H,
ArH), 3.3 (br m, 2H, 2.times.NCH.sub.2), 2.8 (m, 4H,
2.times.pyrroleCH.sub.2), 2.5 (br m, 4H,
N(CH.sub.2CH.sub.3).sub.2), 1.6 (br m, 8H,
2.times.pyrroleCH.sub.2CH.sub.- 2, CH.sub.2CH.sub.2CH.sub.2 and
CONHCH.sub.2).
[0522] MS-EI m/z 497 and 499 [M.sup.+ and M.sup.++2].
Example 20
[0523]
3-(2-Oxo-6-pyridin-3-yl-1,2-dihydroindol-3-ylidenemethyl)-4,5,6,7-t-
etrahydro-2H-isoindole-1-carboxylic Acid
(2-diethylaminoethyl)amide
[0524] 6-Pyridin-3-yl-1,3-dihydroindol-2-one (60 mg, 0.4 mmol) was
condensed with
3-formyl-4,5,6,7-tetrahydro-2H-isoindole-1-carboxylic acid
(2-diethylaminoethyl)amide (80 mg) to give 50 mg (38%) of the title
compound as a reddish solid.
[0525] .sup.1H NMR (360-MHz, DMSO-d6) .delta. 13.4 (s, 1H, NH), 11
(s, 1H, NH), 8.9 (d, 1H, NH), 8.7 (dd, 1H, ArH), 8.1 (dd, 1H, ArH),
7.9 (d, 1H, ArH), 7.6 (s, 1H, CH), 7.5 (dd, 1H, ArH), 7.3 (dd, 1H,
ArH), 7.1 (m, 2H, ArH), 3.35 (m, 2H, CONHCH.sub.2), 2.8 (m, 4H,
2.times.pyrroleCH.sub.2), 2.5 (br m, 6H, N(CH.sub.2CH.sub.3).sub.2
and NCH.sub.2), 1.75 (br s, 4H, 2.times.pyrroleCH.sub.2CH.sub.2),
0.9 (t, 6H, N(CH.sub.2CH.sub.3).sub.2).
[0526] MS-EI m/z 484 [M.sup.+].
Example 21
[0527]
4-Benzoyl-5-(5-bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-3-meth-
yl-1H-pyrrole-2-carboxylic Acid (3-diethylaminopropyl)amide
[0528] To a mixture of benzoyl chloride (1 equiv.) and aluminum
chloride (1 equiv.) in dichloroethane at 0.degree. C. was added
ethyl 3,5-dimethyl-2-pyrrolecarboxylate (1 equiv.). The mixture was
stirred at 80.degree. C. for 4 hr. The mixture was then extracted
with ethyl acetate (EtOAc) and H.sub.2O. The combined organic
extracts were washed with saturated sodium bicarbonate and brine,
dried and concentrated to give (51%) of
4-benzoyl-3,5-dimethyl-1H-pyrrole-2-carboxylic acid.
[0529] A mixture of 4-benzoyl-3,5-dimethyl-1H-pyrrole-2-carboxylic
acid ethyl ester (4.13 g, 15.2 mmol) and ceric ammonium nitrate (33
g, 4 equiv.) in 50 mL of tetrahydrofuran (THF):acetic acid
(HOAc):H.sub.2O 1:1:1 was refluxed overnight. The reaction mixture
was then cooled, extracted with EtOAc and then basified to pH 9
with sodium carbonate. The organic layer was then washed with
brine, dried (MgSO.sub.4) and concentrated followed by column
chromatography to give 3.25 g (75%) of
4-benzoyl-5-formyl-3-methyl-1H-pyrrole-2-carboxylic acid ethyl
ester as a yellow solid.
[0530] 5-Bromo-1,3-dihydro-indol-2-one was condensed with
4-benzoyl-5-formyl-3-methyl-1H-pyrrole-2-carboxylic acid using
method D to give
4-benzoyl-5-(5-bromo-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-3-m-
ethyl-1H-pyrrole-2-carboxylic acid.
[0531] The above carboxylic acid was then coupled with
N,N-diethyl-1,3-propanediamine using method C to give the title
compound.
[0532] .sup.1H NMR (360 MHz, DMSO-d6) .delta. 7.96 (m, 1H,
CONHCH.sub.2), 7.76 (d, J=7.0 Hz, 2H), 7.68 (t, 1H), 7.56 (m, 2H),
7.40 (s, 2H), 7.33 (dd, J=1.6 & 8.3 Hz, 1H, H-6), 6.84 (d,
J=8.3 Hz, 1H, H-7), 3.33 (m, 2H, CH.sub.2), 2.42-2.46 (m, 6H,
3.times.CH.sub.2), 2.10 (s, 3H, CH.sub.3), 1.65 (m, 2H, CH.sub.2),
0.94 (t, J=7.0 Hz, 6H, N(CH.sub.2CH.sub.3).sub.2)- .
[0533] MS Electron Impact m/z 564 [M.sup.++1].
Example 22
[0534]
4-Benzoyl-5-(5-bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-3-meth-
yl-1H-pyrrole-2-carboxylic Acid (3-morpholin-4-ylpropyl)amide
[0535] .sup.1H NMR (360 MHz, DMSO-d6) .delta. 14.10 (s, 1H, NH),
11.14 (br s, 1H, NH), 7.92 (m, 1H, CONHCH.sub.2), 7.75 (m, 2H),
7.69 (t, 1H), 7.56 (m, 2H), 7.42 (m, 2H), 7.33 (dd, J=1.9 & 8.3
Hz, 1H, H-6), 6.85 (d, J=8.3 Hz, 1H, H-7), 3.56 (m, 4H,
2.times.CH.sub.2), 3.33 (m, 2H, CH.sub.2), 2.35 (m, 6H,
3.times.CH.sub.2), 2.10 (s, 3H, CH.sub.3), 1.70 (m, 2H,
CH.sub.2).
Example 23
[0536]
4-Benzoyl-3-methyl-5-(2-oxo-1,2-dihydroindol-3-ylidenemethyl)-1H-py-
rrole-2-carboxylic Acid (3-pyrrolidin-1-ylpropyl)amide
[0537] .sup.1H NMR (300 MHz, DMSO-d6) .delta. 14.18 (s, 1H, NH),
11.14 (br s, 1H, NH), 8.01 (m, 1H, CONHCH.sub.2), 7.74 (m, 1H),
7.67 (m, 1H), 7.55 (m, 1H), 7.32 (s, 1H, H-vinyl), 7.17 (m, 1H),
6.92 (m, 1H), 3.36 (m, 2H, CH.sub.2), 2.44 (m, 6H,
3.times.CH.sub.2), 2.11 (s, 3H, CH.sub.3), 1.65-1.75 (m, 6H,
3.times.CH.sub.2).
[0538] MS Electron Impact m/z 482 [M.sup.+].
Example 24
[0539]
4-Benzoyl-5-(5-bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-3-meth-
yl-1H-pyrrole-2-carboxylic Acid (3-pyrrolidin-1-ylpropyl)amide
[0540] .sup.1H NMR (360 MHz, DMSO-d6) .delta. 14.01 (s, 1H, NH),
11.18 (br s, 1H, NH), 7.98 (m, 1H, CONHCH.sub.2), 7.75 (m, 2H),
7.68 (m, 1H), 7.55 (m, 2H), 7.40 (m, 2H), 7.33 (dd, J=2.0 & 8.2
Hz, 1H, H-6), 6.84 (d, J=8.2 Hz, 1H, H-7), 3.34 (m, 2H, CH.sub.2),
2.42-2.47 (m, 6H, 3.times.CH.sub.2); 2.09 (s, 3H, CH.sub.3), 1.70
(m, 2H, CH.sub.2), 1.64 (m, 4H, 2.times.CH.sub.2).
Example 25
[0541]
4-Benzoyl-3-methyl-5-(2-oxo-6-phenyl-1,2-dihydroindol-3-ylidenemeth-
yl)-1H-pyrrole-2-carboxylic Acid (3-pyrrolidin-1-ylpropyl)amide
[0542] .sup.1H NMR (300 MHz, DMSO-d6) .delta. 14.15 (s, 1H, NH),
11.16 (br s, 1H, NH), 7.98 (m, 1H, CONHCH.sub.2), 7.77 (d, J=7.7
Hz, 2H), 70.69 (m, 1H), 7.53-7.63 (m, 4H), 7.44 (m, 2H), 7.33-7.37
(m, 2H), 7.24 (s, 2H), 7.12 (1H), 3.36 (m, 2H, CH.sub.2), 2.43-2.48
(m, 6H, 3.times.CH.sub.2), 2.12 (s, 3H, CH.sub.3), 1.74 (m, 2H,
CH.sub.2), 1.69 (m, 4H, 2.times.CH.sub.2).
[0543] MS Electron Impact m/z 558 [M.sup.+].
Example 26
[0544]
4-Benzoyl-5-(6-methoxy-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-3-me-
thyl-1H-pyrrole-2-carboxylic Acid
(3-pyrrolidin-1-ylpropyl)amide
[0545] .sup.1H NMR (300 MHz, DMSO-d6) .delta. 13.99 (s, 1H, NH),
11.05 (br s, 1H, NH), 7.93 (m, 1H, CONHCH.sub.2), 7.72 (m, 2H),
7.65 (m, 1H), 7.54 (m, 2H), 7.15 (s, 1H, H-vinyl), 7.04 (d, J=8.4
Hz, 1H, H-4), 6.51 (dd, J=2.3 & 81.4 Hz, 1H, H-5), 6.44 (d,
J=2.3 Hz, 1H, H-7), 3.74 (s, 3H, OCH.sub.3), 3.35 (m, 2H,
CH.sub.2), 2.42-2.46 (m, 6 H, 3.times.CH.sub.2), 2.10 (s, 3H,
CH.sub.3), 1.72 (m, 2H, CH.sub.2), 1.65 (m, 4H,
2.times.CH.sub.2).
[0546] MS Electron Impact m/z 512 [M.sup.+].
Example 27
[0547]
4-Benzoyl-5-(5-methoxy-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-3-me-
thyl-1H-pyrrole-2-carboxylic Acid
(3-pyrrolidin-1-ylpropyl)amide
[0548] .sup.1H NMR (360 MHz, DMSO-d6) .delta. 14.24 (s, 1H, NH),
10.90 (br s, 1H, NH), 7.97 (m, 1H, CONHCH.sub.2), 7.75 (d, J=7.2
Hz, 2H), 7.69 (m, 1H), 7.5 (m, 2H), 7.24 (s, 1H, H-vinyl), 6.79 (m,
2H), 6.66 (m, 1H), 3.67 (s, 3H, OCH.sub.3), 3.34 (m, 2H, CH.sub.2),
2.43-2.48 (m, 6 H, 3.times.CH.sub.2), 2.14 (s, 3H, CH.sub.3), 1.71
(m, 2H, CH.sub.2), 1.66 (m, 4H, 2.times.CH.sub.2).
[0549] MS Electron Impact m/z 512 [M.sup.+].
Example 28
[0550]
4-Benzoyl-5-(5-fluoro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-3-met-
hyl-1H-pyrrole-2-carboxylic Acid (3-pyrrolidin-1-ylpropyl)amide
[0551] .sup.1H NMR (300 MHz, DMSO-d6) .delta. 14.20 (s, 1H, NH),
11.14 (br s, 1H, NH), 8.03 (m, 1H, CONHCH.sub.2), 7.75 (m, 2H),
7.68 (m, 1H), 7.55 (m, 2H), 7.38 (s, 1H, H-vinyl), 7.08 (m, 1H),
7.01 (m, 1H), 6.87 (m, 1H), 3.34 (m, 2H, CH.sub.2), 2.42-2.48 (m,
6H, 3.times.CH.sub.2), 2.09 (s, 3H, CH.sub.3), 1.70 (m, 2H,
CH.sub.2), 1.65 (m, 4H, 2.times.CH.sub.2).
[0552] MS Electron Impact m/z 500 [M.sup.+].
Example 29
[0553]
4-Acetyl-5-(5-bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-3-methy-
l-1H-pyrrole-2-carboxylic Acid (3-diethylaminopropyl)amide
[0554] 5-Bromo-1,3-dihydro-indol-2-one was condensed with
4-acetyl-5-formyl-3-methyl-1H-pyrrole-2-carboxylic acid
(3-diethylaminopropyl)amide (prepared from
4-acetyl-5-formyl-3-methyl-1H-- pyrrole-2-carboxylic acid ethyl
ester by method B then C) to give the title compound.
[0555] .sup.1H NMR (300 MHz, DMSO-d6) .delta. 14.19 (s, 1H, NH),
11.19 (br s, 1H, NH), 8.15 (m, 1H, CONHCH.sub.2), 8.11 (s, 1H,
H-vinyl), 7.72 (d, J=1.8 Hz, 1H, H-4), 7.38 (dd, J=1.8 & 8.2
Hz, 1H, H-6), 6.87 (d, J=8.2 Hz, 1H, H-7), 3.27 (m, 2H, CH.sub.2),
2.57 (s, 3H, CH.sub.3CO), 2.46 (m, 9H, CH.sub.3 &
3.times.CH.sub.2), 1.64 (m, 2H, CH.sub.2), 0.93 (t, J=7.1 Hz, 6H,
N(CH.sub.2CH.sub.3).sub.2).
Example 30
[0556]
4-Acetyl-5-(5-bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-3-methy-
l-1H-pyrrole-2-carboxylic Acid (3-pyrrolidin-1-ylpropyl)amide
[0557] .sup.1H NMR (300 MHz, DMSO-d6) .delta. 8.14 (m, 1H,
CONHCH.sub.2), 8.10 (s, 1H, H-vinyl), 70.70 (d, 1H, H-4), 7.36 (dd,
J=1.6 & 8.1 Hz, 1H, H-6), 6.85 (d, J=8.1 Hz, 1H, H-7), 3.32 (m,
2H, CH.sub.2), 2.57 (s, 3H, CH.sub.3CO), 2.44 (s, 3H, CH.sub.3),
2.35-2.48 (m, 6H, 3.times.CH.sub.3), 1.65-1.71 (m, 6H,
0.3.times.CH.sub.2).
[0558] MS m/z 499 & 501 [M.sup.+] & [M.sup.++2].
Example 31
[0559]
4-Acetyl-5-(5-bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-3-methy-
l-1H-pyrrole-2-carboxylic Acid (3-morpholin-4-ylpropyl)amide
[0560] .sup.1H NMR (300 MHz, DMSO-d6) .delta. 14.20 (s, 1H, NH),
11.26 (br s, 1H, NH), 8.09 (m, 2H, H-vinyl & CONHCH.sub.2),
7.73 (d, J=1.5 Hz, 1H, H-4), 7.38 (dd, J=10.5 & 8.3 Hz, 1H,
H-6), 6.87 (d, J=8.3 Hz, 1H, H-7), 3.55 (m, 4H, 2.times.CH.sub.2),
3.26 (m, 2H, CH.sub.2), 2.57 (s, 3H, CH.sub.3CO), 2.44 (s, 3H,
CH.sub.3), 2.35 (m, 6H, 3.times.CH.sub.3), 1.68 (m, 2H,
CH.sub.2).
[0561] MS-EI m/z 514 & 516 [M.sup.+-1] & [M.sup.++1].
Example 32
[0562]
4-Acetyl-5-(5-bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-3-methy-
l-1H-pyrrole-2-carboxylic Acid (3-hydroxypropyl)amide
[0563] .sup.1H NMR (360 MHz, DMSO-d6) .delta. 14.17 (s, 1H, NH),
11.25 (br s, 1H, NH), 8.10 (s, 1H, H-vinyl), 8.03 (m, 1H,
CONHCH.sub.2), 7.71 (br s, 1H, H-4), 7.37 (br d, J=8.4 Hz, 1H,
H-6), 6.87 (d, J=8.4 Hz, 1H, H-7), 4.51 (br s, 1H, OH), 3.51 (br s,
2H, CH.sub.2), 3.36 (m, 2H, CH.sub.2), 2.57 (s, 3H, CH.sub.3CO),
2.43 (s, 3H, CH.sub.3), 1.70 (m, 2H, CH.sub.2).
[0564] MS-EI m/z 445 & 447 [M.sup.+-1] & [M.sup.++1].
Example 34
[0565]
4-Acetyl-5-(5-bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-3-methy-
l-1H-pyrrole-2-carboxylic Acid (2-morpholin-4-ylethyl)amide
[0566] .sup.1H NMR (360 MHz, DMSO-d6) .delta. 14.19 (s, 1H, NH),
11.14 (br s, 1H, NH), 8.10 (s, 1H, H-vinyl), 7.84 (m, 1H,
CONHCH.sub.2), 7.71 (d, J=1.8 Hz, 1H, H-4), 7.38 (dd, J=1.8 &
8.2 Hz, 1H, H-6), 6.87 (d, J=8.2 Hz, 1H, H-7), 3.58 (m, 4H,
2.times.CH.sub.2), 3.40 (m, 2H, CH.sub.2), 2.57 (s, 3H, CH.sub.3C),
2.49 (m, 4H, 2.times.CH.sub.2), 2.45 (m, CH.sub.3 &
CH.sub.2).
[0567] MS-EI m/z 500 & 502 [M.sup.+-1] & [M.sup.++1].
Example 35
[0568]
4-Acetyl-5-(5-bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl))-3-meth-
yl-1H-pyrrole-2-carboxylic Acid (2-pyrrolidin-1-ylethyl)amide
[0569] .sup.1H NMR (360 MHz, DMSO-d6), .delta. 14.17 (s, 1H, NH),
11.23 (s, 1H, NH), 8.11 (s, 1H, H-vinyl), 7.91 (m, 1H,
CONHCH.sub.2), 7.73 (d, J=1.9 Hz, 1H, H-4), 7.39 (dd, J=1.9 &
8.3 Hz, 1H, H-6), 6.88 (d, J=8.3 Hz, 1H, H-7), 3.40 (m, 2H,
CH.sub.2), 2.62 (m, 2H, CH.sub.2), 2.57 (s, 3H, CH.sub.3CO), 2.49
(m, 4H, 2.times.CH.sub.2), 2.44 (s, 3H, CH.sub.3), 1.69 (m, 4H,
2.times.CH.sub.2).
Example 36
[0570]
4-Acetyl-5-(5-bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-3-methy-
l-1H-pyrrole-2-carboxylic Acid [2-(4-hydroxyphenyl)ethyl]amide
[0571] .sup.1H NMR (300 MHz, DMSO-d6) .delta. 14.21 (s, 1H, NH),
11.18 (s, 1H, OH), 9.09 (s, 1H, NH), 8.06-8.10 (m, 2H), 7.73 (s,
1H), 7.38 (d, J=7.8 Hz, 1H), 7.04 (d, J=7.1 Hz, 2H), 6.88 (d, J=7.8
Hz, 1H), 6.67 (d, J=7.1 Hz, 2H), 3.42 (m, 2H, CH.sub.2), 2.72 (m,
2H, CH.sub.2), 2.56 (s, 3H, CH.sub.3CO), 2.37 (s, 3H,
CH.sub.3).
[0572] MS-EI m/z 507 & 509 [M.sup.+-1] & [M.sup.++1].
Example 37
[0573]
5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2-isopropyl-4-ph-
enyl-1H-pyrrole-3-carboxylic Acid (3-diethylaminopropyl)amide
[0574] A mixture of 2-aminoacetophenone hydrochloride (1 equiv.),
ethyl isobutyrylacetate (1.2 equiv.) and sodium acetate (2.4
equiv.) in H.sub.2O was stirred at 100.degree. C. for 18 hours and
then cooled to room temperature. The aqueous layer was decanted off
and the oil was dissolved in ethyl acetate. It was then washed with
water and brine and then dried to give (93%) of
2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid ethyl ester as a
red brown oil.
[0575] .sup.1HNMR (300 MHz, DMSO-d6) .delta. 11.21 (s, br, 1H, NH),
7.14-7.27 (m, 5H), 6.70 (d, J=2.7 Hz, 1H), 4.02 (q, J=7.1 Hz, 2H,
OCH.sub.2CH.sub.3), 3.65 (m, 1H, CH(CH.sub.3).sub.2), 1.22 (d,
J=7.5 Hz, 6H, CH(CH.sub.3).sub.2), 1.04 (t, J=7.1 Hz, 3H,
OCH.sub.2CH.sub.3).
[0576] MS-EI m/z 257 [M.sup.+].
[0577] The above pyrrole was formylated using method A to give
(41%), 5-formyl-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid
ethyl ester as a reddish solid.
[0578] .sup.1HNMR (300 MHz, DMSO-d6) .delta. 12.35 (s, br, 1H, NH),
9.14 (s, 1H, CHO), 7.36 (s, 5H), 3.96 (q, J=7.1 Hz, 2H,
OCH.sub.2CH.sub.3), 33.74 (m, 1H, CH(CH.sub.3).sub.2), 1.29 (d,
J=6.9 Hz, 6H, CH(CH.sub.3).sub.2), 0.90 (t, 7.1 Hz, 3H,
OCH.sub.2CH.sub.3).
[0579] MS-EI m/z 285 [M.sup.+].
[0580] The pyrrolecarboxylic acid ester was hydrolysed using method
B to give (57%) of
5-formyl-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid as a
beige solid.
[0581] .sup.1HNMR (300 MHz, DMSO-d6) .delta. 12.28 (s, br, 1H,
COOH), 12.02 (s, br, 1H, NH), 9.10 (s, 1H, CHO), 7.35 (s, 5H), 3.81
(m, 1H, CH(CH.sub.3).sub.2), 1.28 (d, J=6.9 Hz, 6H,
CH(CH.sub.3).sub.2).
[0582] MS-EI m/z 257 [M.sup.+].
[0583] 5-Bromo-1,3-dihydroindol-2-one (120 mg, 0.31 mmol) was
condensed with
5-formyl-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid
(3-diethylaminopropyl)amide (prepared by method C) to give 120 mg
(71%) of the title compound.
[0584] .sup.1HNMR (300 MHz, DMSO-d6) .delta. 14.23 (s, br, 1H, NH),
11.08 (s, br, 1H, NH), 7.38-7.55 (m, 7H, Ar--H & CONHCH.sub.2),
7.30 (s, 1H, H-vinyl), 7.26 (dd, J=1.8 & 7.8 Hz, 1H), 6.85 (d,
J=8.7 Hz, 1H), 3.36 (m, 1H, CH(CH.sub.3).sub.2), 3.07 (m, 2H,
CH.sub.2), 2.34 (q, J=7.1 Hz, 4H, N(CH.sub.2CH.sub.3).sub.2), 2.22
(t, J=6.9 Hz, 2H, CH.sub.2), 1.40 (m, 2H, CH.sub.2), 1.31 (d,
J=06.9 Hz, 6H, CH(CH.sub.3).sub.2), 0.86 (t, J=7.1 Hz, 6H,
N(CH.sub.2CH.sub.3).sub.2).
[0585] MS m/z 565.1 [M.sup.++1].
Example 38
[0586]
5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2-isopropyl-4-ph-
enyl-1H-pyrrole-3-carboxylic Acid
(3-pyrrolidin-1-ylpropyl)amide
[0587]
5-(5-bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2-isopropyl-4-ph-
enyl-1H-pyrrole-3-carboxylic acid (127 mg, 0.28 mmol) was condensed
with 3-pyrrolidin-1-yl-propylamine (43 mg, 0.336 mmol) to give 140
mg (66%) of the title compound.
[0588] .sup.1HNMR (300 MHz, DMSO-d6) .delta. 14.40 (s, br, 1H, NH),
7.38-7.47 (m, 7H), 7.23-7.27 (m, 2H), 6.84 (d, J=8.1 Hz, 1H), 3.36
(m, 1H, CH(CH.sub.3).sub.2), 3.08 (m, 2H, CH.sub.2), 2.30 (m, 4H,
2.times.CH.sub.2), 2.20 (t, J=7.0 Hz, 2H, CH.sub.2), 1.62 (m, 4H,
2.times.CH.sub.2), 1.42 (t, J=7.0 Hz, 2H, CH.sub.2), 1.31 (d, J=7.2
Hz, 6H, CH(CH.sub.3).sub.2).
[0589] MS-EI m/z 560 and 562 [M.sup.+-1 and M.sup.++1].
Example 39
[0590]
5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2-isopropyl-4-ph-
enyl-1H-pyrrole-3-carboxylic Acid (2-diethylaminoethyl)amide
[0591] 5-Bromo-1,3-dihydroindol-2-one (57, g. 0.27 mmol) was
condensed with
5-formyl-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid
(2-diethylaminoethyl)amide (120 mg) to give 78 mg (53%) of the
title compound as a yellow solid.
[0592] .sup.1HNMR (300 MHz, DMSO-d6) .delta. 14.23 (s, br, 1H, NH),
11.09 (s, br, 1H, NH), 7.38-7.51 (m, 6H), 7.25-7.28 (m, 2H), 7.19
(t, 1H, CONHCH.sub.2), 6.85 (d, J=7.8 Hz, 1H), 33.43 (m, 1H,
CH(CH.sub.3).sub.2), 3.11 (m, 2H, CH.sub.2), 2.28-2.39 (m, 6H,
N(CH.sub.2CH.sub.3).sub.2 & CH.sub.2, 1.31 (d, J=6.9 Hz,
CH(CH.sub.3).sub.2), 0.85 (t, J=7.0 Hz, 6H,
N(CH.sub.2CH.sub.3).sub.2.
[0593] MS-EI m/z 548 and 550 [M.sup.+-1 and M++1].
Example 40
[0594]
5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2-isopropyl-4-ph-
enyl-1H-pyrrole-3-carboxylic Acid
[3-(4-methylpiperazin-1-yl)propyl]amide
[0595] 5-Bromo-1,3-dihydroindol-2-one (53 mg, 0.25 mmol) was
condensed with
5-formyl-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid
[3-(4-methylpiperazin-1-yl)propyl]amide (300 mg) to give 65 mg of
the title compound.
[0596] .sup.1HNMR (300 MHz, DMSO-d6) .delta. 14.22 (s, br, 1H, NH),
11.08 (s, br, 1H, NH), 7.23-7.50 (m, 9H), 6.85 (d, J=8.7 Hz, 1H),
3.37 (m, 1H, CH(CH.sub.3).sub.2), 3.05 (m, 2H, CH.sub.2), 2.24 (m,
8H, 4.times.CH.sub.2), 2.11 (m, 5H, CH.sub.2 & CH.sub.3), 1.42
(m, 2H, CH.sub.2), 1.31 (d, J=7.2 Hz, 6H,
CH(CH.sub.3).sub.2).sub.2.
[0597] MS-EI m/z 589 and 591 [M.sup.++1 and M.sup.++1].
Example 41
[0598]
5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2-isopropyl-4-ph-
enyl-1H-pyrrole-3-carboxylic Acid
[0599] 5-Bromo-1,3-dihydroindol-2-one (170 mg, 0.8 mmol) was
condensed with
5-formyl-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid (205 mg)
using method D to give 210 mg (58%) of the title compound as a
yellow solid.
[0600] .sup.1HNMR (300 MHz, DMSO-d6) .delta. 14.31 (s, br, 1H, NH),
11.16 (s, br, 1H, NH), 7.26-7.44 (m, 7H), 7.11 (s, 1H, H-vinyl),
6.85 (d, J=7.8 Hz, 1H), 3.78 (m, 1H, CH(CH.sub.3).sub.2), 1.34 (d,
J=6.9 Hz, 6H, CH(CH.sub.3).sub.2).
[0601] MS-EI m/z 452 [M.sup.++1].
Example 42
[0602]
5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2-methyl-4-pheny-
l-1H-pyrrole-3-carboxylic Acid (2-pyrrolidin-1-ylethyl)amide
[0603] 5-Bromo-1,3-dihydroindol-2-one (44 mg, 0.21 mmol) was
condensed with 5-formyl-2-methyl-4-phenyl-1H-pyrrole-3-carboxylic
acid (2-pyrrolidin-1-ylethyl)amide (70 mg, prepared in the same
manner as the isopropyl analog, above) to give 0.03 g (27%) of the
title compound as a yellow solid.
[0604] .sup.1HNMR (300 MHz, DMSO-d6) .delta. 13.87 (s, br, 1H, NH),
11.11 (s, br, 1H, NH), 7.36-7.51 (m, 6H), 7.26 (dd, J=1.8 & 8.1
Hz, 1H), 7.2 (s, 1H, H-vinyl), 7.09 (m, 1H, CONHCH.sub.2), 6.83 (d,
J=8.1 Hz, 1H), 3.17 (m, 2H, NCH.sub.2), 2.48 (m, CH.sub.3),
2.29-2.35 (m, 6H, 3.times.NCH.sub.2), 1.59 (m, 4H,
2.times.CH.sub.2).
[0605] MS-EI m/z 518 and 520 [M.sup.++1 and M.sup.++1].
Example 43
[0606]
5-[6-(2-Methoxyphenyl)-2-oxo-1,2-dihydroindol-3-ylidenemethyl]-2-me-
thyl-4-phenyl-1H-pyrrole-3-carboxylic Acid
(2-pyrrolidin-1-ylethyl)amide
[0607] 6-(2-Methoxyphenyl)-1,3-dihydroindol-2-one (50 mg, 0.21
mmol) was condensed with
5-formyl-2-methyl-4-phenyl-1H-pyrrole-3-carboxylic acid
(2-pyrrolidin-1-ylethyl)amide (70 mg) to give 0.04 g (35%) of the
title compound as a yellow-orange solid.
[0608] .sup.1HNMR (300 MHz, DMSO-d6) .delta. 13.82 (s, br, 1H, NH),
11.02 (s, br, 1H, NH), 7.48 (m, 2H), 7.43 (m, 1H), 7.38 (m, 2H),
7.32 (m, 1H), 7.24 (m, 2H), 7.16 (s, 1H, H-vinyl), 7.08 (m, 2H),
7.03 (m, 1H), 7.0 (m, 2H), 3.74 (s, 3H, OCH.sub.3), 3.19 (m, 2H,
NCH.sub.2), 2.49 (m, CH.sub.3), 2.32-2.38 (m, 6H,
3.times.NCH.sub.2), 1.59 (m, 4H, 2.times.CH.sub.2).
[0609] MS-EI m/z 546 [M.sup.+].
Example 44
[0610]
5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2-methyl-4-pheny-
l-1H-pyrrole-3-carboxylic Acid (2-dimethylaminoethyl)amide
[0611] 5-Bromo-1,3-dihydroindol-2-one (46 mg, 0.22 mmol) was
condensed with 5-formyl-2-methyl-4-phenyl-1H-pyrrole-3-carboxylic
acid (2-dimethylaminoethyl)amide (65 mg) to give 60 mg (55%) of the
title compound as a yellow solid.
[0612] .sup.1HNMR (360, MHz, DMSO-d6) .delta. 13.86 (s, br, 1H,
NH), 11.09 (s, br, 1H, NH), 7.47-7.49 (m, 2H), 7.38-7.41 (m, 4H),
7.26 (dd, J=2.2 & 8.3 Hz, 1H), 7.21 (s, 1H, H-vinyl), 7.04 (m,
1H, CONHCH.sub.2), 6.77 (d, J=8.3 Hz, 1H), 3.15 (m, 2H, NCH.sub.2),
2.48 (m, CH.sub.3), 2.16 (t, J=6.8 Hz, 2H, 3.times.NCH.sub.2), 2.02
(s, 6H, 2.times.NCH.sub.3).
[0613] MS m/z 493 and 494.8 [M.sup.+ and M.sup.++2].
Example 45
[0614]
5-[6-(2-Methoxyphenyl)-2-oxo-1,2-dihydroindol-3-ylidenemethyl]-2-me-
thyl-4-phenyl-1H-pyrrole-3-carboxylic Acid
(2-dimethylaminoethyl)amide
[0615] 6-(2-Methoxyphenyl)-1,3-dihydroindol-2-one (53 mg, 0.22
mmol) was condensed with
5-formyl-2-methyl-4-phenyl-1H-pyrrole-3-carboxylic acid
(2-dimethylaminoethyl)amide (65 mg) to give 0.05 g (44%) of the
title compound as a orange gum.
[0616] .sup.1HNMR (300 MHz, DMSO d6) .delta. 13.82 (s, br, 1H, NH),
11.02 (s, br, 1H, NH), 7.37-7.52 (m, 5H), 7.32 (m, 1H), 7.22-7.27
(m, 2H), 7.16 (s, 1H), 7.08 (m, 2H), 7.03 (m, 1H), 7.0 (m, 2H),
3.74 (s, 3H, OCH.sub.3), 3.15 (m, 2H, NCH.sub.2), 2.49 m,
CH.sub.3), 2.16 (t, J=6.5 Hz, 2H, NCH.sub.2), 2.02 (s, 6H,
2.times.NCH.sub.3).
[0617] MS m/z 521 [M.sup.++1].
Example 46
[0618]
5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2-methyl-4-pheny-
l-1H-pyrrole-3-carboxylic Acid Ethyl Ester
[0619] 5-Bromo-1,3-dihydroindol-2-one (60 mg, 0.29 mmol) was
condensed with 5-formyl-2-methyl-4-phenyl-1H-pyrrole-3-carboxylic
acid ethyl ester (75 mg) to give 78 mg (60%) of the title compound
as an orange solid.
[0620] .sup.1HNMR (360 MHz, DMSO-d6) .delta. 14.01 (s, br, 1H, NH),
11.13 (s, br, 1H, NH), 7.42-7.46 (m, 3H), 7.27-7.34 (m, 4H), 7.12
(s, 1H), 6.84 (dd, J=2.2 & 8.3 Hz, 1H), 3.99-4.03 (m, 2H,
OCH.sub.2CH.sub.3), 2.61 (s, 3H, CH.sub.3), 0.98-1.03 (m, 3H,
OCH.sub.2CH.sub.3).
[0621] MS-EI m/z 450 and 452 [M.sup.++1 and M.sup.++1].
Example 47
[0622]
5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2-methyl-4-pheny-
l-1H-pyrrole-3-carboxylic Acid (3-diethylaminopropyl)amide
[0623] 5-bromo-1,3-dihydroindol-2-one (0.47 g, 2.2 mmol) was
condensed with 5-formyl-2-methyl-4-phenyl-1H-pyrrole-3-carboxylic
acid (3-diethylaminopropyl)amide (0.75 g) to give 0.11 g (42%) of
the title compound as an orange solid.
[0624] .sup.1HNMR (300 MHz, DMSO-d6) .delta. 13.86 (s, br, 1H, NH),
7.42-7.46 (m, 3H), 7.37-7.50 (m, 7H), 7.24-7.28 (m, 2H), 6.83 (d,
J=8.1 Hz, 1H), 3.09 (m, 2H, NCH.sub.2), 2.45 (s, 3H, CH.sub.3),
2.38 (q, J=7.1 Hz, 4H, 2.times.NCH.sub.2CH.sub.3), 2.26 (t, J=6.9
Hz, 2H, NCH.sub.2), 1.42 (m, 2H, NCH.sub.2), 0.87 (t, J=7.1 Hz, 6H,
2.times.NCH.sub.2CH.sub.3- ).
[0625] MS-EI m/z 535.0 and 537 [M.sup.+ and M.sup.++2].
Example 48
[0626]
5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H--
pyrrole-3-carboxylic Acid (2-dimethylaminoethyl)amide
[0627] A mixture of tert-butyl 3-oxobutyrate and sodium nitrite (1
equiv.) in acetic acid was stirred at room temperature to give
tert-butyl-2-hydroximino-3-oxobutyrate.
[0628] Ethyl-3-oxobutyrate (1 equiv.), zinc dust (3.8 equiv.) and
the crude tert-butyl-2-hydroximino-3-oxobutyrate in acetic acid was
stirred at 60.degree. C. for 1 hr. The reaction mixture was poured
into H.sub.2O and the filtrate was collected to give (65%)
2-tert-butyloxycarbonyl-3,5-- dimethyl-4-ethoxycarbonylpyrrole.
[0629] A mixture of
2-tert-butyloxycarbonyl-3,5-dimethyl-4-ethoxycarbonylp- yrrole and
triethyl orthoformate (1.5 equiv.) in trifluoroacetic acid was
stirred at 15.degree. C. for 1 hour. The reaction was concentrated
and the residue was purified to give (64%)
2,4-dimethyl-3-ethoxycarbonyl-5-fo- rmylpyrrole as yellow
needles.
[0630] 2,4-Dimethyl-3-ethoxycarbonyl-5-formylpyrrole was hydrolyzed
using method B to give (90%),
5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid.
[0631] .sup.1H NMR (360 MHz, DMSO-d6) .delta. 12 (br s, 2H, NH and
CO.sub.2H), 9.58 (s, 1H, CHO), 2.44 (s, 3H, CH.sub.3), 2.40 (s, 3H,
CH.sub.3).
[0632] MS m/z 267 [M.sup.+].
[0633] 5-Bromo-1,3-dihydroindol-2-one (0.17 g, 0.8 mmol) was
condensed with 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid
(2-dimethylaminoethyl)amide (0.2 g, prepared by method C), using
method B to give 0.3 g (83%) of the title compound as a yellow
solid.
[0634] .sup.1HNMR (360 MHz, DMSO-d6) .delta. 13.60 (s, br, 1H, NH),
10.94 (s, br, 1H, NH), 8.07 (d, J=1.8 Hz, 1H, H-4), 7.75 (s, 1H,
H-vinyl), 7.44 (t, J=5.2 Hz, 1H, CONHCH.sub.2), 7.24 (dd, J=1.8
& 8.4 Hz, 1H, H-6), 6.82 (d, J=8.4 Hz, 1H, H-7), 3.26-3.33 (m,
2H, NCH.sub.2), 2.42 (s, 3H, CH.sub.3), 2.41 (s, 3H, CH.sub.3),
2.38 (t, J=6.77 Hz, 2H, NCH.sub.2), 2.18 (6H,
N(CH.sub.3).sub.2).
[0635] MS-EI m/z 430 and 432 [M.sup.++1 and M.sup.++1].
Example 49
[0636]
2,4-Dimethyl-5-(2-oxo-6-phenyl-1,2-dihydroindol-3-ylidenemethyl)-1H-
-pyrrole-3-carboxylic Acid (2-dimethylaminoethyl)amide
[0637] 6-Phenyl-1,3-dihydroindol-2-one (0.17 g, 0.8 mmol) was
condensed with 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid
(2-dimethylaminoethyl)amide (0.2 g) to give 0.13 g (36%) of the
title compound as a yellow-orange solid.
[0638] .sup.1HNMR (360 MHz, DMSO-d6) .delta. 13.59 (s, br, 1H, NH),
10.93 (, br, 1H, NH), 7.85 (d, J=7.92 Hz, 1H, H), 7.63-7.65 (m,
3H), 7.40-7.47 (m, 3H,), 7.32-7.36 (m, 1H, Ar--H), 7.30 (dd, J=1.6
& 7.9 Hz, 1H, H-5), 7.11 (d, J=1.6 Hz, 1H, H-7), 3.28-3.34 (m,
2H, NCH.sub.2), 2.43 (s, 3H, CH.sub.3), 2.41 (s, 3H, CH.sub.3),
2.38 (t, J=6.8 Hz, 2H, NCH.sub.2), 2.18 (s, 6H,
N(CH.sub.3).sub.2).
[0639] MS-EI m/z 428 [M.sup.+].
Example 50
[0640]
5-(5-Chloro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-
-pyrrole-3-carboxylic Acid (2-dimethylaminoethyl)amide
[0641] 5-Chloro-1,3-dihydroindol-2-one (0.1 g, 0.6 mmol) was
condensed with 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid
(2-dimethylaminoethyl)amide (0.15 g) to give 0.22 g (90%) of the
title compound as a yellow solid.
[0642] .sup.1HNMR (300 MHz DMSO-d6) .delta. 13.61 (s, br, 1H, NH),
10.98 (, br, 1H, NH), 7.96 (d, J=2.0 Hz, 1H, H-4), 7.75 (s, 1H, H-O
vinyl), 7.50 (t, J=5.5 Hz, 1H, CONHCH.sub.2), 7.12 (dd, J=2.0 &
0.3 Hz, 1H, H-6), 6.86 (d, J=8.3 Hz, 1H, H-7), 3.26-3.31 (m, 2H,
NCH.sub.2), 2.42 (s, 3H, CH.sub.3), 2.40 (s, 3H, CH.sub.3), 2.36
(t, J=6.6 Hz, 2H, NCH.sub.2), 2.17 (s, 6H, N(CH.sub.3).sub.2).
[0643] MS-EI m/z 386 [M.sup.+].
Example 51
[0644]
5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H--
pyrrole-3-carboxylic Acid (2-diethylaminoethyl)amide
[0645] 5-Bromo-1,3-dihydroindol-2-one (0.17 g, 0.8 mmol) was
condensed with 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid
(2-diethylaminoethyl)amide (0.2 g) to give 0.09 g (26%) of the
title compound as a yellow solid.
[0646] .sup.1HNMR (360 MHz, DMSO-d6) .delta. 13.61 (s, br, 1H, NH),
10.98 (, br, 1H, NH), 8.09 (d, J=1.7 Hz, 1H, H-4), 7.76 (s, 1H,
H-vinyl), 7.42 (t, J=5.5 Hz, 1H, CONHCH.sub.2), 7.24 (dd, J=1.7
& 8.0 Hz, 1H, H-6), 6.82 (d, J=8.0 Hz, 1H, H-7), 3.23-13.32 (m,
2H, NCH.sub.2), 2.46-2.55 (m, 6H, 3.times.NCH.sub.2), 2.43 (s, 3H,
CH.sub.3), 2.42 (s, 3H, CH.sub.3), 0.96 (t, J=70.2 Hz, 6H,
2.times.NCH.sub.2CH.sub.3).
[0647] MS-EI m/z 458 and 460 [M.sup.++1 and M.sup.+1].
Example 52
[0648]
5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H--
pyrrole-3-carboxylic Acid (2-pyrrolidin-1-yl-ethyl)amide
[0649] 5-Bromo-1,3-dihydroindol-2-one (0.09 g, 0.4 mmol) was
condensed with 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid
(2-pyrrolidin-1-ylethyl)amide (0.1 g) to give 0.14 g (81%) of the
title compound as a yellow-orange solid.
[0650] .sup.1HNMR (300 MHz, DMSO-d6) .delta. 13.61 (s, br, 1H, NH),
10.98 (, br, 1H, NH), 8.09 (d, J=1.9 Hz, 1H, H-4), 7.76 (s, 1H,
H-vinyl), 7.53 (t, J=5.5 Hz, 1H, CONHCH.sub.2), 7.24 (dd, J=1.9
& 8.5 Hz, 1H, H-6), 6.81 (d, J=8.5 Hz, 1H, H-7), 3.29-3.35 (m,
2H, NCH.sub.2), 2.54 (t, J=6.9 Hz, 2H, NCH.sub.2), 2.47 (m, under,
DMSO), 2.42 (s, 3H, CH.sub.3), 2.40 (s, 3H, CH.sub.3), 1.66-1.69
(m, 4H, 2.times.CH.sub.2).
[0651] MS-EI m/z 456 and 458 [M.sup.+-1 and M.sup.++1].
Example 53
[0652]
5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H--
pyrrole-3-carboxylic Acid (3-imidazol-1-ylpropyl)amide
[0653] 5-Bromo-1,3-dihydroindol-2-one (0.09 g, 0.4 mmol) was
condensed with 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid
(3-imidazol-1-ylpropyl)amide (0.1 g) to give 0.1 g (59%) of the
title compound as an orange solid.
[0654] .sup.1HNMR (300 MHz, DMSO-d6) .delta. 13.63 (s, br, 1H, NH),
10.99 (, br, 1H, NH), 8.09 (d, J=2.2 Hz, 1H, H-4), 7.77 (s, 1H,
H-vinyl), 7.71 (t, J=5.7 Hz, 1H, CONHCH.sub.2), 7.65 (s, 1H,
Ar--H), 7.25 (dd, J=2.2 & 8.4 Hz, 1H, H-6), 7.20 (s, 1H,
Ar--H), 6.89 (s, 1H, Ar--H), 6.81 (d, J=8.4 Hz, 1H, H-7), 4.02 (t,
J=6.7 Hz, 2H, NCH.sub.2), 3.18 (q, J=6.7 Hz, 2H, NCH.sub.2), 2.43
(s, 3H, CH.sub.3), 2.41 (s, 3H, CH.sub.3), 1.93 (m, 2H,
CH.sub.2).
[0655] MS-EI m/z 467 and 469 [M.sup.++1 and M.sup.++1].
Example 54
[0656]
5-[6-(2-Methoxyphenyl)-2-oxo-1,2-dihydroindol-3-ylidenemethyl]-2,4--
dimethyl-1H-pyrrole-3-carboxylic Acid
(2-dimethylaminoethyl)amide
[0657] 6-(2-Methoxyphenyl)-1,3-dihydroindol-2-one (30 mg, 0.13
mmol) was condensed with
5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid
(2-dimethylaminoethyl)amide (30 mg) to give 0.06 g (100%) of the
title compound as a yellow-orange gum.
[0658] .sup.1HNMR (300 MHz, DMSO-d6) .delta. 13.60 (s, br, 1H, NH),
10.89 (s, br, 1H, NH), 7.79 (d, J=8.4 Hz, 1H), 7.63 (s, 1H,
H-vinyl), 7.46 (t, J=5.5 Hz, 1H, CONHCH.sub.2), 7.28-7.35 (m, 2H),
6.99-7.11 (m, 4H), 3.76 (s, 3H, OCH.sub.3), 3.27-3.31 (m, 2H,
NCH.sub.2), 2.43 (s, 3H, CH.sub.3), 2.39 (s, 3H, CH.sub.3), 2.37
(m, 2H, NCH.sub.2), 2.18 (s, 6H, N(CH.sub.3).sub.2).
[0659] MS-EI m/z 458 [M.sup.+].
Example 55
[0660]
5-[6-(3-Methoxyphenyl)-2-oxo-1,2-dihydroindol-3-ylidenemehyl]2,4-di-
methyl-3H-pyrrole-3-carboxylic Acid (2-dimethylaminoethyl)amide
[0661] 6-(3-Methoxyphenyl)-1,3-dihydroindol-2-one (30 mg, 0.13
mmol) was condensed with
5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid
(2-dimethylaminoethyl)amide (30 mg) to give 8 mg (14%) of the title
compound as a yellow-orange solid.
[0662] .sup.1HNMR (360 MHz, DMSO-d6) .delta. 13.59 (s, br, 1H, NH),
10.92 (s, br, 1H NH), 7.84 (d, J=7.6 Hz, 1H), 7.65 (s, 1H,
H-vinyl), 7.42 (m, 1H, CONHCH.sub.2), 7.36 (d, J=7.8, Hz, 1H), 7.29
(dd, J=1.6 & 7.6 Hz, 1H), 7.20 (d, J=7.8 Hz, 1H), 7.14 (d,
J=2.8 Hz, 1H), 7.11 (d, J=1.6 Hz, 1H), 6.91 (dd, J=2.8 & 7.8
Hz, 1H), 3.82 (s, 3H, OCH.sub.3), 3.21-3.33 (m, 2H, NCH.sub.2),
2.43 (s, 3H, CH.sub.3), 2.40 (s, 3H, CH.sub.3), 2.36-2.40 (m, 2H,
NCH.sub.2), 2.18 (s, 6H, N(CH.sub.3).sub.2).
[0663] MS-EI m/z 458 [M.sup.+].
Example 56
[0664]
2,4-Dimethyl-5-(2-oxo-5-phenyl-1,2-dihydroindol-3-ylidenemethyl)-1H-
-pyrrole-3-carboxylic Acid (2-diethylaminoethyl)amide
[0665] 5-Phenyl-1,3-dihydroindol-2-one (80 mg, 0.4 mmol) was
condensed with 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid
(2-diethylaminoethyl)amide (0.1 g) using method B to give 79 mg
(46%) of the title compound.
[0666] .sup.1HNMR (300 MHz, DMSO-d6) .delta. 13.66 (s, br, 1H, NH),
10.95 (, br, 1H, NH), 8.15 (d, J=1.2 Hz, 1H), 7.81 (s, 1H,
H-vinyl), 7.71 (d, J=7.5 Hz, 1H), 7.40-7.47 (m, 4H), 7.31 (m, 1H),
6.95 (d, J=8.1 Hz, 1H), 3.2-3.31 (m 2H, NCH.sub.2), 2.46-2.55 (m,
6H, 3.times.NCH.sub.2), 2.44 (s, 6H, 2.times.CH.sub.3), 0.96 (t,
J=7.4 Hz, 6H, 2.times.NCH.sub.2CH.sub- .3).
[0667] MS-EI m/z 456 [M.sup.+].
Example 57
[0668]
2,4-Dimethyl-5-(2-oxo-5-phenyl-1,2-dihydroindol-3-ylidenemethyl)-1H-
-pyrrole-3-carboxylic Acid (2-pyrrolidin-1-ylethyl)amide
[0669] 5-Phenyl-1,3-dihydroindol-2-one (0.04 g, 0.2 mmol) was
condensed with 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid
(2-pyrrolidin-1-ylethyl)amide (0.04 g) to give the title compound
as a yellow-orange solid.
[0670] .sup.1HNMR (300 MHz, DMSO-d6) .delta. 13.65 (s, br, 1H, NH),
10.96 (, br, 1H, NH), 8.15 (d, J=1.0 Hz, 1H), 7.80 (s, 1H,
H-vinyl), 7.71 (d, J=7.2 Hz, 2H), 7.49 (t, J=6.3 Hz, 1H,
CONHCH.sub.2), 7.41-7.46 (m, 3H), 7.31 (m, 1H), 6.95 (d, J=7.8 Hz,
1H), 4.08 (m, 4H, 2.times.NCH.sub.2), 3.32 (m, 2H, NCH.sub.2), 2.55
(t, J=7.1 Hz, 2H, NCH.sub.2), 2.47 (m, under DMSO), 2.43 (s, 6H,
2.times.CH.sub.3), 1.66 (m, 4H, 2.times.CH.sub.2).
[0671] MS-EI m/z 445 [M.sup.+].
Example 58
[0672]
2,4-Dimethyl-5-(2-oxo-5-phenyl-1,2-dihydroindol-3-ylidenemethyl)-1H-
-pyrrole-3-carboxylic Acid (3-imidazol-1-ylpropyl)amide
[0673] 5-Phenyl-1,3-dihydroindol-2-one (8 mg, 0.04 mmol) was
condensed with 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid
(3-imidazol-1-ylpropyl)amide (10 mg) to give 10 mg (59%) of the
title compound as an orange solid.
[0674] .sup.1HNMR (300 MHz, DMSO-d6) .delta. 13.67 (s, br, 1H, NH),
10.96 (, br, 1H, NH), 8.16 (d, J=1.2 Hz, 1H), 7.81 (s, 1H,
H-vinyl), 7.65-7.72 (m, 4H), 7.44 (m, 3H), 7.31 (m, 1H,
CONHCH.sub.2), 7.21 (s, 1H, Ar--H), 4.02 (t, J=6.5 Hz, 2H,
NCH.sub.2), 3.19 (q, J=6.5 Hz, 2H, CONHCH.sub.2), 2.44 (s, 6H,
2.times.CH.sub.3), 1.93 (m, 2H, CH.sub.2CH.sub.2CH.sub.2).
[0675] MS-EI m/z 465 [M.sup.+].
Example 59
[0676]
2,4-Dimethyl-5-(2-oxo-6-phenyl-1,2-dihydroindol-3-ylidenemethyl)-1H-
-pyrrole-3-carboxylic Acid (2-diethylaminoethyl)amide
[0677] 6-Phenyl-1,3-dihydroindol-2-one (0.08 g, 0.4 mmol) was
condensed with 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid
(2-diethylaminoethyl)amide (0.1 g) to give 65 mg (38%) of the title
compound as a yellow solid.
[0678] .sup.1HNMR (300 MHz, DMSO-d6) .delta.13.61 (s, br, 1H, NH),
10.99 (, br, 1H, NH), 7.86 (d, J=7.8 Hz, 1H), 7.62-7.66 (m, 3H),
7.40-7.47 (m, 3H), 7.28-7.36 (m, 2H), 7.10 (d, J=1.2 Hz, 1H), 3.26
(m, 2H, NCH.sub.2), 2.46-2.55 (m, 6H, 3.times.NCH.sub.2), 2.44 (s,
3H, CH.sub.3), 2.41 (s, 3H, CH.sub.3), 0.97 (t, J=7.2 Hz, 6H,
2.times.NCH.sub.2CH.sub.3).
[0679] MS-EI m/z 456 [M.sup.+].
Example 60
[0680]
2,4-Dimethyl-5-(2-oxo-6-phenyl-1,2-dihydroindol-3-ylidenemethyl)-1H-
-pyrrole-3-carboxylic Acid (2-pyrrolidin-1-ylethyl)amide
[0681] 6-Phenyl-1,3-dihydroindol-2-one (30 mg, 0.15 mmol) was
condensed with 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid
(2-pyrrolidin-1-ylethyl)amide (40 mg) to give 5.9 mg (8.5%) of the
title compound as a yellow-orange solid.
[0682] .sup.1HNMR (300 MHz, DMSO-d6) .delta. 13.60 (s, br, 1H, NH),
10.99 (, br, 1H, NH), 7.86 (d, J=7.8 Hz, 1H), 7.63-7.66 (m, 3H),
7.51 (m, 1H, CONHCH.sub.2), 7.45 (m, 2H), 7.28-7.36 (m, 2H), 7.10
(d, J=1.5 Hz, 1H), 3.31 (m, 6H, 3.times.NCH.sub.2), 2.55 (t, J=6.6
Hz, 2H, NCH.sub.2), 2.43 (s, 3H, CH.sub.3), 2.40 (s, 3H, CH.sub.3),
1.67 (m, 4H, 2.times.CH.sub.2).
[0683] MS-EI m/z 454 [M.sup.+].
Example 61
[0684]
2,4-Dimethyl-5-(2-oxo-6-phenyl-1,2-dihydroindol-3-ylidenemethyl)-1H-
-pyrrole-3-carboxylic Acid (3-imidazol-1-ylpropyl)amide
[0685] 6-Phenyl-1,3-dihydroindol-2-one (8 mg, 0.04 mmol) was
condensed with 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid
(3-imidazol-1-ylpropyl)amide (10 mg) to give 7.3 mg (43%) of the
title compound as an orange solid.
[0686] .sup.1HNMR (300 MHz, DMSO-d6) .delta. 13.62 (s br, 1H, NH),
10.99 (, br, 1H, NH), 786 (d, J=8.2 Hz, 0.1H), 7.62-7.70 (m, 5H),
7.45 (m, 2H), 7.35 (m, 1H), 7.30 (dd, J=1.4 & 8.2 Hz, 1H), 7.21
(s, 1H), 7.10 (d, J=1.4 Hz, 1H), 6.89 (s, 1H), 4.02 (t, J=6.9 Hz,
2H, CH.sub.2), 3.19 (m, 2H, NCH.sub.2CH.sub.2), 2.43 (s, 3H,
CH.sub.3), 2.41 (s, 3H, CH.sub.3), 1.93 (t, J=6.9 Hz, 2H,
NCH.sub.2).
[0687] MS-EI m/z 465 [M.sup.+].
Example 62
[0688]
5-[6-(3,5-Dichlorophenyl)-2-oxo-1,2-dihydroindol-3-ylidenemethyl]-2-
,4-dimethyl-1H-pyrrol-3-carboxylic Acid
(2-diethylaminoethyl)amide
[0689] 6-(3,5-Dichlorophenyl)-1,3-dihydroindol-2-one (64 mg, 0.23
mmol) was condensed with
5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid
(2-diethylaminoethyl)amide (60 mg) to give 53 mg (44%) of the title
compound as a light brown solid.
[0690] .sup.1HNMR (360 MHz, DMSO-d6) .delta. 13.62 (s, br, 1H, NH),
10.99 (s, 1H, NH), 7.89 (d, J=7.9 Hz, 1H, H-4), 7.69-7.71 (m, 3H),
7.55 (m, 1H, CONHCH.sub.2), 7.37 (m, 2H), 7.14 (d, J=1.4 Hz, 1H,
H-7), 3.27 (m, 2H, NCH.sub.2), 2.48-2.58 (m, 6H,
3.times.NCH.sub.2), 2.45 (s, 3H, CH.sub.3), 2.42 (s 3H, CH.sub.3),
0.97 (t, J=6.8 Hz, 6H, 3.times.NCH.sub.2CH.sub.3).
[0691] MS m/z 526.9 [M.sup.++1].
Example 63
[0692]
2,4-Dimethyl-5-(2-oxo-6-pyridin-3-yl-1,2-dihydroindol-3-ylidenemeth-
yl)-1H-pyrrole-3-carboxylic Acid (2-diethylaminoethyl)amide
[0693] 6-Pyridin-3-yl-1,3-dihydroindol-2-one (40 mg, 0.19 mmol) was
condensed with 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid
(2-diethylaminoethyl)amide (50 mg) give 29 mg (33%) of the title
compound as a light orange solid.
[0694] .sup.1HNMR (300 MHz, DMSO-d6) .delta. 13.62 (3, br, 1H, NH),
11.05 (s, br, 1H, NH), 8.86 (s br, 1H), 8.53 (d, J=5.8 Hz, 1H) 8.04
(m, 1H), 7.91 (d, J=8.1 Hz, 1H), 7.70 (s, 1H, H-vinyl), 7.40-7.48
(m, 2H), 7.35 (d, J=7.5 Hz, 1H), 7.14 (s, 1H), 3.26 (m, 2H,
NCH.sub.2), 2.48-2.55 (m, 3.times.NCH.sub.2), 2.42 (s, 3H,
CH.sub.3), 2.38 (s, 3H, CH.sub.3), 0.96 (t, J=6.9 Hz, 6H,
2.times.NCH.sub.2CH.sub.3).
[0695] MS-EI m/z 457 [M.sup.+].
Example 64
[0696]
2,4-Dimethyl-5-(2-oxo-6-pyridin-3-yl-1,2-dihydroindol-3-ylidenemeth-
yl)-1H-pyrrole-3-carboxylic Acid (2-pyrrolidin-1-ylethyl)amide
[0697] 6-Pyridin-3-yl-1,3-dihydroindol-2-one (60 mg, 0.28 mmol) was
condensed with 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid
(2-pyrrolidin-1-ylethyl)amide (75 mg) to give 90 mg (71%) of the
title compound as a light orange solid.
[0698] .sup.1HNMR (300 MHz, DMSO-d6) .delta. 13.61 (s, br, 1H, NH),
11.05 (s, br, 1H, NH), 8.86 (d, J=1.5 Hz, 1H), 8.54(dd, J=1.5 &
4.8 Hz, 1H), 8.05 (m, 1H), 7.91 (d, J=7.8 Hz, 1H), 7.70 (s, 1H,
H-vinyl), 7.44-7.53 (m, 2H), 7.36 (dd, J=1.5 & 8 Hz 1H), 7.15
(d, J=1.2 Hz, 1 Hz), 3.33 (m, 2H, NCH.sub.2), 2.47-2.57 (m, 6H,
3.times.NCH.sub.2), 2.43 (s, 3H, CH.sub.3), 2.41 (s, 3H, CH.sub.3),
1.67 (m, 4H, 2.times.CH.sub.2).
[0699] MS-EI m/z 455 [M.sup.+].
Example 65
[0700]
2,4-Dimethyl-5-(2-oxo-6-pyridin-3-yl-1,2-dihydroindol-3-ylidenemeth-
yl)-1H-pyrrole-3-carboxylic Acid (3-dimethylaminopropyl)amide
[0701] 6-Pyridin-3-yl-1,3-dihydroindol-2-one (42 mg, 0.2 mmol) was
condensed with 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid
(3-dimethylaminopropyl)amide (50 mg) to give 67 mg (75%) of the
title compound as yellow-brown solid.
[0702] .sup.1HNMR (360 MHz, DMSO-d6) .delta. 13.61 (s, br, 1H, NH),
11.00 (s, br, 1H, NH), 8.86 (s, br, 1H), 8.54 (s, br, 1H) 8.04 (m,
1H), 7.90 (d, J=8.0 Hz, 1H), 7.69 (s, 1H, H-vinyl), 7.63 (m, 1H),
7.45-7.48 (m, 1H), 7.35 (dd, J=1.7 & 8.0 Hz, 1H), 7.15 (d,
J=1.7 Hz, 1H), 3.21-3.27 (m, 2H, NCH.sub.2), 2.43 (s, 3H,
CH.sub.3), 2.41 (s, 3H, CH.sub.3), 2.28 (m, 2H, NCH.sub.2), 2.14
(s, 6H, 2.times.NCH.sub.3), 1.64 (m, 2H, CH.sub.2).
[0703] MS-EI m/z 443 [M.sup.+].
Example 66
[0704]
2,4-Dimethyl-5-(2-oxo-5-phenyl-1,2-dihydroindol-3-ylidenemethyl)-1H-
-pyrrole-3-carboxylic Acid (3-dimethylaminopropyl)amide
[0705] 5-Phenyl-1,3-dihydroindol-2-one (67 mg, 0.32 mmol) was
condensed with 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid
(3-dimethylaminopropyl)amide (81 mg) to give 40 mg (28%) of the
title compound as an orange solid.
[0706] .sup.1HNMR (360 MHz, DMSO-d6) .delta. 13.66 (s, br, 1H, NH),
10.92 (s, br, 1H, NH), 8.14 (s, 1H), 7.79 (s, 1H), 7.71 (m, 2H),
7.62 (m, 1H), 7.44 (m, 3H), 7.32 (m, 1H), 6.95 (m, 1H), 3.33 (m,
2H, NCH.sub.2), 2.43 (s, 6H, 2.times.CH.sub.3), 2.27 (m, 2H,
NCH.sub.2), 2.13 (s, 6H, 2.times.NCH.sub.3), 1.63 (m, 2H,
CH.sub.2).
[0707] MS-EI m/z 442 [M.sup.+].
Example 67
[0708]
2,4-Dimethyl-5-(2-oxo-5-phenyl-1,2-dihydroindol-3-ylidenemethyl)-1H-
-pyrrole-3-carboxylic acid (3-diethylaminopropyl)amide
[0709] 5-Phenyl-1,3-dihydroindol-2-one (1.5 g, 7.16 mmol) was
condensed with 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid
(3-diethylaminopropyl)amide (2 g) to give 1.3 g (40%) of the title
compound as a yellow-orange solid.
[0710] .sup.1HNMR (360 MHz, DMSO-d6) .delta. 13.64 (s, 1H, NH),
10.91 (s, 1H, NH), 8.14 (d, J=1.4 Hz, 1H, ArH), 7.8 (s, 1H, ArH),
7.7 (dd, J=1.2 and 8.5 Hz, 2H, ArH), 7.6 (t, J=5.3 Hz, 1H,
CONHCH.sub.2), 7.4 (m, 3H, ArH), 7.3 (t, J=7.4 Hz, 1H, ArH), 6.9
(d, J=8.0 Hz, 1H, ArH), 3.2 (m, 2H, CONHCH.sub.2), 2.5 (m, 12H,
3.times.NCH.sub.2 and 2.times.CH.sub.3), 1.61 (m, 2H,
CH.sub.2CH.sub.2CH.sub.2), 0.93 (t, J=6.7 Hz, 6H,
NCH.sub.2CH.sub.3).
[0711] MS-EI m/z 470 [M.sup.+].
Example 68
[0712]
2,4-Dimethyl-5-(2-oxo-6-phenyl-1,2-dihydroindol-3-ylidenemethyl)-1H-
-pyrrole-3-carboxylic Acid (3-diethylaminopropyl)amide
[0713] 6-Phenyl-1,3-dihydroindol-2-one (1.5 g, 7.16 mmol) was
condensed with 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid
(3-diethylaminopropyl)amide (2 g) to give 1.9 g (57%) of the title
compound as an orange solid.
[0714] .sup.1HNMR (360 MHz, DMSO-d6) .delta. 13.58 (s, 1H, NH),
10.94 (s, 1H, NH), 7.8 (d, J=7.9 Hz, 1H, ArH), 7.6 (m, 4H, ArH),
7.4 (t, J=7.5 Hz, 2H, ArH), 7.3 (m, 2H), 7.1 (d, J=1.4 Hz, 1H,
ArH), 3.2 (m, 2H, CONHCH.sub.2), 2.5 (m, 12H, 3.times.NCH.sub.2 and
2.times.CH.sub.3), 1.61 (m, 2H, CH.sub.2CH.sub.2CH.sub.2), 0.93 (t,
J=6.7 Hz, 6H, NCH.sub.2CH.sub.3).
[0715] MS-EI m/z 470 [M.sup.+].
Example 69
[0716]
3-[4-(3-Diethylaminopropylcarbamoyl)-3,5-dimethyl-1H-pyrrol-2-ylmet-
hylene]-2-oxo-2,3-dihydro-1H-indole-4-carboxylic Acid
(3-chloro-4-methoxyphenyl)amide
[0717] 2-Oxo-2,3-dihydro-1H-indole-4-carboxylic acid
(3-chloro-4-methoxyphenyl)amide (1 g, 3.16 mmol) was condensed with
5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid
(3-diethylaminopropyl)amide (1 g, 3.58 mmol) to give 1.7 g (85%) of
the title compound as a yellow-orange solid.
[0718] MS-EI m/z 578.2 [M.sup.+].
Example 70
[0719]
5-(5-Bromo-2-oxo-1,12-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-
-pyrrole-3-carboxylic Acid (3-diethylaminopropyl)amide
[0720] 5-Bromo-1,3-dihydroindol-2-one (0.5 g, 2.36 mmol) was
condensed with 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid
(3-diethylaminopropyl)amide (0.51 g) to give 0.84 g of the title
compound as a red-orange solid.
[0721] .sup.1HNMR (360 MHz, DMSO-d6) .delta. 13.61 (s, 1H, NH),
10.99 (s, 1H, NH), 8.09 (d, J=1.8 Hz, 1H, ArH), 7.7 (m, 4H), 7.2
(dd, J=1.8 and 8.3 Hz, 2H, ArH), 6.8 (d, J=7.8 Hz, 1H, ArH), 3.3
(br s, 4H, 2.times.NCH.sub.2), 3.2 (m, 2H, CONHCH.sub.2), 2.6 (br
s, 2H, NCH.sub.2 and 2.times.CH.sub.3), 2.4 (s, 6H,
2.times.CH.sub.3), 1.66 (m, 2H, CH.sub.2CH.sub.2CH.sub.2), 0.98 (t,
J=7.1 Hz, 6H, NCH.sub.2CH.sub.3).
[0722] MS-EI m/z 472 and 474 [M.sup.++1 and M.sup.++1].
Example 71
[0723]
5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-diisopropyl--
1H-pyrrole-3-carboxylic Acid (2-diethylaminoethyl)amide
[0724] 5-Bromo-1,3-dihydroindol-2-one (100 mg, 0.47 mmol) was
condensed with 5-formyl-2,4-diisopropyl-1H-pyrrole-3-carboxylic
acid (2-diethylaminoethyl)amide (150 mg) to give 0.15 g (62%) of
the title compound as a yellow-orange solid.
[0725] .sup.1HNMR (300 MHz, DMSO-d6) .delta. 13.97 (s, 1H, NH),
10.95 (s, 1H, NH), 8.09 (d, J=1.3 Hz, 1H, ArH), 7.84 (m, 1H), 7.79
(s, 1H), 7.23 (dd, J=1.3 and 8.1 Hz, 1H, ArH), 6.8 (d, J=8.1 Hz,
1H, ArH), 3.5 (m, 1H, CH), 3.3 (m, 3H, CH and NHCH.sub.2), 2.5 (br
m, 6H, 3.times.NCH.sub.2), 1.28 (d, J=6.9 Hz, 6H,
2.times.CH.sub.3), 1.23 (d, J=6.6 Hz, 6H, 2.times.CH.sub.3), 0.96
(m, 6H, 2.times.CH.sub.2CH.sub.3).
[0726] MS-EI m/z 514 and 516 [M.sup.+-1 and M.sup.++1].
Example 72
[0727]
5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-diisopropyl--
1H-pyrrole-3-carboxylic Acid (3-diethylaminopropyl)amide
[0728] 5-Bromo-1,3-dihydroindol-2-one (90 mg, 0.42 mmol) was
condensed with 5-formyl-2,4-diisopropyl-1H-pyrrole-3carboxylic acid
(3-diethylaminopropyl)amide (140 mg) to give 54 mg (25%) of the
title compound as red-brown solid.
[0729] .sup.1HNMR (300 MHz, DMSO-d6) .delta. 13.98 (s, 1H, NH),
10.96 (s, 1H, NH), 8.09 (d, J=1.7 Hz, 2H), 7.78 (s, 1H, H-vinyl),
7.23 (dd, J=1.7 and 8.1 Hz, 1H, ArH), 6.82 (d, J=8.1 Hz, 1H, ArH),
3.5 (m, 1H, CH), 3.25 (m, 2H, NHCH.sub.2), 3.15 (m, 1H, CH), 2.7
(br s, 6H, 3.times.NCH.sub.2), 1.7 (br m, 2H, CH.sub.2CH.sub.2H),
1.28 (d, J=6.9 Hz, 6H, 2.times.CH.sub.3), 1.24 (d, J=5.9 Hz, 6H,
2.times.CH.sub.3), 1.06 (m, 6H, 2.times.CH.sub.2CH.sub.3).
[0730] MS-EI m/z 528 and 530 [M.sup.+-1 and M.sup.++1].
Example 73
[0731]
5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-diisopropyl--
1H-pyrrole-3-carboxylic Acid (3-pyrrolidin-1-ylpropyl)amide
[0732] 5-Bromo-1,3-dihydroindol-2-one (130 mg, 0.6 mmol) was
condensed with 5-formyl-2,4-diisopropyl-1H-pyrrole-3-carboxylic
acid (3-pyrrolidin-1-ylpropyl)amide (150 mg, 0.45 mmol) to give 36
mg (15%) of the title compound as a tan-orange solid.
[0733] .sup.1HNMR (300 MHz, DMSO-d6) .delta. 13.98 (s, 1H, NH),
10.97 (s, 1H, NH), 8.10 (d, J=1.6 Hz, 2H), 7.78 (s, 1H, H-vinyl),
7.23 (dd, J=1.6 and 7.6 Hz, 1H, ArH), 6.82 (d, J=7.6 Hz, 1H, ArH),
3.5 (m, 1H, CH), 3.25 (m, 2H, NHCH.sub.2), 3.15 (m, 1H, CH), 2.7
(br s, 6H, 3.times.NCH.sub.2), 1.7 (br m, 6H,
3.times.NCH.sub.2CH.sub.2), 1.28 (d, J=5.6 Hz, 6H,
2.times.CH.sub.3), 1.24 (d, J=5.7 Hz, 6H, 2.times.CH.sub.3).
[0734] MS-EI m/z 526 and 528 [M.sup.+-1 and M.sup.++1].
Example 74
[0735]
5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H--
pyrrole-3-carboxylic Acid (pyridin-4-ylmethyl)amide
[0736] 5-Bromo-1,3-dihydroindol-2-one (170 mg, 0.8 mmol) was
condensed with 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid
(pyridin-4-ylmethyl)amide (200 mg) to give 14 mg (4%) of the title
compound as a yellow solid.
[0737] .sup.1HNMR (300 MHz, DMSO-d6) .delta. 13.67 (s, 1H, NH),
11.01 (s, br, 1H, NH), 8.51 (dd, J=1.6 & 4.3 Hz, 2H), 8.23 (t,
J=6.0 Hz, 1H, CONHCH.sub.2), 8.11 (d, J=1.9 Hz, 1H), 7.78 (s, 1H,
H-vinyl), 7.31 (d, J=6.0 Hz, 2H), 7.25 (dd, J=1.9 & 8.1 Hz,
1H), 6.82 (d, J=8.1 Hz, 1H), 4.45 (d, J=6.0 Hz, 2H, NCH.sub.2),
2.46 (s, 6H, 2.times.CH.sub.3).
[0738] MS-EI m/z 450 and 452 [M.sup.+-1 and M.sup.++1].
Example 75
[0739]
5-[6-(4-Butylphenyl)-2-oxo-1,2-dihydroindol-3-ylidenemethyl]-2,4-di-
methyl-1H-pyrrole-3-carboxylic Acid
(2-pyrrolidin-1-ylethyl)amide
[0740] 5-[6-(4-Butylphenyl)]-1,3-dihydroindol-2-one (50 mg, 0.19
mmol) was condensed with
5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid
(2-pyrrolidin-1-ylethyl)amide (50 mg) to give 74 mg (76%) of the
title compound as an orange solid.
[0741] .sup.1HNMR (360 MHz, DMSO-d6) .delta. 13.58 (s, 1H, NH),
10.93 (s, br, 1H, NH), 7.82 (d, J=7.9 Hz, 1H), 7.63 (s, 1H,
H-vinyl), 7.54 (d, J=7.9 Hz, 2H), 7.46 (m, 1H, CONH), 7.26 (m, 3H),
7.09 (s, 1H), 3.30 (m, 2H, CH.sub.2), 2.52-2.63 (m, 4H,
2.times.CH.sub.2), 2.49 (m, 4H, 2.times.CH.sub.2), 2.43 (s, 3H,
CH.sub.3), 2.40 (s, 3H, CH.sub.3), 1.68 (m, 4H, 2.times.CH.sub.2),
1.58 (m, 2H, CH.sub.2), 1.34 (m, 2H, CH.sub.2), 0.91 (t, J=77.2 Hz,
3H, CH.sub.2CH.sub.3).
[0742] MS-EI m/z 510 [M.sup.+].
Example 76
[0743]
5-[6-(5-Isopropyl-2-methoxyphenyl)-2-oxo-1,2-dihydroindol-3-ylidene-
methyl]-2-2,4-dimethyl-1H-pyrrole-3-carboxylic Acid
(2-pyrrolidin-1-ylethyl)amide
[0744] 6-(5-Isopropyl-2-methoxyphenyl)-1,3-dihydroindol-2-one (50
mg, 0.17 mmol) was condensed with
5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid
(2-pyrrolidin-1-yl-ethyl)amide (45 mg) to give 67 mg (75%) of the
title compound as an orange solid.
[0745] .sup.1HNMR (360 MHz, DMSO-d6) .delta. 13.60 (s, 1H, NH),
10.82 (s, br, 1H, NH), 7.770 (d, J=7.9 Hz, 1H), 7.61 (s, 1H,
H-vinyl), 7.45 (m, 1H, CONH), 7.0-7.19 (m, 5H), 3.73 (s, 3H,
OCH.sub.3), 3.32 (m, 2H, CH.sub.2), 2.87 (m, 1H,
CH(CH.sub.3).sub.2), 2.56 (m, 2H, CH.sub.2), 2.48 (m, 4H,
2.times.CH.sub.2), 2.43 (s, 3H, CH.sub.3), 2.40 (s, 3H, CH.sub.3),
1.68 (m, 4H, 2.times.CH.sub.2), 1.21 (d, J=6.8 Hz, 6H,
CH(CH.sub.3).sub.2).
[0746] MS m/z 527.2 [M.sup.++1].
Example 77
[0747]
5-[6-(4-Ethylphenyl)-2-oxo-1,2-dihydroindol-3-ylidenemethyl]-2,4-di-
methyl-1H-pyrrole-3-carboxylic Acid
(2-pyrrolidin-1-ylethyl)amide
[0748] 6-(4-Ethylphenyl)-1,3-dihydroindol-2-one (45 mg, 0.19 mmol)
was condensed 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid
(2-pyrrolidin-1-ylethyl)amide (50 mg) to give 60 mg (65%) of the
title compound as a yellow-orange solid.
[0749] .sup.1HNMR (300 MHz, DMSO-d6) .delta. 13.59 (s, 1H, NH),
10.96 (s, br, 1H), 7.8 (d J=84 Hz, 1H), 7.64 (s, 1H, H-vinyl),
7.51-70.56 (m, 3H), 7.25-7.30 (m 3H), 7.08 (d, J=1 Hz, 1H), 3.31
(m, 2H, CH.sub.2), 2.63 (m, 2H, CH.sub.2CH.sub.3), 2.55 (m, 2H,
CH.sub.2), 2.49 (m, 4H, 2.times.CH.sub.2), 2.42 (s, 3H, CH.sub.3),
2.40 (s, 3H, CH.sub.3), 1.67 (m, 4H, 2.times.CH.sub.2), 1.20 (t,
J=7.5 Hz, 3H, CH.sub.2CH.sub.3).
[0750] MS-EI m/z 482 [M.sup.+].
Example 78
[0751]
5-[6-(2,4-Dimethoxyphenyl)-2-oxo-1,2-dihydroindol-3-ylidenemethyl]--
2,4-dimethyl-1H-pyrrole-3-carboxylic Acid
(2-pyrrolidin-1-ylethyl)amide
[0752] 6-(2,4-Dimethoxyphenyl)-1,3-dihydroindol-2-one (51 mg, 0.19
mmol) was condensed with
5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid
(2-pyrrolidin-1-ylethyl)amide (50 mg) to give 30 mg (31%) of the
title compound as an orange solid.
[0753] .sup.1HNMR (300 MHz, DMSO-d6) .delta. 13.59 (s, 1H, NH),
10.86 (s, br, 1H, NH), 7.75 (d, J=7.8 Hz, 1H), 7.60 (s, 1H,
H-vinyl), 749 (m, 1H, CONH), 7.22 (d, J=8.4 Hz, 1H), 7.03 (m, 1H),
6.97 (s, 1H), 6.58-6.65 (m, 2H), 3.79 (s, 3H, OCH.sub.3), 3.76 (s,
3H, OCH.sub.3), 3.33 (m, 2H, CH.sub.2), 2.55 (m, 2H, CH.sub.2),
2.50 (m, 4H, 2.times.CH.sub.2), 2.427 (s, 3H, CH.sub.3), 2.39 (s,
3H, CH.sub.3), 1.67 (m, 4H, 2.times.CH.sub.2).
[0754] MS-EI m/z 514 [M.sup.+].
Example 79
[0755] 5-[6-(3-Isopropylphenyl)-2-oxo-1,2-dihydroindol
3-ylidenemethyl]-2,4-dimethyl-1H-pyrrole 3-carboxylic Acid
(2-pyrrolidin-1-ylethyl)amide
[0756] 6-(3-Isopropylphenyl)-1,3-dihydroindol-2-one (48 mg, 0.19
mmol) was condensed with
5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid
(2-pyrrolidin-1-ylethyl)amide (50 mg) to give 59 mg (63%) of the
title compound as an orange solid.
[0757] .sup.1HNMR (300 MHz, DMSO-d6) .delta. 13.63 (s, 1H, NH),
10.97 (s, br, 1H, NH), 7.87 (d, J=77.8 Hz, 1H), 7.68 (s, 1H,
H-vinyl), 7.24-7.55 (m, 6H), 7.13 (s, 1H), 3.34 (m, 2H, CH.sub.2),
3.30 (m, 1H, CH(CH.sub.3).sub.2), 2.60 (m, 2H, CH.sub.2), 2.50 (m,
4H, 2.times.CH.sub.2), 2.45 (s, 3H, CH.sub.3), 2.43 (s, 3H,
CH.sub.3), 1.70 (m, 4H, 2.times.CH.sub.2), 1.27 (d, J=6.9 Hz, 6H,
CH(CH.sub.3).sub.2).
[0758] MS-EI m/z 496 [M.sup.+].
Example 80
[0759]
5-(5-Fluoro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-
-pyrrole-3-carboxylic Acid (2-diethylaminoethyl)amide
[0760] 5-Fluoro-1,3-dihydroindol-2-one (0.54 g, 3.8 mmol) was
condensed with 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid
(2-diethylaminoethyl)amide to give 0.83 g (55%) of the title
compound as a yellow green solid.
[0761] .sup.1HNMR (360 MHz, DMSO-d6) .delta. 13.66 (s, 1H, NH),
10.83 (s, br, 1H, NH), 7.73 (dd, J=2.5 & 9.4 Hz, 1H), 7.69 (s,
1H, H-vinyl), 7.37 (t, 1H, CONHCH.sub.2CH.sub.2), 6.91 (m, 1H),
6.81-6.85 (m, 1H), 3.27 (m, 2H, CH.sub.2), 2.51 (m, 6H,
3.times.CH.sub.2), 2.43 (s, 3H, CH.sub.3), 2.41 (s, 3H, CH.sub.3),
0.96 (t, J=6.9 Hz, 6H, N(CH.sub.2CH.sub.3).sub.2)- .
[0762] MS-EI m/z 398 [M.sup.+].
Example 80
Alternative Synthesis
[0763]
5-[5-Fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethy-
l-1H-pyrrole-3-carboxylic Acid (2-diethylamino-ethyl)amide
[0764] Hydrazine hydrate (55%, 3000 mL) and 5-fluoroisatin (300 g)
were heated to 100.degree. C. An additional 5-fluoro-isatin (500 g)
was added in portions (100 g) over 120 minutes with stirring. The
mixture was heated to 110.degree. C. and stirred for 4 hours. The
mixture was cooled to room temperature and the solids collected by
vacuum filtration to give crude (2-amino-5-fluoro-phenyl)-acetic
acid hydrazide (748 g). The hydrazide was suspended in water (700
mL) and the pH of the mixture adjusted to <pH 3 with 12 N
hydrochloric acid. The mixture was stirred for 12 hours at room
temperature. The solids were collected by vacuum filtration and
washed twice with water. The product was dried under vacuum to give
5-fluoro-1,3-dihydro-indol-2-one (600 g, 73% yield) as as a brown
powder. .sup.1H-NMR (dimethylsulfoxide-d6) .delta. 3.46 (s, 2H,
CH.sub.2), 6.75, 6.95, 7.05 (3.times.m, 3H, aromatic), 10.35 (s,
1H, NH).
[0765] MS m/z 152 [M+1].
[0766] 3,5-Dimethyl-1H-pyrrole-2,4-dicarboxylic acid 2-tert-butyl
ester 4-ethyl ester (2600 g) and ethanol (7800 mL) were stirred
vigorously while 10 N hydrochloric acid (3650 mL) was slowly added.
The temperature increased from 25.degree. C. to 35.degree. C. and
gas evolution began. The mixture was warmed to 54.degree. C. and
stirred with further heating for one hour at which time the
temperature was 67.degree. C. The mixture was cooled to 5.degree.
C. and 32 L of ice and water were slowly added with stirring. The
solid was collected by vacuum filtration and washed three times
with water. The solid was air dried to constant weight to give of
2,4-dimethyl-1H-pyrrole-3-carboxylic acid ethyl ester (1418 g, 87%
yield) as a pinkish solid. .sup.1H-NMR (dimethylsulfoxide-d6)
.delta. 2.10, 2.35 (2.times.s, 2.times.3H, 2.times.CH.sub.3), 4.13
(q, 2H, CH.sub.2), 6.37 (s, 1H, CH), 10.85 (s, 1H, NH). MS m/z 167
[M+1].
[0767] Dimethylformamide (322 g) and dichloromethane (3700 mL) were
cooled in an ice bath to 4.degree. C. and phosphorus oxychloride
(684 g) was added with stirring. Solid
2,4-dimethyl-1H-pyrrole-3-carboxylic acid ethyl ester (670 g) was
slowly added in aliquots over 15 minutes. The maximum temperature
reached was 18.degree. C. The mixture was heated to reflux for one
hour, cooled to 10.degree. C. in an ice bath and 1.6 L of ice water
was rapidly added with vigorous stirring. The temperature increased
to 15.degree. C. 10 N Hydrochloric acid (1.6 L) was added with
vigorous stirring. The temperature increased to 22.degree. C. The
mixture was allowed to stand for 30 minutes and the layers allowed
to separate. The temperature reached a maximum of 40.degree. C. The
aqueous layer was adjusted to pH 12-13 with 10 N potassium
hydroxide (3.8 L) at a rate that allowed the temperature to reach
and remain at 55.degree. C. during the addition. After the addition
was complete the mixture was cooled to 10.degree. C. and stirred
for 1 hour. The solid was collected by vacuum filtration and washed
four times with water to give
5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid ethyl ester (778
g, 100% yield) as a yellow solid. .sup.1H-NMR (DMSO-d6) .delta.
1.25 (t, 3H, CH.sub.3), 2.44, 2.48 (2.times.s, 2.times.3H,
2.times.CH.sub.3), 4.16 (q, 2H, CH.sub.2), 9.59 (s, 1H, CHO), 12.15
(br s, 1H, NH). MS m/z 195 [M+1].
[0768] 5-Formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid ethyl
ester (806 g), potassium hydroxide (548 g), water (2400 mL) and
methanol (300 mL) were refluxed for two hours with stirring and
then cooled to 8.degree. C. The mixture was extracted twice with
dichloromethane. The aqueous layer was adjusted to pH 4 with 1000
mL of 10 N hydrochloric acid keeping the temperature under
15.degree. C. Water was added to facilitate stirring. The solid was
collected by vacuum filtration, washed three times with water and
dried under vacuum at 50.degree. C. to give
5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic (645 g, 93.5% yield)
acid as a yellow sold. NMR (DMSO-d6) .delta. 2.40, 2.43 (2.times.s,
2.times.3H, 2.times.CH.sub.3), 9.57 (s, 1H, CHO), 12.07 (br s, 2H,
NH+COOH). MS m/z 168 [M+1].
[0769] 5-Formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (1204 g)
and 6020 mL of dimethylformamide were stirred at room temperature
while 1-(3-dimethyl-aminopropyl-3-ethylcarbodiimide hydrochloride
(2071 g), hydroxybenzotriazole (1460 g), triethylamine (2016 mL)
and diethylethylenediamine (1215 mL) were added. The mixture was
stirred for 20 hours at room temperature. The mixture was diluted
with 3000 mL of water, 2000 mL of brine and 3000 mL of saturated
sodium bicarbonate solution and the pH adjusted to greater than 10
with 10 N sodium hydroxide. The mixture was extracted twice, with
5000 mL each time of 10% methanol in dichloromethane and the
extracts combined, dried over anhydrous magnesium sulfate and
rotary evaporated to dryness. The mixture was with diluted with
1950 mL of toluene and rotary evaporated again to dryness. The
residue was triturated with 3:1 hexane:diethyl ether (4000 mL). The
solids were collected by vacuum filtration, washed twice with 400
mL of ethyl acetate and dried under vacuum at 34.degree. C. for 21
hours to give 5-formyl-2,4-(dimethyl-1H-pyrrole-3-carboxylic acid
(2-diethylamino-ethyl)amide (819 g, 43% yield) as a light brown
solid. .sup.1H-NMR (dimethylsulfoxide-d6) .delta. 0.96 (t, 6H,
2.times.CH.sub.3), 2.31, 2.38 (2.times.s, 2.times.CH.sub.3), 2.51
(m, 6H 3.times.CH.sub.2), 3.28 (m, 2H, CH.sub.2), 7.34 (m, 1H,
amide NH), 9.56 (s, 1H, CHO), 11.86 (s, 1H, pyrrole NH). MS m/z 266
[M+1].
[0770] 5-Formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid
(2-diethylaminoethyl)-amide (809 g),
5-fluoro-1,3-dihydro-indol-2-one (438 g), ethanol (8000 mL) and
pyrrolidine (13 mL) were heated at 78.degree. C. for 3 hours. The
mixture was cooled to room temperature and the solids collected by
vacuum filtration and, washed with ethanol. The solids were stirred
with ethanol (5900 mL) at 72.degree. C. for 30 minutes. The mixture
was cooled to room temperature. The solids were collected by vacuum
filtration, washed with ethanol and dried under vacuum at
54.degree. C. for 130 hours to give 5-[5-fluoro-2-oxo-1,2-dihyd-
ro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic
acid (2-diethylamino-ethyl)-amide (1013 g, 88% yield) as an orange
solid. .sup.1H-NMR (dimethylsulfoxide-d.sub.6) .delta. 0.98 (t, 6H,
2.times.CH.sub.3), 2.43, 2.44 (2.times.s, 6H, 2.times.CH.sub.3),
2.50 (m, 6H, 3.times.CH.sub.2), 3.28 (q, 2H, CH.sub.2), 6.84, 6.92,
7.42, 7.71, 7.50 (5.times.m, 5H, aromatic, vinyl, CONH), 10.88 (s,
1H, CONH), 13.68 (s, 1H, pyrrole NH). MS m/z 397 [M-1].
Example 81
[0771]
3-[4-(2-Diethylaminoethylcarbamoyl)-3,5-dimethyl-1H-pyrrol-2-ylmeth-
ylene]-2-oxo-2,3-dihydro-1H-indole-6-carboxylic Acid
[0772] 2-Oxo-2,3-dihydro-1H-indole-6-carboxylic acid (80 mg, 0.45
mmol) was condensed with
5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid
(2-diethylaminoethyl)amide to give 210 mg (92%) of the title
compound as a yellow orange solid.
[0773] .sup.1HNMR (360 MHz, DMSO-d6) .delta. 13.6 (s, 1H, NH), 7.76
(d, J=8.0 Hz, 1H), 7.66 (s, 1H, H-vinyl), 7.57 (dd, J=1.5 & 8.0
Hz, 1H), 7.40-7.42 (m, 2H), 3.28 (m, 2H, CH.sub.2), 2.88 (m,
H-piperidine), 2.54 (m, 6H, 3.times.CH.sub.2), 2.44 (s, 3H,
CH.sub.3), 2.40 (s, 3H, CH.sub.3), 1.56 (m, H-piperidine), 0.97 (t,
J=6.98 Hz, 6H, N(CH.sub.2CH.sub.3).sub.2).
[0774] MS m/z 424 [M.sup.+].
Example 82
[0775]
5-(5-Dimethylsulfamoyl-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4--
dimethyl-1H-pyrrole-3-carboxylic Acid
(2-pyrrolidin-1-ylethyl)amide
[0776] 2-Oxo-2,3-dihydro-1H-indole-5-sulfonic acid dimethylamide
(90 mg, 0.38 mmol) was condensed with
5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxyl- ic acid
(2-pyrrolidin-1-ylethyl)amide (100 mg) to give 100 mg (54%) of the
title compound as a yellow solid.
[0777] .sup.1HNMR (360 MHz, DMSO-d6) .delta. 13.65 (s, 1H, NH),
11.30 (s, br, 1H, NH), 8.25 (d, 1H), 7.92 (s, 1H, H-vinyl),
7.48-7.53 (m, 2H), 7.07 (d, J=8.2 Hz, 1H), 3.33 (m, 2H, CH.sub.2),
2.61 (s, 6H, N(CH.sub.3).sub.2), 2.56 (t, 2H, CH.sub.2), 2.49 (m,
4H, 2.times.CH.sub.2), 2.45 (s, 3H, CH.sub.3), 2.44 (s, 3H,
CH.sub.3), 1.67 (m, 4H, 2.times.CH.sub.2).
[0778] MS-EI m/z 485 [M.sup.+].
Example 83
[0779]
5-[5-(3-Chlorophenylsulfamoyl)-2-oxo-1,2-dihydroindol-3-ylidenemeth-
yl]-2,4-dimethyl-1H-pyrrole-3-carboxylic Acid
(2-pyrrolidin-1-ylethyl)amid- e
[0780] 2-Oxo-2,3-dihydro-1H-indole-5-sulfonic acid
(3-chlorophenyl)amide (120 mg, 0.38 mmol) was condensed with
5-formyl-2,4-dimethyl-1H-pyrrole-3- -carboxylic acid
(2-pyrrolidin-1-ylethyl)amide (100 mg) to give 150 mg (69%) of the
title compound as a yellow orange solid.
[0781] .sup.1HNMR (360 MHz, DMSO-d6) .delta. 13.55 (s, 1H, NH),
11.26 (br s, 1H, NH), 10.30 (br s, 1H, NH), 8.26 (d, 1H), 7.79 (s,
1H, H-vinyl), 7.51-7.57 (m, 2H), 7.22 (t, J=8.1 Hz, 1H), 7.15 (m,
1H), 7.07 (m, 1H), 7.0 (m, 2H), 3.444 (m, 2H, CH.sub.2), 2.57 (t,
J=7.0 Hz, 2H, CH.sub.2), 2.49 (m, 4H, 2.times.CH.sub.2), 2.44 (s,
3H, CH.sub.3), 2.43 (s, 3H, CH.sub.3), 1.68 (m, 4H,
2.times.CH.sub.2).
[0782] MS m/z 568 [M.sup.+].
Example 84
[0783]
2,4-Dimethyl-5-[2-oxo-5-(pyridin-3-ylsulfamoyl)-1,2-dihydroindol-3--
ylidenemethyl]-1H-pyrrole-3-carboxylic Acid
(2-pyrrolidin-1-ylethyl)amide
[0784] 2-Oxo-2,3-dihydro-1H-indole-5-sulfonic acid
pyridin-3-ylamide (110 mg, 0.38 mmol) was condensed with
5-formyl-2,4-dimethyl-1H-pyrrole-3-carb- oxylic acid
(2-pyrrolidin-1-ylethyl)amide (100 mg) to give 150 mg (74%) of the
title compound as an orange solid.
[0785] .sup.1HNMR (360 MHz, DMSO-d6) .delta. 13.58 (s, 1H, NH),
8.21 (d, J=2.0 Hz, 2H), 8.04 (m, 1H), 7.76 (s, 1H, H-vinyl),
7.49-7.54 (m, 2H), 7.41 (m, 1H), 7.14 (m, 1H), 6.94 (d, J=8.5 Hz,
1H), 3.33 (m, 2H, CH.sub.2), 2.56 (t, J=7.06 Hz, 2H, CH.sub.2),
2.49 (m, 4H, 2.times.CH.sub.2), 2.43 (s, 6H, 2.times.CH.sub.3),
1.68 (m, 4H, 2.times.CH.sub.2).
[0786] MS m/z 535 [M .sup.+].
Example 85
[0787]
3-[3,5-Dimethyl-4-(4-methylpiperazine-1-carbonyl)-1H-pyrrol-2-ylmet-
hylene]-4-(2-hydroxyethyl)-1,3-dihydroindol-2-one
[0788] 4-(2-Hydroxyethyl)-1,3-dihydroindol-2-one (71 mg, 0.4 mmol)
was condensed with
3,5-dimethyl-4-(4-methyl-piperazine-1-carbonyl)-1H-pyrrole-
-2-carbaldehyde to give 90 mg (55%) of the title compound as an
orange solid.
[0789] .sup.1HNMR (300 MHz, DMSO-d6) .delta. 14.25 (s, 1H, NH),
10.88 (s, 1H, NH), 7.57 (s, 1H, H-vinyl), 7.03 (m, 1H), 6.75-6.82
(m, 2H), 4.86 (m, 1H, OH), 3.70 (m, 2H, CH.sub.2), 3.04 (m, 2H,
CH.sub.2), 2.48 (m, 4H, 2.times.CH.sub.2), 2.28 (br s, 7H), 2.19
(s, 3H, CH.sub.3), 2.18 (s, 3H, CH.sub.3).
[0790] MS m/z (+ve) 4.09.3 [M.sup.+].
Example 86
[0791]
3-[3,5-Dimethyl-4-(4-methylpiperazine-1-carbonyl)-1H-pyrrol-2-ylmet-
hylene]-2-oxo-2,3-dihydro-1H-indole-5-sulfonic Acid Phenylamide
[0792] 2-Oxo-2,3-dihydro-1H-indole-5-sulfonic acid phenylamide (110
mg, 0.4 mmol) was condensed with
3,5-dimethyl-4-(4-methylpiperazine-1-carbony-
l)-1H-pyrrole-2-carbaldehyde (100 mg) to give 50 mg (24%) of the
title compound as a yellow solid.
[0793] .sup.1HNMR (300 MHz, DMSO-d6) .delta. 13.52 (s, 1H, NH),
11.26 (s, 1H, NH), 10.08 (s, 1H, NH), 8.21 (d, J=1.6 Hz, 1H), 7.75
(s, 1H, H-vinyl), 7.50 (dd, J=1.6 & 8.3 Hz, 1H), 7.19 (m,
0.2H), 7.10 (m, 2H), 6.97 (m, 2H), 2.49 (m, 4H, 2.times.CH.sub.2),
2.28 (m, 10H, 2.times.CH.sub.3 & 2.times.CH.sub.2), 2.18 (s,
3H, CH.sub.3).
[0794] MS-EI m/z 519 [M.sup.+].
Example 87
[0795]
5-(5-Dimethylsulfamoyl-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4--
dimethyl-1H-pyrrole-3-carboxylic Acid
(2-diethylaminoethyl)amide
[0796] 2-Oxo-2,3-dihydro-1H-indole-5-sulfonic acid dimethylamide
(90 mg, 0.38 mmol) was condensed with
5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxyl- ic acid
(2-diethylaminoethyl)amide (100 mg) to give 80 mg (43%) of the
title compound as a yellow solid.
[0797] .sup.1HNMR (300 MHz, DMSO-d6) .delta. 11.30 (s, 1H, NH),
8.27 (d, J=1.7 Hz, 1H), 7.94 (s, 1H, H-vinyl), 7.49 (dd, J=1.7
& 8.0 Hz, 1H), 7.44 (m, 1H, CONHCH.sub.2CH.sub.2), 7.07 (d,
J=8.0 Hz, 1H), 3.26 (m, 2H, CH.sub.2), 2.60 (s, 6H,
N(CH.sub.3).sub.2), 2.53 (m, 2H, CH.sub.2), 2.45-2.50 (m, 10H,
2.times.CH.sub.3 & N(CH.sub.2CH.sub.3).sub.2, 0.96 (t, J=7.2
Hz, 6H, N(CH.sub.2CH.sub.3).sub.2).
[0798] MS-EI m/z 487 [M.sup.+].
Example 88
[0799]
5-[5-(3-Chlorophenylsulfamoyl)-2-oxo-1,2-dihydroindol-3-ylidenemeth-
yl]-2,4-dimethyl-1H-pyrrole-3-carboxylic Acid
(2-diethylaminoethyl)amide
[0800] 2-Oxo-2,3-dihydro-1H-indole-5-sulfonic acid
(3-chlorophenyl)amide (120 mg, 3.8 mmol) was condensed with
5-formyl-2,4-dimethyl-1H-pyrrole-3-- carboxylic acid
(2-diethylaminoethyl)amide (100 mg) to give 80 mg (37%) of the
title compound as a yellow solid.
[0801] .sup.1HNMR (360 MHz, DMSO-d6) .delta. 13.55 (s, 1H, NH),
11.24 (s, 1H, NH), 10.29 (s, 1H, NH), 8.25 (d, J=1.87 Hz, 1H), 7.79
(s, 1H, H-vinyl), 7.52 (dd, J=1.87 & 8.3 Hz, 1H), 7.42 (m, 1H,
CONHCH.sub.2CH.sub.2), 7.22 (t, J=8.02 Hz, 1H), 7.15 (t, J=2 Hz,
1H), 7.08 (m, 1H), 7.0 (m, 2H), 3.27 (m, 2H, CH.sub.2), 2.48-2.57
(m, 6H, 3.times.CH.sub.2), 2.45 (s, 3H, CH.sub.3), 2.44 (s, 3H,
CH.sub.3), 0.97 (t, J=7.0 Hz, 6H, N(CH.sub.2CH.sub.3).sub.2).
[0802] MS m/z 570.1 [M.sup.+].
Example 95
[0803]
3-(2-Oxo-5-phenyl-1,2-dihydroindol-3-ylidenemethyl)-4,5,6,7-tetrahy-
dro-2H-isoindole-1-carboxylic Acid Ethyl Ester
[0804] .sup.1HNMR (360 MHz, DMSO-d6) 613.74 (s, 1H, NH), 11.00 (s,
1H NH), 8.13 (d, J=1.7 Hz, 1H), 7.74 (s, 1H, H-vinyl), 7.70 (d, 7.7
Hz, 2H), 7.49 (dd, J=1.7 & 8.0 Hz, 1H), 7.44 (t, J=7.7 Hz, 2H),
7.32 (m, 1H), 6.96 (d, J=8.0 Hz, 1H), 4.26 (q, J=7.0 Hz, 2H,
OCH.sub.2CH.sub.3), 2.79 (m, 2H, CH.sub.2), 2.72 (m, 2H, CH.sub.2),
1.73 (m, 4H, 2.times.CH.sub.2), 1.30 (t, J=7.0 Hz, 3H,
OCH.sub.2CH.sub.3).
[0805] MS-EI m/z 412 [M.sup.+].
Example 99
[0806]
3-(2-Oxo-5-phenylsulfamoyl-1,2-dihydroindol-3-ylidenemethyl)-4,5,6,-
7-tetrahydro-2H-isoindole-1-carboxylic Acid Ethyl Ester
[0807] .sup.1HNMR (360 MHz, DMSO-d6) .delta. 13.64 (s, 1H, NH),
11.33 (s, 1H, NH), 10.07 (s, 1H, NH), 8.24 (d, J=1.8 Hz, 1H), 7.74
(s, 1H, H-vinyl) 7.57 (dd, J=18 & 8.0 Hz, 1H), 7.21 (t, J=7.6
Hz, 2H), 7.11 (d, J=7.6 Hz, 2H), 6.99 (d, J=8.0 Hz, 1H), 6.98 (d,
J=7.6 Hz, 1H), 4.27 (q, J=7.0 Hz, 2H, OCH.sub.2CH.sub.3), 2.80 (m,
2H, CH.sub.2), 2.73 (m, 2H, CH.sub.2), 1.73 (m, 4H,
2.times.CH.sub.2), 1.30 (t, J=7.0 Hz, 3H, OCH.sub.2CH.sub.3).
[0808] MS-EI m/z 491 [M.sup.+].
Example 109
[0809]
3-[3-(Morpholine-4-carbonyl)-4,5,6,7-tetrahydro-2H-isoindol-1-ylmet-
hylene]-2-oxo-2,3-dihydro-1H-indole-6-carboxylic Acid
[0810] .sup.1HNMR (360 MHz, DMSO d6), .delta. 13.60 (s, 1H, NH),
12.75 (br s, 1H, COOH), 11.08 (s, 1H, NH), 7.85 (d, J=7.8 Hz, 1H),
7.71 (s, 1H, H-vinyl), 7.62 (dd, J=1.4 & 7.8 Hz, 1H), 7.41 (d,
J=1.4 Hz, 1H), 3.65 (m, 4H, 2.times.CH.sub.2), 3.55 (m, 4H,
2.times.CH.sub.2), 2.81 (m, 2H, CH.sub.2), 2.54 (m, 2H, CH.sub.2).
1.73 (m, 4H, 2.times.CH.sub.2).
[0811] MS-EI m/z 421 [M.sup.+].
Example 112
[0812]
5-Bromo-3-[3-(pyrrolidine-1-carbonyl)-4,5,6,7-tetrahydro-2H-isoindo-
l-1-ylmethylene]-1,3-dihydro-indol-2-one
[0813] .sup.1HNMR (360 MHz, DMSO-d6) .delta. 13.56 (s, 1H, NH),
11.00 (s, 1H, NH), 8.05 (d, J=1.8 Hz, 1H), 7.74 (s, 1H, H-vinyl),
7.28 (dd, J=1.3 & 8.3 Hz, 1H), 6.83 (d, J=8.3 Hz, 1H), 3.57 (m,
4H, 2.times.CH.sub.2), 2.79 (m, 2H, CH.sub.2), 2.65 (m, 2H,
CH.sub.2), 1.88 (m, 4H, 2.times.CH.sub.2), 1.71 (m, 4H,
2.times.CH.sub.2).
[0814] MS-EI m/z 439 & 441 [M.sup.+-1] & [M.sup.++1].
Example 114
[0815]
3-(3-Dimethylcarbamoyl-4,5,6,7-tetrahydro-2H-isoindol-1-ylmethylene-
)-2-oxo-2,3-dihydro-1H-indole-6-carboxylic Acid
[0816] .sup.1HNMR (360 MHz, DMSO-d6) .delta. 13.60 (s, 1H, NH),
12.72 (br s, 1H, COOH), 11.05 (s, 1H, NH), 7.85 (d, J=7.9 Hz, 1H),
7.72 (s, 1H, H-vinyl), 7.62 (dd, J=1.3 & 7.9 Hz, 1H), 7.42 (d,
J=1.3 Hz, 1H), 3.03 (s, 6H, N(CH.sub.3).sub.2), 2.81 (m, 2H,
CH.sub.2), 2.55 (m, 2H, CH.sub.2), 1.73 (m, 4H,
2.times.CH.sub.2).
[0817] MS-EI m/z 379 [M.sup.+].
Exapmle 115
[0818]
4-Methyl-5-(5-methylsulfamoyl-2-oxo-1,2-dihydro-indol-3-ylidenemeth-
yl)-1H-pyrrole-3-carboxylic Acid
[0819] .sup.1HNMR (300 MHz, DMSO-d6) .quadrature. 13.56 (br s, 1H,
NH), 8.24 (d, J=1.5 Hz, 1H), 7.86 (s, 1H, H-vinyl), 7.74 (d, J=2.96
Hz, 1H), 7.56 (dd, J=1.5 & 8.1 Hz, 1H), 7.20 (br m, 1H,
NHCH.sub.3), 7.03 (d, J=8.1 Hz, 1H), 2.57 (s, 3H, CH.sub.3), 2.41
(s, 3H, CH.sub.3).
[0820] MS-EI m/z 361 [M.sup.+].
Example 116
[0821]
{[4-Methyl-5-(4-methyl-5-methylsulfamoyl-2-oxo-1,2-dihydroindol-3-y-
lidenemethyl)-1H-pyrrole-3-carbonyl]-amino}-acetic Acid Ethyl
Ester
[0822] 4-Methyl-1H-pyrrole-3-carboxylic acid ethyl ester (lit. ref.
D. O. Cheng, T. L. Bowman and E. LeGoff; J. Heterocyclic Chem.;
1976; 13; 1145-1147) was formylated using method A, hydrolysed
using method B followed by amidation (method C) to give
[(5-formyl-4-methyl-1H-pyrrole-3- -carbonyl)-amino]-acetic acid
ethyl ester.
[0823] 4-Methyl-5-methylaminosulfonyl-2-oxindole (50 mg, 0.21 mmol)
was condensed with
[(5-formyl-4-methyl-1H-pyrrole-3-carbonyl)-amino]-acetic acid ethyl
ester (100 mg, 0.42 mmol) and piperidine (0.1 mL) in ethanol (2 mL)
to give 50 mg (52%) of the title compound.
[0824] .sup.1HNMR (360 MHz, DMSO-d6) .delta. 13.59 (s, 1H, NH),
11.29 (v.br. s, 1H, NH--CO), 8.33 (t, J=5.8 Hz, 1H, CONHCH.sub.2),
7.83 (d, J=3.11 Hz, 1H), 7.80 (s, 1H, H-vinyl), 7.71 (d, J=8.5 Hz,
1H), 7.34 (br m, 1H, NHCH.sub.3), 6.89 (d, J=8.5 Hz, 1H), 4.11 (q,
J=7.1 Hz, 2H, OCH.sub.2CH.sub.3), 3.92 (d, J=5.8 Hz, 2H,
GlyCH.sub.2), 2.86 (s, 3H, CH.sub.3), 2.48 (s, 3H, CH.sub.3), 2.42
(d, J=4.71 Hz, 3H, HNCH.sub.3), 1.20 (t, J=7.1 Hz, 3H,
OCH.sub.2CH.sub.3).
[0825] MS-EI m/z 460 [M.sup.+].
Example 117
[0826]
{[4-Methyl-5-(5-methylsulfamoyl-2-oxo-1,2-dihydro-indol-3-ylideneme-
thyl)-1H-pyrrole-3-carbonyl]-amino}-acetic Acid Ethyl Ester
[0827] A mixture of 5-methylaminosulfonyl-2-oxindole (0.06 g, 0.22
mmol), [(5-formyl-4-methyl-1H-pyrrole-3-carbonyl)-amino]-acetic
acid ethyl ester (0.075 g, 0.27 mmol) and piperidine (2 drops) in
ethanol (5 mL) was heated in a sealed tube at 90.degree. C. for 12
hrs. After cooling, the precipitate was collected by vacuum
filtration, washed with ethanol, triturated with
dichloromethane/ether and dried to give 0.035 g (36%) of the title
compound as a yellowish brown solid.
[0828] .sup.1H NMR (360 MHz, DMSO-d6) .delta. 13.6 (s, 1H, NH), 11
(v.br. s, 1H, NH--CO), 8.30 (t, J=5.7 Hz, 1H, CONHCH.sub.2), 8.25
(d, J=1.2 Hz, 1H), 7.88 (s, 1H, H-vinyl), 7.84 (d, J=3.3 Hz, 1H),
7.57 (dd, J=1.9 & 8.5 Hz, 1H), 7.14 (br m, 1H, NHCH.sub.3),
7.04 (d, J=8.5 Hz, 1H), 4.11 (q, J=6.7 Hz, 2H, OCH.sub.2CH.sub.3),
3.92 (d, J=5.7 Hz, 2H, GlyCH.sub.2), 2.55 (s, 3H, CH.sub.3), 2.41
(m, 3H, NCH.sub.3), 1.20 (t, J=6.7 Hz, 3H, OCH.sub.2CH.sub.3).
[0829] MS m/z 446 [M.sup.+].
Example 118
[0830]
{[4-Methyl-5-(5-methylsulfamoyl-2-oxo-1,2-dihydro-indol-3-ylideneme-
thyl)-1H-pyrrole-3-carbonyl]-amino}-acetic Acid
[0831] A mixture of
[(5-formyl-4-methyl-1H-pyrrole-3-carbonyl)-amino]-acet- ic acid
ethyl ester (0.142 g, 0.59 mmol) and 1N NaOH (1.2 mL) in methanol
(10 mL) was stirred at room temperature for 1 hr. The reaction was
concentrated and the residue was condensed with
5-methylaminosulfonyl-2-o- xindole (0.13 g, 0.48 mmol) and
piperidine (0.12 mL) in ethanol (12 mL) to give 0.11 g (52%) of the
title compound.
[0832] .sup.1HNMR (300 MHz, DMSO-d6) .delta. 13.98 (br s, 1H, NH),
8.17 (s, 1H), 7.80 (s, 1H), 7.75 (d, J=3.1 Hz, 1H), 7.51 (dd, J=2
& 8.2 Hz, 1H), 7.21 (m on br s, 2H), 6.97 (d, J=8.1 Hz, 1H),
3.41 (d, J=4.2 Hz, 2H, CH.sub.2NH), 2.54 (s, 3H, pyrrole-CH.sub.3),
2.39 (s, 3H, ArCH.sub.3).
[0833] MS m/z 417 [M-1].sup.+.
Example 120
[0834]
5-Methyl-2-(2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-1H-pyrrole-3-c-
arboxylic Acid
[0835] .sup.1HNMR (300 MHz, DMSO-d6) .delta. 13.77 (br s, 1H, NH),
12.49 (s, 1H, COOH), 11.07 (s, 1H, NH), 8.39 (s, 1H, H-vinyl), 7.43
(d, J=7.47 Hz, 1H), 7.20 (t, J=7.47 Hz, 1H), 7.03 (t, J=7.47 Hz,
1H), 6.91 (d, J=7.47 Hz, 1H), 6.49 (d, J=1.53 Hz, 1H), 2.34 (s, 3H,
CH.sub.3).
[0836] MS m/z 269 [M+H].sup.+.
Example 121
[0837]
5-Methyl-2-(2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-1H-pyrrole-3-c-
arboxylic Acid Ethyl Ester
[0838] .sup.1HNMR (300 MHz, DMSO-d6) .delta. 13.79 (s, 1H, NH),
11.08 (s, 1H, NH), 8.31 (s, 1H, H-vinyl), 7.45 (d, J=7.52 Hz, 1H),
7.20 (t, J=7.52 Hz, 1H), 7.03 (t, J=7.52 Hz, 1H), 6.91 (d, J=7.52
Hz, 1H), 6.50 (d, J=2.1 Hz, 1H), 4.26 (q, J=7.2 Hz, 2H,
OCH.sub.2CH.sub.3), 2.33 (s, 3H, CH.sub.3), 1.32 (t, J=7.2 Hz, 3H,
OCH.sub.2CH.sub.3).
[0839] MS m/z 297.1 [M+H].sup.+.
Example 122
[0840]
2-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-5-methyl-1H-pyrr-
ole-3-carboxylic Acid Ethyl Ester
[0841] .sup.1HNMR (360 MHz, DMSO-d6) .delta. 13.72 (s, 1H, NH),
11.16 (s, 1H, NH), 8.29 (s, 1H, H-vinyl), 7.53 (d, J=2.0 Hz, 1H),
7.35 (dd, J=2.0 & 8.05 Hz, 1H), 6.87 (t, J=0.5 Hz, 1H), 6.53
(d, J=2.4 Hz, 1H), 4.28 (q, J=7.03 Hz, 2H, OCH.sub.2CH.sub.3), 2.35
(s, 3H, CH.sub.3), 1.33 (t, J=7.03 Hz, 3H, OCH.sub.2CH.sub.3).
[0842] MS m/z 375 & 377 [M+H].sup.+.
Example 123
[0843]
2-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-5-methyl-1H-pyrr-
ole-3-carboxylic Acid
[0844] .sup.1HNMR (300 MHz, DMSO-d6) .delta. 13.72 (s, 1H, NH),
12.57 (s, 1H, COOH), 11.19 (s, 1H, NH), 8.36 (s, 1H, H-vinyl), 7.51
(d, J=1.4 Hz, 1H), 7.34 (dd, J=1.4 & 8.17 Hz, 1H), 6.87 (t,
J=8.17 Hz, 1H), 6.52 (4, J=2.5 Hz, 1H), 2.35 (s, 3H, CH.sub.3).
[0845] MS m/z 347 & 349 [M+H].sup.+.
Example 124
[0846]
2-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-5-methyl-1H-pyrr-
ole-3-carboxylic Acid (2-pyrrolidin-1-ylethyl)-amide
[0847] To a solution of 2-formyl-5-methyl-1H-pyrrole-3-carboxylic
acid (250 mg, 1.63 mmol) in dimethylformamide (3 mL) was added
1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (376 mg, 1.22
equiv.), 1-hydroxybenzotriazole (265 mg, 1.2 equiv.), triethylamine
(0.45 mL, 2 equiv.) and 1-(2-aminoethyl)pyrrolidine (0.23 mL, 1.1
equiv.). After stirring at room temperature overnight, the reaction
was diluted with saturated sodium bicarbonate and brine (with extra
salt) and extracted with 10% methanol in dichloromethane. The
combined organic layers were washed with brine, dried over
anhydrous sodium sulfate and concentrated to give 130 mg of
2-formyl-5-methyl-1H-pyrrole-3-carboxylic acid
(2-pyrrolidin-1-yl-ethyl)-amide.
[0848] A mixture of 5-bromo-2-oxindole (106 mg, 0.5 mmol),
2-formyl-5-methyl-1H-pyrrole-3-carboxylic acid
(2-pyrrolidin-1-yl-ethyl)-- amide (125 mg, 1 equiv.) and piperidine
(0.2 mL) in ethanol (2 mL) was heated in a sealed tube at
80.degree. C. for 1 hr and then cooled. The precipitate which
formed was collected by vacuum filtration, washed with ethanol and
ethyl acetate and dried to give the title compound as an orange
solid.
[0849] .sup.1HNMR (300 MHz, DMSO-d6) .delta. 13.62 (s, 1H, NH),
11.06 (br s, 1H, NH), 8.56 (s, 1H, H-vinyl), 8.15 (m, 1H,
CONHCH.sub.2), 7.48 (d, J=1.8 Hz, 1H), 7.31 (dd, J=1.8 & 7.9
Hz, 1H), 6.86 (d, J=7.9 Hz, 1H), 6.60 (d, J=2.3 Hz, 1H), 3.35 (m,
2H, HNCH.sub.2CH.sub.2), 2.56 (t, J=6.91 Hz, 2H,
HNCH.sub.2CH.sub.2), 2.35 (s, 3H, CH.sub.3), 1.67 (m, 4H,
2.times.CH.sub.2).
[0850] MS m/z 443/445 [M.sup.+ and M.sup.++2].
Example 125
[0851]
2-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-5-methyl-1H-pyrr-
ole-3-carboxylic Acid (2-diethylaminoethyl)-amide
[0852] To a solution of 2-formyl-5-methyl-1H-pyrrole-3-carboxylic
acid (320 mg, 2.1 mmol) in dimethylformamide (3 mL) was added
1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (483 mg, 1.2 equiv.),
1-hydroxybenzotriazole (340 mg, 1.2 equiv.), triethylamine (0.59
mL, 2 equiv.) and N,N-diethylethylenediamine (0.32 mL, 1.1 equiv.).
After stirring at room temperature overnight, the reaction was
diluted with saturated sodium bicarbonate and brine (with extra
salt) and extracted with 10% methanol in dichloromethane. The
combined organic layers were washed with brine, dried over
anhydrous sodium sulfate and concentrated to give
2-formyl-5-methyl-1H-pyrrole-3-carboxylic acid
(2-diethylaminoethyl)-amide.
[0853] A mixture of 5-bromo-2-oxindole (106 mg, 0.5 mmol),
2-formyl-5-methyl-1H-pyrrole-3-carboxylic acid
(2-diethylaminoethyl)-amid- e (126 mg, 1 equiv.) and piperidine
(0.2 mL) in ethanol (2 mL) was heated in a sealed tube at
80.degree. C. for 1 hr and then cooled. The precipitate was
collected by vacuum filtration, washed with ethanol and ethyl
acetate and dried to give the title compound as an orange
solid.
[0854] .sup.1HNMR (360 MHz, DMSO-d6) .delta. 13.62 (s, 1H, NH),
11.11 (br s, 1H, NH), 8.54 (s, 1H, H-vinyl), 8.1 (m, 1H,
CONHCH.sub.2), 7.49 (d, J=2.2 Hz, 1H), 7.31 (dd, J=2.2 & 8.3
Hz, 1H), 6.86 (d, J=8.3 Hz, 1H), 6.58 (d, J=2.24 Hz, 1H), 3.31 (m,
2H, HNCH.sub.2CH.sub.2), 2.59 (m, 6H, 3.times.CH.sub.2), 2.36 (s,
3H, CH.sub.3), 0.99 (t, J=6.8 Hz, 6H,
N(CH.sub.2CH.sub.3).sub.2).
[0855] MS m/z 445/447 [M.sup.+ and M.sup.++2].
Example 126
[0856]
2,4-Dimethyl-5-(2-oxo-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole--
3-carboxylic Acid (2-diethylamino-ethyl)-amide
[0857] A mixture of 1,3-dihydro-indol-2-one (266 mg, 2 mmol),
5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid
(2-diethylamino-ethyl)-amide (530 mg, 2 mmol) and piperidine (1
drop) in ethanol was heated at 90.degree. C. for 2 hours. The
reaction was cooled to room temperature, the resulting precipitate
was collected by vacuum filtration, washed with ethanol and dried
to give 422 mg (55%) of the title compound as a light yellow
solid.
[0858] .sup.1H NMR (400 MHz, DMSO-d6) .delta. 13.7 (s, 1H, NH),
10.9 (s, 1H, NH), 7.88 (d, J=7.6 Hz, 1H), 7.64 (s, 1H, H-vinyl),
7.41 (t, J=5.4 Hz, 1H, NH), 7.13 (dt, J=1.2 & 7.6 Hz, 1H), 6.99
(dt, J=1.2 & 7.6 Hz, 1H), 6.88 (d, J=7.6 Hz, 1H), 3.28 (m, 2H),
2.48-2.55 (m, 6H), 2.44 (s, 3H, CH.sub.3), 2.41 (s, 3H, CH.sub.3),
0.97 (t, J=7.2 Hz, 6H, N(CH.sub.2CH.sub.3).sub.2).
[0859] MS+ve APCI 381 [M.sup.++1].
Example 127
[0860]
5-(5-Chloro-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-2,4-dimethyl-1-
H-pyrrole-3-carboxylic Acid (2-diethylamino-ethyl)-amide
[0861] A mixture of 5-Chloro-1,3-dihydro-indol-2-one (335 mg, 2
mmol), 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid
(2-diethylamino-ethyl)-amide (530 mg, 2 mmol) and piperidine (1
drop) in ethanol was heated at 90.degree. C. for 2 hours. The
reaction was cooled to room temperature, the resulting precipitate
was collected by vacuum filtration, washed with ethanol and dried
to give 565 mg (68%) of the title compound as an orange solid.
[0862] .sup.1H NMR (400 MHz, DMSO-d6) .delta. 13.65 (s, 1H, NH),
11.0 (s, 1H, NH), 7.98 (d, J=2.1 Hz, 1H), 7.77 (s, 1H, H-vinyl),
7.44 (t, NH), 7.13 (dd, J=2.1 & 8.4 Hz, 1H), 6.87 (d, J=8.4 Hz,
1H), 3.28 (g, 2H), 2.48-2.53 (m, 6H), 2.44 (s, 3H, CH.sub.3), 2.43
(s, 3H, CH.sub.3), 0.97 (t, J=7.0 Hz, 6H,
N(CH.sub.2CH.sub.3).sub.2).
[0863] MS+ve APCI 415 [M+1].
Example 128
[0864]
2,4-Dimethyl-5-(2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-1H-pyrrole-
-3-carboxylic Acid (2-pyrrolidin-1-ethyl)-amide
[0865] 1,3-Dihydro-indol-2-one was condensed with
5-formyl-2,4-dimethyl-1H- -pyrrole-3-carboxylic acid
(2-pyrrolidin-1-yl-ethyl)-amide to give the title compound.
[0866] MS+ve APCI 379 [M.sup.++1].
Example 129
[0867]
5-(5-Fluoro-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-2,4-dimethyl-1-
H-pyrrole-3-carboxylic Acid (2-pyrrolidin-1-yl-ethyl)-amide
[0868] 5-Fluoro-1,3-dihydro-indol-2-one was condensed with
5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid
(2-pyrrolidin-1-yl-ethyl)-amide to give the title compound.
[0869] MS+ve APCI 397 [M.sup.++1].
[0870] Scale-Up Procedure:
[0871] 5-Formyl-2',4-dimethyl-1H-pyrrole-3-carboxylic acid (61 g),
5-fluoro-1,3-dihydro-indol-2-one (79 g), ethanol (300 mL), and
pyrrolidine (32 mL) were refluxed for 4.5 hours. Acetic acid (24
mL) was added to the mixture and refluxing was continued for 30
minutes. The mixture was cooled to room temperature and the solids
collected by vacuum filtration and washed twice with ethanol. The
solids were stirred for 130 minutes in 40% acetone in water (400
mL) containing 12 N hydrochloric acid (6.5 mL). The solids were
collected by vacuum filtration and washed twice with 40% acetone in
water. The solids were dried under vacuum to give
5-[5-fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-
-1H-pyrrole-3-carboxylic acid (86 g, 79% yield) as an orange solid.
.sup.1H-NMR (dimethylsulfoxide-d.sub.6) .delta. 2.48, 2.50
(2.times.s, 6H, 2.times.CH.sub.3), 6.80, 6.88, 7.68, 7.72
(4.times.m, 4H, aromatic and vinyl), 10.88 (s, 1H, CONH), 12.12 (s,
1H, COOH), 13.82 (s, 1H, pyrrole NH). MS m/z 299 [M-1].
[0872]
5-[5-Fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethy-
l-1H-pyrrole-3-carboxylic acid (100 g) and dimethylformamide (500
mL) were stirred and
benzotriazol-1-yloxytris(dimethylamino)phosphonium
hexafluorophosphate (221 g), 1-(2-aminoethyl)pyrrolidine (45.6 g)
and triethylamine (93 mL) were added. The mixture was stirred for 2
hours at ambient temperature. The solid product was collected by
vacuum filtration and washed with ethanol. The solids were
slurry-washed by stirring in ethanol (500 mL) for one hour at
64.degree. C. and cooled to room temperature. The solids were
collected by vacuum filtration, washed with ethanol, and dried
under vacuum to give 5-[5-fluoro-2-oxo-1,2-dihydro-ind-
ol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid
(2-pyrrolidin-1-yl-ethyl)-amide (101.5 g, 77% yield). .sup.1H-NMR
(dimethylsulfoxide-d.sub.6) .delta. 1.60 (m, 4H, 2.times.CH.sub.2),
2.40, 2.44 (2.times.s, 6H, 2.times.CH.sub.3), 2.50 (m, 4H,
2.times.CH.sub.2), 2.57, 3.35 (2.times.m, 4H, 2.times.CH.sub.2),
7.53, 7.70, 7.73, 7.76 (4.times.m, 4H, aromatic and vinyl), 10.88
(s, 1H, CONH), 13.67 (s, 1H, pyrrole NH). MS m/z 396 [M+1].
Example 130
[0873]
5-(5-Chloro-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-2,4-dimethyl-1-
H-pyrrole-3-carboxylic Acid (2-pyrrolidin-1-ylethyl)-amide
[0874] 5-Chloro-1,3-dihydro-indol-2-one was condensed with
5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid
(2-pyrrolidin-1-yl-ethyl)-amide to give the title compound.
[0875] MS+ve APCI 413 [M.sup.++1].
Example 131
[0876]
2,4-Dimethyl-5-(2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-1H-pyrrole-
-3-carboxylic Acid (2-dimethylaminoethyl)-amide
[0877] 1,3-Dihydro-indol-2-one was condensed with
5-formyl-2,4-dimethyl-1H- -pyrrole-3-carboxylic acid
(2-dimethylaminoethyl)amide to give the title compound.
[0878] .sup.1H NMR (400 MHz, DMSO-d6) .delta. 13.63 (s, 1H, NH),
10.90 (s, 1H, NH), 7.78 (d, J=7.8 Hz, 1H), 7.63 (s, 1H H-vinyl),
7.48 (t, 1H, NH), 7.13 (dt, 1H), 6.98 (dt, 1H), 6.88 (d, J=7.7 Hz,
1H), 3.31 (q, J=6.6 Hz, 2H), 2.43 (s, 3H, CH.sub.3), 2.40 (s, 3H,
CH.sub.3), 2.38 (t, J=6.6 Hz, 2H), 2.19 (s, 6H,
N(CH.sub.2CH.sub.3).sub.2).
[0879] MS+ve APCI 353 [M.sup.++1].
Example 132
[0880]
5-(5-Fluoro-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-2,4-dimethyl-1-
H-pyrrole-3-carboxylic Acid (2-dimethylaminoethyl)-amide
[0881] 5-Fluoro-1,3-dihydro-indol-2-one was condensed with
5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid
(2-dimethylaminoethyl)amide to give the title compound.
[0882] .sup.1H NMR (400 MHz, DMSO-d6) .delta. 13.68 (s, 1H, NH),
10.90 (s, 1H, NH), 7.76 (dd, J=2.4 & 9.4 Hz, 1H), 7.71 (s, 1H,
H-vinyl), 7.51 (t, 1H, NH), 6.93 (m, 1H), 6.84 (dd, J=4.6 & 8.4
Hz, 1H), 3.31 (q, J=6.6 Hz, 2H), 2.43 (s, 3H, CH.sub.3), 2.41 (s,
3H, CH.sub.3), 2.38 (t, J=6.6 Hz, 2H), 2.19 (s, 6H,
N(CH.sub.2CH.sub.3).sub.2)
[0883] MS+ve APCI 371 [M.sup.++1].
Example 193
[0884]
5-[5-Fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethy-
l-1H-pyrrole-3-carboxylic Acid (2-ethylamino-ethyl)-amide
[0885] 5-Formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid
(2-ethylamino-ethyl)-amide (99 g), ethanol (400 mL),
5-fluoro-2-oxindole (32 g) and pyrrolidine (1.5 g) were refluxed
for 3 hours with stirring. The mixture was cooled to room
temperature and the solids collected by vacuum filtration. The
solids were stirred in ethanol at 60.degree. C., cooled to room
temperature and collected by vacuum filtration. The product was
dried under vacuum to give 5-[5-fluoro-2-oxo-1,2-dihydroindol-
-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid
(2-ethylamino-ethyl)-amide (75 g, 95% yield). .sup.1H-NMR
(dimethylsulfoxide-d.sub.6) .delta. 1.03 (t, 3H, CH.sub.3), 2.42,
2.44 (2.times.s, 6H, 2.times.CH.sub.3), 2.56 (q, 2H, CH.sub.2),
2.70, 3.30 (2.times.t, 4H, 2.times.CH.sub.2), 6.85, 6.92, 7.58,
7.72, 7.76 (5.times.m, 5H, aromatic, vinyl and CONH), 10.90 (br s,
1H, CONH), 13.65 (br s, 1H, pyrrole NH).
[0886] MS m/z 369 [M-1].
Example 195
[0887]
5-[5-Fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethy-
l-1H-pyrrole-3-carboxylic acid
(2-diethyl-N-oxoamino-ethyl)-amide
[0888] Method A:
[0889]
5-[5-Fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethy-
l-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)-amide (598 mg)
and dichloromethane (60 mL) in an ice bath were treated with
3-chloroperbenzoic acid (336 mg) and the mixture stirred at room
temperature overnight. The solvent was rotary evaporated and the
residue suspended in methanol (20 mL). Water (20 mL) containing
sodium hydroxide (240 mg) was added and the mixture stirred for one
hour. The precipitate was collected by vacuum filtration, washed
with 5 mL of water and dried under a vacuum to give
5-[5-fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylideneme-
thyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid
(2-diethyl-N-oxoamino-ethy- l)-amide (510 mg, 82% yield) as an
orange solid. .sup.1H-NMR (DMSO-d6) .delta. 13.72 (br s, 1H, NH),
11.02 (br s, 1H, CONH), 9.81 (br s, 1H, CONH), 7.75 (dd, 1H,
aromatic), 7.70 (s, 1H, aromatic), 6.93 (td, 1H, aromatic), 6.84
(m, 1H, aromatic), 3.63 (m, 0.2H, CH.sub.2), 3.29 (m, 2H,
CH.sub.2), 3.14 (m, 4H, 2.times.CH.sub.2), 2.47 (s, 1H, CH.sub.3),
2.45 (s, 3H, CH.sub.3), 1.64 (t, 6H, 2.times.CH.sub.3). MS m/z 415
[M+1].
[0890] Method B:
[0891] 5-Formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid
(2-diethylamino-ethyl)-amide (10 g) was suspended in
dichloromethane (100 mL) and cooled in an ice bath.
3-Chloroperoxybenzoic acid (13.1 g) was added with stirring and the
mixture allowed to warm to room temperature and then stirred
ovenight. The mixture was rotary evaporated to dryness and
chromatographed on a column of silica gel eluting with 20% methanol
in dichloromethane. Fractions containing product were combined and
rotary evaporated to dryness to give
5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxyl- ic acid
(2-diethyl-N-oxoamino-ethyl)-amide (9 g, 83% yield).
[0892] 5-Formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid
(2-diethyl-N-oxoamino-ethyl)-amide (9 g),
5-fluoro-1,3-dihydroindol-2-one ((9 g, 83% yield)), and pyrrolidine
((9 g, 83% yield (0.1 g) were refluxed in ethanol (30 mL) for 4
hours. The mixture was cooled in an ice bath and the precipitate
collected by vacuum filtration and washed with ethanol. The solids
were stirred in ethyl acetate (30 mL), collected by vacuum
filtration, washed with ethyl acetate and dried under vacuum to
give
5-[5-fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-
-1H-pyrrole-3-carboxylic acid (2-diethyl-N-oxoamino-ethyl)-amide
(10.3 g 80% yield) as an orange solid. .sup.1H-NMR (DMSO-d6)
.delta. 13.72 (br s, 1H, NH), 11.02 (br s, 1H, CONH), 9.81 (br s,
1H, CONH), 7.75 (dd, 1H, aromatic), 7.70 (s, 1H, aromatic), 6.93
(td, 1H, aromatic), 6.84 (m, 1H, aromatic), 3.63 (m, 2H, CH.sub.2),
3.29 (m, 2H, CH.sub.2), 3.14 (m, 4H, 2.times.CH.sub.2), 2.47 (s, 1
Hr CH.sub.3), 2.45 (s, 3H, CH.sub.3), 1.64 (t, 6H,
2.times.CH.sub.3). MS m/z 415 [M+1].
Example 190
[0893]
5-[5-fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethy-
l-1H-pyrrole-3-carboxylic Acid [2-(pyridin-1-yl)ethyl]-amide.
[0894]
5-[5-Fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethy-
l-1H-pyrrole-3-carboxylic acid (120 mg, 0.4 mmol) was shaken with
EDC, HCl (96 mg, 0.5 mmol), anhydrous 1-hydroxy-benztriazole (68
mg, 0.5 mmol), and 2-(2-aminoethylpyridine purchased from Aldrich
in anhydrous DMF (3 mL) for 2-3 days at room temperature. The
reaction mixture was diluted with 1M NaHCO3 (1.5 ml), then with 8
ml of water. The precipitated crude product was collected by
filtration, washed with water, dried and purified by
crystallization or chromatography to give
5-[5-fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-p-
yrrole-3-carboxylic acid [2-(pyridin-1-yl)-ethyl]amide.
Example 189
[0895]
5-[5-Chloro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethy-
l-1H-pyrrole-3-carboxylic Acid [2-(pyridin-1-yl)ethyl]amide.
[0896] Proceeding as described in previous example but substituting
5-[5-fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-p-
yrrole-3-carboxylicacid with
5-[5-chloro-2-oxo-1,2-dihydro-indol-(3Z)-ylid-
enemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (127 mg)
provided
5-[5-chloro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-p-
yrrole-3-carboxylic acid [2-(pyridin-1-yl)ethyl]amide.
Example 192
[0897]
5-[5-Bromo-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-
-1H-pyrrole-3-carboxylic Acid [2-(pyridin-1-yl)ethyl]amide.
[0898] Proceeding as described in Example 190 above but
substituting
5-[5-fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-p-
yrrole-3-carboxylic acid with
5-[5-bromo-2-oxo-1,2-dihydro-indol-(3Z)-ylid-
enemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (145 mg)
provided
5-[5-bromo-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-py-
rrole-3-carboxylic acid [2-(pyridin-1-yl)ethyl]amide.
Example 191
[0899]
5-[2-Oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrr-
ole-3-carboxylic Acid [2-(pyridin-1-yl)ethyl]amide.
[0900] Proceeding as described in Example 190 above but
substituting
5-[5-fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-p-
yrrole-3-carboxylic acid with
5-[2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethy-
l]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (113 mg) provided
5-[2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3--
carboxylic acid [2-(pyridin-1-yl)ethyl]amide.
Example 203
[0901]
5-[5-Cyano-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-
-1H-pyrrole-3-carboxylic Acid [2-(pyridin-1-yl)ethyl]amide
[0902] Proceeding as described in Example 190 above but
substituting
5-[5-fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-p-
yrrole-3-carboxylic acid with
5-[5-cyano-2-oxo-1,2-dihydro-indol-(3Z)-ylid-
enemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (123 mg)
provided
5-[5-cyano-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-py-
rrole-3-carboxylic acid [2-(pyridin-1-yl)ethyl]amide.
Examples 142, 186, 187, 188 and 204
[0903] Proceeding as described in Examples 190, 189, 191, 192, and
203 above but substituting 2-(2-aminoethyl)pyridine with
1-(2-aminoethyl)pyrrolidine, purchased from Aldrich Chemical
Company, Inc. provided the desired compounds.
Examples 143-147
[0904] Proceeding as described in Examples 190, 189, 191, 192, and
203 above but substituting 2-(2-aminoethyl)pyridine with
1-(2-aminoethyl)imidazolin-2-one (prepared by heating dimethyl
carbonate with bis(2-aminoethyl) amine (2 equivalents) in a sealed
flask to 150.degree. C. for 30 min., following the procedure
described in U.S. Pat. No. 2,613,212 (1950), to Rohm & Haas Co.
The crude product was purified on silica using an eluent mixture
chloroform-methanol-aqueous ammonia 80:25:2) provided the desired
compounds.
Examples 148-151 and 184
[0905] Proceeding as described in Examples 190, 189, 191, 192, and
203 above but substituting 2-(2-aminoethyl)pyridine with
4-(2-aminoethyl)piperazine-1-acetic acid ethyl ester (prepared as
follows: Piperazine-1-acetic acid ethyl ester (11.22 g) was treated
with iodoacetonitrile (5.0 mL) in the presence of potassium
carbonate (6.9 g) in ethyl acetate (260 mL) at 0.degree. C. After
complete iodoacetonitrile addition;(45 min), the reaction mixture
was subsequently stirred at room temperature for 11 hours. The
reaction mixture was filtered and the filtrates evaporated. The
residue was hydrogenated in a presence of cobalt boride (prepared
from CoCl2 and sodium borohydride) at room temperature at 50 psi
for 2 days in ethanol. Filtration, evaporation and chromatographic
purification using an eluent mixture chloroform-methanol-aqueous
ammonia 80:25:2 provided the desired amine (3.306 g) as a pale
yellow oil) provided the desired compounds.
Example 152-153
[0906] Proceeding as described in Examples 190, 189, 191, 192, and
203 above but substituting 2-(2-aminoethyl)pyridine with
2-[(2-aminoethylamino)]acetonitrile (prepared as follows: A
solution of iodoacetonitrile (50 mmol) in ethyl alcohol (80 ml),
was added to a solution of ethylene diamine (150 ml) in ethyl
alcohol (60 ml) at 0.degree. C. over a period of 30 minutes. The
stirring was continued for another 1 hr. at 0.degree. C., then at
room temperature for 14 hours. 55 mmol of potassium carbonate was
added, stirred for 30 minutes, filtered and the filtrate was
concentrated at room temperature. The residue was purified on
silica using an eluent mixture chloroform-methanol-aqueous ammonia
80:15:1.5 to give 2-[(2-aminoethylamino)]-acetonitrile (3.550 g)
which was used immediately) provided the desired compounds.
Example 154-158
[0907] Proceeding as described in Examples 190, 189, 191, 192, and
203 above but substituting 2-(2-aminoethyl)pyridine with
1-(3-aminopropyl)-azepin-2-one (prepared according to the procedure
in Kraft A.: J. Chem. Soc. Perkin Trans. 1, 6, 1999, 705-14, except
that the hydrolysis of DBU was performed at 145.degree. C. neat in
a presence of lithium hydroxide (1 hr, 5 ml of DBU, 2 ml of water,
420 mg of lithium hydroxyde hydrate). Purification of the crude
product on silica using an eluent mixture
chloroform-methanol-aqueous ammonia 80:40:4 provided
1-(3-aminopropyl)azepin-2-one (4.973 g, 87% yield)) provide the
desired compounds.
Examples 133-135, 159 and 200
[0908] Proceeding as described in Examples 190, 189, 191, 192, and
203 above but substituting 2-(2-aminoethyl)pyridine with N-acetyl
ethylene diamine, (prepared by heating a mixture of ethyl acetate
with ethylene diamine (1.5 equivalents) to 160.degree. C. for 1 hr
in a sealed vessel. The vacuum distillation provided the desired
product in 56% yield. N-acetylethylene diamine is also available
from Aldrich) provide the desired compounds.
Examples 146-140
[0909] Proceeding as described in Examples 190, 189, 191, 192, and
203 above but substituting 2-(2-aminoethyl)pyridine with
1-(3-aminopropyl)-tetrahydro-pyrimidin-2-one (prepared in the same
way as 1-(3-aminopropyl)-azepin-2-one according to the procedure in
Kraft A.: J. Chem. Soc. Perkin Trans. 1, 6, 1999, 705-14: Briefly,
1,3,4,6,7,8-hexahydro-2H-pyrimido[1,2-a]pyrimidine (4.939 g),
lithium hydroxyde hydrate (918 mg) and 2 ml of water was heated
without a solvent in a sealed vessel to 145.degree. C. for 1 hr.
The crude product was purified on a column of silica in
chloroform-methanol-aqueous ammonia 80:40:4 to give pure amine
(5.265 g, 94% yield).
Examples 141, 160-162 and 185
[0910] Proceeding as described in Examples 190, 189, 191, 192, and
203 above but substituting 2-(2-aminoethyl)pyridine with
1-(2-aminoethyl)-piperazine-2-one (prepared as follows: Neat
tert-butyldiphenylsilyl chloride (25 mL, 97.7 mmol) was added
dropwise into a solution of DBU (19.5 ml, 130 mmol) and
bis(2-aminoethyl)amine (4.32 mL, 40 mmol) in anhydrous dimethyl
acetamide (80 mL) at room temperature upon cooling on water bath
within 5 minutes. The mixture was stirred for 5 hours. Bromoacetic
acid ethyl ester (6.70 mL, 60 mmol) was added neat upon cooling to
room temperature. The reaction was stirred for 25 minutes, then
evaporated on high vacuum. The residue was dissolved in methanol
(200 ml), KHCO.sub.3 (10 g) and KF (12 g, 200 mmol) were added and
the mixture was stirred at 60.degree. C. for 5 hours. 10 g of
Na.sub.2CO.sub.3 was added, stirred for 10 minutes, cooled and
filtered. The filtrates were evaporated. The residue was extracted
with hexanes (2 times 250 ml). The hexane-insoluble material was
dissolved in ethanol (60 ml), filtered and evaporated. The residue
was purified on a column of silica in chloroform-methanol-aqueous
ammonia 80:40:4 to give pure amine (4.245 g, 74% yield)) provided
the desired compounds.
Examples 163-167
[0911] Proceeding as described in Examples 190, 189, 191, 192, and
203 above but substituting 2-(2-aminoethyl)pyridine with
3-[(2-aminoethyl)amino]propionitrile (prepared from ethylene
diamine (150 mmol) and acrylonitrile (50 mmol) in THF at room
temperature, as described in Israel, M. et al: J. Med Chem. 7,
1964, 710-16., provided the desired amine (4.294 g)) provided the
desired compounds.
Example 168
[0912]
5-(5-Fluoro-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-2,4-dimethyl-1-
H-pyrrole-3-carboxylic Acid
[2-(4-methylpiperazin-1-yl)-ethyl]-amide
[0913] To a stirred yellow muddy mixture of
5-[5-fluoro-2-oxo-1,2-dihydro--
indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid
(90 mg), DMF (0.8 mL) and TEA (0.084 mL) in a 20 mL reaction tube,
was added BOP reagent (199 mg). The mixture became clear in 5 min.
2-(4-Methylpiperazin-1-yl)ethylamine.sup.1 (51 mg) was added into
the clear mixture. The resulting solution was stirred at room
temperature over night. Yellow solid products precipitated from the
reaction system. Thin layer chromatography (10% methanol in
methylene chloride) showed that all the starting material had been
converted into the product. The solid was isolated by vacuum
filtration and washed once with ethanol (1 mL). The solid was
sonicated in diethyl ether (2 mL) for 20 mm and collected by vacuum
filtration. After drying under vacuum,
5-(5-Fluoro-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrr-
ole-3-carboxylic acid (4-methylpiperazin-1-yl-ethyl)-amide (79 mg,
62% yield) was obtained.
[0914] .sup.1H NMR (DMSO-d.sub.6) .delta. 2.13 (s, 3H, CH.sub.3),
2.40, 2.42 (2.times.s, 6H, 2.times.CH.sub.3), 2.41 (m, 2H,
CH.sub.2), 2.47 (m, 8H, 4.times.CH.sub.2), 3.30 (m, 2H, CH.sub.2),
6.82 (dd, J=4.5, 8.7 Hz, 1H), 6.91 (td, .sup.2J=2.4, .sup.3J=8.8
Hz, 1H), 7.43 (t, J=5.6 Hz, 1H), 7.70 (s, 1H), 7.75 (dd, J=20.8,
9.6 Hz, 1H) (aromatic and vinyl), 10.88 (s, 1H, CONH), 13.67 (s,
1H, NH). LC-MS (m/z) 424.44 (M-1).
Example 169
[0915]
5-(5-Chloro-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-2,4-dimethyl-1-
H-pyrrole-3-carboxylic Acid (4-methylpiperazin-1-ylethyl)-amide
[0916] Following the procedure in Example 168 above but
substituting
5-[5-fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-p-
yrrole-3-carboxylic acid with
5-[5-chloro-2-oxo-1,2-7-dihydro-indol-(3Z)-y-
lidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (95 mg, 0.3
mmol) gave
5-(5-chloro-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-2,4-dimethyl-1H-
-pyrrole-3-carboxylic acid (4-methylpiperazin-1-ylethyl)-amide (76
mg, 58%).
[0917] .sup.1HNMR (DMSO-d.sub.6) .delta. 2.13 (s, 3H, CH.sub.3),
2.41, 2.042 (2.times.s, 6H, 2.times.CH.sub.3), 2.42 (m, 2H,
CH.sub.2), 2.48 (m, 8H, 4.times.CH.sub.2), 3.30 (m, 2H, CH.sub.2),
6.84 (d, J=8.0 Hz, 1H), 7.11 (dd, J=2.0, 8.0 Hz, 1H), 7.44 (t,
J=5.6 Hz, 1H), 7.76 (s, 1H), 7.97 (d, J=2.0 Hz, 1H) (aromatic and
vinyl), 10.98 (s, 1H, CONH), 13.62 (s, 1H, NH). LC-MS (m/z) 440.2
(M-1).
Example 170
[0918]
5-(5-Bromo-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-2,4-dimethyl-1H-
-pyrrole-3-carboxylic Acid (4-methylpiperazin-1-ylethyl)-amide
[0919] Following the procedure described in Example 168, but
substituting
5-(5-chloro-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrr-
ole-3-carboxylic acid with
5-(5-bromo-2-oxo-1,2-dihydro-indol-3-ylidenemet-
hyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid gave
5-(5-bromo-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrro-
le-3-carboxylic acid (4-methylpiperazin-1-yl-ethyl)-amide (39 mg,
54%) was obtained from SU011670 (54 mg, 0.15 mmol).
[0920] .sup.1H NMR (DMSO-d.sub.6) .delta. 2.14 (s, 3H, CH.sub.3),
2.41, 2.42 (2.times.s, 6H, 2.times.CH.sub.3), 2.42 (m, 2H,
CH.sub.2), 2.48 (m, 8H, 4.times.CH.sub.2), 3.31 (m, 2H, CH.sub.2),
6.80 (d, J=8.0 Hz, 1H), 7.23 (dd, J=2.0, 8.0 Hz, 1H), 7.44 (t,
J=5.6 Hz, 1H), 7.76 (s, 1H), 8.09 (d, J=2.0 Hz, 1H) (aromatic and
vinyl), 10.99 (s, 1H, CONH), 13.61 (s, 1H, NH). LC-MS (m/z) 486.6
(M).
Example 172
[0921]
5-(2-Oxo-1,2-dihydro-indol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-
-3-carboxylic Acid (4-methylpiperazin-1-yl-ethyl)-amide
[0922] Following the procedure described in Example 168 above but
substituting
5-(0.5-fluoro-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-2,4-d-
imethyl-1H-pyrrole-3-carboxylic acid SU014900 with
5-(2-oxo-1,2-dihydro-in-
dol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid gave
5-(2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-car-
boxylic acid (4-methylpiperazin-1-yl-ethyl)-amide, SU014903 (136
mg, 84%) was obtained from SU012120 (112.8 mg, 0.4 mmol).
[0923] .sup.1H-NMR(DMSO-d.sub.6) .delta. 2.13 (s, 3H, CH.sub.3),
2.39, 2.42 (2.times.s, 6H, 2.times.CH.sub.3), 2.42 (m, 2H,
CH.sub.2), 22.48 (m, 8H, 4.times.CH.sub.2), 3.30 (t, 2H, CH.sub.2),
6.86 (d, J=8.0 Hz, 1H), 6.96 (t, J=7.4 Hz, 1H), 7.10 (t, J=7.8 Hz,
1H), 7.41 (t, J=5.4 Hz, 1H), 7.62 (s, 1H), 7.76 (d, J=7.6 Hz, 1H)
(aromatic and vinyl), 10.88 (s, 1H, CONH), 13.61 (s, 1H, NH). LC-MS
(m/z) 406.6 (M-1).
Example 171
[0924]
5-[2-Oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrr-
ole-3-carboxylic Acid
[2-(3,5-dimethylpiperazin-1-yl)ethyl)amide
[0925] To a stirred yellow muddy mixture of
5-[2-oxo-1,2-dihydro-indol-(3Z-
)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (112.8
mg, 0.4 mmol), DMF (0.5 mL) and triethylamine (0.111 mL) in a 20 mL
reaction tube, was added BOP reagent (265 mg). The mixture became
clear in 5 min. 2-(2,6-dimethylpiperazin-1-yl)ethylamine (68.6 mg)
(see., Tapia, L. Alonso-Cires, P. Lopez-Tudanca, R. Mosquera, L.
Labeaga, A., Innerarity, A. Orjales, J. Med. Chem., 1999, 42,
2870-2880) was added into the clear mixture. The resulting solution
was stirred at room temperature over night. Thin layer
chromatography (10% methanol in methylene chloride) showed that all
the starting material had been converted into the product. The
reaction mixture was evaporated to dryness and then purified by
flash chromatography (CH.sub.2Cl.sub.2/CH.sub.3OH=20/1-15/1)
followed by recrystalization to give
5-[2-oxo-1,2-dihydroindol-(3Z)-ylidenemethyl]-
-2,4-dimethyl-1H-pyrrole-3-carboxylic acid
[2-(3,5-dimethylpiperazin-1-yl)- ethyl)amide (83 mg, 50%
yield).
[0926] .sup.1H NMR (DMSO-d.sub.6) .delta. 1.15, 1.16 (2.times.s,
6H, 2.times.CH.sub.3), 1.95 (t, J=11.6 Hz, 2H, CH.sub.2), 2.41,
2.47 (2.times.s, 6H, 2.times.CH.sub.3), 2.50 (m, 2H, CH.sub.2),
3.03 (d, J=10 Hz, 2H), 3.19 (m, 2H), 3.30 (m, 2H, CH.sub.2), 6.86
(d, J=8.0 Hz, 1H), 6.97 (t, J=7.2 Hz, 1H), 7.11 (t, J=7.8 Hz, 1H),
7.48 (t, J=5.6 Hz, 1H), 7.61 (s, 1H), 7.75 (d, J=7.6 Hz, 1H)
(aromatic and vinyl), 10.88 (s, 1H, CONH), 13.62 (s, 1H, NH). LC-MS
(m/z) 422.2 (M+1).
Example 173
[0927]
5-[5-Fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethy-
l-1H-pyrrole-3-carboxylic Acid
[2-(3,5-dimethylpiperazin-1-yl)ethyl)amide
[0928] Following the procedure described in Example 168 above the
desired compound was obtained (60 mg, 0.2 mmol).
[0929] .sup.1H NMR (DMSO-d.sub.6) .delta. 0.891, 0.907 (2.times.s,
6H, 2.times.CH.sub.3), 1.49 (t, J=10.4 Hz, 2H), 2.40, 2.42
(2.times.s, 6H, 2.times.CH.sub.3), 2.41 (m, 2H, CH.sub.2), 2.74 (m,
4H), 3.30 (m, 2H), 6.82 (dd, J=4.5, 8.7 Hz, 1H), 6.90 (td,
.sup.2J=2.4, .sup.3J=8.4 Hz, 1H), 7.42(t, J=5.6 Hz, 1H), 7.70 (s,
1H), 7.74 (dd, J=4.6, 8.4 Hz, 1H) (aromatic and vinyl), 10.88 (s,
1H, CONH), 13.65 (s, 1H, NH). LC-MS (m/z) 438.4 (M-1).
Example 174
[0930]
5-[5-Chloro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethy-
l-1H-pyrrole-3-carboxylic Acid
[2-(3,5-dimethylpiperazin-1-yl)ethyl)amide
[0931] Following the procedure for Example 171 above the desired
compound (31.2 mg, 0.34%) was obtained from
5-[5-chloro-2-oxo-1,2-dihydro-indol-(3-
Z)-ylidenemethyl]-2.4-dimethyl-1H-pyrrole-3-carboxylic acid (63 mg,
0.2 mmol).
[0932] .sup.1H NMR (DMSO-d.sub.6) .delta. 1.15, 1.16 (2.times.s,
6H, 2.times.CH.sub.3), 1.95 (t, J=11.6 Hz, 2H, CH.sub.2), 2.40,
2.42 (2.times.s, 6H, 2.times.CH.sub.3), 2.50 (m, 2H, CH.sub.2),
3.03 (d, J=11.2 Hz, 2H), 3.19 (m, 2H), 3.30 (m, 2H, CH.sub.2), 6.85
(d, J=8.4 Hz, 1H), 7.11 (dd, J=2.0, 8.0 Hz, 1H), 7.52 (t, J=5.6 Hz,
1H), 7.76 (s, 1H), 7.97 (d, J=2.0 Hz, 1H) (aromatic and vinyl),
10.99 (s, 1H, CONH), 13.63 (s, 1H, NH). LC-MS (m/z) 456.2
(M+1).
Example 175
[0933]
5-[5-Bromo-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-
-1H-pyrrole-3-carboxylic Acid
[2-(3,5-dimethylpiperazin-1-yl)ethyl)amide
[0934] Following the procedure described in Example 171 the desired
compound (40 mg, 40%) was obtained from
5-[5-bromo-2-oxo-1,2-dihydro-indo-
l-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (74
mg, 0.2 mmol).
[0935] .sup.1H NMR (DMSO-d.sub.6) .delta. 1.15, 1.16 (2.times.s,
6H, 2.times.CH.sub.3), 1-0.95 (t, J=11.6 Hz, 2H, CH.sub.2), 2.40,
2.42 (2.times.s, 6H, 2.times.CH.sub.3), 2.50 (m, 2H, CH.sub.2),
3.03 (d, J=10.4 Hz, 2H), 3.19 (m, 2H), 3.30 (m, 2H, CH.sub.2), 6.81
(d, J=8.4 Hz, 1H), 7.24 (dd, J=2.0, 8.4 Hz, 1H), 7.51 (t, J=5.6 Hz,
1H), 7.76 (s, 1H), 8.10 (d, J=2.0 Hz, 1H) (aromatic and vinyl),
10.99 (s, 1H, CONH), 13.62 (s, 1H, NH). LC-MS (m/z) 498.4
(M-1).
BIOLOGICAL EXAMPLES
[0936] The following assays are employed to find those compounds:
demonstrating the optimal degree of the desired activity.
[0937] A. Assay Procedures.
[0938] The following assays may be used to determine the level of
activity and effect of the different compounds of the present
invention on one or more of the PKs. Similar assays can be designed
along the same lines for any PK using techniques well known in the
art.
[0939] Several of the-assays described herein are performed in an
ELISA (Enzyme-Linked Immunosorbent Sandwich Assay) format (Voller,
et al., 1980, "Enzyme-Linked Immunosorbent Assay," Manual of
Clinical Immunology, 2d ed., Rose and Friedman, Am. Soc. Of
Microbiology, Washington, D.C., pp. 359-371). The general procedure
is as follows: a compound is introduced to cells expressing the
test kinase, either naturally or recombinantly, for a selected
period of time after which, if the test kinase is a receptor, a
ligand known to activate the receptor is added. The cells are lysed
and the lysate is transferred to the wells of an ELISA, plate
previously coated with a specific antibody recognizing the
substrate of the enzymatic phosphorylation reaction. Non-substrate
components of the cell lysate are washed away and the amount of
phosphorylation on the substrate is detected with an antibody
specifically recognizing phosphotyrosine compared with control
cells that were not contacted with a test compound.
[0940] The presently preferred protocols for conducting the ELISA
experiments for specific PKs is provided below. However, adaptation
of these protocols for determining the activity of compounds
against other RTKs, as well as for CTKs and STKs, is well within
the scope of knowledge of those skilled in the art. Other assays
described herein measure the amount of DNA made in response to
activation of a test kinase, which is a general measure of a
proliferative response. The general procedure for this assay is as
follows: a compound is introduced to cells expressing the test
kinase, either naturally or recombinantly, for a selected period of
time after which, if the test kinase is a receptor, a ligand known
to activate the receptor is added. After incubation at least
overnight, a DNA labeling reagent such as 5-bromodeoxyuridine
(BrdU) or H.sup.3-thymidine is added. The amount of labeled DNA is
detected with either an anti-BrdU antibody or by measuring
radioactivity and is compared to control cells not contacted with a
test compound.
[0941] GST-FLK-1 Bioassay
[0942] This assay analyzes the tyrosine kinase activity of GST-Flk1
on poly(glu,tyr) peptides.
[0943] Materials and Reagents:
[0944] 1. Corning 96-well ELISA plates (Corning Catalog No.
5805-96).
[0945] 2. poly(glu,tyr) 4:1, lyophilizate (Sigma Catalog #
P0275).
[0946] 3. Preparation of poly(glu,tyr)(pEY) coated assay plates:
Coat 2 ug/well of poly(glu,tyr)(pEY) in 100 ul PBS, hold at room
temperature for 2 hours or at 4.degree. C. overnight. Cover plates
well to prevent evaporation.
[0947] 4. PBS Buffer: for 1 L, mix 0.2 g KH.sub.2PO.sub.4, 1.15 g
Na.sub.2HPO.sub.4, 0.2 g KCl and 8 g NaCl in approx. 900 ml
dH.sub.2O. When all reagents have dissolved, adjust the pH to 7.2
with HCl. Bring total volume to 1 L with dH.sub.2O.
[0948] 5. PBST Buffer: to 1 L of PBS Buffer, add 1.0 ml
Tween-20.
[0949] 6. TBB--Blocking Buffer: for 1 L, mix 1.21 g TRIS, 8.77 g
NaCl, 1 ml TWEEN-20 in approximately 900 ml dH.sub.2O. Adjust pH to
7.2 with HCl. Add 10 g BSA, stir to dissolve. Bring total volume to
1 L with dH.sub.2O. Filter to remove particulate matter.
[0950] 7. 1% BSA in PBS: To make a 1.times. working solution, add
10 g BSA to approx. 990 ml PBS buffer, stir to dissolve. Adjust
total volume to 1 L with PBS buffer, filter to remove particulate
matter.
[0951] 8. 50 mM Hepes pH 7.5.
[0952] 9. GST-Flk1cd purified from sf9 recombinant baculovirus
transformation (SUGEN, Inc.).
[0953] 10. 4% DMSO in dH.sub.2O.
[0954] 11. 10 mM ATP in dH.sub.2O.
[0955] 12. 40 mM MnCl.sub.2
[0956] 13. Kinase Dilution Buffer (KDB): mix 10 ml Hepes (pH 7.5),
1 ml 5M NaCl, 40 .mu.L 100 mM sodium orthovanadate and 0.4 ml of 5%
BSA in dH.sub.2O with 88.56 ml dH.sub.2O.
[0957] 14. NUNC 96-well V bottom polypropylene plates, Applied
Scientific Catalog # AS-72092
[0958] 15. EDTA: mix 14.12 g ethylenediaminetetraacetic acid (EDTA)
to approx. 70 ml dH.sub.2O. Add 10 N NaOH until EDTA dissolves.
Adjust pH to 8.0. Adjust total volume to 100 ml with dH.sub.2O.
[0959] 16. 1.sup.0 Antibody Dilution Buffer: mix 10 ml of 5% BSA in
PBS buffer with 89.5 ml TBST.
[0960] 17. Anti-phosphotyrosine monoclonal antibody conjugated to
horseradish peroxidase (PY99 HRP, Santa Cruz Biotech).
[0961] 18. 2,2'-Azinobis(3-ethylbenzthiazoline-6-sulfonic acid
(ABTS, Moss, Cat. No. ABST).
[0962] 19. 10% SDS.
[0963] Procedure:
[0964] 1. Coat Corning 96-well ELISA plates with 2 .mu.g of polyEY
peptide in sterile PBS as described in step 3 of Materials and
Reagents.
[0965] 2. Remove unbound liquid from wells by inverting plate. Wash
once with TBST. Pat the plate on a paper towel to remove excess
liquid.
[0966] 3. Add 100 .mu.l of 1% BSA in PBS to each well. Incubate,
with shaking, for 1 hr. at room temperature.
[0967] 4. Repeat step 2.
[0968] 5. Soak wells with 50 mM HEPES (pH 7.5) (150
.mu.l/well).
[0969] 6. Dilute test compound with dH.sub.2O/4% DMSO to 4 times
the desired final assay concentration in 96-well polypropylene
plates.
[0970] 7. Add 25 .mu.l diluted test compound to ELISA plate. In
control wells, place 25 .mu.l of dH.sub.2O/4% DMSO.
[0971] 8. Add 25 .mu.l of 40 mM MnCl.sub.2 with 4.times.ATP (2
.mu.M) to each well.
[0972] 9. Add 25 .mu.l 0.5M EDTA to negative control wells.
[0973] 10. Dilute GST-Flk1 to 0.005 .mu.g (5 ng)/well with KDB.
[0974] 11. Add 50 .mu.l of diluted enzyme to each well.
[0975] 12. Incubate, with shaking, for 15 minutes at room
temperature.
[0976] 13. Stop reaction by adding 50 .mu.l of 250 mM EDTA (pH
8.0).
[0977] 14. Wash 3.times. with TBST and pat plate on paper towel to
remove excess liquid.
[0978] 15. Add 100 .mu.l per well anti-phosphotyrosine HRP
conjugate, 1:5,000 dilution in antibody dilution buffer. Incubate,
with shaking, for 90 min. at room temperature.
[0979] 16. Wash as in step 14.
[0980] 17. Add 100 .mu.l of room temperature ABTS solution to each
well.
[0981] 18. Incubate, with shaking, for 10 to 15 minutes. Remove any
bubbles.
[0982] 19. Stop reaction by adding 20 .mu.l of 10% SDS to each
well.
[0983] 20. Read results on Dynatech MR7000 ELISA reader with test
filter at 410 nM and reference filter at 630 nM.
[0984] PYK2 Bioassay
[0985] This assay is used to measure the in vitro kinase activity
of HA epitope-tagged full length pyk2 (FL.pyk2-HA) in an ELISA
assay.
[0986] Materials and Reagents:
[0987] 1. Corning 96-well Elisa plates.
[0988] 2. 12CA5 monoclonal anti-HA antibody (SUGEN, Inc.)
[0989] 3. PBS (Dulbecco's Phosphate-Buffered Saline (Gibco Catalog
# 450-1300EB)
[0990] 4. TBST Buffer: for 1 L, mix 8.766 g NaCl, 6.057 g TRIS and
1 ml of 0.1% Triton X-100 in approx. 900 ml dH.sub.2O. Adjust pH to
7.2, bring volume to 1 L.
[0991] 5. Blocking Buffer: for 1 L, mix 100 g 10% BSA, 12.1 g 100
mM TRIS, 58.44 g 1M NaCl and 10 mL of 1% TWEEN 20.
[0992] 6. FL.pyk2-HA from sf9 cell lysates (SUGEN, Inc.).
[0993] 7. 4% DMSO in MilliQue H.sub.2O.
[0994] 8. 10 mM ATP in dH.sub.2O.
[0995] 9. 1M MnCl.sub.2.
[0996] 10. 1M MgCl.sub.2.
[0997] 11. 1M Dithiothreitol (DTT).
[0998] 12. 10.times. Kinase buffer phosphorylation: mix 5.0 ml 1M
Hepes (pH 7.5), 0.2 ml 1M MnCl.sub.2, 1.0 ml 1 M MgCl.sub.2, 1.0 ml
10% Triton X-100 in 2.8 ml dH.sub.2O. Just prior to use, add 0.1 ml
1M DTT.
[0999] 13. NUNC 96-well V bottom polypropylene plates.
[1000] 14. 500 mM EDTA in dH.sub.2O.
[1001] 15. Antibody dilution buffer: for 100 mL, 1 mL 5% BSA/PBS
and 1 mL 10% Tween-20 in 88 mL TBS.
[1002] 16. HRP-conjugated anti-Ptyr PY99), Santa Cruz Biotech Cat.
No. SC-7020.
[1003] 17. ABTS, Moss, Cat. No. ABST-2000.
[1004] 18. 10% SDS.
[1005] Procedure:
[1006] 1. Coat Corning 96 well ELISA plates with 0.5 .mu.g per well
12CA5 anti-HA antibody in 100 .mu.l PBS. Store overnight at
4.degree. C.
[1007] 2. Remove unbound HA antibody from wells by inverting plate.
Wash plate with dH.sub.2O. Pat the plate on a paper towel to remove
excess liquid.
[1008] 3. Add 150 .mu.l Blocking Buffer to each well. Incubate,
with shaking, for 30 min at room temperature.
[1009] 4. Wash plate 4.times. with TBS-T.
[1010] 5. Dilute lysate in PBS (1.5 .mu.g lysate/100 .mu.l
PBS).
[1011] 6. Add 100 .mu.l of diluted lysate to each well. Shake at
room temperature for 1 hr.
[1012] 7. Wash as in step 4.
[1013] 8. Add 50 .mu.l of 2.times. kinase Buffer to ELISA plate
containing captured pyk2-HA.
[1014] 9. Add 25 .mu.L of 400 .mu.M test compound in 4% DMSO to
each well. For control wells use 4% DMSO alone.
[1015] 10. Add 25 .mu.L of 0.5 M EDTA to negative control
wells.
[1016] 11. Add 25 .mu.l of 20 .mu.M ATP to all wells. Incubate,
with shaking, for 10 minutes.
[1017] 12. Stop reaction by adding 25 .mu.l 500 mM EDTA (pH 8.0) to
all wells.
[1018] 13. Wash as in step 4.
[1019] 14. Add 100 .mu.L HRP conjugated anti-Ptyr diluted 1:6000 in
Antibody Dilution Buffer to each well. Incubate, with shaking, for
1 hr. at room temperature.
[1020] 15. Wash plate 3.times. with TBST and 1.times. with PBS.
[1021] 16. Add 100 .mu.L of ABST solution to each well.
[1022] 17. If necessary, stop the development reaction by adding 20
.mu.L 10% SDS to each well.
[1023] 18. Read plate on ELISA-reader with test filter at 410 nM
and reference filter at 630 nM.
[1024] FGER1 Bioassay
[1025] This assay is used to measure the in vitro kinase activity
of FGF1-R in an ELISA assay.
[1026] Materials and Reagents:
[1027] 1. Costar 96-well Elisa plates (Corning Catalog # 3369).
[1028] 2. Poly(Glu-Tyr) (Sigma Catalog # PO275).
[1029] 3. PBS (Gibco Catalog # 450-1300EB)
[1030] 4. 50 mM Hepes Buffer Solution.
[1031] 5. Blocking Buffer (5% BSA/PBS).
[1032] 6. Purified GST-FGFR1 (SUGEN, Inc.)
[1033] 7. Kinase Dilution Buffer.
[1034] Mix 500 .mu.l 1M Hepes (GIBCO), 20 .mu.l 5% BSA/PBS, 10
.mu.l 100 mM sodium orthovanadate and 50 .mu.l 5M NaCl.
[1035] 8. 10 mM ATP
[1036] 9. ATP/MnCl.sub.2 phosphorylation mix: mix 20 .mu.L ATP, 400
.mu.L 1M MnCl.sub.2 and 9.56 ml dH.sub.2O.
[1037] 10. NUNC 96-well V bottom polypropylene plates (Applied
Scientific Catalog # AS-72092).
[1038] 11. 0.5M EDTA.
[1039] 12. 0.05% TBST
[1040] Add 500 mL TWEEN to 1 liter TBS.
[1041] 13. Rabbit polyclonal anti-phosphotyrosine serum (SUGEN,
Inc.).
[1042] 14. Goat anti-rabbit IgG peroxidase conjugate (Biosource,
Catalog # ALI0404)
[1043] 15. ABTS Solution.
[1044] 16. ABTS/H.sub.2O.sub.2 solution.
[1045] Procedure:
[1046] 1. Coat Costar 96 well ELISA plates with 1 .mu.g per well
Poly(Glu,Tyr) in 100 .mu.l PBS. Store overnight at 4.degree. C.
[1047] 2. Wash coated plates once with PBS.
[1048] 3. Add 150 .mu.L of 5% BSA/PBS Blocking Buffer to each well.
Incubate, with shaking, for 1 hr. room temperature.
[1049] 4. Wash plate 2.times. with PBS, then once with 50 mM Hepes.
Pat plates on a paper towel to remove excess liquid and
bubbles.
[1050] 5. Add 25 .mu.L of 0.4 mM test compound in 4% DMSO or 4%
DMSO alone (controls) to plate.
[1051] 6. Dilute purified GST-FGFR1 in Kinase Dilution Buffer (5 ng
kinase/50 ul KDB/well).
[1052] 7. Add 50 .mu.L of diluted kinase to each well.
[1053] 8. Start kinase reaction by adding 25 .mu.l/well of freshly
prepared ATP/Mn++ (0.4 ml 1M MnCl.sub.2, 40 .mu.L 10 mM ATP, 9.56
ml dH.sub.2O), freshly prepared).
[1054] 9. This is a fast kinase reaction and must be stopped with
25 .mu.L of 0.5M EDTA in a manner similar to the addition of
ATP.
[1055] 10. Wash plate 4.times. with fresh TBST.
[1056] 11. Make up Antibody Dilution Buffer: Per 50 ml:
[1057] Mix 5 ml of 5% BSA, 0.250 .mu.l of 5% milk and 50 .mu.l of
100 mM sodium vanadate, bring to final volume with 0.05% TBST.
[1058] 12. Add 100 .mu.l per well of anti-phosphotyrosine (1:10000
dilution in ADB). Incubate, with shaking for 1 hr. at room
temperature.
[1059] 13. Wash as in step 10.
[1060] 14. Add 100 .mu.l per well of Biosource Goat anti-rabbit IgG
peroxidase conjugate (1:6000 dilution in ADB). Incubate, with
shaking for 1 hr. at room temperature.
[1061] 15. Wash as in step 10 and then with PBS to remove bubbles
and excess TWEEN.
[1062] 16. Add 100 .mu.l of ABTS/H.sub.2O.sub.2 solution to each
well.
[1063] 17. Incubate, with shaking, for 10 to 20 minutes. Remove any
bubbles.
[1064] 18. Read assay on Dynatech MR7000 elisa reader: test filter
at 410 nM, reference filtrate 630 nM.
[1065] EGFR Bioassay
[1066] This assay is used to the in vitro kinase activity of FGF1-R
in an ELISA assay.
[1067] Materials and Reagents:
[1068] 1. Corning 96-well Elisa plates.
[1069] 2. SUMO1monoclonal anti-EGFR antibody (SUGEN Inc.).
[1070] 3. PBS
[1071] 4. TBST Buffer
[1072] 5. Blocking Buffer: for 100 ml, mix 5.0 g Carnation Instant
Non-fat Milk.RTM. with 100 ml of PBS.
[1073] 6. A431 cell lysate (SUGEN, Inc.)
[1074] 7. TBS Buffer:
[1075] 8. TBS+10% DMSO: for 1L, mix 1.514 g TRIS, 2.192 g NaCl and
25 ml DMSO; bring to 1 liter total volume with dH.sub.2O.
[1076] 9. ATP (Adenosine-5'-triphosphate, from Equine muscle, Sigma
Cat. No. A-5394), 1.0 nM solution in dH.sub.2O. This reagent should
be made up immediately prior to use and kept on ice.
[1077] 10. 1.0 mM MnCl.sub.2.
[1078] 11. ATP/MnCl.sub.2 Phosphorylation mix: to make 10 ml, mix
300 .mu.l of 1 mM ATP, 500 .mu.l MnCl.sub.2 and 9.2 ml dH.sub.2O.
Prepare just prior to use, keep on ice.
[1079] 12. NUNC 96-well V bottom polypropylene plates.
[1080] 13. EDTA.
[1081] 14. Rabbit polyclonal anti-phosphotyrosine serum (SUGEN,
Inc.).
[1082] 15. Goat anti-rabbit IgG peroxidase conjugate (Biosource
Cat. No. ALI0404).
[1083] 16. ABTS.
[1084] 17. 30% Hydrogen peroxide.
[1085] 18. ABTS/H.sub.2O.sub.2.
[1086] 19. 0.2 M HCl.
[1087] Procedure:
[1088] 1. Coat Corning 96 well ELISA plates with 0.5 .mu.g SUMO1 in
100 .mu.l PBS per well, store overnight at 4.degree. C.
[1089] 2. Remove unbound SUMO1 from wells by inverting plate to
remove liquid. Wash 1.times. with dH.sub.2O. Pat the plate on a
paper towel to remove excess liquid.
[1090] 3. Add 150 .mu.l of Blocking Buffer to each well. Incubate,
with shaking, for 30 min. at room temperature.
[1091] 4. Wash plate 3.times. with deionized water, then once with
TBST. Pat plate on a paper towel to remove excess liquid and
bubbles.
[1092] 5. Dilute lysate in PBS (7 .mu.g lysate/100 .mu.l PBS).
[1093] 6. Add 100 .mu.l of diluted lysate to each well. Shake at
room temperature for 1 hr.
[1094] 7. Wash plates as in 4, above.
[1095] 8. Add 120 .mu.l TBS to ELISA plate containing captured
EGFR.
[1096] 9. Dilute test compound 1:10 in TBS, place in well
[1097] 10. Add 13.5 .mu.l diluted test compound to ELISA plate. To
control wells, add 13.5 .mu.l TBS in 10% DMSO.
[1098] 11. Incubate, with shaking, for 30 minutes at room
temperature.
[1099] 12. Add 15 .mu.l phosphorylation mix to all wells except
negative control well. Final well volume should be approximately
150 .mu.l with 3 .mu.M ATP/5 mM MnCl.sub.2 final concentration in
each well. Incubate with shaking for 5 minutes.
[1100] 13. Stop reaction by adding 16.5 .mu.l of EDTA solution
while shaking. Shake for additional 1 min.
[1101] 14. Wash 4.times. with deionized water, 2.times. with
TBST.
[1102] 15 Add 100 .mu.l anti-phosphotyrosine (1:3000 dilution in
TBST) per well. Incubate, with shaking, for 30-45 min. at room
temperature.
[1103] 16. Wash as in 4, above.
[1104] 17. Add 100 .mu.l Biosource Goat anti-rabbit IgG peroxidase
conjugate (1:2000 dilution in TBST) to each well. Incubate with
shaking for 30 min. at room temperature.
[1105] 18. Wash as in 4, above.
[1106] 19. Add 100 .mu.l of ABTS/H.sub.2O.sub.2 solution to each
well.
[1107] 20. Incubate 5 to 10 minutes with shaking. Remove any
bubbles.
[1108] 21. If necessary, stop reaction by adding 100 .mu.l 0.2 M
HCl per well.
[1109] 22. Read assay on Dynatech MR7000 ELISA reader: test filter
at 410 nM, reference filter at 630 nM.
[1110] PDGFR Bioassay
[1111] This assay is used to the in vitro kinase activity of FGF1-R
in an ELISA assay.
[1112] Materials and Reagents:
[1113] 1. Corning-96-well Elisa plates
[1114] 2. 28D4C10 monoclonal anti-PDGFR antibody (SUGEN, Inc.).
[1115] 3. PBS.
[1116] 4. TBST Buffer.
[1117] 5. Blocking Buffer (same as for EGFR bioassay).
[1118] 6. PDGFR-.beta. expressing NIH 3T3 cell lysate (SUGEN,
Inc.).
[1119] 7. TBS Buffer.
[1120] 8. TBS+10% DMSO.
[1121] 9. ATP.
[1122] 10. MnCl.sub.2.
[1123] 11. Kinase buffer phosphorylation mix: for 10 ml, mix 250
.mu.l 1M TRIS, 200 .mu.l 5M NaCl, 100 .mu.l 1M MnCl.sub.2 and 50
.mu.l 100 mM Triton X-100 in enough dH.sub.2O to make 10 ml.
[1124] 12. NUNC 96-well V bottom polypropylene plates.
[1125] 13. EDTA.
[1126] 14. Rabbit polyclonal anti-phosphotyrosine serum (SUGEN,
Inc.).
[1127] 15. Goat anti-rabbit IgG peroxidase conjugate (Biosource
Cat. No. ALI0404).
[1128] 16. ABTS.
[1129] 17. Hydrogen peroxide, 30% solution.
[1130] 18. ABTS/H.sub.2O.sub.2.
[1131] 19. 0.2 M HCl.
[1132] Procedure:
[1133] 1. Coat Corning 96 well ELISA plates with 0.5 .mu.g. 28D4C10
in 100 .mu.l PBS per well, store overnight at 4.degree. C.
[1134] 2. Remove unbound 28D4C10 from wells by inverting plate to
remove liquid. Wash 1.times. with dH.sub.2O. Pat the plate on a
paper towel to remove excess liquid.
[1135] 3. Add 150 .mu.l of Blocking Buffer to each well. Incubate
for 30 min. at room temperature with shaking.
[1136] 4. Wash plate 3.times. with deionized water, then once with
TBST. Pat plate on a paper towel to remove excess liquid and
bubbles.
[1137] 5. Dilute lysate in HNTG (10 .mu.g lysate/100 .mu.l
HNTG).
[1138] 6. Add 100 .mu.l of diluted lysate to each well. Shake at
room temperature for 60 min.
[1139] 7. Wash plates as described in Step 4.
[1140] 8. Add 80 .mu.l working kinase buffer mix to ELISA plate
containing captured PDGFR.
[1141] 9. Dilute test compound 1:10 in TBS in 96-well polypropylene
plates.
[1142] 10. Add 10 .mu.l diluted test compound to ELISA plate. To
control wells, add 10 .mu.l TBS+10% DMSO. Incubate with shaking for
30 minutes at room temperature.
[1143] 11. Add 10 .mu.l ATP directly to all wells except negative
control well (final well volume should be approximately 100 .mu.l
with 20 .mu.M ATP in each well.) Incubate 30 minutes with
shaking.
[1144] 12. Stop reaction by adding 10 .mu.l of EDTA solution to
each well.
[1145] 13. Wash 4.times. with deionized water, twice with TBST.
[1146] 14. Add 100 .mu.l anti-phosphotyrosine (1:3000 dilution in
TBST) per well. Incubate with shaking for 30-45 min. at room
temperature.
[1147] 15. Wash as in Step 4.
[1148] 16. Add 100 .mu.l Biosource Goat anti-rabbit IgG peroxidase
conjugate (1:2000 dilution in TBST) to each well. Incubate with
shaking for 30 min. at room temperature.
[1149] 17. Wash as in Step 4.
[1150] 18. Add 100 .mu.l of ABTS/H.sub.2O.sub.2 solution to each
well.
[1151] 19. Incubate 10 to 30 minutes with shaking. Remove any
bubbles.
[1152] 20. If necessary stop reaction with the addition of 100
.mu.l 0.2 M HCl per well.
[1153] 21. Read assay on Dynatech MR7000 ELISA reader with test
filter at 410 nM and reference filter at 630 nM.
[1154] Cellular HER-2 Kinase Assay
[1155] This assay is used to measure HER-2 kinase activity in whole
cells in an ELISA format.
[1156] Materials and Reagents:
[1157] 1. DMEM (GIBCO Catalog #11965-092).
[1158] 2. Fetal Bovine Serum (FBS, GIBCO Catalog #16000-044), heat
inactivated in a water bath for 30 min. at 56.degree. C.
[1159] 3. Trypsin (GIBCO Catalog #25200-056).
[1160] 4. L-Glutamine (GIBCO Catalog #25030-081);
[1161] 5. HEPES (GIBCO Catalog #15630-080).
[1162] 6. Growth Media
[1163] Mix 500 ml DMEM, 55 ml heat inactivated FBS, 10 ml HEPES and
5.5 ml L-Glutamine.
[1164] 7. Starve Media
[1165] Mix 500 ml DMEM, 2.5 ml heat inactivated FBS, 10 ml HEPES
and 5.5 ml L-Glutamine.
[1166] 8. PBS.
[1167] 9. Flat Bottom 96-well Tissue Culture Micro Titer Plates
(Corning Catalog # 25860).
[1168] 10. 15 cm Tissue Culture Dishes (Corning Catalog
#08757148).
[1169] 11. Corning 96-well ELISA Plates.
[1170] 12. NUNC 96-well V bottom polypropylene plates.
[1171] 13. Costar-Transfer Cartridges for the Transtar 96 (Costar
Catalog. #7610).
[1172] 14. SUMO 1: monoclonal anti-EGFR antibody (SUGEN, Inc.)
[1173] 15. TBST Buffer.
[1174] 16. Blocking Buffer: 5% Carnation Instant Milk.RTM. in
PBS.
[1175] 17. EGF Ligand: EGF-201, Shinko American, Japan. Suspend
powder in 100 uL of 10 mM HCl. Add 100 uL 10 mM NaOH. Add 800 uL
PBS and transfer to an Eppendorf tube, store at -20.degree. C.
until ray to use.
[1176] 18. HNTG Lysis Buffer
[1177] For Stock 5.times.HNTG, mix 23.83 g Hepes, 43.83 g NaCl, 500
ml glycerol and 100 ml Triton X-100 and enough dH.sub.2O to make 1
L of total solution.
[1178] For 1.times.HNTG*, mix 2 ml HNTG, 100 .mu.L 0.1M
Na.sub.3VO.sub.4, 250 .mu.L 0.2M Na.sub.4P.sub.2O.sub.7 and 100
.mu.L EDTA.
[1179] 19. EDTA.
[1180] 20. Na.sub.3VO.sub.4. To make stock solution, mix 0.84 g
Na.sub.3VO.sub.4 with 90 ml dH.sub.2O. Adjust pH to 10. Boil in
microwave for one minute (solution becomes clear). Cool to room
temperature. Adjust pH to 10. Repeat heating/cooling cycle until pH
remains at 10.
[1181] 21. 200 mM Na.sub.4P.sub.2O.sub.7.
[1182] 22. Rabbit polyclonal antiserum specific for phosphotyrosine
(anti-Ptyr antibody SUGEN, Inc).
[1183] 23. Affinity purified antiserum, goat anti-rabbit IgG
antibody, peroxidase conjugate (Biosource Cat# ALI0404).
[1184] 24. ABTS Solution.
[1185] 25. 30% Hydrogen peroxide solution.
[1186] 26. ABTS/H.sub.2O.sub.2.
[1187] 27. 0.2 M HCl.
[1188] Procedure:
[1189] 1. Coat Corning 96 well ELISA plates with SUMO1 at 1.0 ug
per well in PBS, 100 ul final volume/well. Store overnight at
4.degree. C.
[1190] 2. on day of use, remove coating buffer and wash plate 3
times with dH.sub.2O and once with TBST buffer. All washes in this
assay should be done in this manner, unless otherwise
specified.
[1191] 3. Add 100 ul of Blocking Buffer to each well. Incubate
plate, with shaking, for 30 min. at room temperature. Just prior to
use, wash plate.
[1192] 4. Use EGFr/HER-2 chimera/3T3-C7 cell, line for this
assay.
[1193] 5. Choose dishes having 80-90% confluence. Collect cells by
trypsinization and centrifuge at 1000 rpm at room temperature for 5
min.
[1194] 6. Resuspend cells in starve medium and count with trypan
blue. Viability above 90% is required. Seed cells in starve medium
at a density of 2,500 cells, per well, 90 ul per well, in a 96 well
microtiter plate. Incubate seeded cells overnight at 37.degree.
under 5% CO.sub.2.
[1195] 7. Start the assay two days after seeding.
[1196] 8. Test compounds are dissolved in 4% DMSO. Samples are then
further diluted directly on plates with starve-DMEM. Typically,
this dilution will be 1:10 or greater. All wells are then
transferred to the cell plate at a further 1:10 dilution (10 .mu.l
sample and media into 90 .mu.l of starve media. The final DMSO
concentration should be 1% or lower. A standard serial dilution may
also be used.
[1197] 9. Incubate under 5% CO.sub.2 at 37.degree. C. for 2
hours.
[1198] 10. Prepare EGF ligand by diluting stock EGF (16.5 uM) in
warm DMEM to 150 nM.
[1199] 11. Prepare fresh HNTG* sufficient for 100 ul per well place
on ice.
[1200] 12. After 2 hour incubation with test compound, add prepared
EGF-ligand to cells, 50 ul per well, for a final concentration of
50 nM. Positive control wells receive the same amount of EGF.
Negative controls do not receive EGF. Incubate at 37.degree. C. for
10 min.
[1201] 13. Remove test compound, EGF, and DMEM. Wash cells once
with PBS.
[1202] 14. Transfer HNTG* to cells, 100 ul per well. Place on ice
for 5 minutes. Meanwhile, remove blocking buffer from ELISA plate
and wash.
[1203] 15. Scrape cells from plate with a micropipettor and
homogenize cell material by repeatedly aspirating and dispensing
the HNTG* lysis buffer. Transfer lysate to a coated, blocked,
washed ELISA plate. Or, use a Costar transfer cartridge to transfer
lysate to thee plate.
[1204] 16. Incubate, with shaking, at room temperature for 1
hr.
[1205] 17. Remove lysate, wash. Transfer freshly diluted anti-Ptyr
antibody (1:3000 in TBST) to ELISA plate, 100 ul per well.
[1206] 18. Incubate, with shaking, at room temperature, for 30
min.
[1207] 19. Remove anti-Ptyr antibody, wash. Transfer freshly
diluted BIOSOURCE antibody to ELISA plate (1:8000 in TBST, 100 ul
per well).
[1208] 20. Incubate, with shaking, at room temperature for 30
min.
[1209] 21. Remove BIOSOURCE antibody wash. Transfer freshly
prepared ABTS/H.sub.2O.sub.2Solution to ELISA plate, 100 ul per
well.
[1210] 22. Incubate, with shaking, or 51 minutes. Remove any
bubbles.
[1211] 23. Stop reaction with the addition of 100 ul of 0.2M HCl
per well.
[1212] 24. Read assay on Dynatech MR7000 ELISA reader with test
filter set at 410 nM and reference filter at 630 nM.
[1213] CDK2/Cyclin A Assay
[1214] This assay is used to measure the in vitro serine/threonine
kinase activity of human cdk2/cyclin A in a Scintillation Proximity
Assay (SPA).
[1215] Materials and Reagents.
[1216] 1. Wallac 96-well polyethylene terephthalate (flexi) plates
(Wallac Catalog #1450-401).
[1217] 2. Amersham Redivue [.gamma..sup.33P] ATP (Amersham catalog
#AH 9968).
[1218] 3. Amersham streptavidin coated polyvinyltoluene SPA beads
(Amersham catalog #RPNQ0007). The beads should be reconstituted in
PBS without magnesium or calcium, at 20 mg/ml.
[1219] 4. Activated cdk2/cyclin A enzyme complex purified from Sf9
cells (SUGEN, Inc.).
[1220] 5. Biotinylated peptide substrate (Debtide). Peptide
biotin-X-PKTPKKAKKL is dissolved in dH.sub.2O at a concentration of
5 mg/ml.
[1221] 6. Peptide/ATP Mixture: for 10 ml, mix 9.979 ml dH.sub.2O,
0.0015 ml "cold" ATP, 0.010 ml Debtide and 0.010 ml .gamma..sup.33P
ATP. The ultimate, concentration per well will be 0.5 .mu.M "cold"
ATP, 0.1 .mu.g Debtide and 0.2 .mu.Ci .gamma..sup.33P ATP.
[1222] 7. Kinase buffer: for 10 ml, mix 8.85 ml dH.sub.2O, 0.625 ml
TRIS (pH 7.4), 0.25 ml 1M MgCl, 0.25 ml 10% NP40 and 0.025 ml 1M
DTT, added fresh just prior to use.
[1223] 8. 10 mM ATP in dH.sub.2O.
[1224] 9. 1M Tris, pH adjusted to 7.4 with HCl.
[1225] 10. 1M MgCl.sub.2.
[1226] 11. 1M DTT.
[1227] 12. PBS (Gibco Catalog #14190-144).
[1228] 13. 0.5M EDTA.
[1229] 14. Stop solution: For 10 ml, mix 9.25 ml PBS, 0.005 ml 100
mM ATP, 0.1 ml 0.5 M EDTA, 0.1 ml 10% Triton X-100 and 1.25 ml of
20 mg/ml SPA beads.
[1230] Procedure:
[1231] 1. Prepare solutions of test compounds at 5.times. the
desired final concentration in 5% DMSO. Add 10 ul to each well. For
negative controls, use 10 ul 5% DMSO alone in wells.
[1232] 2. Dilute 5 .mu.l of cdk2/cyclin A solution with 2.1 ml
2.times. kinase buffer.
[1233] 3. Add 20 ul enzyme to each well.
[1234] 4. Add 10 .mu.L of 0.5 M EDTA to the negative control
wells.
[1235] 5. To start kinase reaction, add 20 .mu.L of peptide/ATP
mixture to each well. Incubate for 1 hr. without shaking.
[1236] 6. Add 200 .mu.l stop solution to each well.
[1237] 7. Hold at least 10 min.
[1238] 8. Spin plate at approx. 2300 rpm for 3-5 min.
[1239] 9. Count plate using Trilux or similar reader.
[1240] Met Transphosphorylation Assay
[1241] This assay is used to measure phosphotyrosine levels on a
poly(glutamic acid:tyrosine (4:1)) substrate as a means for
identifying agonists/antagonists of met transphosphorylation of the
substrate.
[1242] Materials and Reagents:
[1243] 1. Corning 96-well Elisa plates, Corning Catalog #
25805-96.
[1244] 2. Poly(glu, tyr) 4:1, Sigma; Cat; No; P 0275.
[1245] 3. PBS, Gibco Catalog # 450-1300EB
[1246] 4. 50 mM HEPES
[1247] 5. Blocking Buffer: Dissolve 25 g Bovine Serum Albumin,
Sigma Cat. No A-7888, in 500 ml PBS, filter through a 4 .mu.m
filter.
[1248] 6. Purified GST fusion protein containing the Met kinase
domain, Sugen, Inc.
[1249] 7. TBST Buffer.
[1250] 8. 10% aqueous (MilliQue H.sub.2O) DMSO.
[1251] 9. 10 mM aqueous (dH.sub.2O) Adenosine-5'-triphosphate,
Sigma Cat. No. A-5394.
[1252] 10. 2.times. Kinase Dilution Buffer: for 100 ml, mix 10 mL
1M HEPES at pH 7.5 with 0.4 mL 5% BSA/PBS, 0.2 mL 0.1 M sodium
orthovanadate and 1 mL 5M sodium chloride in 88.4 mL dH.sub.2O.
[1253] 11. 4.times. ATP Reaction Mixture: for 10 mL, mix 0.4 mL 1 M
manganese chloride and 0.02 mL 0.1 M ATP in 9.56 mL
[1254] 12. 4.times. Negative Controls Mixture: for 10 mL, mix 0.4
mL 1 M manganese chloride in 9.6 mL dH.sub.2O.
[1255] 13. NUNC 96-well V bottom polypropylene plates, Applied
Scientific Catalog # S-72092
[1256] 14. 500 mM EDTA.
[1257] 15. Antibody Dilution Buffer: for 100 mL, mix 10 mL 5%
BSA/PBS, 0.5 mL 5% Carnation Instant Milk.RTM. in PBS and 0.1 mL
0.1 M sodium orthovanadate in 88.4 mL TBST.
[1258] 16. Rabbit polyclonal antophosphotyrosine antibody, Sugen,
Inc.
[1259] 17. Goat anti-rabbit horseradish peroxidase conjugated
antibody, Biosource, Inc.
[1260] 18. ABTS Solution: for 1 L, mix 19.21 g citric acid, 35.49 g
Na.sub.2HPO.sub.4 and 500 mg ABTS with sufficient dH.sub.2O to make
1 L.
[1261] 19. ABTS/H.sub.2O.sub.2: mix 15 mL ABST solution with 2
.mu.L H.sub.2O.sub.2 five minutes before use.
[1262] 20. 0.2 M HCl
[1263] Procedure:
[1264] 1. Coat ELISA plates with 2 .mu.g Poly(Glu-Tyr) in 100 .mu.L
PBS, store overnight at 4.degree. C.
[1265] 2. Block plate with 150 .mu.L of 5% BSA/PBS for 60 min.
[1266] 3. Wash plate twice with PBS, once with 50 mM Hepes buffer
pH 7.40.
[1267] 4. Add 50 .mu.l of the diluted kinase to all wells.
(Purified kinase is diluted with Kinase Dilution Buffer. Final
concentration should be 10 ng/well.)
[1268] 5. Add 25 .mu.L of the test compound (in 4% DMSO) or DMSO
alone (4% in dH.sub.2O) for controls to plate.
[1269] 6. Incubate the kinase/compound mixture for 15 minutes.
[1270] 7. Add 25 .mu.L of 40 mM MnCl.sub.2 to the negative control
wells.
[1271] 8. Add 25 .mu.L ATP/MnCl.sub.2 mixture to the all other
wells (except the negative controls). Incubate for 5 min.
[1272] 9. Add 25 .mu.L 500 mM EDTA to stop reaction.
[1273] 10. Wash plate 3.times. with TBST.
[1274] 11. Add 100 .mu.L rabbit polyclonal anti-Ptyr diluted
1:10,000 in Antibody Dilution Buffer to each well. Incubate, with
shaking, at room temperature forgone hour.
[1275] 12. Wash plate 3.times. with TBST.
[1276] 13. Dilute Biosource HRP conjugated anti-rabbit antibody
1:6,000 in Antibody Dilution buffer. Add 100 .mu.L per well and
incubate at room temperature, with shaking, for one hour.
[1277] 14. Wash plate 1.times. with PBS.
[1278] 15. Add 100 .mu.l of ABTS/H.sub.2O.sub.2 solution to each
well.
[1279] 16. If necessary, stop the development reaction with the
addition of 100 .mu.l of 0.2M HCl per well.
[1280] 17. Read plate on Dynatech MR7000 elisa reader with the test
filter at 410 nM and the reference filter at 630 nM.
[1281] IGF-1 Transphosphorylation Assay
[1282] This assay is used to measure the phosphotyrosine level in
poly(glutamic acid:tyrosine)(4:1) for the identification of
agonists/antagonists of gst-IGF-1 transphosphorylation of a
substrate.
[1283] Materials and Reagents:
[1284] 1. Corning 96-well Elisa plates.
[1285] 2. Poly (Glu-tyr) (4:1), Sigma Cat. No. P 0275.
[1286] 3. PBS, Gibco Catalog # 450-1300EB.
[1287] 4. 50 mM HEPES
[1288] 5. TBB Blocking Buffer: for 1 L, mix 100 g BSA, 12.1 gTRIS
(pH 7.5), 58.44 g sodium chloride and 10 mL 1% TWEEN-20.
[1289] 6. Purified GST fusion protein containing the IGF-1 kinase
domain (Sugen, Inc.)
[1290] 7. TBST Buffer: for 1 L, mix 6.057 g Tris, 8.766 g sodium
chloride and 0.5 ml TWEEN-20 with enough dH.sub.2O to make 1
liter.
[1291] 8. 4% DMSO in Milli-Q H.sub.2O.
[1292] 9. 10 mM ATP in dH.sub.2O.
[1293] 10. 2.times. Kinase Dilution Buffer: for 100 mL, mix 10 mL 1
M HEPES (pH 7.5), 0.4 mL 5% BSA in dH.sub.2O, 0.2 mL 0.1 M sodium
orthovanadate and 1 mL 5 M sodium chloride with enough dH.sub.2O to
make 100 mL.
[1294] 11. 4.times. ATP Reaction Mixture: for 10 mL, mix 0.4 mL 1 M
MnCl.sub.2 and 0.008 mL 0.01 M ATP and 9.56 mL dH.sub.2O.
[1295] 12. 4.times. Negative Controls Mixture: mix 0.4 mL 1 M
manganese chloride in 9.60 mL dH.sub.2O.
[1296] 13. NUNC 96-well V bottom polypropylene plates.
[1297] 14. 500 mM EDTA in dH.sub.2O.
[1298] 15. Antibody Dilution Buffer: for 100 mL, mix 10 mL 5% BSA
in PBS, 0.5 mL 5% Carnation Instant Non-fat Milk.RTM. in PBS and
0.1 mL 0.1 M sodium orthovanadate in 88.4 mL TBST.
[1299] 16. Rabbit Polyclonal antiphosphotyrosine antibody, Sugen,
Inc.
[1300] 17. Goat anti-rabbit HRP conjugated antibody, Biosource.
[1301] 18. ABTS Solution.
[1302] 20. ABTS/H.sub.2O.sub.2: mix 15 mL ABTS with 2 .mu.L
H.sub.2O.sub.2 5 minutes before using.
[1303] 21. 0.2 M HCl in dH.sub.2O.
[1304] Procedure:
[1305] 1. Coat ELISA plate with 2.0 .mu.g/well Poly(Glu, Tyr), 4:1
(Sigma P0275) in 100 .mu.l PBS. Store plate overnight at 4.degree.
C.
[1306] 2. ash plate once with PBS.
[1307] 3. Add 100 .mu.l of TBB Blocking Buffer to each well.
Incubate plate for 1 hour with shaking at room temperature.
[1308] 4. Wash plate once with PBS, then twice with 501 mM Hepes
buffer pH 7.5.
[1309] 5. Add 25 .mu.L of test compound in 4% DMSO (obtained by
diluting a stock solution of 10 mM test compound in 100% DMSO with
dH.sub.2O) to plate.
[1310] 6. Add 10.0 ng of gst-IGF-1 kinase in 50 .mu.l Kinase
Dilution Buffer) to all wells.
[1311] 7. Start kinase reaction by adding 25 .mu.l 4.times. ATP
Reaction Mixture to all test wells and positive controls wells. Add
25 .mu.l 4.times. Negative Controls Mixture to all negative control
wells. Incubates for 10 minutes with shaking at room
temperature.
[1312] 8. Add 25 .mu.l 0.5M EDTA (pH 8.0) to all wells.
[1313] 9. Wash plate 4.times. with TBST Buffer.
[1314] 10. Add rabbit polyclonal anti-phosphotyrosine antisera at a
dilution of 1:10,000 in 100 .mu.l Antibody Dilution Buffer to all
wells. Incubate, with shaking, at room temperature for 1 hour.
[1315] 11. Wash plate as in step 9.
[1316] 12. Add 100 .mu.L Biosource anti-rabbit HRP at a dilution of
1:10,000 in Antibody dilution buffer to all wells. Incubate, with
shaking, at room temperature for 1 hour.
[1317] 13. Wash plate as in step 9, follow with one wash with PBS
to reduce bubbles and excess Tween-20.
[1318] 14. Develop by adding 100 .mu.l/well ABTS/H.sub.2O.sub.2 to
each well.
[1319] 15. After about 5 minutes, read on ELISA reader with test
filter at 410 nm and referenced filter at 630 nm.
[1320] BrdU Incorporation Assays
[1321] The following assays use cells engineered to express a
selected receptor and then evaluate the effect of a compound of
interest on the activity of ligand-induced DNA synthesis by
determining BrdU incorporation into the DNA.
[1322] The following materials, reagents and procedure are general
to each of the following BrdU incorporation assays. Variances in
specific assays are noted.
[1323] Materials and Reagents:
[1324] 1. The appropriate ligand.
[1325] 2. The appropriate engineered cells.
[1326] 3. BrdU Labeling Reagent: 10 mM, in PBS (pH 7.4) (Boehringer
Mannheim, Germany).
[1327] 4. FixDenat: fixation solution (ready to use) (Boehringer
Mannheim, Germany).
[1328] 5. Anti-BrdU-POD: mouse monoclonal antibody conjugated with
peroxidase (Boehringer Mannheim, Germany).
[1329] 6. TMB Substrate Solution: tetramethylbenzidine (TMB,
Boehringer Mannheim, Germany).
[1330] 7. PBS Washing Solution: 1.times. PBS, pH 7.4.
[1331] 8. Albumin, Bovine (BSA), fraction V powder (Sigma Chemical
Co., USA).
[1332] General Procedure:
[1333] 1. Cells are seeded at 8000 cells/well in 10% CS, 2 mM Gln
in DMEM, in a 96 well plate. Cells are incubated overnight at
37.degree. C. in 5% CO.sub.2.
[1334] 2. After 24 hours, the cells are washed with PBS, and then
are serum-starved in serum free medium (0% CS DMEM with 0.1% BSA)
for 24 hours.
[1335] 3. On day 3, the appropriate ligand and the test compound
are added to the cells simultaneously. The negative control wells
receive serum free DMEM with 0.1% BSA only; the positive control
cells receive the ligand but no test compound. Test compounds are
prepared in serum free DMEM with ligand in a 96 well plate, and
serially diluted for 7 test concentrations.
[1336] 4. After 18 hours of ligand activation, diluted BrdU
labeling reagent (1:100 in DMEM, 0.1% BSA) is added and the cells
are incubated with BrdU (final concentration=10 .mu.M) for 1.5
hours.
[1337] 5. After incubation with labeling reagent, the medium is
removed by decanting and tapping the inverted plate on a paper
towel. FixDenat solution is added (50 .mu.l/well) and the plates
are incubated at room temperature for 45 minutes on a plate
shaker.
[1338] 6. The FixDenat solution is thoroughly removed by decanting
and tapping the inverted plate on a paper towel. Milk is added (5%
dehydrated milk in PBS, 200 .mu.l/well) as a blocking solution and
the plate is incubated for 30 minutes at room temperature on a
plate shaker.
[1339] 7. The blocking solution is removed by decanting and the
wells are washed once with PBS. Anti-BrdU-POD solution (1:200
dilution in PBS, 1% BSA) is added (50 .mu.l/well) and the plate is
incubated for 90 minutes at room temperature on a plate shaker.
[1340] 8. The antibody conjugate is thoroughly removed by decanting
and rinsing the wells 5 times with PBS, and the plate is dried by
inverting and tapping on a paper towel.
[1341] 9. TMB substrate solution is added (100 .mu.l/well) and
incubated for 20 minutes at room temperature on a plate shaker
until color development is sufficient for photometric
detection.
[1342] 10. The absorbance of the samples are measured at 410 nm (in
"dual wavelength" mode with a filter reading at 490 nm, as a
reference wavelength) on a Dynatech ELISA plate reader.
[1343] EGF-Induced BrdU Incorporation Assay
[1344] Materials and Reagents:
[1345] 1. Mouse EGF, 201 (Toyobo Co., Ltd., Japan).
[1346] 2. 3T3/EGFRc7.
[1347] EGF-Induced Her-2-Driven BrdU Incorporation Assay
[1348] Materials and Reagents:
[1349] 1. Mouse EGF, 201 (Toyobo Co., Ltd., Japan).
[1350] 2. 3T3/EGFr/Her2/EGFr (EGFr with a Her-2 kinase domain).
[1351] EGF-Induced Her-4-Driven BrdU Incorporation Assay
[1352] Materials and Reagents:
[1353] 1. Mouse EGF, 201 (Toyobo Co., Ltd., Japan).
[1354] 2. 3T3/EGFr/Her4/EGFr (EGFr with a Her-4 kinase domain).
[1355] PDGF-Induced BrdU Incorporation Assay
[1356] Materials and Reagents:
[1357] 1. Human PDGF B/B (Boehringer Mannheim, Germany).
[1358] 2. 3T3/EGFRc7.
[1359] FGF-Induced BrdU Incorporation Assay
[1360] Materials and Reagents:
[1361] 1. Human FGF2/bFGF (Gibco, BRL, USA).
[1362] 2. 3T3c7/EGFr
[1363] IGF1-Induced BrdU Incorporation Assay
[1364] Materials and Reagents:
[1365] 1. Human, recombinant F (G511, PromegaCorp., USA)
[1366] 2. 3T3/IGF1r.
[1367] Insulin-Induced BrdU Incorporation Assay
[1368] Materials and Reagents:
[1369] 1. Insulin, crystalline, bovine, Zinc (13007, Gibco BRL,
USA).
[1370] 2. 3T3/H25.
[1371] HGF-Induced BrdU Incorporation Assay
[1372] Materials and Reagents:
[1373] 1. Recombinant human HGF (Cat. No. 249-HG, R&D Systems,
Inc. USA).
[1374] 2. BxPC-3 cells (ATCC CRL-1687).
[1375] Procedure:
[1376] 1. Cells are seeded at 9000 cells/well in RPMI 10% FBS in a
96 well plate. Cells are incubated overnight at 37.degree. C. in 5%
CO.sub.2.
[1377] 2. After 24 hours, the cells are washed with PBS, and then
are serum starved in 100 .mu.l serum-free medium (RPMI with 0.1%
BSA) for 24 hours.
[1378] 3. On day 3, 25 .mu.l containing ligand (prepared at 0.1
.mu.g/ml in RPMI with 0.1% BSA; final HGF conc. is 200 ng/ml) and
test compounds are added to the cells. The negative control wells
receive 25 .mu.l serum-free RPMI with 0.1% BSA only; the positive
control cells receive the ligand (HGF) but no test compound. Test
compounds are prepared at 5 times their final concentration in
serum-free RPMI with ligand in a 96 well plate, and serially
diluted to give 7 test concentrations. Typically, the highest final
concentration of test compound is 100 .mu.M, and 1:3 dilutions are
used (i.e. final test compound concentration range is 0.137-100
.mu.M).
[1379] 4. After 18 hours of ligand activation, 12.5 .mu.l of
diluted BrdU labeling reagent (1:100 in RPMI, 0.1% BSA) is added to
each well and the cells are incubated with BrdU (final
concentration is 10 .mu.M) for 1 hour.
[1380] 5. Same as General Procedure.
[1381] 6. Same as General Procedure.
[1382] 7. The blocking solution is removed by decanting and the
wells are washed once with PBS. Anti-BrdU-POD solution (1:100
dilution in PBS, 1% BSA) is added (100 .mu.l/well) and the plate is
incubated for 90 minutes at room temperature on a plate shaker.
[1383] 8. Same as General Procedure.
[1384] 9. Same as General Procedure.
[1385] 10. Same as General Procedure.
[1386] HUV-EC-C Assay
[1387] This assay is used to measure a compound's activity against
PDGF-R, FGF-R, VEGF, aFGF or Flk-1/KDR, all of which are naturally
expressed by HUV-EC cells.
[1388] Day 0
[1389] 1. Wash and trypsinize HUV-EC-C cells (human umbilical vein
endothelial cells, (American Type Culture Collection, catalogue no.
1730 CRL). Wash with Dulbecco's phosphate-buffered saline (D-PBS,
obtained from Gibco BRL, catalogue no. 14190-029) 2 times at about
1 ml/10 cm.sup.2 of tissue culture flask. Trypsinize with 0.05%
trypsin-EDTA in non-enzymatic cell dissociation solution (Sigma
Chemical Company, catalogue no. C-1544). The 0.05% trypsin is made
by diluting 0.25% trypsin/1 mM EDTA (Gibco, catalogue no.
25200-049) in the cell dissociation solution. Trypsinize with about
1 ml/25-30 cm.sup.2 of tissue culture flask for about 5 minutes at
37.degree. C. After cells have detached from the flask, add an
equal volume of assay medium and transfer to a 50 ml sterile
centrifuge tube (Fisher Scientific, catalogue no. 05-539-6).
[1390] 2. Wash the cells with about 35 ml assay medium in the 50 ml
sterile centrifuge tube by adding the assay medium, centrifuge for
10 minutes at approximately 200.times.g, aspirate the supernatant,
and resuspend with 35 ml D-PBS. Repeat the wash two more times with
D-PBS, resuspend the cells in about 1 ml assay medium/15 cm.sup.2
of tissue culture flask. Assay medium consists of F12K medium
(Gibco BRL, catalogue no. 21127-014) and 0.5% heat-inactivated
fetal bovine serum. Count the cells with a Coulter Counter.RTM.
(Coulter Electronics, Inc.) and add assay medium to the cells to
obtain a concentration of 0.8-1.0.times.10.sup.5 cells/ml.
[1391] 3. Add cells to 96-well flat-bottom plates at 100 .mu.l/well
or 0.8-1.0.times.10.sup.4 cells/well, incubate .about.24 h at
37.degree. C., 5% CO.sub.2.
[1392] Day 1
[1393] 1. Make up two-fold test compound titrations in separate
96-well plates, generally 50 .mu.M on down to 0 .mu.M. Use the same
assay medium as mentioned in day 0, step 2 above. Titrations are
made by adding 90 .mu.l/well of test compound at 200 .mu.M
(4.times. the final well concentration) to the top well of a
particular plate column. Since the stock test compound is usually
20 mM in DMSO, the 200 .mu.M drug concentration contains 2%
DMSO.
[1394] A diluent made up to 2% DMSO in assay medium (F12K+0.5%
fetal bovine serum) is used as diluent for the test compound
titrations in order to dilute the test compound but keep the DMSO
concentration constant. Add this diluent to the remaining wells in
the column at 60 .mu.l/well. Take 60 .mu.l from the 120 .mu.l of
200 .mu.M test compound dilution in the top well of the column and
mix with the 60 .mu.l in the second well of the column. Take 60
.mu.l from this well and mix with the 60 .mu.l in the third well of
the column, and so on until two-fold titrations are completed. When
the next-to-the-lasts well is mixed, take 60 .mu.l of the 120 .mu.l
in this well and discard it. Leave the last well with 60 .mu.l of
DMSO/media diluent as a non-test compound-containing control. Make
9 columns of titrated test compound, enough for triplicate wells
each for: (1) VEGF (obtained from Pepro Tech Inc., catalogue no.
100-200, (2) endothelial cell growth factor (ECGF) (also known as
acidic fibroblast growth factor, or aFGF) (obtained from Boehringer
Mannheim Biochemica, catalogue no. 1439 600), or, (3) human PDGF
B/B (1276-956, Boehringer Mannheim, Germany) and assay media
control. ECGF comes as a preparation with sodium heparin.
[1395] 2. Transfer 50 .mu.l/well of the test compound dilutions to
the 96-well assay plates containing the 0.8-1.0.times.10.sup.4
cells/100 .mu.l/well of the HUV-EC-C cells from day 0 and incubate
.about.2 h at 37.degree. C., 5% CO.sub.2.
[1396] 3. In triplicate, add 50 .mu.l/well of 80 .mu.g/ml VEGF, 20
ng/ml ECGF, or media control to each test compound condition. As
with the test compounds, the growth factor concentrations are
4.times. the desired final concentration. Use the assay media from
day 0 step 2 to make the concentrations of growth factors. Incubate
approximately 24 hours at 37.degree. C., 0.5% CO.sub.2. Each well
will have 50 .mu.l test compound dilution, 50 .mu.l growth factor
or media, and 100 .mu.l cells, which calculates to 200 .mu.l/well
total. Thus the 4.times. concentrations of test compound and growth
factors become 1.times. once everything has been added to the
wells.
[1397] Day 2
[1398] 1. Add .sup.3H-thymidine (Amersham, catalogue no. TRK-686)
at 1 .mu.Ci/well (10 .mu.l/well of 100 .mu.Ci/ml solution made up
in RPMI media+10% heat-inactivated fetal bovine serum) and incubate
.about.24 h at 37.degree. C., 5% CO.sub.2. RPMI is obtained from
Gibco BRL, catalogue no. 11875-051.
[1399] Day 3
[1400] 1. Freeze plates overnight at -20.degree. C.
[1401] Day 4
[1402] Thaw plates and harvest with a 96-well plate harvester
(Tomtec Harvester 96.RTM.) onto filter mats (Wallac, catalogue no.
1205-401), read counts oh a Wallac Betaplate.TM. liquid
scintillation counter.
[1403] TABLE 3 shows the results of biological testing of some
exemplary compounds of this invention. The results are reported in
terms of IC.sub.50, the micromolar (.mu.M) concentration of the
compound being tested which causes a 50% change in the activity of
the target PKT compared to the activity of the PTK in a control to
which no test compound has been added. Specifically, the results
shown indicate the concentration of a test compound needed to cause
a 50% reduction of the activity of the target PTK. Bioassays which
have been or can be used to evaluate compounds are described in
detail below.
3TABLE 3 bio Her2 flkGST bio FGFR1 bio PDCF bio EGF cell EGF Kinase
cdk2spa bio pyk2 IC50 IC50 IC50 IC50 IC50 IC50 C50 IC50 Example
(.mu.M) (.mu.M) (.mu.M) (.mu.M) (.mu.M) (.mu.M) (.mu.M) (.mu.M) 1
57.68 15.16 >100 >100 >100 >100 2 >100 >100
>100 >100 3 9.85 9.62 >100 >100 >100 >100 4 3.57
>20 >100 >100 >100 >100 5 8.3 16.06 >100 >100
>100 >100 6 4.04 >100 3.26 7.82 2.43 7 7.74 >100 5.07
9.8 4.24 8 12.1 >100 51.34 20.08 5.5 9 0.96 >100 >100
>100 16.38 10 5.72 >100 94.04 15.86 8.06 11 9.77 >100
>100 >10.0 >100 12 >20 21.46 >100 27.73 13 >20
81.92 8.17 2.66 14 13.01 42.41 >100 66.02 15 >20 >100
>100 98.61 16 >20 98.06 >100 23.32 17 8.25 2.47 94.35 0.83
11.47 15.94 >10 18 2.67 2.57 9.23 4.99 19 7.5 6.86 34.18 8.37 20
11.53 >100 41.16 8 21 7.18 >100 40.34 27.69 22 >20 >100
>100 87.67 23 >20 >100 36.64 4.05 24 >100 16.84 5.31 25
12.55 >100 23.48 7.9 26 16.03 66.87 34.67 10.04 27 >100 26.5
3.91 28 4.5 71.27 53.66 2.67 29 10.12 >100 26.72 3.98 30 9.4
>100 18.69 4.1 31 >50 >100 9.83 47.19 32 45.74 5.94
>100 >100 34 >50 >100 >100 >100 35 >20 >100
80.4 54.14 36 >20 >100 >100 >100 37 0.22 3.06 10.78
9.84 1.4 38 4.17 3.06 6.04 8.97 2.16 39 3.38 4.69 3.67 14.54 3.53
40 4.5 7.9 6.52 6.27 42 0.1 0.12 11.95 74.55 20.43 43 1.12 8.38
>100 37.33 53.37 44 <0.05 0.02 20.73 67.46 6.99 45 1.71
>100 >100 29.95 >100 46 30.62 6.18 >100 >100 >100
47 0.08 1.5 60.06 11.42 41.54 8.4 >20 1.05 48 0.006 0.3 <0.78
17.88 21.58 7.93 0.09 49 <0.78 >100 43.86 >100 50 <0.78
>100 20.34 >100 51 0.006 1.66 0.01 18.1 21.61 23.24 16.69
0.35 52 0.08 1.26 <0.78 12.53 >100 >100 10.66 0.45 53
<0.78 >100 >100 >100 54 1.98 <0.78 23.88 9.76 7.02
55 0.27 0.53 6.03 35.99 77.82 56 2.32 3.19 >100 10.03 7.11 57
0.06 7.98 >100 9.97 6.94 58 21.14 >100 >100 >100 59
<0.78 >100 >100 >100 60 <0.78 >100 >100
>100 61 <0.78 >100 >100 >100 62 8.00 8.32 >100
>100 >100 63 0.21 <0.78 8.59 >100 >100 64 0.55
<0.78 30.49 >100 >100 65 0.37 <0.05 >100 74.36 15.97
66 <0.05 >100 11.84 2.76 67 0.39 24.77 31.38 19.79 2.56 68
1.16 0.03 >100 23.52 34.13 69 0.3 56.55 >100 97.54 >100 70
0.09 1.50 0.0030 10.57 6.42 7.99 12.62 0.63 71 15.21 22.5 >100
9.91 72 6.06 10.54 >100 39.94 9.65 73 5.95 14.12 >100 39.5
8.59 74 1.2 0.09 46.75 >100 75 2.7 61.55 >100 >100 76 3.33
19.18 5.11 3.01 77 0.49 25.01 >100 >100 78 1.94 70.62 9.33
4.25 79 1.49 >100 27.39 >100 80 0.13 4.29 0.001 >100 50.19
17.19 0.28 81 0.21 0.18 >100 >100 82 2.03 7.69 6.88 >100
>100 0.31 83 0.34 0.41 9.46 2.18 86.9 0.008 84 1.38 12.51 67.2
5.86 0.006 85 0.2 0.8 2.59 >100 3.76 86 1.45 1.3 19.6 41.8
>100 3.58 87 3.27 7.56 6.46 >100 9.1 0.17 88 0.35 1.18 8.06
2.36 >100 0.09 89 7.84 47.58 8.53 9.67 15.97 115 7.3 7.48
>100 >100 0.006 116 >20 >100 >100 >100 <0.0005
117 0.91 12.9 >100 >100 0.006 118 1.93 1.2 >100 >100
0.0020 119 1.38 61.63 >100 >100 <0.0005
[1404] In Vivo Animal Models
[1405] Xenograft Animal Models
[1406] The ability of human tumors to grow as xenografts in athymic
mice (e.g., Balb/c, nu/nu) provides a useful in vivo model for
studying the biological response to therapies for human tumors.
Since the first successful xenotransplantation of an tumors into
athymic mice, (Rygaard and Povlsen, 1969, Acta Pathol. Microbial.
Scand. 77:758-760), many different human tumor cell lines (e.g.,
mammary, lung, genitourinary, gastro-intestinal, head and neck,
glioblastoma, bone, and malignant melanomas) have been transplanted
and successfully grown in nude mice. The following assays may be
used to determine the level of activity, specificity and effect of
the different compounds of the present invention. Three general
types of assays are useful for evaluating compounds:
cellular/catalytic, cellular/biological and in vivo. The object of
the cellular/catalytic assays is to determine the effect of a
compound on the ability of a TK to phosphorylate tyrosines on a
known substrate in a cell. The object of the cellular/biological
assays is to determine the effect of a compound on the biological
response stimulated by a TK in a cell. The object of the in vivo
assays is to determine the effect of a compound in an animal model
of a particular disorder such as cancer.
[1407] Suitable cell lines for subcutaneous xenograft
experiments-include C6 cells (glioma, ATCC # CCL 107), A375 cells
(melanoma, ATCC # CRL 1619), A431 cells (epidermoid carcinoma, ATCC
# CRL 1555), Calu 6 cells (lung, ATCC # HTB 56), PC3 cells
(prostate, ATCC # CRL 1435), SKOV3TP5 cells and NIH 3T3 fibroblasts
genetically engineered to overexpress EGFR, PDGFR, IGF-1R or any
other test kinase. The following protocol can be used to perform
xenograft experiments:
[1408] Female athymic mice (BALB/c, nu/nu) are obtained from
Simonsen Laboratories (Gilroy, Calif.). All animals are maintained
under clean-room conditions in Micro-isolator cages with Alpha-dri
bedding. They receive sterile rodent chow and water ad libitum.
[1409] Cell lines are grown in appropriate medium (for example,
MEM, DMEM, Ham's F10, or Ham's F12 plus, 5% 10% fetal bovine serum
(FBS) and 2 mM glutamine (GLN)). All cell culture media, glutamine,
and fetal bovine serum are purchased from Gibco Life Technologies
(Grand Island, N.Y.) unless otherwise specified. All cells are
grown in a humid atmosphere of 90-95% air and 5-10% CO.sub.2 at
37.degree. C. All cell lines are routinely subcultured twice a week
and are negative for mycoplasma as determined by the Mycotect
method (Gibco).
[1410] Cells are harvested at or near confluency with 0.05%
Trypsin-EDTA and pelleted at 450.times.g for 10 min. Pellets are
resuspended in sterile PBS or media (without FBS) to a particular
concentration and the cells are implanted into the hindflank of the
mice (8-10 mice per group, 2-10.times.10.sup.6 cells/animal). Tumor
growth is measured over 3 to 6 weeks using venier calipers. Tumor
volumes are calculated as a product of
length.times.width.times.height unless otherwise indicated. P
values are calculated using the Students t-test. Test compounds in
50-100 .mu.L excipient (DMSO, or VPD:D5W) can be delivered by IP
injection at different concentrations generally starting at day one
after implantation.
[1411] Tumor Invasion Model
[1412] The following tumor invasion model has been developed and
may be used for the evaluation of therapeutic value and efficacy of
the compounds identified to selectively inhibit KDR/FLK-1
receptor.
[1413] Procedure
[1414] 8 week old nude mice (female) (Simonsen Inc.) are used as
experimental animals. Implantation of tumor cells can be performed
in a laminar flow hood. For anesthesia, Xylazine/Ketamine Cocktail
(100 mg/kg ketamine and 5 mg/kg Xylazine) are administered
intraperitoneally. A midline incision is done to expose the
abdominal cavity (approximately 1.5 cm in length) to inject
10.sup.7 tumor cells in a volume of 100 .mu.l medium. The cells are
injected either into the duodenal lobe of the pancreas or under the
serosa of the colon. The peritoneum and muscles are closed with a
6-0 silk continuous suture and the skin is closed by using wound
clips. Animals are observed daily.
[1415] Analysis
[1416] After 2-6 weeks, depending on gross observations of the
animals, the mice are sacrificed, and the local tumor metastases to
various organs (lung, liver, brain, stomach, spleen, heart, muscle)
are excised and analyzed (measurement of tumor size, grade of
invasion, immunochemistry, in situ hybridization determination,
etc.).
[1417] c-Kit Assay,
[1418] This assay is used to detect the level of c-kit tyrosine
phosphorylation.
[1419] MO7E (human acute myeloid leukemia) cells were serum starved
overnight in 0.1% serum. Cells were pre-treated with the compound
(concurrent with serum starvation), prior to ligand stimulation.
Cells were stimulated with 250 ng/ml rh-SCF for 15 minutes.
Following stimulation, cells were lysed and immunoprecipitated with
an anti-c-kit antibody. Phosphotyrosine and protein levels were
determined by Western blotting.
[1420] MTT Proliferation Assay
[1421] MO7E cells were serum starved and pre-treated with compound
as described for the phosphorylation experiments. Cells were plated
@ 4.times.10.sup.5 cells/well in a 96 well dish, in 100 .mu.l
RPMI+10% serum. rh-SCF (100 ng/mL) was added and the plate was
incubated for 48 hours. After 48 hours, 10 .mu.l of 5 mg/ml MTT
[3-(4,5-dimethythiazol-2-y- l)-2,5-diphenyl tetrazolium bromide)
was added and allowed to incubate for 4 hours. Acid isopropanol
(100 .mu.l of 0.04N HCl in isopropanol) was added and the optical
density was measured at a wavelength of 550 nm.
[1422] Apoptosis Assay
[1423] MO7E cells were incubated +/-SCF and +/-compound in 10% FBS
with rh-GM-CSF (10 ng/mL) and rh-IL-3 (10 ng/mL). Samples were
assayed at 24 and 48 hours. To measure activated caspase-3, samples
were washed with PBS and permeabilized with ice-cold 70% ethanol.
The cells were then stained with PE-conjugated polyclonal rabbit
anti-active caspase-3 and analyzed by FACS. To measure cleaved
PARP, samples were lysed and analyzed by western blotting with an
anti-PARP antibody.
[1424] Additional Assays
[1425] Additional assays which may be used to evaluate the
compounds of this invention include, without limitation, a
bio-flk-1 assay, an EGF receptor-HER2 chimeric receptor assay in
whole cells, a bio-src assay, a bio-lck assay and an assay
measuring the phosphorylation function of raf. The protocols for
each of these assays may be found in U.S. application Ser. No.
09/099,842, which is incorporated by reference, including any
drawings, herein.
[1426] Measurement of Cell Toxicity
[1427] Therapeutic compounds should be more potent in inhibiting
receptor tyrosine kinase activity than in exerting a cytotoxic
effect. A measure of the effectiveness and cell toxicity of a
compound can be obtained by determining the therapeutic index,
i.e., IC.sub.50/LD.sub.50. IC.sub.50, the dose required to achieve
50% inhibition, can be measured using standard techniques such as
those described herein. LD.sub.50, the dosage which results in 50%
toxicity, can also be measured by standard techniques as well
(Mossman, 1983, J. Immunol. Methods, 65:55-63), by measuring the
amount of LDH released (Korzeniewski and Callewaert, 1983, J.
Immunol. Methods, 64:313, Decker and Lohmann-Matthes, 1988, J.
Immunol. Methods, 115:61), or by measuring the lethal dose in
animal models. Compounds with a large therapeutic index are
preferred. The therapeutic index should be greater than 2,
preferably at least 10, more preferably at least 50.
[1428] B. Example of Cellular Assay Results Using
5-(5-Fluoro-2-oxo-1,2-di-
hydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic
Acid (2-diethylamino-ethyl)amide.
[1429] To confirm the potency of
5-(5-fluoro-2-oxo-1,2-dihydroindol-3-ylid-
enemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid
(2-diethylamino-ethyl)amide (Compound 80) detected in biochemical
assays (vide infra), the ability of said compound to inhibit
ligand-dependent RTK phosphorylation was evaluated in cell-based
assays using NIH-3T3 mouse cells engineered to overexpress Flk-1 or
human PDGFR.beta..
5-(5-Fluoro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrro-
le-3-carboxylic acid (2-diethylamino-ethyl)amide (Compound 80)
inhibited VEGF-dependent Flk-1 tyrosine phosphorylation with an
IC.sub.50 value of approximately 0.03 .mu.M. This value is similar
to the 0.009 .mu.M K.sub.i value determined for inhibition of Flk-1
by
5-(5-fluoro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrro-
le-3-carboxylic acid (2-diethylamino-ethyl)amide (Compound 80)
determined in biochemical assays. This indicates that
5-(5-fluoro-2-oxo-1,2-dihydroi-
ndol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid
(2-diethylamino-ethyl)amide (Compound 80) readily penetrates into
cells. Consistent with the biochemical data (vide infra) indicating
that
5-(5-fluoro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrro-
le-3-carboxylic acid (2-diethylamino-ethyl)amide (Compound 80) had
comparable activity against Flk-1 and PDGFR.beta., it was also
found that it inhibited PDGF-dependent receptor, phosphorylation in
cells with an IC.sub.50 value of approximately 0.03 .mu.M. The
ability of
5-(5-fluoro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrro-
le-3-carboxylic acid (2-diethylamino-ethyl)amide (Compound 80) to
inhibit c-kit, a closely related RTK that binds stem cell factor
(SCF), was determined using MO7E cells that express this receptor.
In these cells,
5-(5-fluoro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrro-
le-3-carboxylic acid (2-diethylamino-ethyl)amide (Compound 80)
inhibited SCF-dependent c-kit phosphorylation with an IC.sub.50
value of 0.01-0.1 .mu.M. This compound also inhibited
SCF-stimulated c-kit phosphorylation in acute myeloid leukemia
(AML) blasts isolated from the peripheral blood of patients.
[1430] In addition to testing the ability of
5-(5-fluoro-2"oxo-1,2-dihydro-
indol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid
(2-diethylamino-ethyl)amide (Compound 80) to inhibit
ligand-dependent receptor phosphorylation in cells, its effect on
ligand-dependent proliferative response of cells was also examined
in vitro (see Table 4). In these studies, cells quiesced by
overnight serum starvation were induced to undergo DNA synthesis
upon addition of the appropriate mitogenic ligand. As shown in
Table 4, 5-(5-fluoro-2-oxo-1,2-dihydroindol-
-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid
(2-diethylamino-ethyl)amide (Compound 80) inhibited the
PDGF-induced proliferation of NIH-3T3 cells overexpressing
PDGFR.beta. or PDGFR.alpha.with IC.sub.50 values 0.031 and 0.069
.mu.M, respectively, and the SCF-induced proliferation of MO7E
cells with an IC.sub.50 value of 0.007 .mu.M.
4 TABLE 4 Cellular IC.sub.50 Biochemical Receptor K.sub.i.sup.1
Phosphorylation Ligand-dependent Receptor (.mu.M) (.mu.M)
Proliferation (.mu.M) Flk- 0.009 0.03.sup.2 0.004.sup.3 1/KDR
PDGFR.alpha. 0.008 0.03.sup.4 0.031.sup.4 PDGFR.beta. ND ND
0.069.sup.5 FGFR 0.83 ND 0.7.sup.3 c-kit ND 0.01-0.1.sup.6
0.007.sup.6 ND = Not Determined .sup.1Determined using recombinant
enzyme .sup.2Determined using serum-starved NIH-3T3 cells
expressing Flk-1 .sup.3Determined using serum-starved HUVECs
.sup.4Determined using serum-starved NIH-3T3 cells expressing
PDGFR.quadrature. .sup.5Determined using serum-starved NIH-3T3
cells expressing PDGFR.quadrature. .sup.6Determined using
serum-starved MO7E cells
[1431] As shown in Table 4, there is a general agreement between
the biochemical and cellular activities of
5-(5-fluoro-2-oxo-2-dihydroindol-3-
-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid
(2'-diethylamino-ethyl)amide (Compound 80), supporting the
conclusion that this compound crosses cellular membranes. Further,
it can be concluded that the cellular responses are a result of the
activity of compound 80 against the indicated target. In contrast,
when tested in the presence of complete growth medium in vitro,
substantially higher concentrations of
5-(5-fluoro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-
-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylamino-ethyl)amide
(Compound 80) (>10 .mu.M) were required to inhibit the growth of
a variety of human tumor cells (see Table 5). This indicates that
the compound did not directly inhibit the growth of these tells at
concentrations required to inhibit ligand dependent receptor
phosphorylation and cell proliferation.
5 TABLE 5 Cell Line Origin IC.sub.50 (.mu.M) LD.sub.50 (.mu.M) HT29
Colon carcinoma 10 22 A549 Lung carcinoma 9.5 22 NCI-H460 NSC lung
8.9 20 carcinoma SF767T Glioma 7.9 14 A431 Epidermoid 6.0 18
carcinoma
[1432] Briefly, the results shown in Table 5 were obtained by
incubating cells for 48 hr in complete growth medium in the
presence of serial dilutions
5-(5-Fluoro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethy-
l-1H-pyrrole-3-carboxylic acid (2-diethylamino-ethyl)amide. At the
end of the growth period, the relative number of cells was
determined. IC.sub.50 values were calculated as the concentration
of compound that inhibited the growth of cells by 50% relative to
untreated cells. LD.sub.50 values were calculated as the
concentration of compound that caused a 50% reduction in the number
of cells relative to those at the start of the experiment.
[1433] A more relevant cell-based assay in which to evaluate the
anti-angiogenic potential of
5-(5-fluoro-2-oxo-1,2-dihydroindol-3-ylidene-
methyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid
(2-diethylamino-ethyl)am- ide (Compound 80) is the in vitro
mitogenesis assay using human umbilical vein endothelial cells
(HUVECs) as a model system for the endothelial cell proliferation
critical to the angiogenic process. In this assay, a mitogenic
response, measured as an increase in DNA synthesis, is induced in
serum-starved HUVECs upon addition of VEGF or FGF. In these cells,
5-(5-fluoro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrro-
le-3-carboxylic acid (2-diethylamino-ethyl)amide (Compound 80)
inhibited the VEGF- and FGF-induced mitogenic response in a
dose-dependent manner with IC.sub.50 values of 0.004 .mu.M and 0.7
.mu.M, respectively, when compound was present throughout the 48-hr
assay.
[1434] Briefly, the aforementioned results were obtained using
Serum-starved HUVECs that were incubated with mitogenic
concentrations of VEGF (100 ng/ml) or FGF (30 ng/ml) in the
presence of serial dilutions of
5-(5-fluoro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrro-
le-3-carboxylic acid (2-diethylamino-ethyl)amide (Compound 80) for
24 hrs. The mitogenic response during the following 24 hrs. in the
presence of ligand and inhibitor was quantitated by measurement of
DNA synthesis based on incorporation of bromodeoxyuridine into
cellular DNA.
[1435] In separate experiments, compound 80 inhibited the
VEGF-dependents phosphorylation of ERK 1/2 (p42/44MAP kinase), an
early downstream target of Flk-1/KDR, in a dose-dependent, manner.
The inhibitory activity of compound 80 was also shown to be
long-lasting in this system; inhibiting VEGF-dependent
phosphorylation of ERK 1/2 for as long as 48 hours after removal of
5-(5-fluoro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimeth-
yl-1H-pyrrole-3-carboxylic acid (2-diethylamino-ethyl)amide
(Compound 80) from the medium following a short (2 hr) exposure to
micromolar concentrations of the compound.
[1436] VEGF has been recognized to be an important survival factor
for endothelial cells. Since
5-(5-fluoro-2-oxo-1,2-dihydroindol-3-ylidenemeth-
yl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid
(2-diethylamino-ethyl)amide (Compound 80) inhibits the
VEGF-dependent mitogenic response of HUVECs, the effect of the
compound on HUVEC survival was investigated. In these experiments,
cleavage of the caspase 3 substrate poly-ADP-ribosyl polymerase
(PARP) was used as a readout for apoptosis. HUVECs cultured in
serum-free conditions for 24 hours exhibited substantial levels of
PARP cleavage, as detected by the accumulation of the 23 kDa PARP
cleavage fragment. This was largely prevented by the addition of
VEGF to the cell medium, indicating that VEGF acts as a survival
factor in this assay.
5-(5-Fluoro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrro-
le-3-carboxylic acid (2-diethylamino-ethyl)amide (Compound 80) has
been shown to inhibit KDR signaling. Accordingly,
5-(5-fluoro-2-oxo-1,2-dihydr-
oindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid
(2-diethylamine-ethyl)amide.(Compound 80) inhibited VEGF-mediated
HUVEC survival in a dose-dependent manner. Thus, these data
indicate that compound 80 induced apoptosis in endothelial cells in
culture in the presence of VEGF.
[1437] C. In Vivo Efficacy Studies
[1438] i. Efficacy Against Established Tumor Xenografts
[1439] The in vivo efficacy of
5-(5-fluoro-2-oxo-1,2-dihydroindol-3-yliden-
emethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid
(2-diethylamino-ethyl)a- mide (Compound 80) was studied in
subcutaneous (SC) xenograft models using human tumor cells
implanted into the hindflank region of athymic mice. Following
implantation, tumors were allowed to become established to a size
of 100-550 mm.sup.3 prior to starting oral treatment with the
compound.
[1440] Daily oral administration of compound 80 caused a
dose-dependent inhibition of A431 tumor-growth when treatment was
initiated after tumors had grown to a size of 400 mm.sup.3.
Statistically significant (P<0.05) inhibition of tumor growth
was seen at doses of 40 mg/kg/day (74% inhibition) and 80 mg/kg/day
(84% inhibition) (see Table 6). In preliminary experiments, a
higher (160 mg/kg/day) dose of the compound was not more
efficacious against established A431 tumors than the 80 mg/kg/day
dose. In addition, mice treated at the 160 mg/kg/day dose of the
compound lost body weight, indicating that the higher dose was not
as well tolerated. Similar results were obtained in an experiment
in which A431 tumors were only allowed to reach 100 mm.sup.3 in
size (see Table 5). In this second experiment, complete regression
of the tumors occurred in six of the eight animals treated at the
80 mg/kg/day for 21 days. In these six animals, the tumors did not
regrow during a 110-day observation period following the end of
treatment. In the two animals in which the tumors regrew to a large
size (2000-3000 mm.sup.3), the tumors regressed in response to a
second round of treatment with compound 80. Importantly, in all
efficacy experiments, 5-(5-fluoro-2-oxo-1,2-dihydroindol-3-ylidene-
methyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid
(2-diethylamino-ethyl)am- ide (Compound 80) at 80 mg/kg/day has
been well tolerated, even when dosed continuously for more than 100
days.
6 TABLE 6 Initial Tumor % Volume Compound.sup.1 Inhibition
(mm.sup.3) (mg/kg/day) (day) P-Value 400 80 84 (36) 0.001 40 74
(36) 0.003 20 51 (36) 0.130 100 80 93 (40) 0.002 40 75 (40) 0.015
10 61 (40) 0.059 .sup.1Compound 80.
[1441] Briefly, the results shown in Table 6 were obtained using
A431 cells (0.5.times.10 6 cells/mouse) which were implanted SC
into the hindflank region of athymic mice. Daily oral
administration of
5-(5-fluoro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrro-
le-3-carboxylic acid (2-diethylamino-ethyl)amide (Compound 80) in a
Cremophore-based vehicle or vehicle control began when tumors
reached the indicated average volume. Tumors were measured using
vernier calipers and tumor volume was calculated as the product of
length.times.width.times.he- ight. P-values were calculated by
comparing the size of the tumors for animals that were treated with
compound 80 (n=8) to those of animals that were treated with a
vehicle (n=16) on the last day of the experiment, using the
two-tailed Student's t-test.
[1442] The efficacy compound 80 against established human tumors of
different origins was determined using Colo205 (colon carcinoma),
SF763T (glioma), and NCI-H460 (non-small cell lung carcinoma)
xenografts (see Table 7). These experiments were conducted using
5-(5-fluoro-2-oxo-1,2-di-
hydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic
acid (2-diethylamino-ethyl)amide (Compound 80) administered orally
at 80 mg/kg/day; a dose that was effective and well tolerated.
7 TABLE 7 Initial Tumor % Volume Inhibition Tumor Type (mg/kg/day)
(day) P-Value A431.sup.1 Epidermoid 100 93 (40) 0.002 A431.sup.1
Epidermoid 400 84 (36) 0.001 Colo205 Colon 370 77 (54) 0.028
NCI-H460 Lung 300 61 (54) 0.003 SF763T Glioma 550 53 (30) 0.001
.sup.1Data are from experiment reported in Table 5.
[1443] In the abovementioned experiments, compound 80 was
administered once daily at 80 mg/kg in a Cremophor-based vehicle
once tumors reached the indicated size. Percent inhibition compared
to the vehicle-treated control group was calculated at termination
of the experiments. P-values were calculated by comparing tumor
sizes of the animals that had been treated with the compound to
tumor sizes of those animals that had been treated with the
vehicle, using the two-tailed Student's t-test.
[1444] Although
5-(5-fluoro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-di-
methyl-1H-pyrrole-3-carboxylic acid (2-diethylamino-ethyl)amide
(Compound 80) inhibited the growth of all the tumor types shown in
Table 7, there was a difference in the response of the different
xenograft models. Specifically, the growth of NCI-H460 and SF763T
tumors was arrested or greatly slowed whereas the Colo205 tumors,
like A431 tumors, regressed when treated with
5-(5-Fluoro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-
-dimethyl-1H-pyrrole-3-carboxylic acid
(2-diethylamino-ethyl)amide.
[1445] In order to determine the molecular basis-for the difference
in response between xenograft models, the SF763T tumors were
studied. Therefore, SF763T-tumors, which were less responsive to
treatment with
5-(5-Fluoro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrro-
le-3-carboxylic acid (2-diethylamino-ethyl)amide, have been
evaluated at the molecular level using immunohistological
techniques to determine the effect of treatment with the compound.
These studies were initially conducted in this tumor type because
SF763T tumors are highly vascularized with microvessels that
strongly express the endothelial cell marker CD31 and are hence
well suited for studies of tumor microvessel density (MVD).
Immunohistological evaluation of SF763T tumors indicated that
tumors from treated animals had reduced MVD relative to
vehicle-treated controls, consistent with an anti-angiogenic
mechanism of action for compound 80; MVD was 24.2.+-.4.1 in animals
treated with compound 80, compared to 39.3.+-.5.7 for those that
were treated with just the vehicle. As anticipated from the
associated tumor growth arrest, a pronounced inhibition of tumor
cell proliferation was evident in tumors that were treated with
compound 80. These tumors had half the mitotic index of those in
vehicle-treated tumors (data not shown). The effect compound 80 on
MVD and tumor cell proliferation indicates that the compound has
profound anti-angiogenic and anti-tumor effects, even under
conditions in which tumors do not regress.
[1446] The ability of compound 80 to inhibit PDGFR phosphorylation
and subsequent signaling in vivo was also evaluated in the SF763T
tumors, which express high levels of PDGFR.beta.. Treatment of the
SF763T tumors with compound 80 strongly inhibited PDGFR.beta.
tyrosine phosphorylation in established SF763T tumors. Compound 80
also reduced the levels of phosphorylated (activated) phospholipase
C gamma (PLC-.gamma.), an immediate downstream indicator of PDGFR
activation. These data demonstrate that oral administration of
compound 80 causes a direct effect on target (PDGFR) activity in
tumors in vivo.
[1447] Based on the demonstration that the ability of compound 80
to inhibit VEGF-dependent signaling in HUVECs in vitro was
long-lasting (vide supra), the efficacy of the compound was
evaluated when the compound was administered infrequently in the
Colo205 tumor model. As shown in Table 8, 80 mg/kg (91% inhibition)
and 40 mg/kg (84% inhibition) were efficacious when administered
daily, but not when administered twice weekly. In contrast, a
higher dose of compound 80 (160 mg/kg) did inhibit (52% inhibition)
the growth of established Colo205 tumors when administered twice
weekly, suggesting that this compound can demonstrate efficacy when
administered infrequently at a higher dose. It should be noted that
dosing regimens may be determined by those with ordinary skill in
the art without undue experimentation.
8TABLE 8 Dose (mg/kg) Frequency % Inhibition P-Value 160 Twice
weekly 52 0.085 Once weekly 17 NS 80 Daily 91 0.039 Twice weekly 19
NS Once weekly 0 NS 40 Daily 84 0.028 Twice weekly 36 NS NS: not
significant (P > 0.05)
[1448] Briefly, the results shown in Table 8 were obtained using
Colo205 cells (0.5.times.10.sup.6 cells/mouse) that had been
implanted SC into the hindflank region of athymic mice. Oral
administration of compound 80 according to the indicated schedule
began when tumors reached 400 mm.sup.3. Tumors were measured using
vernier calipers and tumor volume was calculated as the product of
length.times.width.times.height. P-values were calculated by
comparing the size of the tumors for animals that were treated with
compound 80 to those of animals that were treated with a vehicle on
the last day of the experiment, using the two-tailed Student's
t-test.
[1449] ii. Efficacy of Compound 80 in a Model of Disseminated
Disease
[1450] In addition to supporting the sustained growth of solid
primary tumors, angiogenesis is also an essential component
supporting the development of disseminated disease due to
metastasis from the primary tumor. The effect of compound 80 on the
development of disseminated disease was examined in the B16-F1
mouse melanoma lung colonization model. In this model, B16-F1 cells
inoculated intravenously via the tail vein of athymic mice colonize
the lungs and form tumors. As shown in Table 8, oral administration
of compound 80 at 80 mg/kg/day effectively reduced the burden of
B16-F1 cells in the lung as evaluated by measurements of total lung
weight. These data suggest that compound 80 can inhibit
disseminated disease in vivo.
9 TABLE 9 Lung Weight (g) % Inhibition P-Value Vehicle 0.83 .+-.
0.07 -- -- Compound.sup.1 0.41 .+-. 0.04 50 <0.001
.sup.1Compound 80
[1451] Briefly, the results shown in Table 9 were obtained using
athymic mice that had been inoculated with B16-F1 tumor cells
(5.times.10.sup.5 cells/mouse) via the tail vein. Mice were treated
daily with orally administered compound 80 at 80 mg/kg/day (n=10)
or vehicle (n=18) for 24 days after tumor cell inoculation. At the
end of the treatment period, the mice were sacrificed and their
lungs removed and weighed. Percent inhibition was calculated by
comparing the lung weight of those animals that had been treated
with compound 80, with the lung weight of the animals that had only
been treated with vehicle. P-values were determined using the
two-tailed Student's t-test.
[1452] D. Examples of Biological Activity.
[1453] Examples of the in vitro potency of compounds of this
invention are shown in Table 2.
CONCLUSION
[1454] In studies to investigate the pharmacokinetic
characteristics of the compounds of the preferred embodiments of
the present invention it has been demonstrated that oral
administration of a single dose of said compounds resulted in high
oral bioavailability in mice. The good oral bioavailability and
linear pharmacokinetics indicate that the compounds of the
preferred embodiments of the present have favorable pharmacokinetic
characteristics.
[1455] In addition, the compounds of the preferred embodiments of
the present invention are potent inhibitor of the tyrosine kinase
activity of the split-kinase domain RTKs Flk-1/KDR and PDGFR, which
are involved in angiogenesis, and the RTK c-kit, a receptor for
stem cell factor (SCF), that is involved in certain hematologic
cancers. At higher concentrations, the compounds of the preferred
embodiments of the present invention also inhibit the tyrosine
kinase activity of FGFR-1, a third RTK involved in angiogenesis.
Consistent with their biochemical activity, the compounds of the
preferred embodiments of the present invention inhibit the
ligand-dependent tyrosine phosphorylation of target RTKs and the in
vitro mitogenic response of human umbilical vein endothelial cells
(HUVECs) stimulated with VEGF or FGF, of PDGFR-expressing NIH-3T3
cells stimulated with PDGF, and of MO7E acute myeloid leukemia
cells stimulated with SCF. In contrast, the compounds of the
preferred embodiments of the present invention do not directly
inhibit the proliferation of tumor cells in complete growth medium
except at concentrations 2 to 3 orders of magnitude higher than
those required to inhibit the ligand-dependent mitogenic responses.
In mouse xenograft studies, the compounds of the prefered
embodiments of the present invention inhibited the growth of
established human tumors of various origins in a dose-dependent
manner and at concentrations that were well tolerated even upon
extended (>100 days) dosing. At 80 mg/kg/day, the compounds of
the preferred embodiments of the present invention induced
regression of large established A431 and Colo205 tumors, and caused
substantial growth inhibition or stasis of SF763T and NCI-H460
tumors. In mice bearing SF763T tumors, the compounds of the
preferred embodiments of the present invention caused reductions in
microvessel density, phosphorylation of PDGFR in the tumors, and
mitotic index in the tumor cells. At this dose, the compounds of
the preferred embodiments of the present invention also inhibited
lung colonization by B16-F1 tumor cells in a model of tumor
metastasis. Regimen studies demonstrated that the compounds of the
preferred embodiments of the present invention are most efficacious
when administered daily. Direct evidence of the anti-angiogenic
activity of the compounds of the preferred embodiments of the
present invention was detected in SF763T tumors in which
microvessel density was reduced. Direct evidence that the compounds
of the preferred embodiments of the present invention inhibit PDGFR
phosphorylation and signaling in vivo was also obtained in SF763T
tumors.
[1456] Taken together, these data support the notion that orally
administered compounds of the preferred embodiments of the present
invention are anti-angiogenic agents for the treatment of cancers,
including solid tumors and hematological malignancies in which
angiogenesis and/or signaling through c-kit are important in the
disease pathology.
[1457] It will be appreciated that the compounds, methods and
pharmaceutical compositions of the present invention are effective
in modulating PK activity and therefore are expected to be
effective as therapeutic agents against RTK, CTK-, and STK-related
disorders.
[1458] One skilled in the art would also readily appreciate that
the present invention is well adapted to carry out the objects and
obtain the ends and advantages mentioned, as well as those inherent
herein. The molecular complexes and the methods, procedures,
treatments, molecules, specific compounds described herein are
presently representative of preferred embodiments, are exemplary,
and are not intended as limitations on the scope of the invention.
Changes therein and other uses will occur to those skilled in the
art which are encompassed within the spirit of the invention are
defined by the scope of the claims.
[1459] It will be readily apparent to one skilled in the art that
varying substitutions and modifications may be made to the
invention disclosed herein without departing from the scope and
spirit of the invention.
[1460] All patents and publications mentioned in the specification
are indicative of the levels of those skilled in the art to which
the invention pertains. All patents and publications are herein
incorporated by reference to the same extent as if each individual
publication was specifically and individually indicated to be
incorporated by reference.
[1461] The invention illustratively described herein suitably may
be practiced in the absence of any element or elements, limitation
or limitations which is not specifically disclosed herein. Thus,
for example, in each instance herein any of the terms "comprising",
"consisting essentially of" and "consisting of" may be replaced
with either of the other two terms. The terms and expressions which
have been employed are used as terms of description and not of
limitation, and there is no intention that in the use of such terms
and expressions of excluding any equivalents of the features shown
and described or portions thereof, but it is recognized that
various modifications are possible within the scope of the
invention claimed. Thus, it should be understood that although the
present invention has been specifically disclosed by preferred
embodiments and optional features, modification and variation of
the concepts herein disclosed may be resorted to by those skilled
in the art, and that such modifications and variations are
considered to be within the scope of this invention as defined by
the appended claims.
[1462] In addition, where features or aspects of the invention are
described in terms of Markush groups, those skilled in the art will
recognize that the invention is also thereby described in terms of
any individual member or subgroup of members of the Markush group.
For example, if X is described as selected from the group
consisting of bromine, chlorine, and iodine, claims for X being
bromine and claims for X being bromine and chlorine are fully
described.
[1463] Other embodiments are within the following claims.
* * * * *